Converted by EDGARwiz

0001551163-13-000067.txt : 20130715 0001551163-13-000067.hdr.sgml : 20130715 20130715135857 ACCESSION NUMBER: 0001551163-13-000067 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20121231 FILED AS OF DATE: 20130715 DATE AS OF CHANGE: 20130715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROTECT PHARMACEUTICAL Corp CENTRAL INDEX KEY: 0001493526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271877179 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54001 FILM NUMBER: 13967803 BUSINESS ADDRESS: STREET 1: 2681 EAST PARLEYS WAY STREET 2: SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 BUSINESS PHONE: 8013223401 MAIL ADDRESS: STREET 1: 2681 EAST PARLEYS WAY STREET 2: SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 10-K 1 f12dec10kprotect_vedgar2.htm Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)


x	Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

For the Fiscal Year Ended December 31, 2012


o	Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

For the transition period from _______________ to _______________

Commission File Number: 000-54001

PROTECT PHARMACEUTICAL CORPORATION

(Exact name of registrant as specified in its charter)


Nevada	27-1877179
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

2681 Parleys Way, Ste 204, Salt Lake City, UT 84109

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 322-3401

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ¨ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act

Yes ¨ No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ¨ No x

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.


Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

The aggregate market value of the voting stock held by non-affiliates of the registrant based on the closing sales price, or the average bid and asked price on such stock, as of June 30, 2012, the last business day of the registrant’s most recently completed second quarter, was $4,088,775. Shares of the registrant’s common stock held by each executive officer and director and by each entity or person that, to the registrant’s knowledge, owned 10% or more of registrant’s outstanding common stock as of June 30, 2012 have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

The number of shares of the registrant’s common stock outstanding as of July 6, 2013 was 44,573,012.

DOCUMENTS INCORPORATED BY REFERENCE

A description of "Documents Incorporated by Reference" is contained in Part IV, Item 15.

Protect Pharmaceutical Corporation

TABLE OF CONTENTS


		Page
PART I

Item 1.	Business	4

Item 1A.	Risk Factors	15

Item 1B.	Unresolved Staff Comments	26

Item 2.	Description of Properties	26

Item 3.	Legal Proceedings	26

Item 4.	Removed and Reserved	26

PART II

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer
	Purchases of Equity Securities	27

Item 6.	Selected Financial Data	29

Item 7.	Management's Discussion and Analysis of Financial Condition and Results
	of Operations	29

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	32

Item 8.	Financial Statements and Supplementary Data	32

Item 9.	Changes in and Disagreements with Accountants on Accounting and
	Financial Disclosure	32

Item 9A(T).	Controls and Procedures	32

Item 9B	Other Information	32

PART III

Item 10.	Directors, Executive Officers and Corporate Governance	27

Item 11.	Executive Compensation	28

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related
	Stockholder Matters	29

Item 13.	Certain Relationships and Related Transactions and Director Independence	30

Item 14.	Principal Accounting Fees and Services	32

PART IV

Item 15.	Exhibits, Financial Statement Schedules.	35

	Signatures	57

PART I

Item 1. Business.

History

Protect Pharmaceutical Corporation was originally incorporated in the State of Idaho on August 5, 1987, under the name of Interstate Mining and Development Properties, Inc., for the purpose of engaging in the acquisition and development of mining prospects. The company staked certain gold placer mining claims, however the claims did not yield a sufficient amount of ore and the company never became profitable. Operational activities were halted in approximately 1989.

The company remained inactive until January 9, 1996 when it was reinstated in the State of Idaho. On August 2, 1996, the company changed its name to Interstate Development, Inc. During that same month H. Deworth Williams and Geoff Williams acquired controlling interest of the company through the purchase of common stock from the company’s two largest shareholders. The company then became engaged in the search for and evaluation of prospective business opportunities and, if justified, potentially to acquire and/or merge with one or more businesses or business opportunities.

On July 3, 2006 at a special meeting of stockholders, the stockholders approved the change of the corporation’s domicile from Idaho to Nevada. Stockholders also approved the acquisition of Nanolution Technologies, Inc., a Delaware corporation focused on developing technologies for medical devices, device coatings, and pharmaceutical dosage forms to repurpose drugs and develop novel, improved drug delivery methods for existing, approved drugs. However, the acquisition was never finalized and was abandoned.

On December 14, 2006, the change of domicile to Nevada was finalized by way of merging with and into Interstate Acquisition, Inc. (incorporated in Nevada on June 15, 2006) for the sole purpose of changing domicile. The Idaho entity was then dissolved. On December 15, 2006, we changed the name of the Nevada entity to Pro-Tect, Inc. and continued to explore possible business opportunities.

In January 2008, we began preliminary discussions with Medvices Corporation concerning the possible acquisition of certain technology and related proprietary, manufacturing, marketing and distribution rights related to the technology. An agreement to acquire the technology was reached in January 2009. The Medvices technology related to certain processes and equipment of a selected algae cultivation used for production of health products and cosmetics. However, no operations were conducted in connection with the technology and the acquisition was abandoned later in 2009.

On February 12, 2010, we entered into a Patent Acquisition Agreement with Nectid, Inc., a privately held Princeton, New Jersey based company, whereby we acquired from Nectid a portfolio of pending patent applications relating to three drug delivery technologies:


	●	a gastro-retentive platform for drugs that otherwise have short time windows for absorption:


	●	an abuse deterrent platform for prescription drugs that are prone to abuse, especially narcotic pain-killers; and


	●	a once-daily platform that allows two or more drugs commonly taken in combination to be delivered via a single dose with fewer side effects.

At the closing of the acquisition, Ramesha Sesha, President of Nectid and the inventor of all the acquired technology, was appointed to our board of directors and as Chief Operating Officer and Chief Scientific Officer.

In exchange for the acquired patent applications, we issued to Nectid 5.0 million shares of our common stock and agreed to issue an additional 2.0 million shares upon realizing financing of $2.0 million. The acquisition agreement provided certain registration rights whereby the company would use its best efforts to file with the SEC a registration statement under the Securities Act of 1933, which would include shares issued to Nectid under the agreement. Any shares included in the registration statement may be subject to certain limitations. As of the date hereof, we have not realized the financing nor issued the additional 2 million shares and, accordingly, we have not filed a registration statement under the 1933 Act.

As further consideration, upon commercialization of the patent applications, the acquisition agreement provided that we would pay Nectid a royalty of 20% of the gross revenues realized from third parties, including license fees and milestone payments, or 20% of the net sales if from direct sales. If we realize milestone payments from our direct from exploitation of the patent applications, we will pay Nectid 10% of those payments. For example, if a project is licensed to another pharmaceutical company, we are obligated to pay Nectid 20% of the licensing and milestone payments and share 20% of the royalty revenue received from our licensing partner. However, if a product is developed and marketed directly by the company, we will be obligated to pay Nectid 20% of net sales (after deducting returns discounts and allowances) and/or 10% of any milestone payments received. In December 2010, we amended the acquisition agreement to provide that in the event the company sold outright any of the patents acquired from Nectid, without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Protect.

On January 31, 2011, we finalized a Patent Purchase Agreement with Grünenthal GmbH, a company organized under the laws of Germany. Pursuant to the terms of that agreement, we sold to Grünenthal all of the company’s rights, title and interest in and to certain inventions described and claimed in certain patents and patent applications, including without limitation, all extensions, continuations, provisionals, derivatives and related applications thereof. The sold patents relate to Opioid Formulations and Methods of treating acute and chronic pain.

In exchange for the patents, Grünenthal paid the Company the cash consideration of $1.6 million. Pursuant to our agreement with Nectid, because the patents were sold outright without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to Protect. Accordingly, we realized 40%, or $640,000 from the proceeds of the sale and the balance was paid to Nectid. Protect retains all other inventions, patents and technologies initially acquired from Nectid.

Current Business

As a result of the acquisition of patents, we are proceeding with a comprehensive program to develop and commercialize the acquired drugs and related technologies. In March 2010 we relocated our principal offices to West Caldwell, New Jersey and in December 2010, relocated our offices to Princeton, New Jersey

On March 25, 2010, in order to reflect our current business our board of directors unanimously agreed to change the corporate name to Protect Pharmaceutical Corporation. The name change was approved by the written consent a majority of the outstanding share holders of common stock. A Certificate of Amendment was filed with the State of Nevada on April 26, 2010 to reflect the change.

On January 24, 2012, Mr. Ramesha Sesha tendered his resignation as an officer and director of the Company. He was replaced on February 12, 2012 by Mr. Geoff Williams as the Company’s chief executive officer, president, and treasurer, and as a member of the Company’s board of directors. Also on February 12, 2012 Ms. Nancy Ah Chong was appointed to serve as the Company’s corporate secretary, and as a member of the Company’s board of directors.

Our principal offices are currently located at 2681 Parleys Way, Suite 204, Salt Lake City, UT 84109 and our telephone number is (801) 322-3401.

In June 2010, we filed with the SEC a registration statement on Form 10 under the Securities Exchange Act of 1934. As a result of filing the registration statement, we are obligated to file with the SEC certain interim and periodic reports, including an annual report containing audited financial statements.

Protect is engaged in developing drug delivery technologies and solutions through innovative dosing and/or delivery. Using the portfolio of patents applications acquired from Nectid, Inc., our goal is to develop innovative drug delivery technologies and drugs that will improve the quality of life for people who suffer from pain. In doing so we are focusing on the research, development, and commercialization of drug delivery technologies that minimize the pharmaceutical dose, frequency, and side effects.

While the oral route is the most convenient method of drug administration, we believe there is a need to develop advances in oral drug delivery technologies that can make significant differences in (i) enhancing patient compliance, (ii) drug bioavailability, (iii) preventing abuse of prescription drugs and (iv) reducing dosages. Although there are a number of once daily drugs and a number of combination drugs on the market, we believe that there is not a single once daily combination drug approved for treating pain. Similarly, one of the significant challenges in oral drug delivery is to develop gastric retention platforms for long-term (ranging from 6 to 24 hours) delivery of drugs by oral administration. Additionally, prescription drug abuse is a major social and medical issue and efforts to develop abuse deterrent drug delivery design have met with limited success.

Management believes that the application of drug delivery platform technologies to pain drugs provides a significant business opportunity because fewer new pain drugs are being developed. Also, potential demand for pain drugs will be driven by the increasing demographic segment of elderly population who often consume pain drugs over a long period of time. Medical efforts to treat pain, known as pain management, address a large market. Clinical pain is a worldwide problem with serious health and economic consequences.

Further, although most people take medicines only for the reasons their doctors prescribe them, prescription drug abuse remains a serious problem in the United States and around the world. The major abused drugs include narcotic painkillers, sedatives and tranquilizers, and stimulants. Abuse of prescription drugs to get high has become increasingly prevalent among teens and young adults. Thus, there is a serious need to develop abuse deterrent drugs and abuse deterrent drug delivery systems that can be used to minimize prescription drug abuse.

Glossary of Terms

To better understand the information provided herein, we are including the following description of some of the terms used herein.

Fibromyalgia Syndrome (FMS): A complex, chronic condition that causes widespread pain and severe fatigue. FMS is a syndrome because it is a set of signs and symptoms that occur together, affecting muscles and their attachments to bones.

GABA Analog Therapy: y-Aminobutyric acid (GABA) is the chief inhibitory neurotransmitter in the mammalian central nervous system. It plays a role in regulating neuronal excitability throughout the nervous system. In humans, GABA is also directly responsible for the regulation of muscle tone. GABA Analogues are modulators and they include gabapentin, pregabalin that binds to a (alpha2delta) subunit of the voltage-dependent calcium channel in the central nervous system. This reduces calcium influx into the nerve terminals thereby reducing the neorpathic and other pain.

Naloxone Methiodide and Methyl Naltrexone: Methylnaltrexone (MNTX, trade name Relistor) and Naloxone Methiodide are opioid antagonists that act to reverse some of the side effects of opioid drugs (for example Tramadol) such as constipation without affecting analgesia or precipitating withdrawals.

Neuropathic Pain: Neuropathic pain results from damage to or dysfunction of the peripheral or central nervous system, rather than stimulation of pain receptors. Although neuropathic pain responds to opioids, treatment is often with adjuvant drugs such as antidepressants, anticonvulsants, baclofen and topical drugs.

Opioid: A chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these organ systems mediate both the beneficial effects and the side effects of opioids.

Postherpetic Neuralgia: Postherpetic neuralgia is a kind of pain involving damage to restricted regions of the peripheral nervous system. PHN is, therefore, a type of neuropathic pain that has a regional topographic restriction. Current clinical practitioners use, among others, Pregabalin, Gabapentin, anti-depressants such as Cymbalta/Nucynta, traditional painkillers like tramadol and Oxycontin, and localized patches like lidocaine and capsaicin.

Pregabalin/Gabapentin: Analogues of γ-Aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the mammalian central nervous system.

Tapentadol/Tramadol: Tapentadol and Tramadol are synthetic opioid drugs, similar to morphine and Oxycodone that occur naturally, which modulate mu-opioid and other pain receptors to reduce pain.

Technologies

The acquired patent applications enabled three key drug delivery platform technologies: Once daily (“Pro24™”), gastro-retentive (“ProRet™”) and abuse-deterrent (“ProProof™”) platform technologies. Following the sale of two patents to Grunenthal, the Company no longer owns the intellectual properties and technologies related to Once daily (“Pro24™”) platform technology. Our remaining technologies are intended to deploy these three proprietary drug delivery technologies to enable a number of new-generation drugs with enhanced clinical benefits in multiple therapeutic areas. Our primary focus is to develop novel and clinically efficient drugs for chronic and acute pain.

ProRet™: ProRet™ is a unique gastro-retentive delivery platform that we believe can formulate drugs with a narrow absorption window. We also believe that the ProRet™ gastro-retentive systems has the potential to remain in the gastric region for several hours, thus significantly prolonging the absorption window for a number of key drugs. ProRet™ system includes both prolonged resident osmotic cup and pouch based delivery of drugs over 24 hours. We believe ProRet™’s prolonged gastric formulation enabled by one of the acquired patents has the potential to improve bioavailability and solubility for drugs that are less soluble in a high pH environment. Its anticipated applications include those that require local drug delivery to the stomach and proximal small intestines. We have not conducted clinical studies or formulated the ProRet™ platform. Our expectations are premised on the patent application for the technology supported by 12 examples and accompanying dissolution studies involving seven different drugs that all are hard to formulate as gastro-retentive dosage forms.

ProProof™: We believe the ProProof™ abuse-deterrent platform, enabled by one of our acquired patents, could potentially reduce the abuse of drugs that are prone for abuse. The technology uses twin methods of efficacy enhancement and abuse neutralization to achieve its objectives. We believe ProProof™ has the potential to reduce specific forms of prescription opioid abuse and can be applied to a number of prescription drugs that are prone for abuse. We have not formulated any ProProof™ abuse deterrent drugs nor have we conducted any studies using such products. Our acquired patent application provides 13 examples of a number of abuse prone products such as morphine, oxycodone, tapentadol, hydromorphone, hydrocodone, tramadol and tapentadol. The patent application also provides some clinical data and experimental data on marketed and inventive products that we believe supports the possibility of the platform’s ability to lower the abuse of such drugs.

According to the current understanding of pain treatment methods, opioid painkillers produce their pain relieving effect by activating an inhibitory pathway in the nervous system. Inhibitory pathways inhibit the transmission of pain signals into the brain. There are reports that opioids also stimulate an excitatory pathway in the nervous system. The excitatory pathway partially counteracts pain inhibition and is believed to be a major cause of adverse side effects associated with opioid use, including the development of tolerance and addiction. At the normal clinical doses, the activation of the excitatory pathway was previously undetected probably due to masking by the inhibitory pathway. We believe that the selective blockade of the excitatory pathway promotes the pain relieving potency of opioid by blocking the excitatory pain-enhancing effect.

We believe that the excitatory pathway plays an important role in modulating the adverse side effects of opioid use and low doses and that opioid antagonists can enhance the clinical efficacy of the opioids. In the product designs enabled by the acquired patent applications, this efficacy enhancement is combined with the abuse deterrence using

either the same or a different antagonist, either singly or in combination with a gelling agent or an irritating agent. The design uses activity modifiers, physical barriers to tampering, agonist-antagonist formulations and aversion agents. It is our belief that ProProof™ has the potential to reduce specific forms of prescription opioid abuse.

We believe our platform technologies enable drugs that offer enhanced pain relief either at lower dosages and or reduced tolerance/physical dependence or addiction potential as compared to many of today’s commonly prescribed opioid painkillers. If approved by the FDA, we believe our drugs could replace many commonly used opioid painkillers, diabetic neuropathic pain and fibromyalgia treatments. We also believe our drugs could be used in chronic pain cases where physicians have been reluctant to prescribe opioid painkillers due to concerns about adverse side effects or addiction.

Business Development Strategies

Our business strategy is focused on the development and commercialization of differentiated products based on our proprietary oral drug delivery technologies acquired from Nectid. We plan to combine known molecules with innovative proprietary technologies to enhance the therapeutic potential of existing medications that could possibly provide a revenue stream through licensing and royalty. Project selection is based on a clear, unmet and under-served market, large business potential and strong intellectual property protection with innovation.

After the Patent Sale Agreement with Grunenthal, we no longer own the rights to PRTT-100 as envisaged. In the near term, we intend to proceed with a comprehensive program to develop and commercialize PRTT-200 that is used for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. We also have future plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations (PRTT-300) for moderate to severe pain.

We intend to optimize the use and value of our drug delivery technologies in three ways. First, we are seeking to assemble a number of pharmaceutical products that can be highly differentiated from existing versions of the compounds upon which they are based. These unique drugs may be promoted together within a specialty pharmaceutical field, such as pain and ER specialists.

Second, we plan to out-license product candidates after we have increased their value through our formulation and clinical development efforts. Third, we plan to enter into collaborative partnerships whereby the unique capabilities of our technology can provide value to a partner's product, particularly for non-analgesic drug markets.

Our goal is to become a drug discovery company focusing on inventing and developing better drugs, initially for pain and pain related disorders like depression later for therapeutic areas, where better medication and compliance can improve the clinical benefits and quality of life. We intend to achieve this goal by:

Building Proprietary Drug Discovery and Delivery Platforms: We intend to strengthen the two drug delivery technologies; ProRet™ and ProProof™ that can be used to develop novel and efficient drugs. While we believe these platform technologies can be use to develop a new-generation of drugs with improved clinical benefits in multiple therapeutic areas, we are focusing initial resources to develop only pain drugs, more specifically PRTT-200 and PRTT-300, once daily drugs to treat moderate to severe pain, diabetic neuropathic pain and fibromyalgia. If approved by the Food and Drug Administration (“FDA”), we believe our proprietary drugs could replace certain existing pain drugs commonly used to treat moderate to severe pain, diabetic neuropathic pain and fibromyalgia.

We intend to acquire additional intellectual properties that enable us to undertake drug discovery and new chemical entity development for pain and pain related disorders.

Building a Drug Franchise in Pain Medications: We intend to develop drugs that we believe may have broad use for patients with moderate to severe pain, diabetic neuropathic pain and to treat fibromyalgia. We believe this approach may help alleviate physicians’ current tendency to under-prescribe opioid painkillers and prescribe off-label drugs for diabetic neuropathic pain and fibromyalgia

Focusing on Clinical Development and Late Stage Products: We believe that our clinical development focus will enable us to generate product revenues earlier than if we were discovering and developing new chemical entities. We also believe this focus enables us to explore a wider range of product candidates

Retaining Significant Rights: We currently retain worldwide commercialization rights to all of our technology and pain management product candidates in all markets and indications. In general, we intend to independently develop product candidates through late-stage clinical trials. As a result, we expect to capture a greater percentage of the profits from drug sales than we would if we out-licensed our drugs earlier in the development process. In market segments that require large or specialized sales forces, such as the market for opioids or diabetic neuropathic pain products, we may seek sales and marketing alliances with third parties. We believe that such alliances will enable us to deploy our resources effectively and commercialize our drugs rapidly and cost-effectively.

Using Our Technology to Develop Multiple Drugs for Both Pain and Non-Pain Indications: We are initially focusing our efforts on developing pain drugs. However, we believe our technology can be broadly applied to additional therapeutic areas enabling us to target wider and deeper business opportunities.

Outsourcing Key Functions: We intend to outsource preclinical studies, clinical trials, formulation and manufacturing. We believe outsourcing will produce significant time savings and allow for more efficient deployment of our resources. However, these development activities all require substantial expenditures and currently we do not have revenues or capital to fund these activities. We have commenced preliminary discussions with prospective investors to capitalize the company, fund the development of potential products and to license one or more products. Our ability to fund development activities depends on achieving success in either licensing or finding an industry partner, of which there can be no assurance.

Products in Development

We intend to use our proprietary technologies, ProRet™, and ProProof™ to develop novel drugs. It is our plan to develop a number of products to the proof of concept stage and then see a partner.

PRTT-200: PRTT-200 is a gastro-retentive once daily calcium channel inhibitor that we believe has the potential to treat diabetic neuropathic pain and fibromyalgia. It uses Protect’s proprietary gastro-retentive platform ProRet™ to overcome absorption window challenges. We have not conducted any clinical studies or formulated the PRTT-200.

We have not incurred any developmental costs in connection with PRTT-200 except for those associated with the patent acquisition agreement. We have not identified an external development partner that will be necessary to first formulate the product and then conduct dose ranging studies with between 40 to 50 patients. This will be followed by pivotal studies using several hundred patients to gather data sufficient for FDA submission. We estimate the costs to includes approximately $2.0 million for formulation, $2.0 million for dose ranging studies and several million dollars for pivotal studies. We expect that we will know the details of patients size and type of patients after completing formulation and dose ranging studies and then meet with the FDA officials to provide an indicative cost for pivotal studies.

If we are successful in securing adequate funding for product development, we estimate that it will take 12 to 18 months for product formulation, an additional 6 to 12 months for dosage finding studies, followed by additional 24 to 36 months of pivotal studies and 12 months of FDA review period. If product development is successful, we estimate that we could realize a revenue stream from PRTT-200 after a minimum of 50 to 60 months.

PRTT-200 is a gastro-retentive drug delivery of GABA analog and unless we are able to demonstrate that it provides better clinical benefit than the currently marketed GABA analog, product development will fail. Product development could also fail if the designed product is not retained in the stomach long enough. If the event the FDA and/or other regulators require a higher clinical efficacy bar to approve the product, our cost and time estimates may escalate significantly. Further, similar and competitive products may enter the marketplace that would limit the potential market opportunities for PRTT-200. We believe there are two competitive products currently under

development. Depomed and Pfizer are developing similar products and their approval may limit the opportunities for PRTT-200.

PRTT-300: We believe that PRTT-300 could potentially be an abuse deterrent, once daily opioid combination with antagonist that could provide clinical benefits over existing opioid formulations. PRTT-300 uses Protect’s proprietary abuse deterrent platform ProProof™ design. We believe that PRTT-300 has the possibility of enhancing analgesic property by minimizing the side effects of nausea, vomiting, dizziness and head ache. We have not conducted any clinical studies or formulated the PRTT-300.

We have not incurred any developmental costs in connection with PRTT-300 except for those associated with the patent acquisition agreement. We have not identified an external development partner that will be necessary to first formulate the product and then conduct dose ranging studies with between 40 to 50 patients. This will be followed by pivotal studies using several hundred patients to gather data sufficient for FDA submission. We expect that we will have to demonstrate that the product is indeed abuse deterrent, which will require several comparative studies with normal non-abuse deterrent products currently marketed. We estimate costs to includes approximately $3.0 million for formulation, $3.0 million for dose ranging studies and several million dollars for pivotal studies. We expect that we will know details of patients size and type of patients after completing formulation and dose ranging studies and then meet with the FDA officials to provide an indicative cost for pivotal studies, which we estimate will be $10 to $15 million.

If we are successful in securing adequate funding for product development, we estimate that it will take 12 to 24 months for product formulation, an additional 12 to 24 months for dosage finding studies, followed by additional 24 to 36 months of pivotal studies and 12 months of FDA review period. If product development is successful, we estimate that we could realize a revenue stream from PRTT-300 after a minimum of 50 to 60 months. If product development is successful, we estimate that we could realize a revenue stream from PRTT-300 after a minimum of 60 to 72 months.

Unless we can demonstrate PRTT-300 is clinically non-inferior to the currently marketed products, product development will fail. Also, we must demonstrate PRTT-300 is abuse deterrent enough for regulators to approve it. PRTT-300 is an abuse deterrent delivery of an opioid and we will need to demonstrate that it provides clinical benefit that is not inferior to that from currently marketed drugs. The product may fail to meet this requirement if not delivered enough or long enough to show non-inferiority. In the event FDA and other regulators require a higher clinical efficacy bar to approve the product, our cost and time estimates may escalate significantly. We are aware that there is at least one similar approved product in the marketplace, EMBEDA® from King Pharmaceuticals, Inc. Further , similar and competitive products may enter the marketplace that would limit the potential market opportunities for PRTT-300. We believe there are several competitive products in under development including Remoxy® and Acurox from King Pharmaceuticals/ Pain Therapeutics and King/Acura Pharmaceuticals respectively, and other unknown products from Labopharm, Grünenthal, Theraquest whose product approval may also limit the our opportunities.

Other Product Candidates

We believe our acquired patent applications and technologies will enable us to preliminarily explore the possible development of other analgesic drugs that are being contemplated. It is our further belief that the following products represent reasonable potential opportunities for development. However, we are still in the early planning stage for each product and intend to proceed with development when our capital resources permit.

PRTT-400: PRTT-400 is a once daily abuse deterrent opioid formulation with a second analgesic. If successful, it would be the first once daily and first abuse deterrent combination of two or more drugs. Though there are number of once daily opioids and combinations, we are not aware of a single approved once daily combination of two analgesic drugs.

There is no assurance that we will successfully complete development of any of the above projects in the near future or than any project will result in a commercially viable product. We do not plan to conduct significant clinical activities on these projects until such time as we have additional funding to advance the projects.

Research and Development

We have not made any expenditure on research and development activities prior to acquiring the patent applications from Nectid. Because we have no research facilities and limited qualified personnel, we intend to rely on collaborative agreements with other companies to conduct our research and development activities. We intend to rely on contractual partners to formulate, test, supply, store and distribute drug supplies for our clinical trials. Presently, we have not entered into any such agreements and there is no assurance that we can secure a favorable partnership arrangement in the future.

Our near term goal is to proceed with a comprehensive program to develop and commercialize PRTT-200, with once-daily drug for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Subsequently and as capital and resources permit, we intend to develop and commercialize once-daily opioid combinations (PRTT-300) and abuse-deterrent opioid combinations for moderate to severe pain. In order to conduct our research and development activities we will have to raise capital, most likely through a private placement of our securities. We estimate that research and development expenses will be approximately $2.5 million during the next 12 months. We are currently exploring possible funding sources, but we have no assurance that we will be able to raise the necessary funds on terms favorable to the company, or at all.

Manufacturing

Presently we have no manufacturing or research and development facilities. We plan to enter into agreements and rely upon qualified third parties for the formulation and manufacture of our drugs. These supplies and the manufacturing facilities must comply with U.S. Drug Enforcement Agency (“DEA”) regulations and current good manufacturing practices enforced by the FDA and other government agencies. Drug manufacturers are subject to ongoing periodic, unannounced inspection by the FDA, the DEA and corresponding state and foreign government agencies to ensure strict compliance with good manufacturing practices and other government regulations. We plan to continue to outsource all formulation and manufacturing and related activities.

Marketing

Currently we are not engaged in the research and development of any products. We intend to rely on contractual partners to develop our potential products. When we have finalized a commercially viable product, we intend to formulate a comprehensive marketing plan.

Employees

We currently have three employees - our Chief Operating Officer, our Chief Financial Officer, and our Secretary/Treasurer. We are presently considering the possibility of additional employees, but will add employees only as our business demands warrant and we have the necessary available funds. We also plan to engage consultants from time to time to perform services on a per diem or hourly basis.

We entered into employment agreements with William D. Abajian, our former President and Chief Executive Officer, and Ramesha Sesha, our current Chief Operating Officer. Mr. Abajian resigned in December 2010. Mr. Sesha resigned in January, 2012.

Pursuant to Mr. Abajian’s agreement, we issued 5.0 million shares of our common stock in consideration for services in connection with the acquisition of our patents and related technology and other services performed. His agreement was terminated with his resignation in December 2010

Intellectual Properties

We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent applications with respect to our technology and products and their uses. The acquired patent applications, if successfully granted, will not expire earlier than September 2028. We currently hold 4 patent applications that are summarized below.


	●	Abuse Proof Delivery Systems, dated June 1, 2009
	·	Novel GABA Analog Dosage Form, dated March 17, 2011


	·	Tapentadol Compositions, Dated May 24, 2010
	·	Novel Slow Release Tapentadol Compositions dated June 1, 2010

We plan to prosecute and defend our patent applications, issued patents and proprietary information. Our competitive position and potential future revenues will depend in large part upon our ability to protect our intellectual property from challenges and to enforce our patent rights against potential infringers. We will continue to file new patent applications based on additional developments. If

competitors are able to successfully challenge the validity of our patent rights, claims, based on the existence of prior art, tests, experiments or otherwise, they would be able to market products that contain features and clinical benefits similar to those of our products, and demand for our products could decline as a result.

There can be no assurance that any current or future patent application will result in patents being issued, or that existing patent pending applications, or any new patents applications, if issued, will afford meaningful protection from competitors. Also, there can be no assurance that we will have the financial resources necessary to enforce any patent rights we may hold. We are not aware of any claim that our patent pending application may infringe, or will infringe any existing patent. However, in the event such a claim is made and we are unsuccessful against such claim, we may be required to obtain licenses to such other patents or proprietary technology in order to develop or market our services. There can be no assurance that we will be able to obtain such licenses on commercially reasonable terms or that the patents underlying the licenses will be valid and enforceable.

If we are unable to secure patent protection for our technology and products, current competitors and/or other businesses could duplicate the same technology, products and services in direct competition with us. Presently, we anticipate filing additional patent applications if new and/or improved product services are developed. We do not hold any registered trademarks.

Government Regulation

Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in our ongoing research and development activities.

All of our products will require regulatory approval by governmental agencies prior to commercialization. In particular, human therapeutic products are subject to rigorous preclinical testing and clinical trials and other pre-marketing approval requirements by the FDA and regulatory authorities in other countries. In the United States, various federal and in some cases state statutes and regulations, also govern or impact upon the manufacturing, safety, labeling, storage, record keeping and marketing of our products. The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require us to spend substantial resources. Regulatory approval, when and if obtained, may be limited in scope which may significantly limit the indicated uses for which our products may be marketed. Further, approved drugs, as well as their manufacturers, are subject to ongoing review and discovery of previously unknown problems with such products which may result in restrictions on their manufacture, sale or use or in their withdrawal from the market.

Applicable FDA regulations treat our combination of opioid painkillers, once daily gastro-retentive drugs and once daily combination drugs as new drugs and require the filing of a New Drug Application, or NDA, and approval by

the FDA prior to commercialization in the United States. Our clinical trials will seek to demonstrate that our formulations and designs produce greater beneficial effects than either drug alone or against an existing drug.

The Drug Approval Process

We will be required to complete several activities before we can market any of our drugs for human use in the United States, including:


	●	preclinical studies;

● submission to the FDA of an Investigational New Drug Application (“IND”), that is a request for authorization from the FDA to administer an investigational drug or biological product to humans, which must become effective before human clinical trials commence;

● adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate;


	●	submission to the FDA of an NDA; and

● FDA approval of the NDA prior to any commercial sale or shipment of the drug.

Preclinical tests include laboratory evaluation of product chemistry and formulation, as well as animal studies to assess the potential safety of the product. Preclinical safety tests must be conducted by laboratories that comply with FDA regulations regarding Good Laboratory Practice, or GLP regulations. We plan to conduct and submit the results of preclinical tests to the FDA as part of our INDs prior to commencing clinical trials. We may be required to conduct extensive toxicology studies concurrently with the clinical trials.

Based on preclinical testing, an IND is filed with the FDA to begin human testing of the drug. The IND becomes effective if not rejected by the FDA within 30 days. The IND must indicate the results of previous experiments, how, where and by whom the new studies will be conducted, the chemical structure of the compound, the method by which it is believed to work in the human body, any toxic effects of the compound found in the animal studies and how the compound is manufactured. All clinical trials must be conducted in accordance with good clinical practice, or GCP, regulations. In addition, an Institutional Review Board, or IRB, generally comprised of physicians at the hospital or clinic where the proposed studies will be conducted, must review and approve the IND. The IRB also continues to monitor the study. We must submit progress reports detailing the results of the clinical trials to the FDA at least annually. In addition, the FDA may, at any time during the 30-day period or at any time thereafter, impose a clinical hold on proposed or ongoing clinical trials. If the FDA imposes a clinical hold, clinical trials cannot commence or recommence without FDA authorization and then only under terms authorized by the FDA. In some instances, the IND application process can result in substantial delay and expense.

Clinical trials are typically conducted in three sequential phases that may overlap. Phase I tests typically take approximately one year to complete. The tests study a drug’s safety profile, and may include the safe dosage range. Phase I clinical studies also determine how a drug is absorbed, distributed, metabolized and excreted by the body, and the duration of its action. In addition, we may, to the extent feasible, assess pain relief in our Phase I trials. In Phase II clinical trials, controlled studies are conducted on volunteer patients with the targeted disease or condition. The primary purpose of these tests is to evaluate the effectiveness of the drug on the volunteer patients as well as to determine if there are any side effects. These studies may be conducted concurrently with Phase I clinical trials. In addition, Phase I/II clinical trials may be conducted to evaluate not only the efficacy of the drug on the patient population, but also its safety. During Phase III clinical trials, the drug is studied in an expanded patient population and in multiple sites. Physicians monitor the patients to determine efficacy and to observe and report any reactions that may result from long-term or expanded use of the drug.

The FDA publishes industry guidelines specifically for the clinical evaluation of painkillers. We rely in part on these guidelines to design a clinical strategy for the approval of each of our product candidates. In particular, FDA guidelines recommend that we demonstrate efficacy of our new pain drugs in more than one clinical model of pain.

Acceptable clinical models of pain include different neuropathic pains, fibromyalgia, post-operative pain, and various types of trauma and arthritis pain. Since models differ in their pain intensity and their sensitivity to detect pain, we expect to complete several Phase II studies in multiple clinical models of pain. Upon a clear demonstration of the safety and efficacy of painkillers in multiple clinical models of pain, the FDA has historically approved painkillers with broad indications. Such general purpose labeling often takes the form of “for the management of moderate to severe pain.”

We plan to outsource the formulation and clinical development of all of our products. We may not successfully complete Phase I, Phase II or Phase III testing within any specified time period, or at all, with respect to any of our product candidates. Furthermore, we or the FDA may suspend clinical trials at any time in response to concerns that participants are exposed to an unacceptable health risk

After the completion of clinical trials, if there is substantial evidence that the drug is safe and effective, an NDA is filed with the FDA. The NDA must contain all of the information on the drug gathered to that date, including data from the clinical trials. NDAs are often over 100,000 pages in length.

The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting a NDA for filing. In such an event, the NDA must be resubmitted with the additional information and, again, is subject to review before filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the Federal Food, Drug and Cosmetic Act, the FDA has 365 days in which to review the NDA and respond to the applicant. The review process is often significantly extended by FDA requests for additional information or clarification regarding information already provided in the submission. The FDA may refer the application to an appropriate advisory committee, typically a panel of clinicians, for review, evaluation and a recommendation as to whether the application should be approved.

The FDA is not bound by the recommendation of an advisory committee. If FDA evaluations of the NDA and the manufacturing facilities are favorable, the FDA may issue either an approval letter, or an approvable letter which usually contains a number of conditions that must be met in order to secure final approval of the NDA. When and if those conditions have been met to the FDA’s satisfaction, the FDA will issue an approval letter, authorizing commercial marketing of the drug for certain indications. If the FDA’s evaluation of the NDA submission or manufacturing facilities is not favorable, the FDA may refuse to approve the NDA or issue a not approvable letter.

If the FDA approves the NDA, the drug becomes available for physicians to prescribe. Periodic reports must be submitted to the FDA, including descriptions of any adverse reactions reported. The FDA may request additional post marketing studies, or Phase IV studies, to evaluate long-term effects of the approved drug.

Other Regulatory Requirements

The FDA mandates that drugs be manufactured in conformity with current GMPs. If the FDA approves any of our product candidates, we will be subject to requirements for labeling, advertising, record keeping and adverse experience reporting. Failure to comply with these requirements could result, among other things, in suspension of regulatory approval, recalls, injunctions or civil or criminal sanctions. We may also be subject to regulations under other federal, state, and local laws, including the Occupational Safety and Health Act, the Environmental Protection Act, the Clean Air Act, national restrictions on technology transfer, and import, export, and customs regulations. In addition, any of our products that contain narcotics will be subject to DEA regulations relating to manufacturing, storage, distribution and physician prescribing procedures. It is possible that any portion of the regulatory framework under which we operate may change and that such change could have a negative impact on our current and anticipated operations.

The Controlled Substances Act imposes various registrations, record-keeping and reporting requirements, procurement and manufacturing quotas, labeling and packaging requirements, security controls and a restriction on prescription refills on certain pharmaceutical products. A principal factor in determining the particular requirements, if any, applicable to a product is, its actual or potential abuse profile. The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk of substance

abuse and Schedule V substances the lowest risk. Any of our product candidates that contain a scheduled substance will be subject to regulation by the DEA.

Competition

Our future success will depend, in part, upon our ability to develop products and achieve market share at the expense of existing and established and future products in the relevant target markets. Existing and future products, therapies, technological approaches or delivery systems will compete directly with our products. Competing products may provide greater therapeutic benefits for a specific indication, or may offer comparable performance at a lower cost. Companies that currently sell generic or proprietary pain drugs and novel formulations include, but are not limited to, Pfizer, Depomed, Pain Therapeutics, Roxane Laboratories, Purdue Pharma, Grünenthal, Janssen Pharmaceutica, Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. Alternative technologies are being developed to increase opioid potency, as well as alternatives to GABA Analog therapy for pain management, several of which are in clinical trials or are awaiting approval from the FDA.

We compete with fully integrated pharmaceutical companies, smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors have pain products, such as opioids and GABA analogs and SNRIs already approved by the FDA or in development and operate larger research and development programs in these fields than we do. In addition, many of these competitors, either alone or together with their collaborative partners, have substantially greater financial resources than we do, as well as significantly greater experience in:


	●	developing drugs;


	●	undertaking preclinical testing and human clinical trials;


	●	obtaining FDA and other regulatory approvals of drugs;


	●	formulating and manufacturing drugs; and


	●	launching, marketing, distributing and selling drugs.

Developments by competitors may render our product candidates or technologies obsolete or non-competitive. Alternatively, competitors may challenge our patents and prevail in a court of law rendering our products, even if they are successfully developed, tested and approved, unmarketable.

Facilities

Our principal offices are located at 2681 Parleys Way, Suite 204, Salt Lake City, UT 84109. Because we anticipate that our products will be developed by contract manufacturers, we will not initially require production or research space. Management believes that the current facilities are adequate for the immediate future.

Industry Segments

No information is presented regarding industry segments. We are presently engaged in the development of certain patents and technology related to drug delivery technologies and drugs. We have no current plans to participate in another business or industry. Reference is made to the statements of income in our financial statements included herein for a report of our operating history for the past two fiscal years.

Item 1A. Risk Factors.

You should carefully consider the risks and uncertainties described below and other information in this report. If any of the following risks or uncertainties actually occur, our business, financial condition and operating results, would likely suffer. Additional risks and uncertainties, including those that are not yet identified or that we currently believe are immaterial, may also adversely affect our business, financial condition or operating results.

Risk Factors Related to Our Business

Our auditors have expressed a going concern opinion.

Our independent auditors include a statement in their report to our financial statements that certain matters regarding the company raise substantial doubt as to our ability to continue as a going concern. Note 3 to the financial statements states that we do not have significant cash or other material assets, nor do we have an established source of revenues sufficient to cover operating costs and allow us to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We have a limited operating history and have not recorded revenues or profits since inception. Continuing losses may exhaust capital resources and force us to discontinue operations.

Although the company was formed in 1987, we have had only limited operations and no significant revenues since inception. We are considered a development stage company, which are considered inherently more risky than established companies. Because we have no earnings history and there is no assurance that we will realize future revenues, there is doubt as whether we will ever achieve profitability. If we are unsuccessful in the development and commercialization of differentiated products based on our proprietary oral drug delivery technologies, the substantial negative effect on our business would be substantial and our future would be questionable.

The success of future operations depends on our ability to develop our patent applications and technology and generate revenues from the commercialization of products developed there from, which may be subject to many factors.

Our operations to date have been limited to acquiring the patent applications and organizing and staffing our company. Although we did sell a portion of our patent applications for cash, we have not yet demonstrated the ability to formulate and manufacture commercially viable products, obtain regulatory approval or organize sales and marketing activities. There can be no assurance that we will be able to develop commercially viable products from our patents and technology, or that we will realize material revenues or achieve profitability in the foreseeable future. The potential to generate revenues and profits from our business depends on many factors, including, but not limited to the following:

●

our ability to secure adequate funding to complete development of our patents and technology into commercially viable products and to mark///et those products;


	●	our ability to obtain regulatory approval of our products;


	●	the cost and expenses associated with developing products and gaining regulatory approvals;

●

the size and timing of future customer orders, product delivery and customer acceptance, if required;

●

the costs of maintaining and expanding operations;

●

our ability to compete with existing and new entities that offer the same or similar products and services; and

●

our ability to attract and retain a qualified work force as business warrants.

There can be no assurance that we will be able to achieve any of the foregoing factors or realize profitability in the immediate future, or at any time.

If outside collaborators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, our regulatory submissions and product introductions will be materially and negatively affected.

We will depend on independent investigators and collaborators, such as universities and medical institutions, to conduct our clinical trials under agreements with us. Presently, we do not have any definitive agreements for the performance of these duties. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, the approval of our regulatory submissions and our introductions of new drugs will be delayed.

Our collaborators may also have relationships with other commercial entities, some of which may compete with us. If outside collaborators assist our competitors to our detriment, the approval of our regulatory submissions will be delayed and future sales from our products will be less than expected.

If we are unable to design, conduct and complete clinical trials successfully, we will not be able to submit a new drug application to the FDA.

In order to obtain FDA approval of any of our product candidates, we must submit to the FDA a New Drug Application that demonstrates the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials.

We have acquired patent applications that potentially enable several drug candidates. We are currently seeking capital to complete technology optimization for clinical development. If we are successful in securing the requisite funding to develop the products, we believe that we can complete technology development, production of clinical supplies and patient enrollment for PRTT-100, PRTT-200 and PRTT-300 during the current fiscal year and early next year. If clinical data from the studies does not support our hypothesis, we may also elect to discontinue further development of drug candidates that use our technology.

Product development and clinical trials are very expensive. They are difficult to design and implement, in part because they are subject to rigorous requirements. The clinical trial process is also time consuming. Furthermore, if we or the FDA believe that production process may not be safe, or the participating patients are being exposed to unacceptable health risks, we will have to suspend development and or clinical trials. Failure can occur at any stage of the development and clinical trials, and we could encounter problems that cause us to abandon development and clinical trials or to repeat formulations and or clinical studies.

Success in early trials may not predict success of future trials.

Success in formulation, manufacturing and pre-clinical testing and early clinical trials does not ensure that products will be successful. Results of later clinical trials may not replicate the results of prior clinical trials and pre-clinical testing.

Even if formulation, manufacturing and clinical trials are completed as planned, their results may not support our product claims. The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Such failure would cause us to abandon a product candidate and could delay development of other product candidates.

Developments by competitors may establish standards of care that affect our ability to conduct our clinical trials as planned.

Changes in standards related to clinical trial design could affect our ability to design and conduct clinical trials as planned. For example, regulatory authorities may not allow us to compare our drug to a placebo in a particular clinical indication where approved products are available. In that case, both the cost and the amount of time required to conduct a trial could increase and have a negative affect on our financial condition

If we fail to obtain necessary regulatory approvals, we will not be allowed to commercialize our drugs and we will not generate revenues.

Satisfaction of all regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product candidate, and requires the expenditure of substantial resources for research and development and testing. Our research and clinical approaches may not lead to drugs that the FDA considers safe for humans and effective for indicated uses. The FDA may require us to conduct additional clinical testing, in which case we would have to expend additional time and resources. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:

●

delay commercialization of, and product revenues from, our product candidates;

●

impose costly procedures on us; and


	●	diminish the competitive advantages that we would otherwise enjoy.

Even if we comply with all FDA requests, the FDA may ultimately deny one or more of our NDAs, and we may never obtain regulatory approval for any of our product candidates. If we fail to achieve regulatory approval of any of our leading product candidates we will have fewer saleable products and corresponding product revenues. Even if we receive regulatory approval of our products, such approval may involve limitations on the indicated uses or marketing claims we may make for our products. Further, later discovery of previously unknown problems could result in additional regulatory restrictions, including withdrawal of products. The FDA may also require us to commit to perform post-approval studies, for which we would have to expend additional resources, which could have an adverse effect on our operating results and financial condition.

In foreign jurisdictions, we must receive marketing authorizations from the appropriate regulatory authorities before we can commercialize our drugs. Foreign regulatory approval processes generally include all of the aforementioned requirements and risks associated with FDA approval.

We risk losing the rights to commercialize the acquired patent applications if milestones are not attained in a timely manner.

The patent acquisition agreement with Nectid requires Protect to meet certain developmental milestones in a timely manner. Under the terms of the agreement, we are required to (i) file an IND application for at least one product within two years of closing of the agreement, (ii) initiate clinical studies for at least one product within three years of closing, and (iii) commercialize at least one product within five years of closing. If we fail to meet these developmental milestones, we could lose the rights to commercialize the acquired patent applications. This failure would have a negative material impact on our business, including the loss of all investments made in the patent applications and projects, the loss of any possible future revenues, and the ability to continue as a viable, ongoing entity unless we have been able to develop alternative products or technologies.

Government agencies may establish and promulgate guidelines that directly apply to us and our products that may affect the use of our drugs.

Government agencies, professional societies, and other groups may establish guidelines that apply to our drugs. These guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could mitigate the use of our drugs.

If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.

Even if we are successful in successfully formulating, manufacturing and testing our drugs and if FDA approves the drugs, physicians and patients may not accept and use them. Acceptance and use of our drugs will depend on a number of factors including:

● perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our drugs;

● cost-effectiveness of our drugs relative to competing products;

● availability of reimbursement for our products from government or healthcare payers; and

● effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.

We expect to rely on sales generated by our current lead product candidates for substantially all of our product revenues for the foreseeable future. However, we have not performed a feasibility study related to the potential market of our proprietary oral drug delivery technologies, nor have we commissioned anyone else to do so. Because there has not been a market analysis made, we have no evidence to support the potential demand for our future products. Failure of our products and services to achieve and maintain meaningful levels of market acceptance would materially and adversely affect our business, financial condition and results of operations and market penetration.

We plan to rely on third party commercial drug manufacturers that could fail to devote sufficient time and resources to our concerns resulting in delayed product introductions and higher costs than expected.

The company has no prior experience or track record in developing or manufacturing drugs. We lack the resources and expertise to formulate, manufacture or test the technical performance of our product candidates. We intend to rely on a very limited number of company personnel and a small number of contract manufacturers and other vendors to formulate, test, supply, store and distribute drug supplies for our clinical trials. If these manufacturers fail to devote sufficient time and resource to our product candidates, or if their performance is substandard, our clinical trials and product introduction would be adversely affected. Drug manufacturers are subject to ongoing periodic, unannounced inspection by the FDA, the DEA and corresponding state and foreign government agencies to ensure strict compliance with good manufacturing practice, other government regulations and corresponding foreign standards. We have no control over third-party manufacturers’ compliance with these regulations and standards.

The use of alternate manufacturers may be difficult because of the limited number of potential manufacturers that have the necessary governmental licenses to produce narcotic products.

The FDA must approve any alternative manufacturer of our product before we may use them to produce our supplies and products. It may be difficult or impossible for us to find a replacement manufacturer on acceptable terms quickly, or at all. Our contract manufacturers and vendors may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products. If any third party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to such innovation.

Our collaborative agreements may not succeed or may give rise to disputes over intellectual property.

Our strategy to focus on drug discovery of novel drugs discovered by third parties requires us to enter into collaborative agreements from time to time. Collaborative agreements are generally complex and contain provisions that could give rise to legal disputes. Such disputes can delay the development of potential new drug products, or can lead to lengthy, expensive litigation or arbitration. Collaborative agreements often take longer to conclude and may be more expensive than originally expected. Other factors relating to collaborative agreements may adversely affect the success of our potential products, including:

● the development of parallel products by our collaborators or by a competitor;

● arrangements with collaborative partners that limit or preclude us from developing certain products or technologies;

● premature termination of a collaborative agreement; or

● failure by a collaborative partner to devote sufficient resources to the development of our potential products.

If we are unable to develop our own sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, our product revenues could be adversely affected.

We currently have no sales, marketing or distribution capabilities. In order to commercialize our products, if any are approved by the FDA, we will either have to develop such capabilities internally or collaborate with third parties who can perform these services for us. If we decide to commercialize any of our drugs ourselves, we may not be able to hire the necessary experienced personnel and build sales, marketing and distribution operations which are capable of successfully launching new drugs and generating sufficient product revenues. In addition, establishing such operations will take time and involve significant expense.

If we decide to enter into co-promotion or other licensing arrangements with third parties, we may be unable to locate acceptable collaborators because the significant number of recent business combinations among pharmaceutical companies has resulted in a reduced number of potential future collaborators. Even if we are able to identify one or more acceptable collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all.

In addition, due to the nature of the market for pain management products, it may be necessary for us to license all, or substantially all of our product candidates to a single collaborator, thereby eliminating our opportunity to commercialize other pain management products independently. If we enter into any collaborative arrangements, our product revenues are likely to be lower than if we marketed and sold our products ourselves.

Any revenues we receive will depend upon the collaborators’ efforts, which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, further business combinations or other factors outside of our control. Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable terms, or at all.

If we cannot compete successfully for market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer.

The market for our product candidates is characterized by intense competition and rapid technological advances. If our products receive FDA approval, they will compete with a number of existing and future drugs and therapies developed, manufactured and marketed by others. Existing or future competing products may provide greater

therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost. If our products are unable to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer.

We will compete for market share against fully integrated pharmaceutical companies or other companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors have opioid painkillers already approved or in development. In addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in:

● developing drugs;

● undertaking preclinical testing and human clinical trials;

● obtaining FDA and other regulatory approvals of drugs;

● formulating and manufacturing drugs; and

● launching, marketing, distributing and selling drugs.

Developments by competitors may render our products or technologies obsolete or non-competitive.

Alternative technologies, drugs and products are being developed by other companies to improve or replace the use of opioids and calcium channel inhibitors and for pain management, several of which are in clinical trials or are awaiting approval from the FDA. In addition, companies that sell generic opioid and calcium channel inhibitors, such as gabapentin, represent substantial competition. Most of these organizations competing with us have substantially greater capital resources, larger research and development staffs and facilities, greater experience in drug development and in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and partners for acquisitions, joint ventures or other collaborations.

If we are unable to protect our intellectual property our competitors could develop and market products with similar features that may reduce demand for our products.

Our future success, competitive position and potential revenues will depend in part on our ability to protect our intellectual property. If either we, or our other collaborators fail to file, prosecute or maintain certain patents, our competitors could market products that contain features and clinical benefits similar to those of our products, and demand for our products could decline as a result. Also, it may be possible for unauthorized third parties to copy or reverse engineer aspects of our products, develop similar products independently or otherwise obtain and use information that we regard as proprietary. Policing the unauthorized use of our technology and products will be difficult. Litigation may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets or patents that we may obtain, or to determine the validity and scope of the proprietary rights of others.

We intend to file additional patent applications relating to our technology, products and processes. We may direct Nectid, Inc. or our collaborators to file additional patent applications relating to the licensed technology or we may do so ourselves. However, our competitors may challenge, invalidate or circumvent any of our current or future patents. These patents may also fail to provide us with meaningful competitive advantages.

We may become involved in expensive litigation or other legal proceedings related to our existing intellectual property rights, including patents.

We expect to rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. Others may independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our products or know-how, or require us to license such information and pay significant fees or royalties in order to produce our products.

Our technology could infringe upon claims of patents owned by others. If we were found to be infringing on a patent held by another, we might have to seek a license to use the patented technology. In that case, we might not be able to obtain such a license on terms acceptable to us, or at all. If a legal action were to be brought against us or our licensors, we could incur substantial defense costs and any such action might not be resolved in our favor. If such a dispute were to be resolved against us, we could have to pay the other party large sums of money and our use of our technology and the testing, manufacture, marketing or sale of one or more of our proposed products could be restricted or prohibited.

The DEA limits the availability of the active ingredients in our current product candidates and, as a result, our quota may not be sufficient to complete clinical trials, meet commercial demand or may result in clinical delays.

The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk of substance abuse and Schedule V substances the lowest risk. The active ingredients in some of our current product candidates, including Tramadol, Tapentadol, or Morphine, Oxycodeine are listed by the DEA as Schedule II or III substances under the Controlled Substances Act of 1970. Consequently, their manufacture, shipment, storage, sale and use are subject to a high degree of regulation. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to a pharmacist and may not be refilled without a new prescription. Furthermore, the amount of Schedule II substances we can obtain for clinical trials and commercial distribution is limited by the DEA and our quota may not be sufficient to complete clinical trials or meet commercial demand. There is a risk that DEA regulations may interfere with the supply of the drugs used for our drug formulation and formulated drugs used in our clinical trials, and in the future, our ability to produce and distribute our products in the volume needed to meet commercial demand.

Conducting clinical trials of our product candidates exposes us to expensive product liability claims and we may not be able to obtain or maintain product liability insurance on reasonable terms or at all.

The risk of product liability is inherent in the testing of medical products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or terminate testing of one or more of our products. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our products. We currently do not carry clinical trial insurance or product liability insurance. We may not be able to obtain such insurance at a reasonable cost, if at all. If our agreements with any future corporate collaborators entitle us to indemnification against product liability losses, such indemnification may not be available or adequate should any claim arise.

Our ability to generate product revenues will be diminished if we fail to obtain acceptable prices or an adequate level of reimbursement for our products from healthcare payers.

Our ability to commercialize our drugs, alone or with collaborators, will depend in part on the extent to which reimbursement will be available from:

● government and health administration authorities;

● private health maintenance organizations and health insurers; and

● other healthcare payers.

Significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Healthcare payers, including Medicare, health maintenance organizations and managed care organizations, are challenging prices charged for medical products and services and/or are seeking pharmacoeconomic data to justify formulary acceptance and reimbursement practices. Government and other healthcare payers increasingly are attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for drugs and by refusing, in some cases, to provide coverage for uses of approved products for disease indications for which the FDA has or has not granted labeling approval. Third-party insurance coverage may not be available to patients for any products we discover and develop, alone or with collaborators. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for our products, market acceptance could be limited.

Law enforcement concerns over diversion of opioids and social issues around abuse of opioids may make the regulatory approval process very difficult for our drug candidates.

Media stories regarding the diversion of opioids and other controlled substances are commonplace. Law enforcement agencies or regulatory agencies may apply policies that seek to limit the availability of opioids. Such efforts may adversely affect the regulatory approval process for our drug candidates.

If we cannot raise adequate capital on acceptable terms, we may be unable to complete planned formulation, manufacturing and additional clinical trials of any or some of our product candidates.

We plan to fund our near term operations with proceeds from the sale of equity or debt securities, either privately or publicly. No assurance can be made that such financing will be available on acceptable terms, or at all. Debt financing could be in the form of a loan from an individual or financial institution. Such loans could put us at risk for amounts greater than our assets and, if such loan is not promptly repaid, could result in bankruptcy. In such case, our common stock would most likely become worthless. Equity financing could take the form of either a private placement or a secondary public offering. Even if we succeed in selling additional equity or debt securities, existing stockholders’ ownership percentage would be reduced and new investors may demand rights, preferences or privileges senior to those of existing stockholders.

If we do not succeed in raising additional funds, we may be unable to complete formulations, conduct the planned clinical trials or obtain FDA approval of our product candidates. In that event we could be forced to discontinue product development, reduce sales and marketing efforts and forego attractive business opportunities.

Because we are preparing to develop and market new products and we are significantly smaller than the majority of our competitors, we may lack the financial resources required to capture a significant market share.

The future market for our drugs derived from our technology will be highly competitive and rapidly changing. We are significantly smaller than most of our competitors and face such competition on a local, regional and international basis. If we compete for the same geographical markets, our competitors’ financial strength could prevent us from capturing those markets. Additional new competitors may enter the market and competition may intensify. Our inability to successfully compete with companies offering similar products will have a material, negative impact on our results of operations.

Our future success depends on retaining existing key employees and hiring and assimilating new key employees.

In order to achieve success, we must retain our current Chief Operating Officer and also be able to attract new, qualified personnel as needed. We anticipate securing key employees by using employment contracts. Our ability to attract and retain key personnel is influenced by a variety of factors, including compensation, which could be adversely affected by our financial or market performance. It would be difficult for us to replace key individuals. Additionally, as we grow we will need to hire additional qualified key personnel. We may not be able to identify and attract high quality employees or successfully assimilate new employees into our existing management structure.

Competition for qualified personnel in the pharmaceutical industry is intense. We will compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions, however there

is no assurance that our search will be successful. Attracting and retaining qualified personnel will be critical to our success.

As a reporting company under the Securities Exchange Act of 1934, our cost of doing business will increase significantly because of necessary expenses, including compliance with SEC reporting requirements.

Pursuant to the regulations under the Exchange Act, we will incur significant legal, accounting and other expenses to comply with certain SEC requirements, in particular, the Sarbanes-Oxley Act of 2002. Sarbanes-Oxley and other rules implemented by the SEC, require management to assess its internal controls over financial reporting and require auditors to attest to that assessment. Current regulations require us to include this assessment and attestation in our annual report on Form 10-K.

Management will need to invest significant time and energy to stay current with the requisite reporting responsibilities of the Exchange Act, which will limit their time they can apply to other tasks associated with operating company business. Management estimates that compliance with the Exchange Act reporting requirements will cost in excess of $35,000 annually. This is in addition to other costs of doing business. It is important that we maintain adequate cash flow, not only to operate our business, but also to pay the legal and accounting costs associated with reporting requirements. If we fail to pay these costs as such costs are incurred, we could become delinquent in our reporting obligations and our shares may no longer remain qualified for quotation on a public market, if one should develop. Further, investors may lose confidence in the reliability of our financial statements causing our stock price to decline.

Risks Relating to Ownership of Our Common Stock

There is a limited public trading market for our common stock.

Our common stock is currently traded in the over-the-counter market and included on the OTCQB under the trading symbol “PRTT”. Inclusion on the OTCQB permits price quotations for our shares to be published by that service. However, we do not anticipate a substantial public trading market in our shares in the immediate future. There are no plans, proposals, arrangements or understandings with any person concerning the development of a trading market in any of our securities.

Only companies that report their current financial information to the SEC may have their securities included on the OTCQB. Therefore, we must keep current in our filing obligations with the SEC, including periodic and annual reports and the financial statements required thereby. In the event that we become delinquent in our filings or otherwise lose our status as a "reporting issuer," any future quotation of our shares would be jeopardized.

A number of states require that an issuer's securities be registered in their state or appropriately exempted from registration before the securities are permitted to trade in that state. Presently, we have no plans to register our securities in any particular state. Whether stockholders may trade their shares in a particular state is subject to various rules and regulations of that state.

The stock price of our common stock in the public market may be volatile and subject to numerous factors.

There can be no assurance that active trading market for the shares will develop. Accordingly, it could be difficult for holders of our common stock to liquidate their shares. Any trading market for our shares will most likely be very volatile and subject to numerous factors, many beyond our control. Some of the factors that may influence the price of our shares are:

● our ability to develop our patents and technology into commercially viable products;

● our ability to achieve and maintain profitability;

● changes in earnings estimates and recommendations by financial analysts;

● actual or anticipated variations in our quarterly and annual results of operations;

● changes in market valuations of similar companies;

● announcements by us or our competitors of significant contracts, new products or drugs, acquisitions, commercial relationships, joint ventures or capital commitments; and

● general market, political and economic conditions.

In the past, following periods of extreme volatility in the market price of a company's securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert our management's time and attention, which would otherwise be used to benefit our business.

Future operating results are difficult to predict.

We may experience significant quarter-to-quarter fluctuations in revenues and net income (loss). Initially, we will be dependent on securing funding to complete development of our proprietary oral drug delivery technologies. Thus, we believe that quarter-to-quarter comparisons of our historical operating results will not be a good indication of future performance. It is likely that in some future quarter, operating results may fall below expectations of securities analysts and investors, which would have negative impact on the price of our common stock.

Effective voting control of our company is held by directors and certain principal stockholders.

Approximately 98% of our outstanding shares of common stock are held by our director and a small number of principal stockholders. These persons have the ability to exert significant control in matters requiring a stockholder vote and may have interests that conflict with other stockholders. As a result, a relatively small number of stockholders acting together, have the ability to control all matters requiring stockholder approval, including the election of directors and approval of acquisitions, mergers and other significant corporate transactions. This concentration of ownership may have the effect of delaying, preventing or deterring a change in control of our company. It could also deprive stockholders of an opportunity to receive a premium for their shares as part of a sale of our company and it may affect the market price of our common stock.

We do not expect to pay dividends in the foreseeable future, which could make our stock less attractive to potential investors.

We anticipate that we will retain any future earnings and other cash resources for operation and business development and do not intend to declare or pay any cash dividends in the foreseeable future. Any future payment of cash dividends will be at the discretion of our board of directors after taking into account many factors, including operating results, financial condition and capital requirements. Corporations that pay dividends may be viewed as a better investment than corporations that do not.

Trading of our shares in the public market may be subject to certain "penny stock” regulation which could have a negative effect on the price of our shares in the public market.

Public trading of our common stock, whether on the Pink Sheets or the OTCBB, if accepted, may be subject to certain regulations commonly referred to as penny stock rules. A penny stock is generally defined to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. If our stock is deemed to be a penny stock, trading in the shares will be subject to additional sales practice requirements on broker-dealers. These may require a broker-dealer to make a special suitability determination for purchasers of penny stocks and to receive the purchaser's prior written consent to the transaction. A broker-dealer may also be required to deliver to a prospective purchaser of a penny stock, prior to the first transaction, a risk disclosure document relating to the penny stock market.

Consequently, penny stock rules may restrict the ability of broker-dealers to trade and/or maintain a market in our common stock and may affect the ability of stockholders to sell their shares. These requirements may be considered cumbersome by broker-dealers and could impact the willingness of a particular broker-dealer to make a market in our shares, or they could affect the price at which our shares trade. Also, many prospective investors may not want to get involved with the additional administrative requirements, which may have a material adverse effect on the trading of our shares.

Future sales or the potential for sale of a substantial number of shares of our common stock could cause our market value to decline.

We currently have outstanding 44,573,012 shares of common stock, of which 42,835,192 shares are considered restricted securities and may be sold only pursuant to a registration statement or the availability of an appropriate exemption from registration. Sales of a substantial number of these shares in the public markets, or the perception that these sales may occur, could cause the market price of our common stock to decline and materially impair our ability to raise capital through the sale of additional equity securities.

Cautionary Statement Concerning Forward-Looking Information

This report contains forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will” “should," “expect," "intend," "plan," anticipate," "believe," "estimate," "predict," "potential," "continue," or similar terms, variations of such terms or the negative of such terms. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those risks discussed in the “Risk Factors” section above. Although forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment, actual results could differ materially from those anticipated in such statements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Item 1B

Unresolved Staff Comments.

This item is not required for a smaller reporting company.


Item 2.	Description of Property.

We do not own any real property. We currently occupy office space that serves as our principal place of business located at 2681 Parleys Way, Ste 204, Salt Lake City, UT 84109.


Item 3.	Legal Proceedings.

There are no material pending legal proceedings to which the company or any subsidiary is a party, or to which any property is subject and, to the best of our knowledge, no such action against us is contemplated or threatened.


Item 4.	(Removed and Reserved).

PART II


Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Our common stock is currently quoted on the OTCQB under the symbol PRTT. There is currently a limited public trading market for our shares and there has been only sporadic trades. The last reported trade on March 21, 2013 was $0.05 Accordingly, we are not including a historical trading table.

As of the date hereof there are approximately 55 stockholders of record of our common stock.

Secondary trading of our shares may be subject to certain state imposed restrictions. Except for the OTCQB, we have no immediate plans, proposals, arrangements or understandings with any person concerning the development of a trading market in any of our securities. The ability of individual stockholders to trade their shares in a particular state may be subject to various rules and regulations of that state. A number of states require that an issuer's securities be registered in their state or appropriately exempted from registration before the securities are permitted to trade in that state. Presently, we have no plans to register our securities in any particular state.

Recent Issuances of Securities

During the year ended December 31, 2011 the Company issued an aggregate of 1,205,000 common shares as consideration for services rendered. Of these shares, 145,000 shares were issued at $1.05 per share, 150,000 were issued at $1.01 per share, 35,000 shares were issued at $0.98 per share, and 875,000 shares were issued at $1.00 per share. All of the aforementioned shares were all issued pursuant to an exemption from registration under the Securities Act of 1933 provided by Section 4(2) of that Act.

Penny Stock Rule

The ability of individual stockholders to trade their shares in a particular state may be subject to various rules and regulations of that state. A number of states require that an issuer's securities be registered in their state or appropriately exempted from registration before the securities are permitted to trade in that state. Presently, we have no plans to register our securities in any particular state. Further, our common stock most likely will be subject to the provisions of Section 15(g) and Rule 15g-9 of the Exchange Act, commonly referred to as the "penny stock" rule. Section 15(g) sets forth certain requirements for transactions in penny stocks and Rule 15g-9(d)(1) incorporates the definition of penny stock as that used in Rule 3a51-1 of the Exchange Act.

It is unlikely that our securities will be listed on any national or regional exchange or The Nasdaq Stock Market in the foreseeable future. Therefore our shares most likely will be subject to the provisions of Section 15(g) and Rule 15g-9 of the Exchange Act, commonly referred to as the "penny stock" rule. Section 15(g) sets forth certain requirements for broker-dealer transactions in penny stocks and Rule 15g-9(d)(1) incorporates the definition of penny stock as that used in Rule 3a51-1 of the Exchange Act.

The SEC generally defines a penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. Rule 3a51-1 provides that any equity security is considered to be a penny stock unless that security is:

● registered and traded on a national securities exchange meeting specified criteria set by the SEC;

● authorized for quotation on The Nasdaq Stock Market;

● issued by a registered investment company;

● excluded from the definition on the basis of price (at least $5.00 per share) or the issuer's net tangible assets; or

● exempted from the definition by the SEC.

Broker-dealers who sell penny stocks to persons other than established customers and accredited investors are subject to additional sales practice requirements. An accredited investor is generally defined as a person with assets in excess of $1,000,000 or annual income exceeding $200,000, or $300,000 together with their spouse.

For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of such securities and must receive the purchaser's written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the rules require the delivery, prior to the first transaction, of a risk disclosure document relating to the penny stock market. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent to clients disclosing recent price information for the penny stocks held in the account and information on the limited market in penny stocks. Consequently, these rules may restrict the ability of broker-dealers to trade and/or maintain a market in our common stock and may affect the ability of stockholders to sell their shares.

These requirements may be considered cumbersome by broker-dealers and could impact the willingness of a particular broker-dealer to make a market in our shares, or they could affect the value at which our shares trade. Classification of the shares as penny stocks increases the risk of an investment in our shares.

Rule 144

Rule 144 is the common means for a stockholder to resell restricted securities and for an affiliate to sell securities, either restricted or non-restricted (control) shares. Rule 144 was amended by the SEC, effective February 15, 2008.

Under the amended Rule 144, an affiliate of a company filing reports under the Exchange Act who has held their shares for more than six months, may sell in any three-month period an amount of shares that does not exceed the greater of:

● the average weekly trading volume in the common stock, as reported through the automated quotation system of a registered securities association, during the four calendar weeks preceding such sale, or

● 1% of the shares then outstanding.

Sales by affiliates under Rule 144 are also subject to certain requirements as to the manner of sale, filing appropriate notice and the availability of current public information about the issuer.

A non-affiliate stockholder of a reporting company who has held their shares for more than six months, may make unlimited resales under Rule 144, provided only that the issuer has available current public information about itself. After a one-year holding period, a non-affiliate may make unlimited sales with no other requirements or limitations.

An important exception to the above described availability of the amended Rule 144 is that Rule 144 is not available for either a reporting or non-reporting shell company, unless the company:

● has ceased to be a shell company;

● is subject to the Exchange Act reporting obligations;

● has filed all required Exchange Act reports during the preceding twelve months; and

● at least one year has elapsed from the time the company filed with the SEC current Form 10 type information reflecting its status as an entity that is not a shell company.

Because we were considered a shell company prior to our acquisition of patent applications, in February 2010, Rule 144 was not available to our stockholders until one year after the filing or our registration statement on Form 10 in June 2010. Thus, commencing on June 9, 2011, our stockholders became able to avail themselves to the provisions of Rule 144.

We cannot predict the effect any future sales under Rule 144 may have on the market price of our common stock, but such sales may have a substantial depressing effect on such market price.

Dividends Policy

We have never declared cash dividends on our common stock, nor do we anticipate paying any dividends on our common stock in the foreseeable future.


Item 6.	Selected Financial Data.

This item is not required for a smaller reporting company.


Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this report.

We are considered a development stage company with no current revenues. We do not expect to realize revenues until we are successful in developing, achieving approval and marketing one or more of our drug delivery technologies or solutions. We anticipate that in the near term, ongoing expenses, including the costs associated with the preparation and filing reports with the SEC, will be paid for by advances from stockholders or from the private sale of securities, either debt or equity. However, there is no assurance that we will be able to realize such funds on terms favorable to us, or at all.

Results of Operations

We did not realize revenues for the years ended December 31, 2012 and 2011. Our operating expenses totaled $554,298 and $1,435,784, respectively. Our operating expenses decreased in 2012 primarily as a result of administrative restructuring pursuant to the resignation of Ram Sesha, and the resulting reevaluation of our business direction with new administration. Our 2012 expenses consisted of $-0- in research and development, $512,619 in professional fees, $25,726 in executive compensation, and $15,953 in general and administrative expenses. Our 2011expenses consisted of $100,520 in research and development, $728,793 in professional fees, $482,246 in executive compensation, and $124,925 in general and administrative expenses. In 2011 we also recorded a gain on sale of patents in the amount of $640,000. These factors resulted in net losses of $554,298 ($0.01 per share) and $795,784 ($0.02 per share) for the years ended December 31, 2012 and 2011, respectively.

Liquidity and Capital Resources

Total assets at December 31, 2012 and 2011 were $860 and $513,838, respectively. All of the Company’s assets at December 31, 2012 relate to cash held in the Company bank account. Total liabilities at December 31, 2012 and 2011 were $578,049 and $542,729, respectively. In 2012, these liabilities consisted primarily of $70,825 in accounts payable and accrued expenses, $20,398 in accounts payable to related parties, and $486,826 in accrued officer salaries. In 2011 the Company’s liabilities consisted primarily consisting of $60,985 in accounts payable and accrued expenses, $4,507 in accounts payable to related parties, and $477,237 in accrued officer salaries.

Because currently we have no revenues, our only cash reserves are the result of the sale of patent applications in January 2011, for the immediate future we will have to rely on our directors and/or stockholders to pay expenses or raise funds through the private placement of securities. There is no assurance that we will be able to raise adequate capital in the immediate future to satisfy cash needs. At December 31, 2012, we had stockholders’ deficit of $577,189 compared to a stockholders’ deficit of $28,891 at December 31, 2011.

Plan of Operation

Protect Pharmaceutical is developing new generation drug delivery technologies that enable products with improved clinical benefits. We believe our drugs will offer enhanced pain relief and reduced tolerance/physical dependence, reduced addiction potential and side effects compared to existing neuropathic and fibromyalgia drugs and opioid painkillers. We will conduct our research and development through collaborative programs. We anticipate relying on arrangements with third party drug developers such as contract research organizations and clinical research sites for a significant portion of our product development efforts.

We acquired a portfolio of patent applications in 2010, although we are yet to formulate products or receive approvals from regulatory agencies or generate any revenues from product sales. We have not been profitable since our inception through December 31, 2012.

We expect to incur significant operating losses for the next several years and until we are able to formulate a commercially viable product. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will increase substantially in the foreseeable future as we:

● continue to undertake formulation of novel products and subsequent preclinical and clinical trials for our product candidates;

● seek regulatory approvals for our product candidates;

● develop, formulate, manufacture and commercialize our drugs;

● implement additional internal systems and develop new infrastructure;

● acquire or in-license additional products or technologies, or expand the use of our technology;

● maintain, defend and expand the scope of our intellectual property; and

● hire additional personnel.

Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. In the event that our development efforts result in regulatory approval and successful commercialization of our product candidates, we will generate revenue from direct sales of our products and/or, if we license our products to future collaborators, from the receipt of license fees and royalties from licensed products.

Management estimates that our research and development expenses for the next 12 months will be approximately $2.5 million, primarily for research and pilot studies. We also estimate that other expenses, including personnel, general and administrative and miscellaneous expenses could be as much as $1.5 million during the same time period. Because we currently have no revenues, most likely the only source of funding these expenses will be through he private sale of our securities, either equity or debt. We are currently exploring possible funding sources, but we have not entered into any arrangements or agreements for funding as of this time. If we are unable to raise the necessary funding, our research and development plans will be delayed indefinitely. There can be no assurance that we will be able to raise the funds necessary to carry out our business plan on terms favorable to the company, or at all.

Net Operating Loss

We have accumulated approximately $2,860,810 of net operating loss carryforwards as of December 31, 2012. This loss carry forward may be offset against taxable income and income taxes in future years and expires starting in the year 2012 through 2032. The use of these losses to reduce future income taxes will depend on the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. In the event of certain changes in control, there will be an annual limitation on the amount of net operating loss carryforwards which can be used. No tax benefit has been reported in the financial statements for fiscal years ended December 31, 2012 and 2011 because it has been fully offset by a valuation reserve. The use of future tax benefit is undeterminable because presently we have not started full operations.

Inflation

In the opinion of management, inflation has not and will not have a material effect on our operations in the immediate future. Management will continue to monitor inflation and evaluate the possible future effects of inflation on our business and operations.

Off-balance Sheet Arrangements

We have no off-balance sheet arrangements.

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of the Company’s financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.


Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.

This item is not required for a smaller reporting company.


Item 8.	Financial Statements and Supplementary Data.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

The Reports of the Independent Registered Public Accounting firm by Sadler, Gibb & Associates LLC for the audited financial statements for the year ended December 31, 2012 and 2011 and are included herein immediately preceding the audited financial statements.

PROTECT PHARMACEUTICAL CORPORATION

(A Development Stage Company)

AUDIT REPORT OF INDEPENDENT ACCOUNTANTS

AND

FINANCIAL STATEMENTS

For the Years Ended December 31, 2012 and 2011 and

From Inception on August 5, 1997 through December 31, 2012

PROTECT PHARMACEUTICAL CORPORATION

Table of Contents


		Page

Report of Independent Registered Public Accounting Firm		36

Balance Sheets – December 31, 2012 and 2011		37

Statements of Operations for the years ended December 31, 2012 and 2011 and from inception on August 5, 1987 through December 31, 2012		38

Statement of Stockholders’ Equity from inception on August 5, 1987 through December 31, 2012		39 – 42

Statements of Cash Flows for the years ended December 31, 2012 and 2011 and from inception on August 5, 1987 through December 31, 2012		43

Notes to Financial Statements		44 – 49

[f12dec10kprotect_vedgar2001.jpg]

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors

Protect Pharmaceutical Corporation

We have audited the accompanying balance sheets of Protect Pharmaceutical Corporation (the Company) as of December 31, 2012 and 2011 and the related statements of operations, stockholders’ equity (deficit) and cash flows for the years then ended and for the cumulative period from August 5, 1987 (date of inception) through December 31, 2012. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion the financial statements referred to above present fairly, in all material respects, the financial position of Protect Pharmaceutical Corporation as of December 31, 2012 and 2011, and the results of their operations and cash flows for the years then ended and for the cumulative period from August 5, 1987 (date of inception) through December 31, 2012, in conformity with U.S. generally accepted accounting principles.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company had accumulated losses of $12,870,744 for the period from inception through December 31, 2012 which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Sadler, Gibb & Associates, LLC

Salt Lake City, UT

July 11, 2013


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Balance Sheets

ASSETS

			December 31,		December 31,
			2012		2011

CURRENT ASSETS

	Cash			860		22,171
	Prepaid Expenses		$	-	$	491,667

		Total Current Assets		860		513,838

		TOTAL ASSETS	$	860	$	513,838

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES

	Accounts payable and accrued expenses		$	70,825	$	60,985
	Accounts payable - related parties			16,319		4,507
	Related party payables			4,079		-
	Accrued officer salaries			486,826		477,237

		Total Current Liabilities		578,049		542,729

		TOTAL LIABILITIES		578,049		542,729

STOCKHOLDERS' DEFICIT

	Preferred stock; 10,000,000 shares authorized,
	at $0.001 par value, no shares issued or outstanding			-		-
	Common stock; 100,000,000 shares authorized,
	at $0.005 par value, 44,573,012 and 44,573,012
	shares issued and outstanding, respectively			222,865		222,865
	Additional paid-in capital			8,348,980		8,342,980
	Deficit accumulated during the development stage			(9,149,034)		(8,594,736)

		Total Stockholders' Deficit		(577,189)		(28,891)

		TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	860	$	513,838

The accompanying notes are an integral part of these financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Statements of Operations

						From Inception
						on August 5,
		For the Years Ended				1987 Through
		December 31,				December 31,
		2012		2011		2012

REVENUES		$	-	$	-	$	-

EXPENSES

	Research and development		-		100,520		1,353,540
	Professional Fees		512,619		728,793		1,480,984
	Executive compensation		25,726		482,246		5,888,730
	General and administrative		15,953		124,225		446,939

LOSS FROM OPERATIONS			(554,298)		(1,435,784)		(9,170,193)

OTHER INCOME

	Gain on sale of patents		-		640,000		640,000

LOSS BEFORE DISCONTINUED OPERATIONS			(554,298)		(795,784)		(8,530,193)

LOSS FROM DISCONTINUED OPERATIONS			-		-		(4,340,551)

	Income Taxes		-		-		-

NET LOSS		$	(554,298)	$	(795,784)	$	(12,870,744)

BASIC AND DILUTED LOSS PER SHARE OF
	COMMON STOCK	$	(0.01)	$	(0.02)

WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING			44,573,012		43,862,848

The accompanying notes are an integral part of these financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Statements of Stockholders' Equity (Deficit)

						Deficit
						Accumulated
				Additional		During the		Total
	Common Stock			Paid-In		Development		Stockholders'
	Shares	Amount		Capital		Stage		Deficit

Balance August 5, 1987	-	$	-	$	-	$	-		$	-

Net loss for the period ended
December 31, 1987	-		-		-		(30)			(30)

Balance, December 31, 1987	-		-		-		(30)			(30)

Common stock issued for services
rendered at $15.00 per share on
January 27, 1988	624,000		3,120		2,336,880		-			2,340,000

Common stock issued for
Midway Mining Development
Corp. at $15.00 per share
on January 27, 1988	359,592		1,798		1,346,672		-			1,348,470

Common stock issued for mining
claims at predecessor cost
on May 24, 1988	19,420		97		(97)		-			-

Common stock cancelled due to the
acquisition agreement on Midway
Mining and Development Corp.
being rescinded on July 6, 1988	(209,112)		(1,046)		-		-			(1,046)

Common stock issued for
services rendered at $0.00
per share on July 6, 1988	209,112		1,046		-		-			1,046

Additional capital contributed	-		-		33,000		-			33,000

Net loss for the year ended
December 31, 1988	-		-		-		(3,721,500)			(3,721,500)

Balance, December 31, 1988	1,003,012		5,015		3,716,455		(3,721,530)			(60)

Net loss for the year ended
December 31, 1989	-		-		-		(30)			(30)

Balance, December 31, 1989	1,003,012	$	5,015	$	3,716,455	$	(3,721,560)		$	(90)

The accompanying notes are an integral part of these financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Statements of Stockholders' Equity (Deficit)

						Deficit
						Accumulated
				Additional		During the		Total
	Common Stock			Paid-In		Development		Stockholders'
	Shares	Amount		Capital		Stage		Deficit

Balance, December 31, 1989	1,003,012	$	5,015	$	3,716,455	$	(3,721,560)	$	(90)

Net loss for the year ended
December 31, 1990	-		-		-		(30)		(30)

Balance, December 31, 1990	1,003,012		5,015		3,716,455		(3,721,590)		(120)

Net loss for the year ended
December 31, 1991	-		-		-		(30)		(30)

Balance, December 31, 1991	1,003,012		5,015		3,716,455		(3,721,620)		(150)

Net loss for the year ended
December 31, 1992	-		-		-		(30)		(30)

Balance, December 31, 1992	1,003,012		5,015		3,716,455		(3,721,650)		(180)

Net loss for the year ended
December 31, 1993	-		-		-		(30)		(30)

Balance, December 31, 1993	1,003,012		5,015		3,716,455		(3,721,680)		(210)

Quasi - reorganization (Note 4)	-		-		(3,721,710)		3,721,710		-

Net loss for the year ended
December 31, 1994	-		-		-		(30)		(30)

Balance, December 31, 1994	1,003,012		5,015		(5,255)		-		(240)

Common stock issued for
services rendered at $15.00
per share on June 12, 1995	160,000		800		599,200		-		600,000

Additional capital contributed	-		-		2,605		-		2,605

Net loss for the year ended
December 31, 1995	-		-		-		(605,105)		(605,105)

Balance, December 31, 1995	1,163,012	$	5,815	$	596,550	$	(605,105)	$	(2,740)

The accompanying notes are an integral part of these financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Statements of Stockholders' Equity (Deficit)

						Deficit
						Accumulated
				Additional		During the		Total
	Common Stock			Paid-In		Development		Stockholders'
	Shares	Amount		Capital		Stage		Deficit

Balance, December 31, 1995	1,163,012	$	5,815	$	596,550	$	(605,105)	$	(2,740)

Common stock issued for
expenses paid at $0.01 per share	2,000,000		10,000		5,000		-		15,000

Net loss for the year
ended December 31, 1996	-		-		-		(12,260)		(12,260)
Balance, December 31, 1996	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 1997	-		-		-		-		-
Balance, December 31, 1997	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 1998	-		-		-		-		-
Balance, December 31, 1998	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 1999	-		-		-		-
Balance, December 31, 1999	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 2000	-		-		-		-		-
Balance, December 31, 2000	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 2001	-		-		-		-		-
Balance, December 31, 2001	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 2002	-		-		-		-		-
Balance, December 31, 2002	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 2003	-		-		-		-		-
Balance, December 31, 2003	3,163,012		15,815		601,550		(617,365)		-

Net loss for the year
ended December 31, 2004	-		-		-		-		-
Balance, December 31, 2004	3,163,012	$	15,815	$	601,550	$	(617,365)	$	-

The accompanying notes are an integral part of these financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Statements of Stockholders' Equity (Deficit)

						Deficit
						Accumulated
				Additional		During the		Total
	Common Stock			Paid-In		Development		Stockholders'
	Shares	Amount		Capital		Stage		Deficit
Balance, December 31, 2004	3,163,012	$	15,815	$	601,550	$	(617,365)	$	-
Net loss for the year
ended December 31, 2005	-		-		-		(1,476)		(1,476)
Balance, December 31, 2005	3,163,012		15,815		601,550		(618,841)		(1,476)
Net loss for the year
ended December 31, 2006	-		-		-		-		-
Balance, December 31, 2006	3,163,012		15,815		601,550		(618,841)		(1,476)
Common stock issued for
services at $0.005 per
share on May 9, 2007	30,000,000		150,000		-		-		150,000
Net loss for the year
ended December 31, 2007	-		-		-		(150,000)		(150,000)
Balance, December 31, 2007	33,163,012		165,815		601,550		(768,841)		(1,476)
Net loss for the year ended
December 31, 2008	-		-		-		(1,605)		(1,605)
Balance, December 31, 2008	33,163,012		165,815		601,550		(770,446)		(3,081)
Net loss for the year ended
December 31, 2009	-		-		-		(2,150)		(2,150)
Balance, December 31, 2009	33,163,012		165,815		601,550		(772,596)		(5,231)
Common stock issued for patents
at $0.25 per share	5,000,000		25,000		1,225,000		-		1,250,000
Common stock issued for services
at $1.02 per commnon share	5,205,000		26,025		5,283,075		-		5,309,100
Contibuted capital	-		-		13,284		-		13,284
Net loss for the year ended
December 31, 2010	-		-				(7,026,356)		(7,026,356)
Balance, December 31, 2010	43,368,012		216,840		7,122,909		(7,798,952)		(459,203)
Common stock issued for services
at $1.05 per share	145,000		725		151,525		-		152,250
Common stock issued for services
at $1.01 per share	150,000		750		150,750		-		151,500
Common stock issued for services
at $1.00 per share	875,000		4,375		870,625		-		875,000
Common stock issued for services
at $0.98 per share	35,000		175		34,125		-		34,300
Contributed Capital	-		-		13,046		-		13,046
Net loss for the year ended
December 31, 2011	-		-		-		(795,784)		(795,784)
Balance, December 31, 2011	44,573,012		222,865		8,342,980		(8,594,736)		(28,891)
Services contributed by an officers					6,000				6,000
Net loss for the year ended
December 31, 2012	-		-		-		(554,298)		(554,298)
Balance, December 31, 2012	44,573,012	$	222,865	$	8,348,980	$	(9,149,034)	$	(577,189)

The accompanying notes are an integral part of these financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Statements of Cash Flows

							From Inception
							on August 5,
			For the Year Ended				1987 Through
			December 31,				December 31,
			2012		2011		2012

OPERATING ACTIVITIES

	Net loss		$	(554,298)	$	(795,784)	$	(12,870,744)
Adjustments to reconcile net loss
to net cash flows from operating activities
	Services contributed by an officer			6,000				6,000
	Common stock issued for services			-		721,383		9,904,653
	Common stock issued for research and
	development costs			-		-		1,250,000
	Loss from disposition of subsidiary			-		-		564,300
	Expenses paid by related party			3,979		-		69,599
	Gain on sale of patent			-		(640,000)		(640,000)
Changes in operating assets and liabilities
	Accounts payable			9,840		(23,560)		70,825
	Account payable - related parties			11,812		-		160,081
	Prepaid expenses			491,667		-		491,667
	Other accrued expenses			9,589		252,579		486,826
		Net Cash Provided by (Used
		in) Operating Activities		(21,411)		(485,382)		(506,793)

INVESTING ACTIVITIES
	Gain on sale of patent			-		640,000		640,000

		Net Cash Provided by Investing Activities		-		640,000		640,000

FINANCING ACTIVITIES
	Capital contributed by officer			-		13,046		13,046
	Proceeds from related party payables			100		-		100
	Repayment of related party payable			-		(145,493)		(145,493)
		Net Cash Provided by (Used
		in) Financing Activities		100		(132,447)		(132,347)

NET INCREASE IN CASH				(21,311)		22,171		860

CASH AT BEGINNING OF PERIOD				22,171		-		-

CASH AT END OF PERIOD			$	860	$	22,171	$	860

SUPPLEMENTAL CASH FLOW INFORMATION:
	NON-CASH FINANCING ACTIVITIES:
		Common stock issued for prepaid services	$	-	$	750,000	$	750,000

The accompanying notes are an integral part of these financial statements.

PROTECT PHARMACUETICAL CORPORATION

(A Development Stage Company)

Notes to the Financial Statements

December 31, 2012 and 2011

NOTE 1 - ORGANIZATION AND HISTORY

Business and Organization

The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company). The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987. The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Company’s operations ceased. The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.

As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada. Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Method

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Company’s fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.

Reclassification of Financial Statement Accounts

Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.

Revenue Recognition

The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 “Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured.

Advertising Costs

The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively.

PROTECT PHARMACUETICAL CORPORATION

(A Development Stage Company)

Notes to the Financial Statements

December 31, 2012 and 2011

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Research and Development

Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.

Stock-based Compensation

The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services.

Provision for Taxes

The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.

The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a “more-likely-than-not” approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Company’s financial statements.

Basic (Loss) per Common Share

Basic (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.

The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.


	For the Year Ended December 31, 2012			For the Year Ended December 31, 2011

Loss (numerator)	$	(554,298	)	$	(795,784	)
Shares (denominator)		44,573,012			43,862,848
Per share amount	$	(0.01	)	$	(0.02	)

PROTECT PHARMACUETICAL CORPORATION

(A Development Stage Company)

Notes to the Financial Statements

December 31, 2012 and 2011

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements

NOTE 3 – GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses.

NOTE 4 – REORGANIZATION

A special meeting of the shareholders of the Company was held on June 15, 1995. It was agreed upon at the meeting to effect a quasi – reorganization whereby the accumulated deficit of the Company up to December 31, 1994 was eliminated against the paid-in capital of the Company.

NOTE 5 – RELATED PARTY TRANSACTIONS

Various startup expenses of the Company including purchase of property and equipment, officer’s compensation and general and administrative expenses have been paid for using funds provided by two directors of the Company. The liabilities are non-interest bearing, unsecured and due upon demand. The Company owed $16,319 and $4,507 for such payables as of December 31, 2012 and 2011, respectively. These amounts due are for services rendered by related parties.

The Company has recorded advances from a related party of $100 and expenses paid by a related party on behalf of the Company of $3,979 as related party payables. As of December 31, 2012 and December 31, 2011, respectively, the related party payable outstanding balance totaled $4,079 and $-0-. These amounts are non-interest bearing, unsecured, and are due on demand.

Contributed Capital

During the year ended December 31, 2012, a related-party has contributed various administrative services to the Company. These services have been valued at $6,000 for the year ended December 31, 2012.

NOTE 6 – SALE OF PATENTS

On January 31, 2011, the Company finalized and closed a Patent Purchase Agreement (the “Agreement”) with Grünenthal GmbH (“Grünenthal”), a company organized under the laws of Germany. Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Company’s rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively “the Patents”), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof. The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.

PROTECT PHARMACUETICAL CORPORATION

(A Development Stage Company)

Notes to the Financial Statements

December 31, 2012 and 2011

NOTE 6 – SALE OF PATENTS (CONTINUED)

In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent

Acquisition Agreement with Nectid, Inc. (“Nectid”), a privately held New Jersey company. Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company. Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance was paid to Nectid. The Company retains all other inventions, patents and technologies initially acquired from Nectid.

NOTE 7 - STOCK PURCHASE AGREEMENT

On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Company’s common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.

Under the terms of the Agreement, The Company has the right to deliver to Kodiak a “put notice” stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.

The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the “pricing period,” which is seven days from the date the put notice is delivered.

The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.

The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. These shares were issued on June 17, 2011. Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.

In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.

The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.

As of December 31, 2012 the Company has not initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares. The Company has not registered with the SEC the shares to be issued to Kodak. The Agreement expired on June 17, 2013.

PROTECT PHARMACUETICAL CORPORATION

(A Development Stage Company)

Notes to the Financial Statements

December 31, 2012 and 2011

NOTE 8 – COMMON AND PREFERRED STOCK

On June 20, 2011, the Company received written consent from its majority stockholders to amend the Company’s articles of incorporation to change the authorized capitalization. The board of directors previously approved the resolution to increase the number of authorized common stock from 50,000,000 to 100,000,000 shares and to authorize 10,000,000 shares of “blank check” preferred shares.

The newly authorized preferred shares may be issued from time to time in one or more series in the discretion of the board of directors. The board will have the authority to establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. No preferred shares have been issued.

On April 11, 2011, the Board of Directors appointed a new Chief Financial Officer, effective immediately and for a term of twelve months. The Company issued 60,000 shares of its common stock at $1.05 per share to the officer as compensation for his services for an aggregate value of $63,000. On the same date, the Company also issued 85,000 shares of its common stock at $1.05 per share to two consultants as compensation for professional services for an aggregate value of $89,250.

On June 17, 2011, the Company issued 150,000 shares of common stock at $1.01 per share to a consultant for services rendered. The cost of the shares was valued at the trading price on the issuance date of $1.01 per share for an aggregate value of $151,500.

On August 29, 2011 the Company issued 125,000 shares of its common stock to board members as compensation. The cost of the shares was valued at the trading price on the issuance date of $1.00 per share for an aggregate value of $125,000.

On August 29, 2011 the Company issued 750,000 shares of common stock pursuant to a consulting agreement. The cost of services was valued at the trading price of the shares on the issuance date of $1.00 per share for an aggregate value of $750,000. This amount was amortized as appropriate for 2011, with the balance recorded as a prepaid asset as of December 31, 2011.

On October 4, 2011, the Company issued 35,000 shares of common stock for services. The cost of the shares was valued at the trading price on the issuance date of $0.98 per share for an aggregate value of $34,300.

NOTE 9 – RESEARCH AND DEVELOPMENT COSTS

On February 12, 2010, the Company issued 5,000,000 shares of its common stock pursuant to a Patent Acquisition Agreement to purchase various patents to be used in the commercialization of certain drugs. In accordance with ASC 730, the Company has recorded the cost of these expenses as research and development expenses.

As part of the Patent Acquisition Agreement, the Company has agreed to pay a royalty equal to 20% of gross sales from licensing fees or net sales. Additionally, the Company is obligated to achieve the following developmental milestones:


	a)	Commercially reasonable efforts must begin within 12 months of the agreement
	b)	File an Investigational New Drug (IND) application for at least one product within two years of closing
	c)	Initiate clinical studies for at least one product within three years of closing
	d)	Commercialize at least one product within five years of closing

PROTECT PHARMACUETICAL CORPORATION

(A Development Stage Company)

Notes to the Financial Statements

December 31, 2012 and 2011

NOTE 10 – INCOME TAXES

The Company provides for income taxes under ASC 740 “Tax Provisions”. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 34% to net loss before provision for income taxes for the following reasons:


	December 31, 2012			December 31, 2011
Income tax expense at statutory rate	$	(188,461	)	$	(270,567	)
Stock issued for assets and services		-			412,437
Contributed services		2,040				-
Valuation allowance		(186,421	)		141,870
Income tax expense per books	$	-		$	-

Net deferred tax assets consist of the following components as of:


	December 31, 2012			December 31, 2011
NOL carryover	$	(2,860,810	)	$	(2,672,348	)
Stock issued for assets and services		2,642,531			2,642,531
Valuation allowance		216,239			29,817
Net deferred tax asset	$	-		$	-

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $602,043 for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years.

NOTE 11 – SIGNIFICANT AGREEMENTS

On February 6, 2009, the Company entered into a Patent Acquisition Agreement, whereby it was assigned various patents for pharmaceutical products in exchange for 7,000,000 shares of the Company’s common stock. 5,000,000 shares were delivered immediately to the assignor and 2,000,000 shares are held to be delivered upon the successful completion of $2,000,000 financing. The patents are also subject to a 40% royalty on revenues, a 10% milestone payment and an employment agreement. The Company is responsible for the completion of a development program to commercialize products using the patented technologies within 5 years.

Pursuant to the Patent Acquisition Agreement, the Company also entered into an Employment Agreement with the patent holder. The employment agreement provides that the patent holder will become the Company’s Chief Operating Officer. The agreement provides for an annual salary $250,000 in year one, $300,000 in year two and $350,000 in year three. The agreement also provides for compensatory common stock purchase warrants to be issued at not less than 20% of the shares issued for financing and other standard employee benefits. In January, 2012, the Chief Operating Officer resigned.

NOTE 12 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report, and there are no other material subsequent events to report.


Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

Not applicable.


Item 9A(T)	Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this annual report, management, with the participation of our chief executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of our “disclosure controls and procedures”, as defined in the Securities Exchange Act of 1934, Rules 13a-15(e) and 15-d-15(e). Based upon that evaluation, our principal executive officer and financial officer concluded that as of December 31, 2012, our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is:

(i) recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms; and

(ii) accumulated and communicated to our management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment.

Management’s Annual Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Our control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that :

● pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of our assets;

● provide reasonable assurance that the transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles and that receipts and expenditures are being made only with proper authorizations; and

● provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management, including our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2012. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control Over Financial Reporting – Guidance for Smaller Public Companies.Based on our assessment and those criteria, our management concluded that our internal control over financial reporting was ineffective as of December 31, 2012.

Management has concluded that controls over both disclosure controls and financial reporting controls are ineffective due to material weaknesses in maintaining sufficient segregation of duties. Due our size and limited resources, we are unable at this time to implement and maintain proper segregation of duties.

Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal controls over financial reporting or in other factors that could materially affect, or would be likely to materially affect, our internal controls over financial reporting subsequent to the date we carried out our evaluation.


Item 9B.	Other Information.

Not applicable.

PART III


Item 10.	Directors, Executive Officers and Corporate Governance.

The executive officers and directors of the company are as follows:


Name	Age	Position
Geoff Williams	39	President, Chief Operating Officer, Secretary and Director
Keith M Elison	40	Chief Financial Officer

Nancy Ah Chong

41 Treasurer, Director

Ramesha Sesha was the Company’s chief executive officer and sole director at the time of his resignation in January, 2012.

William D. Abajian became a director in February 2010 and serves as our President, Chief Executive Officer and Treasurer until his resignation in December 2010. Anna E. Gluskin became a director in March 2010 and resigned in September 2010. Gerald Bernstein, MD became a director in May 2010 and resigned in December 2010.

All directors hold office until the next annual meeting of stockholders and until their successors have been duly elected and qualified. There are no agreements with respect to the election of directors. We have not compensated directors for service on the board of directors or any committee thereof. However, two former outside directors, Anna E. Gluskin and Dr. Gerald Bernstein each received 20,000 shares of our common stock upon becoming a director. The shares were issued as of May 28, 2010. Directors are entitled to be reimbursed for expenses incurred for attendance at meetings of the board and any committee of the board. However, directors may defer expenses and/or take payment in shares of Protect common stock. As of the date hereof, no director has accrued any expenses or compensation. Officers are appointed annually by the board and each executive officer serves at the discretion of the board. Presently we do not have any standing committees.

No director, officer or affiliate has, within the past five years, filed any bankruptcy petition, been convicted in or been the subject of any pending criminal proceedings, or is any such person the subject or any order, judgment, or decree involving the violation of any state or federal securities laws.

Currently, there is no arrangement, agreement or understanding between management and non-management stockholders under which non-management stockholders may directly or indirectly participate in or influence the management of our affairs. Present management openly accepts and appreciates any input or suggestions from stockholders. However, the board of directors is elected by stockholders and the stockholders have the ultimate say in who represents them on the board. There are no agreements or understandings for any officer or director to resign at the request of another person and none of the current offers or directors are acting on behalf of, or will act at the direction of any other person.

The following sets forth the business experience of our directors, including specific qualifications to serve as director in light of our business:

Geoff Williams. Mr. Williams has served as chief executive officer, president, and director since February, 2012. From 1994 to the present, Mr. Williams has been a representative of Williams Investments Company, a Salt Lake City, Utah financial consulting firm involved in facilitating mergers, acquisitions, business consolidations and financings. Mr. Williams attended the University of Utah and California Institute of the Arts. Mr. Williams also serves as our principal financial officer and principal accounting officer.

Mr. Williams is currently a director, President and C.E.O. of Westgate Acquisitions Corp. and, until he resigned in February 2010, he was a director, President and C.E.O. of Greyhound Commissary, Inc., now known as Tanke Biosciences Corp. Mr. Williams also became a director of U.S. Rare Earths, Inc. on November 29, 2011.

Keith Elison. Mr. Elison has served as chief financial officer since April, 2011, Mr. Elison has more than 14 years of experience in public company accounting and SEC compliance and reporting issues. Mr. Elison was previously associated as an auditor with HJ & Associates, LLC in Salt Lake City, Utah for five years. For the past seven years, he has been a financial consultant and partner with J & J Consulting, LLC in Farmington, Utah. Mr. Elison’s professional experience has mainly involved providing accounting and financial reporting assistance for small and medium-sized publicly held companies.

Nancy Ah Chong. Ms. Ah Chong became a director and Secretary / Treasurer of our company in February, 2012. From August 2004 to the present, she has been an office manager for Williams Investment Company, a Salt Lake City, Utah financial consulting firm involved in facilitating mergers, acquisitions, business consolidations and financings. Previously, Mrs. Ah Chong was an administrative assistant for Forsgren Associates in Salt Lake City from March 2004 to August 2004. She has also worked as a customer service representative for Overstock.com from November 2003 to January 2004 and O’Currance from February 2001 to November 2003, and as a marketing and travel coordinator for MGIS from February 2000 to August 2001. From August 1991 to December 1999, Mrs. Ah Chong was with Barrick Goldstrike Mines, Inc. in Elko, Nevada, first as an exploration draftsperson and then an administrative assistant. Mrs. Ah Chong attended and graduated from the Omaha Institute of Art and Design in Omaha, Nebraska.

Ms. Ah Chong is currently a director and Secretary / Treasurer of Westgate Acquisitions Corp. and, until she resigned in February 2010, she was a director and Secretary / Treasurer of Greyhound Commissary, Inc., now known as Tanke Biosciences Corp.

Committees of the Board of Directors

Currently we do not have any standing committees of the board of directors. Until such time as formal committees are established, our board of directors will perform some of the functions associated with a nominating committee and a compensation committee, including reviewing all forms of compensation provided to our executive officers, directors, consultants and employees, including stock compensation. The board will also perform the functions of an audit committee until we establish a formal audit committee.

Code of Ethics

We have not adopted a Code of Ethics and Business Conduct applicable to our directors and employees, including our principal executive officer, principal financial officer, principal accounting officer and controller, or persons performing similar functions. We anticipate that we will adopt a Code of Ethics during fiscal 2011

Compliance With Section 16(a) of the Exchange Act

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of our common stock, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. We believe that no reports were filed during the fiscal year 2009.


Item 11.	Executive Compensation.

Prior to his resignation in January 2012, under the terms of Mr. Ramesha Sesha’s employment agreement, he was to receive a salary of $250,000 per year, with annual increases, for his services as Chief Operating Officer. No salary was paid to him in 2010. Only a portion of his salary was paid to him in 2011, with the unpaid balance being recorded as accrued liabilities. Upon his resignation in January, 2012, the amount owed to Mr. Sesha remained unpaid.

During the year ended December 31, 2011 we issued 60,000 common shares to Keith Elison as consideration for his services rendered as our chief financial officer.

Upon finalizing our patent acquisition agreement in 2010, we issued 5,000,000 shares of our common stock to our former President and Chief Executive Officer, William Abajian, in consideration for services in connection with the acquisition of our patents and related technology and other services performed.


Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth information regarding the beneficial ownership of our shares of common stock by:

● each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;

● each of our directors;

● our executive officers; and

● by all directors and executive officers as a group.

Beneficial ownership is determined in accordance with SEC rules. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options or warrants held by that person that are currently exercisable or will become exercisable within 60 days after the date of this report, are deemed outstanding, but those shares are not deemed outstanding for purposes of computing percentage ownership of any other person. The number and percentage of shares beneficially owned are based on 44,573,012 shares of common stock outstanding as of July 10, 2013. Each person named in the table has sole voting and investment power with respect to all shares shown as beneficially owned by that person, subject to community property laws, where applicable. The address of each person listed below, unless otherwise indicated, is c/o Protect Pharmaceutical Corporation, 2681 Parleys Way, Ste 204, Salt Lake City, UT 84109.


Name and Address	Amount and Nature of			Percent
of Beneficial Owner	Beneficial Ownership			of Class(1)
Directors and Executive Officers
Geoff Williams		2,785,556			6.2%
2681 East Parleys Way, Suite
204
Salt Lake City, UT 84109
Keith M Elison		60,000			< 1.0%
11544 S. Autumn Hill Dr
Sandy, UT 84094

5% Stockholders
Ramesha Sesha (2)		5,000,000	(2)		11.2	%
Nectid Inc.(3)		5,000,000			11.2	%
116, Village Boulevard
Princeton, NJ 0854
Edward F. Cowle		8,250,000			18.	%
70 Garth Road, Apt. 4A
Scarsdale, NY 10583
GBB Limited (4)
c/o Lion Corporate Services		15,000,000			33.6	%
Cumberland House
#27 Cumberland Street / Box N-10818
Nassau, New Providence
Geoff Williams		2,785,556			6.2	%
2681 East Parleys Way, Suite 204
Salt Lake City, UT 84109
H. Deworth Williams		6,562,556			14.7	%
2681 East Parleys Way, Suite 204
Salt Lake City, UT 84109
William D. Abajian		5,000,000			11.2	%
All directors and officers		2,845,556			6.4	%
a group (2 persons)


	Note:	Unless otherwise indicated, we have been advised that each person above has sole voting power over the shares indicated above.


	(1)	Based upon 44,573,012 shares of common stock outstanding on June 6, 2013.


	(2)	These 5,000,000 shares are held by Nectid, Inc., of which Mr. Sesha was the principal owner, and the shares are depicted above in the name of Nectid, Inc.
	(3)	Nectid Inc. is a Delaware corporation with offices in Princeton, New Jersey and principally owed by Ramesha Sesha, our former director and Chief Operating Officer who has voting control and investment power over the shares.


	(4)	GBB Limited is a Bahamian corporation entity principally controlled by Barry Herman, who has voting control and investment power over the shares.


Item 13.	Certain Relationships and Related Transactions, and Director Independence.

Since the beginning of the company’s last fiscal year, to the best knowledge of the company there was no person who had or has a direct or indirect material interest in any transaction, or proposed transaction to which the company was or is a party, except as follows.

Our former Chief Operating Officer and director, Ramesha Sesha, was the founder, principal owner and President of Nectid, Inc. from which we acquired our patent applications on February 12, 2010. Mr. Sesha is the inventor of all of the acquired patent applications and joined Protect as our Chief Operating Officer and Chief Scientific Officer in March 2010 following the acquisitions. Prior to finalizing the patent acquisition agreement, Mr. Sesha was not a stockholder or otherwise an affiliate of Protect.

Under the terms of the patent acquisition agreement, Nectid received 7,000,000 shares of Protect common stock, 5,000,000 shares issued at the closing and an additional 2,000,000 shares to be issued upon Protect realizing financing of $2.0 million. The 5,000,000 shares were valued at $0.25 per share, or an aggregate of $1,250,000.

On January 31, 2011, we finalized a Patent Purchase Agreement with Grünenthal GmbH, whereby we sold to Grünenthal certain inventions described and claimed in certain patents and patent applications for cash consideration of $1.6 million. Pursuant to our agreement with Nectid, because the patents were sold outright without first undertaking any development of the patents, the proceeds from such sale were divided, 60% ($960,000) to Nectid and 40% ($640,000) to Protect. We did retain all other inventions, patents and technologies initially acquired from Nectid.

Our former Chief Operating Officer, Ramesha, Sesha, was also the principal owner of Nectid. We have not established a formal policy to govern potential related party transactions. The transaction with Grünenthal was created in good faith by the company and the division of proceeds were dictated by our agreement with Nectid, from whom we originally acquired the subject patents.

The Company has recorded advances from GBB Limited, a related party, and expenses paid by GBB Limited on behalf of the Company as related party payables. As of December 31, 2012 and December 31, 2011, respectively, the outstanding balance owed to GBB Limited totaled $4,079 and $-0-. These amounts are non-interest bearing, unsecured, and are due on demand.


Item 14.	Principal Accounting Fees and Services.

We do not have an audit committee and as a result our entire board of directors performs the duties of an audit committee. Our board of directors will approve in advance the scope and cost of the engagement of an auditor before the auditor renders audit and non-audit services. As a result, we do not rely on pre-approval policies and procedures.

Audit Fees

The aggregate fees billed by our independent auditors, Sadler, Gibb & Associates, L.L.C., for professional services rendered for the audit of our annual financial statements included in our annual reports for the years ended December 31, 2012 and 2011 were $11,000, and $8,000, respectively.

Audit Related Fees

For the year ended December 31, 2012and 2011, there were no fees billed for assurance and related services by Sadler, Gibb & Associates, L.L.C. relating to the performance of the audit of our financial statements which are not reported under the caption "Audit Fees" above.

Tax Fees

For the years ended December 31, 2012 and 2011, no fees were billed by Sadler, Gibb & Associates, L.L.C. for tax compliance, tax advice and tax planning.

We do not use Sadler, Gibb & Associates, L.L.C. for financial information system design and implementation. These services, which include designing or implementing a system that aggregates source data underlying the financial statements or generates information that is significant to our financial statements, are provided internally or by other service providers. We do not engage Sadler, Gibb & Associates, L.L.C. to provide compliance outsourcing services.

The board of directors has considered the nature and amount of fees billed by Sadler, Gibb & Associates, L.L.C. and believes that the provision of services for activities unrelated to the audit is compatible with maintaining Sadler, Gibb & Associates, L.L.C.’s independence.

PART 1V


Item 15.	Exhibits, Financial Statement Schedules

(a)

Exhibits


Exhibit No.		Exhibit Name
2.1*		Patent Acquisition Agreement
2.2*		Patent Portfolio
3.1*		Articles of Incorporation
3.2*		Certificate of Amendment - Capitalization Change
3.3*		Certificate of Amendment - Name Change 2006
3.4*		Certificate of Amendment - Name Change 2010
3.5*		By-Laws
4.1*		Instrument defining rights of holders – Specimen Stock Certificate
10.1*		Employment Agreement – Ramesha Sesha
10.2**		Employment Agreement – William D. Abajian
10.3***		Patent Purchase Agreement with Grünenthal GmbH
31.1		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


	*	Previously filed as exhibit to Form 10 filed June 8, 2010.
	**	Previously filed as exhibit to Amendment No.1 Form 10 filed July 21, 2010.


	***	Previously files as exhibit to Form 8-K filed on February 4, 2011.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Protect Pharmaceutical Corporation

	By:	/S/ GEOFF WILLIAMS
		Chief Operating Officer
		Dated: July 11, 2013

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Signature	Title	Date

/S/ GEOFF WILLIAMS	Chief Operating Officer and director	July 11, 2013
Geoff Williams	Principal Executive Officer,
/S/ Keith Elison	Principal Accounting Officer	July 11, 2013
Keith Elison

GRAPHIC 2 f12dec10kprotect_vedgar2001.jpg begin 644 f12dec10kprotect_vedgar2001.jpg M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,# M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_ MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`"\`8$#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B MBB@`HHHH`****`"BBB@`KSCQ[^T7:>`_V@?!?@"73+FXNO&<-Q+%=K*JQVWD MHSD,I&3G;CBO1Z^8?VB?^4D'P+_Z\]3_`/1$E-(3/IZBBBD,****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`***CN[N*PM99YY8X(($,DDDC!4C4#)8D\``< MY-%QI7T1)17YT?MJ_P#!P?X.^#VJWGA_X5Z7!X]UFV8Q2:M<2M%I$+CCY-OS MW&#W4HAX(=J^!?B=_P`%JOVCOB;?22?\)_+X?M7.5M=%L8+1(_8/M,I_X$YK MR,1G>&I/E3YGY?YGZWP_X*\1YG25><8T(/5>T;3:_P`*3:_[>L?T(T5_-[9? M\%0_VA;"X66/XO>-F9>@DOC*O_?+`@_E7K/PC_X+X?M"_#>\B_M;6M$\:V:$ M!H-7TN)&*^@DMQ$V?=BWXUSPXAP[=I1:^[_,]W&?1\SZG!RH5J4WVO)/Y7C; M[VC]Z:*^&_V&/^"Y_@#]K'Q?I/@_Q!HVI>"?&>L2K;6<))O;"^F/`1)E`9&) M[2(%Z#>37W)7L8?$TZT>>D[H_(,]X=S')L1]5S.DZ<]U?9KNFKIKS384445N M>*%?,/[1/_*2#X%_]>>I_P#HB2OIZOF']HG_`)20?`O_`*\]3_\`1$E5$3/I MZBBBI&%%%%`!115?6-8M/#VE7-_J%U;6-C9QM-/<7$BQ10(HRS,S8"J!R2>! M0V.,6W9%BBOSQ_:Y_P"#A?X>_"*_NM&^&NDS?$/5H"8VU!Y3::3&PX^5\&2; M!_NJJGJ'-?#GQ-_X+S?M&>/[R5M/\2:-X2MG/%OI&D0$*/3?.)7_`!#"O)Q& M=86D[7YGY?Y['ZMD7@QQ-F5-5G35&+V=1N+?_;J4I+YI'[XT5_.M;_\`!7[] MI.VG65?BOKA93G#VUJZ_D8B/TKU;X/\`_!PA\>?`%["/$YB_H_\14H.=&I2F^RE)/Y)[RWDPVIW(^] M:;A_RRC/#C^)\@\)S^H7[7?QK'[.?[,/COQN-AG\.:-<75LK?=>XV%85/L96 M0?C7\R.K:K7LK3SS2,6>61F+,S$]2222?>OGL_QDJ<%1@[< MV_I_P3^@_`;@^AC\74SG%QYHT6E!/;G>O-_VZK6\VGND5Z^J?V8?^"-7QS_: MCT*UUFPT"T\+Z!>J'M]0\0SM9I<(>0R1*K3,I'(;9M(Z$U[7_P`$#/V`](_: M#\>ZO\3_`!A81:EX>\%W*6FEV4Z!X+S4=HD+N#PRPHR':>"TJG^'!_:@<<`8 M`K@RO)E6A[6L]'LD?<>)GC'5R;&2RG*(1E4C;GG+51;5^5)-7=K7;=EM9N]O MQ>U#_@VK^*\.G[[7QU\/I[H#)BD:\C3/H&$)_D*^??V@?^"0?Q]_9TLI[[4_ M!%SKNDVX+/?Z!(-1C51U9D3]ZJ@=V0`5_1'17J5<@PTE[MT_4_,^)*%1 M2Q*A5CU3CROY.+5OFGZ'\W'_``3-1HO^"@_PA5E*LOBBT!!&"#YG2OZ1Z\7^ M)7[`'PN^)GQN\-_$B?P[!I7C?PSJ46IPZKIH%M+>/&V[;<`#;,#T)8;P.C"O M:*Z,KP,L+&4).]W='@>)O'&&XGQ&'QF'IN#A#EE%V=GS-Z-;K7>R?D%%%%>H M?F(5\P_M$_\`*2#X%_\`7GJ?_HB2OIZOF']HG_E)!\"_^O/4_P#T1)51$SZ> MHHHJ1A1110!D>/\`Q]HWPM\%:IXC\0ZA;:5HFBVSW=Y=SMMC@C49)/K[`

\3_MR>*[G0]$FO=`^&-C,1::8KE)=4VGBXNL?>)QE8^5 M3CJV6KVO_@O_`/M^S_$3XCGX+>&;YE\/^%Y%F\0R0O\`+?W^`RP$CJD(()'_ M`#T)R,QBOS8@@DNITBB1Y)9&"HB@EF).``!U)-?(9SF'I/1;^;[>A_7/ M@UX;4<'A89]F4+UIJ]-/[$7M*W\TMT^BM;5L;7TO^SI_P2)^//[2^E6^IZ/X M-ET;1;I0T6H:[,-/BE4]&1&_>NI'(94(/K7Z*?\`!)C_`((U:/\``KPYIGQ# M^*6E6^J^/+Q$NK#2KN,26_AU2,J60\/<]"2>(SPOS`M7Z(U>!R'GBIXAVOT7 MZG%QOX[K"8B6"R"$:G+HZDKN-^O*DU=+^9NSZ)JS?XB7O_!N%\<[;3_.B\0_ M#2YFQGR$U*[5_IEK8+^M?/W[0?\`P2[^.G[,UE/?>)?`.J3:1;@L^I:65U&U MC4?Q.T)8QK[R!:_H\HKOJGS3/ MRR_X-C_^14^,/_7WI7_H%W7ZFURW@3X(^$?A?XGU_6?#GAW2M#U+Q0\4FJRV M4`@%\\>_8[JN%+_O'RV,G/).!74UZ6!P[H4(TF[VO^9^;\;\0T\\SJMFM*#@ MJG+H]6K0C%ZK?5.S[=%L%%%%=9\H%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`?)G_``7$O);+_@F1\13$Q0R/IL;8 M[J=2M@1^5?S[5_1]_P`%2OAA/\7_`/@GY\4]&M8VFNDT9M1B11EG:U=+K:/< M^3C\:_G!KX[B*+]O%^7ZL_L'Z/5>#R'$45\4:K;]'"%OR9^\7_!OW:6UO_P3 MKTQ[<*);C7=0>YP.3)YBJ"??8J5]M5^67_!MC^TC:S^%/&WPHO;A8[ZUNAXC MTM&/,T3JD-PJ_P"XR0MC_IJQ[&OU-KZ'*JBGA8-=%;[C^?/%'`5L)Q3C(5E\ M4W)>:E[RM]]O56"BBBO0/@0HHHH`****`"OF']HG_E)!\"_^O/4__1$E?3U? M,/[1/_*2#X%_]>>I_P#HB2JB)GT]1114C"O+OVU/VC+;]D[]ESQGX]N#$T^A M:>QL8I/NSW37R]WRYCZ'HHHK[@_B$****` M"BBB@`HHHH`*^:OVHOVT?$WA3XR6?PO^%WARV\3>.;B%9[I[HG[-8*R[P"`R M\["'+,P50R_>)P/I6OAWQWXH3]D;_@J9<>*?$J&'PO\`$73EM(=0B2`U44)L].^#GQ/_:)T?XKZ)H_Q$\&>'KCPYK$CQ2ZKI+;C8,(V M8%]LC84E0OS*!EA\V>*^A/%OB2W\'>%=3U>[.VUTJTEO)CTPD:%V_0&K\
M>&?\%(_B!_PK[]C?QA*DFRXU:%-*A&<;_/D5''_?KS#^%+ M=AL<=_P3K_;KU_\`:VUGQ1IOB:RT.QO=(A@N;-=.BEC$D;,ZR;M\CY(/E\C' MWJ]I_:?^*&H?!;X`^*?%6E0V<^HZ)9_:(([I&>%FW*,,%921SV(KX]_9U\"? M\,G_`+;OPPT]D-M!X\\$007G93=F(LZ_7S8$_P"^Z^GOV_?^3-_B!_V##_Z, M2J:U!'AW@W]L7]HS4?AA8>/I/AOX1\0>$KJ(W++I4DL5YY2L0S!#-(W&T]$; M'7&*^COV9_VF/#O[4OPZ3Q!H#R1-$_DWME-CS[&;&=C8X((Y##@CT(('-_\` M!//_`),P\`_]>#_^CI*\2^$%BG[.7_!5;Q)X5TY1;:#X_P!.:_CM5^6-)?+, M^0.@PZ7``'0/BDU<+GJWAG]J;Q#K/_!0'Q#\*I;31U\.Z3I27T,ZPR"\9S#; MR89B^PKF5NB`X`Y]??J^-_`?_*9CQK_V+T?_`*2V5?9%*2!'PY\&_P!M']I# M]H:UU:\\'>#OAYJ-CI-X;.9Y1+`ROC(&'NQG@CD<5]`_LY>+_C-JZ:_)\4_# MGA?0HK6"-],.E2%S,_S^8'_?R<`!,=.IZ]O&O^"-W_)-?'W_`&,1_P#12U]? M:S_R![O_`*XO_P"@FFV"/B'X'?MG?M*?'_PG>Z_X5\&>`M:TS3KMK*9/GMY3 M(J(Y50]T,_*Z\].:]F_93_;HA^.?C._\%>*?#]SX+\?:6K-+IMP24N0HRQC+ M`,&`.[:<_*<@L,XX'_@B_P#\FW^)?^QGF_\`26UK._:_MHM#_P""F'P4OM+` MCU>_\J*]\L89X/.=,MCKF-I1D]E]J;6M@1['^WA^W1X5_8*^#A\3^((Y=1U& M^D-KH^D0.$GU.?&=H)SLC48+N0=H(X+%5/RUH7[2?[?7Q%\/Q^,M&^$_P^T[ M0[E15?30'D;EDN5<,1V;RR?[HR`9OV88X'F9]ZL_P#!9G_E&=\5 M/^O2S_\`2^VKQ;QA_P`JZT/_`&(MI_Z/BI8BM.-6<4]H7^=WJ:9!E6"Q.5X3 M$U*2YIXZ--_X'&#Y/35G/?#']OO]M;Q3\'-*^)<'P<^'OB_P5J=L;Y$TAY(M M0DA!()6/[6\F!$Y]J^L/V!OV_?"O[??PRN]9T.VN=&UK195MM:T6Z$T5O`5Q>O:PW$'%K=7#W;.&C(X8$),PQT65>S"LZ, MZE.5)N;DIK5/TO='?G&$RW'T%0EUXNT*^@OM:-L=TEO8I=QW`60CH!%''W@X4XPH\\:L.:,HR5&-1N?O.,HMOE=XK=6=S])M MP]11117O7/P49=6L5];2P31I+#,I1T895U(P01W!%?S>_P#!2#]D6[_8O_:P M\1^$S!(NA7,IU+09B#MFL96)C`/I$TJ&%/'OA027N@S'"FY)`\RT9CT64*,$\!U0\#=GRLWP+Q%&\?BCJOU1^ MJ^$?&L<@S?DQ+M0K6C-](O[,ODVT_)M]#\(_V.O#4XAU;P M_="=$8D1W,9&V2%\=4D0LA]F]<5_2'^RS^TMX;_:W^!^B>.O"]P)-/U>+][` MS`RV$Z\26\@'1T;CT(PPR""?YC=7TFZT#5;JPOK:>SO;*5H+B"9"DD$BL59& M4\A@000>017U#_P2L_X*.:C^P7\9!'J+W-[\/?$DB1:Y8KEC;GHMW$O_`#T0 M=0/OKD=0I'SN49C]7J+?A]_K#@5C<"KXFDO=_OQWBWUMJ>DZM;I=6=W;N'BN(G4,KJ1U!!K0K[= M.^J/XFG"49.,E9K=!1113)"BBB@`KYA_:)_Y20?`O_KSU/\`]$25]/5\P_M$ M_P#*2#X%_P#7GJ?_`*(DJHB9]/4445(PK\(/^#@3XD-XW_X*%:AI8D+P^$=% ML=,49X5G0W3?CFXQ^%?N_7\WW_!4CQ.WBW_@H7\7;MV+F+Q%/9`GT@Q`!^`C MKP>(:EL.H]W^C/WCZ/N"53/ZV(DO@I.WK*45^5SSG]FSX;?\+D_:%\#>$RI9 M/$FO66G2`=DEG1&/X*2:_J%@@2U@2*-%CCC4*JJ,!0!@`5_/%_P1J\*KXN_X M*4_"^!T#I:WES?$>AALYY5/X,@K^A^L^'*=J4Y]W;[E_P3O^D3CG/-,+@[Z0 MIN7SE)K_`-L04445]$?SP%%%%`!1110`4444`%>=?M0_LVZ)^U'\*KOPWJZB M&\0^)M1T6RUG3;C6-(D$=Y M8K.OVBW)4,-T?W@"""#C!]::8'RI_P`$_P#]H/Q#\-_B'>_`CXCEX]=T+7XF\1+$=9%S/X?\`!OAT?:TMY3$Q;:)!AAT/ MF7,8/^YBJ2UN2=!_P5)N(?!&K?"?XB6,D+2^$?$"QR^4P),;%)0#CM^X8?\` M`_>O8/V]+F.\_8N\>31,'BETK>C#D,"Z$'\J\"_:[_X)E?#WX:_LY^*?$/A: MTU>+6M$MA>1&:^>9-B.IERIZ_N]]=?XF^(/_``L[_@D7/JS2>9,?#"6DS9R3 M)!(L+D^Y:,G\:%T&CTO_`()Y?\F8>`/^O!__`$=)7C?Q487W_!9#X>K"H9K3 M07\['.W_`$>^//X,OYUZ9^Q7\0M#^&?[!G@K5]?U2RTG3;/3I&EGN90BC$TG M`SR6/8#))X`->8?L/V-[^TS^UUXX^-]U:3VV@(K:5H(F7:9``L>X?[L2?-CC M=,1V-)=0N3>`_P#E,QXU_P"Q>C_]);*OLBOC7P3.EO\`\%E?&K2.B+_PCT8R MQP/^/6RK[&AO8;AML/+`,CY!(SU'6O!?^".EY#;_#;QZ))8XR?$)(#,`3^Z6OK[4[N*YT MB\$WFK MRW16*R?R(%9&C7YF"J$8D$<-VQFO>/V"_A%J7Q]\;Q_M`^-]'+%F9LB'_@CUHMKXD_96\8Z=?01W-E?^(;FWN( M7&5EC>SME93[$$BLS_@G[K5U^S!^T_XY^!VL32&TGN'U'0Y)#CSL*&X]Y(-C M''`,3#K5/J)'GW[-3+IO_!Q!\;([A=DEWX6'D;CRW[K2FX^JJ3^%=3_P4@O_ M`-J?]GW0OB!\4/"WQ:\,:;\/M#\JXLM#.BP37L,3-%#LWR6[`GS'+/RKC M/^"C)NOV%/\`@IU\,_VBVM;B7P5X@A70/$LL,9?R&\MX2S8[F`HZ#^(VK"O> M_P#@JQXUT?XB_P#!*OXCZYH.IV6L:/J>EVL]K>6DRRPSH;RWPRL.#7SZ5J5: MG=J47*6CMOJC]SG6<\RR;'1I0JT,13H49<$SBI0DH3C[R:C+2Z>]GH>?_MB M_$76/B[_`,$%KOQ3X@NA?:YX@\(Z-?WUP(DB$TTES:,[;4`5,/^ M5=:'_L1;3_T?%1\>_P#E76L/^Q%T+_T?9T>,/^5=:'_L1;3_`-'Q4JC;E)O_ M`)]?YEX&G"GA:%.FK)9G9):))*%DCP_X#?\`!-_X[_M"?L#>#=2\,_':];PY MJVF&:#P3>?:;#3S")'!M7F@E)=&P>J`?-VQFOJ[_`()"_M&>%?$_@?Q!$[7 MX?V7PL\:_#2X,&MZ!;,TD4[[S&URLCDR2$NNUB[.1\GSL"#70_\`!-CXJ>&? MA-_P3$^%NK>)]?T?P_IMKH9>6YU"[CMXU`FE[L1D^PY-?/G_``2RU=_VFO\` M@J7\>OC;X>M+F+P#>63:+9W+Q-&E[*TEKL8`X^8QVAD8=5\YQ\$`_ZP],<^O?L-WA_P"";7[9EO\`#+XO^$M(G\9_$QBND_$NWO;B]EUY MG?"P3-<$LA:3:I";?G\O!7-?\%%OBSHG[VDD'FK\I\J.V9F(.`S*N=V0.>C3A3H0KQ?O\VBWO[UMNFG8^AS3&XK,,]QF M18F*^J>QC*)7M MHPX>S.?O+2E)]5_(WW7V>Z]W=*^A_P`$8/\`@JJ_[,/B:V^&?C[4&/P\UJXQ M87L[$CP[))(V5XW`964Y#`]"#Z5_*+7ZX_ M\$*?^"H#>([>Q^"'C_4=U_;IY?A/4;A^;B-1_P`>#L>K*!F(GJH*=0@+R7,[ M-8>J].C_`$_R)\:/#-5(SXARN'O+6K%=5_.EW7VNZ][=._ZET445]4?RP%%% M%`!7S#^T3_RD@^!?_7GJ?_HB2OIZOF']HG_E)!\"_P#KSU/_`-$2541,^GJ* M**D85_,I^V_=/>?MG?%J5SEW\8ZL3_X&2U_377\R'[:P*_MC?%<$$$>,-6_] M+):^;XC?[N'JS^C/HZK_`(4,8_[D?_2F>_\`_!!&R%U_P4D\,2%T!2"3)I&HJ/;]P3_2OWJKHX?_W9^K_) M'A^/[?\`K+"__/J'_I4PKY.O_P#@M]^S3IE]-;3>/[A)K>1HW7^P=0.&4X(R M(/45]8U_*OXW_P"1TUC_`*_9O_1C5>;YA4PJA[-)WOOY6.#PE\/\NXGEBHYA M.D?G`5X'\??^"Z; M?"(S$*%#,LBN@.`!D`=*]\KYT_:]T:T\7^LS(8_[3U*=9 M[A4/4)M547/&OAA\7?%/C?3VU*;7O%S$WKW,XDC0;]VV M,!1M7(48)/"BO/\`]@.-+"U^(VG:+/<7'@32_%$UKX<,DK2QQQ*B^:D+L26B M63.TY(Z\YS7T'FAL$9_BWPQ:>-O"NIZ-J"-)8ZM:RV=PH."TZ4SQB1E9@K[0`-PST/)-?/'[&'Q'U M2_\`VW/$6MWMS))H7Q5&J/HX9B5;[#=!4QVXB#]*[+XO^#M)_:`_;[3P-\0) MKN?PO9>&EU#0](^U26UMJ5R9,2R'8P+NJA^,]$]`I$PM]?+5"1[9Q7T7X8T/3/"^A6VF:/:V=CIU@@A@MK5%2* M!1T4*O`KY;_:[^'%A^R[^S/IOAWPK?ZWH'@_7_%UK#K*K?Q%X-L;O2YWM&@D\O4II[>]1]I#NLC M,">`0PQU[T,$"6)!!*YQR< MV_#7[7GB'PE_P3ZU;7;V;[;XY\-7TOA,2R`.9[Y9EBCD(/WF".KG/WBISUIN M^UP-&Z_X)`_"6\NI9GF\6;Y7+MC4$`R3G_GG7H_[./[$_@S]ERXUJ7PR^LNV MO0I!<_;+E90%0L1MPBX/SGUK-^`?[$^D?"W6-$\6:IJWB/6O'EO&TNHZC,>M4OB; M^R9X5^*?QB\.^/+U]5LO$GAG8+6XLKA8A(J.759`5.X99ACC(8BOFWX)_$C5 M)_\`@I#JGB:>YD;P[XWU'5O"=DI8F/=I\-NP<=AN*8'N6]:V_P!O/]F+P=I_ MC#P+KD%C?1:EXU\>6.GZO(NIW(6Y@F$AD0+YFU,[1R@!&.,46U"Y]2_%#X6> M'?C5X$U'PQXKT>RUW0=5C\JZL[I-\<@SD'U#`@$,""I`(((S7QM??\&^7P0N M-1F^SZW\3K#1IYO.;18-!I".G)V_AC5O%%PMU:_VC<,\H>)2P\TN9!G`Z-QVKT#QI^SUH/[)_P`#OB#XB^&N MFWUAXA.A3^7(U_]E'%&;97&5/+ M\1*G&6K2>E^]MK^>_F=1XZ_9#\$?$#]E=O@K-'?V?@M-.MM+2"UNS]JA@MWC M>,"1PQSF-#5TN/2`Z7*_;1"C*P/F%"N[* MCG;^%>;_`+*?['?PS\7_``R\#?$"S?5;_P`4RQVVK7&N+JT[7%Q=J5::.0%B MA7S`R,I7.`1G.37U%52H4[[=+?+MZ'-#.\?&*BJLK*?M%K_R\_G_`,6FY\0^ M$O\`@WU_9X\-:I'_UDK$_L?)2-L?\``J^P/AG\+O#GP9\% MV7ASPIHNG:!H>G+MM[*RA$44?5U+;:G\&1'))&)/B M)IJMM8C<-LO!]16Y_P`%!YY+;]C3Q[)$[QR+8H0RD@C]_'W%*CA*5+^'%*_D M=&;\3YMFB4 MS:&4@CE@,"II8.A"7/&*3]#;,>+LZQU!87%XJTO+2=)M'<7%]X0UHO M=>'M3<9^T0@\PN1QYT60K#N"K8`8`?/NCZQ=^']6M;^PN9[.^L9DGMYX7*20 M2*P975AR&!`((Z$5_2I^W)^Q[H/[;W[/>K^"M:6."ZE'VG2=0*;GTR\4'RY1 MWV\E6'\2,PX."/YPOBI\,=:^"_Q'UOPGXBLWL-<\/WDEE>0-SL=#C(/=2,$$ M<$$$<&OALVR]X:IS0^%[>7E_D?W#X4\?1XCRYT,6U]8I)*?]Y;*=O/:2Z/LF MD?OY_P`$H?V]X/VZOV<8;O4IH4\<>%]EAX@@7"^:^T^7=*HZ)*JD^@=9`.`, M_4-?SG_\$L?VO9_V-_VP?#FN7%RT/AK6Y%T;7T+8C-I,P'FGWB?9)GKA&'\1 MK^C!6#`$$$&OIW]U MH****]4_+0KYA_:)_P"4D'P+_P"O/4__`$1)7T]7S#^T3_RD@^!?_7GJ?_HB M2JB)GT]1114C"OYJ?^"BNB-X>_;Q^+]JP*X\6ZC*H_V9+AY%_1A7]*U?SY?\ M%M_`[>"/^"DWQ`.PI#K'V/4XCC`826D6X_\`?Q7'X5\_Q%"]",NS_1G[_P#1 MYQ2CG>(H/[5*_P#X#*/^9/\`\$-];71?^"F/P_5V"K>Q:C;?4M87!`_,"OZ! MJ_FM_P""#?^A1\,?\`@K@_^)K\&_\`@MUH5CX; M_P""D'C>STZRM+"TBM].*06T2Q1KFQ@)PJ@`9)S7]!5?S_\`_!=3_E)AXZ_Z M]M-_]((*\'B"*6'5EU7Y,_=/`'$59\155.3:]C+=M_;IE[_@@K_RDG\*_P#8 M-U+_`-))*_?*OP-_X(*_\I)_"O\`V#=2_P#222OWRJN'O]V?J_R1S_2`_P"2 MEI_]>8_^E3"BBBO=/PX*^6?VM]!U+]L/XOW'P>TB[@TG3_"VF+X@U/4&B$DO MVUE9;2!">4'S;V8P0&-M#DLD"Y51P1+*(])MF`CTFS M\N/R6CE(S+*&B7>0/F)P."2/2_VU?A+K_P`=/@J/">@I"RZQJEFNI-),(O*L MTE$DC#/4Y1.!R']5C.QX)A@^4Q M_P">;D`'K@X.#@@V?VO_`(&S_&_]FWQ!X6T:"V34YXHI-.#$1JDL4J.@W?PY MVXS[UB>)O&_QS\'W-F-,\">&O%MC<:=;;U&M+975E=>4HG#EQLD3S-Q4ISCO M1?L%A?V?OB+9?MI_L[ZII/C+2(XM4M99M`\3::Z[1%=1XW,O=<_*P(Y5@0#\ MN:XS]F3Q'X@_9_\`BGJ'P*\4W4VJ6@L9+[P;JLGW[JS`.;9S_>C`./0*P^[L MJY\,?A'\6?@9X"UOQ#IMCX5U[QQXR\22:YKFDR7+V]K%`Z,!!!+T\Q6VG^'_PQ^(OQ>_:4T'XA^/\`0M*\&V7@ZQN+72]*MM06_N+B6==CR22( M-H4+T`YR!QU-`$G_``2ZF1OV*O"\(&V6UN+^*8=U?[;,V#Z'#"OF_P`1,H_9 M@\;ZL4_XED?QL>\9LG;Y(E4$_3+`9KW6T^&/Q<_9KUKQCHOPXT'0_$?ACQ;? MRZII=Q=ZDMH_ANXG`\P/&PS+$I`*JG/'/)(KL?"W[&&E6/['DOPJU.[-T=0M MG:^U!5RS7KOYIG`/7;+M(!ZJ@![T[]02/;`0P!!!!KY=_8[\9Q?#GX%?&WQ! M,0(M$\:Z_?-GOY<<;X_'&*['X"1?'#PGJNB^&_%UAX/U'P]I2-!<>((+V4W= M[$D;"(B(@8D+!-Q;C&[O@UPEU^RYX^M?V5OBMX0LK:Q36O''B^[U"U)NU""Q MGE@)=F[,41QMZ\TD@/!+3X\>!/!_[+7PCEL_$=O<^-O"/BB#Q#J-L()A(ZS3 M2--_$_PXU[P9I>GZO>^#-7DU&6VN[P6J2`QA0-Q M![^@K3\.^+_C3K^@Z\M_X.\(^'M3AL_,TEVU=KR"XN`X_=RA5#*I7/([XHZ` MCRY-.N_^"?O[0UC%9%Y/A!\2M2%M]FSE?#FI2?=V>D3^G]T'^X-WUA7R]X^\ M"?&']JZ[\.^'O%_A#0/`_AG2=6M]5U*]AUA+^:_\DDB.%%&4W$GE^G'/&#Z) M\+?B?XMU_P#:I^(?A;53ILOAS0;2SN=-:V4&6+S@WR3,"<.=CD*0#MP>A%#! M'+_M\_\`(4^"W_91M,_]!EK>_P""AW_)E_C[_KQ3_P!'QU%^VO\`"GQ9\3=' M\#77@_3['4]3\*>*+;7'M[JZ%M'*D*2?+N/JS*./6L+XI^'_`(M_M"?L^^.O M"^N^#O#^@7NI6,4>F&VUH7(N)/.5F5R5`0!5SGO0N@%O]JVTEO?^"=.NI"I9 MU\,VTA`_NJL3,?P4$UZM\#KZ'4_@MX0N;8JUO/HMG)&1R-I@0C]*\S^&D/Q1 M\5:5:^#?'/@'PY8>$;G3'TR_N[;7!<3&/[.8QB/:,[C@'GC.>U8OP2\`_&S] MGT:7X'M;?PEXG\%:;>)':ZU=W9,M&T0'S2*F0N.`<A527I*,K_C%?([4*,LT<*LMPOT\AY&QW, M:UYV:T/:X6<5NM?N/T+PLSN.5\386O4=H2?)+TFN57\DVG\C\!]'U:XT'5[6 M^M9&BNK*9)X7'5'5@RG\"!7]1/P)^*5I\;O@MX3\86+*UKXFTFVU)`ISL\V) M7*_522#[@U_+=7[7?\&\/[5,7Q+_`&:M2^&FH7*G6O`%RTMFC-\TNGW#EU(S MR=DQD4^@>,=Z^?X?Q"A6=)_:7XK^F?O_`(_Y#/%9/2S*FKNA)I_X9V3?RDH_ M>S]#J***^Q/X^"OY_P#_`(+J?\I,/'7_`%[:;_Z005_0!7\__P#P74_Y28>. MO^O;3?\`T@@KP>(?]V7JOR9^Z?1]_P"2CJ_]>9?^ETR]_P`$%?\`E)/X5_[! MNI?^DDE?OE7X&_\`!!7_`)23^%?^P;J7_I))7[Y4^'O]V?J_R1'T@/\`DI:? M_7F/_I4PHHHKW3\."N%NOB;K&L_%NY\-^']*T^[M-"%L^MWUY>/!Y'GY810H ML;>9*(AYAW%5PR#/S$KW5>1^&_%-C\+OVC?&FGZY.-/;QO=:??:-+*I$=^PM M8K1X$;&#(KP*Q3KB4'IDAH#*C_:-\8+\&=;\=2Z'X:&D67VE+.!;^8#%M53M9B5)(XXZU:\8_M"^*_"?A'QP9?#^@IXB\`6"ZS>PG497L[VP:& MXD62%Q$'$A:W=-CJ`"I.X@BO&-.U#P]+^RAXSTZS\67=QXGD_M`3Z*=3\X6* M_P!K,?,2V.0AP4.CG&6IV`ZWQI^TOXA^'NCZF-2T319=3T_P`,KKX6VO)6 M@=GNO)6/YE\3(JR@2?#BV3*9!!_M`=#ZUO_M`^$?^ M$2\0Z'9Q7FK:DH\+>*&\Z_N6NILM;6WR[VYQQP*$A'2W7QL\;Z1\,]%UN\T7 MPJ;KQ/?:99Z;##?W#1I]K8`M,QB!&W_T]=)U MSP]?-IVI6:S>?'')L217CDVJ7C>.1'4E5/S8(!!KY\M_%WA'3O@)X)GT_P`9 MG68]*U[PY<:L;O5_M::0!(N0=QQ"@VOQP/E]J]A^`!?Q+XL\>^+8HIXM*\2Z MI"--:6-HS=06]K%#YX5@#M>19-I(^954C@@TFAG%:7^V/K=G\*;?Q)K?AK3; M<:UX7O/$>C?9+]Y4F:VA$SVTP:-3&Y4@AEW`@-T(&>I^-O[1UY\*[N^@M=*M MKV2U\.'6T,L[1AG^U0P",X!PO[W.>O'2O)_`/P1O_$?[#4.L7=_?:UJD7P^O M+#1--2W6**R\^UPP"J"TDK;$3"H^8@@UJ?$/\`:&3X<^*_$]A< M::]U%H.C6&HVXADQ-?7%WV\9^&K]-?OY6F::7[6/M0-T_S3PQ(D)#LS;=[*&PN!L_%S4(?B5\0/%6 MO>&9%\0V5CH?AO6(FL#YXO8[/6;N:9(]OWVVQ.`HY+#'6BP(^A?`UUK]YH?F M>)+'2=/U$N<1:?=R7403`(R[QQG<#D'`QP#GG`\Y\(_M:V6L^$_B+K-_ITMM M;>!=1GMH4B?S)-3@0E(I4!Q@RRI(BCIP.>:ZR^^.&A7?P@UWQAHVH6^JZ;HM ME<7+20DE2T41D*'ONZ`CJ"<=>*^:+GX;>,O!GA=-!O\`2;!K[6/!-K+#%I]U M)173*X:)`LTHN9?E!8$@C/%"0'O-]\6O&FER:)HMQX;T`>+_`!(\ MTUK:1ZM*]I96D*(TLMQ+Y`;']4UFZ&D:4_A_ MP;@0@XDU."]M+.$2Q+U98WBF+D?<6/)P,4)`>HZ[^T%<:/X(\4ZN MNF0R/X>\30:`D9F($RR7%K#YI.."!<$X_P!D<\UR_@']HO2K:S\6#2O#6G:7 M?Z=\0D\.WT,($7VW[1J*VOV]B%&YFS(>(T\3M:$@;/:?#GQO\40^)_'4/B+3/#=GI/@. M#SKNXM+V:267=;"Y4JKQJ,!#@Y/!Z9K'O?VR&T/]GCPMX[U+0_LIU36$TK5[ M/S2QTK;-+'5Y3M@@9`/(KF_BZUY820#@`\'I6=<:7?S>)+WPEXET[3HFF^(%CJ3VMG,]Q:FUOK M.7>`[HA(,L=QGY1RQ'/4E@9Z-\5?VA]?\(:/X[OM'T?1KR+P->00S"[NY(C< MQRVL$VY=B-\P:;&#QA%K>;0+>SN=99[N=C,EQ) M(/\`1OD!(1(B=SC#/\OR@;J\.TW2M8T;]G?XZZ3K"327VC:C;:8LS@EKR&"T MLXH9CZF2)4<^[&O5OVAO%FB^'?B7X:U+1]7LD^(.F7]IIYTE)1]JU?3[J=$F MA:+[S(JDS*^"$:$G(!:BP'M=%%%2,R?&7CW1/AUI45_K^K:=HMC-<1VJ7%[< M+!$99&VQIN8@!F;``)Y)`ZUJJP=0RD,IY!'(-?&7_!?'_E&[XD_["NF_^E*U M^5?[(_\`P5N^,_[($-MIVE:^/$?ABWPJZ)KH:[MXE_NQ/D20@#H$8+GDJ:\G M%YM##U_95%I:]T?K'"GA3B^(7U4JD9RCR2T3247=2UL]=FK>:/Z(J*_ M.CX&_P#!Q]\+_%UI#!X[\+^)?!VH$`/-9A=3L1ZG<-DH^@C;ZU[A;?\`!:O] MF6ZT_P"TCXFVZ+C.Q]'U!9/^^3!FNFGF.&FKJHOF[?F?-8[P\XEPE3V=7`U& M_P"[%S7WPYE^)]3U^;O_``<=?M&6'A;]GSPY\,[>XC?6O%6I)J=U"K9:&RMP MV&8=M\Q3;GKY3^E6?VF/^#B_X;^"]#N;7X8Z-JWC36W4K!=WT#6&FQ'LS!L3 M/@\[=B9_O"OR,^//QY\4_M+?%+5/&7C+5)=6UW5GW2RL-J1*.%BC4<)&HX"C M@#WR:\G-LVI.DZ-%W;ZK9(_5_"CPJS2.:4LWS:DZ5.D^:,9:2E+I[NZ2>NMF MVDDMVN/K^C+_`(),_"NX^#O_``3R^%^DW<30W=UI9U656&&!NY9+I01V(251 MCVK\5O\`@F1^Q#J/[V4.I64UM\++!,/#E\YU+P_<-DB M:RD8E4W=VC.Z-NY*9Z,*Y?\`8M_:NUO]B_\`:'T+QYH@:<6#F'4++=M34;-\ M"6!OJ`"I.=KJK8.*_=G_`(*9?L!:5^WS\!I-(#6]AXOT,O=^'M2D'$,Q`W0R M$<^5*``V.A"M@[<'^>_XG?#'7_@SX]U3POXHTN[T;7=&G-O=VEPNUXF'Z%2, M$,,A@002"#7PV98.>$K^TI[-W3[>1_!Q]I5HQY*L7]I-6Y_2 M2WMM+MI?^F[X"_';PQ^TI\*=(\9^$-1BU/0]9A$D3KP\+?Q12+_!(ARK*>A' MXUV%?S<_L.?\%#OB#^P9XRDO?"MXE[H=^X;4]"O2S65]CC=@>@.X M?+7ZS?L_?\%^?@7\6-*@3Q1>:K\/-890);?4K5[FUW=]D\*L"ONZQGVKZ#!9 MS1K12J/EEY[?)G\_<:^#N<93B)5,OIRKT&_=<5>27:45K==TFGOILON"OY__ M`/@NI_RDP\=?]>VF_P#I!!7Z]ZI_P5=_9TTC36NY?BUX5>)%W%89))Y#]$12 MQ/MBOQ._X*G_`+0GA?\`:C_;=\6^-/!MW/?^'M2CLXK:XEMWMVE\JUBB9MC@ M,!N0XR`<=JY<^KTYT%&,DW?H_)GU'@1D6987/:N(Q6'G"'LI+FE"45=R@[7: M2O9/3R/1/^""O_*2?PK_`-@W4O\`TDDK]\J_`W_@@K_RDG\*_P#8-U+_`-)) M*_?*MN'O]V?J_P`D>/\`2`_Y*6G_`->8_P#I4PHHHKW3\."BBB@`HHHH`*** M*`"BBB@`IL4$<`81HB!CN.T`9/K]:=10`4444`%%%%`!36B1I%N*=10`TP1M,)"B&11@-@;@/3-.HHH`****`"FF!&E60HAD48#8&0/K3J*`" MBBB@#QS]O/\`9)B_;<_9JUGX?2:W)X>?498+F&]6W%P(I(9`ZADW+E21@X(/ M-?B;^TW_`,$;_CK^S1<7$\GA6;QCH<))74_#@:^3;ZO"`)DP.I*;1_>/6OZ% M:*\W'972Q+YI73[H_2."/$_-N&H/#891G1;YG"2ZNR;4E9IM);W7D?RCW=I- M874D$\4D$\+%'CD4JZ,.H(/((]*CK^HOXE?L[>`/C+D^+O!/A3Q,^,!]3TJ" MZ=1[,ZDC\#7F%S_P2L_9VN[@RO\`"/P@K,?M6$^D5ETH7Q.$G&7]V49+[WR_D?SAJI9@`"2>`!U-?67[%O\`P1S^+G[7 M.J6=Y=Z3<^!O!TA#2ZSK%NT32Q^MO`V'F)'0_*G^V*_CUT8?AV*=ZTK^2_S/G^(/I"XBK2=+)\/ M[-O[D4K7]6UY'F'[)7[(O@S]B_X26OA#P78&"V0^;>7DV&NM2GP`TTS M@#+'&`!@*,``"O3Z**^CA",(J,59(_G;&8ROBZ\\3B9N>I_\`HB2OIZOF']HG_E)!\"_^O/4__1$E5$3/IZBB MBI&%%%%`!7SE^WW_`,$S/`/[?/AE&UF-M#\76$1CT[Q#9Q`W$(Y(CE7@319. M=I((R=K+DY^C:*SJT85(N%173/0RO-<7EN)CC,#4=.I'9K^M4^J>CV9_.Y^U M?_P22^-7[)U_=37WABZ\3^'822FMZ#&]Y;E/[TB*/,AXZ[U`ST8]:^9V4HQ5 M@58<$'@BOZNZX;XA?LP_#;XM73W'BCP!X,\0W,ARTVH:-;W,I_X&Z%OUKYVO MP[%N]*=O)_YG]!Y)](?$4Z:IYKA5-K[4'RW]8M-7]&EY'\OE7?#OAG4O&&L0 MZ=I&GWVJ:A^'`=>F=`MF M'Y%,5Z1X'^%WACX96;6_AKPYH7AZW88,6F6$5HA_"-0*RAPY._O37R1[&+^D M7A%!_5<%)R_O227X*1^4W_!%+_@FA\7OA)^TWHWQ/\8>&SX4\/:?9742P:G* M(K^Y::%HUVP#+(`6R?,V''3-?KM117T&"P<,-3]G!WZZG\_\8\78OB/,/[0Q MD8QDHJ*4;V23;6[;;U=V%%%%=9\H%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5 M\P_M$_\`*2#X%_\`7GJ?_HB2OIZO/?'7[.VG>._CSX.\?3ZA>P7_`(-BN(K> MVC"F&X$R,I+DC/`;C!IIB9Z%1112&%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% 0%`!1110`4444`%%%%`'_V3\_ ` end GRAPHIC 3 f12dec10kprotect_vedgar2002.jpg begin 644 f12dec10kprotect_vedgar2002.jpg M_]C_[0`L4&AO=&]S:&]P(#,N,``X0DE-`^T``````!`!+`````$``0$L```` M`0`!_^%^N&AT='`Z+R]N&%P+S$N,"\`/#]X<&%C:V5T M(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX* M/'@Z>&UP;65T82!X;6QN#IX;7!T:STB M061O8F4@6$U0($-O&%P+S$N,"]G M+VEM9R\B/@H@("`@("`@("`\>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S M=')A=&]R($-3-B`H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@("`@ M("`@("`\>&UP.D-R96%T941A=&4^,C`Q,BTP-BTR-E0Q.3HP-3HT-RTP-CHP M,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX;7`Z36]D:69Y1&%T93XR M,#$R+3`V+3(W5#`Q.C`U.C4R6CPO>&UP.DUO9&EF>41A=&4^"B`@("`@("`@ M(#QX;7`Z365T861A=&%$871E/C(P,3(M,#8M,C94,3DZ,#4Z-#&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6&UP1TEM9SIH96EG:'0^"B`@ M("`@("`@("`@("`@("`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`W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM# M:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-0 M4TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0 M>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N M9#1E6'`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`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`X<7AW,W)R M928C>$$[<3!92$I19S5Q:54O,E!E;4MO-GHQ2%=B>3)T65$$[9U'%:;V%O5$IB,T1U,C,K*S9U8U5Q3VLO2&5A1F-,.%5.>G)E M&%M*W4V="8C>$$[839D0S@X.7=B-D-7 M0T5O:SEV0DYE4DY*27IY=D=J1V%-$$[>%9#86(K:F92;"]2+T0P=EAM.6)H,#EF,4$$[.51H M+W8S;696-68U6$]T8U923TMU>%8R2W!(-64O=S4Y6G4O,%@V;C%Q:6979G)( M,6HQ9E1Q,W`X9G)0>&5L6&QW-&9",7!I<659<28C>$$[:')4.4@O5TQV-G1W M*W-E;U!R;D@W6'%E;79(;B]S3TY-5E)/2W5X5C)+=7A6+R]:/"]X;7!'26UG M.FEM86=E/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@ M/"]R9&8Z06QT/@H@("`@("`@("`\+WAM<#I4:'5M8FYA:6QS/@H@("`@("`\ M+W)D9CI$97-C&UL;G,Z>&UP34T](FAT='`Z+R]N&%P+S$N,"]M;2\B"B`@("`@("`@("`@('AM;&YS.G-T179T M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O7!E+TUA;FEF97-T271E;2,B/@H@("`@("`@("`\>&UP34TZ2&ES=&]R>3X* M("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@ M7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA M8W1I;VX^&UP+FEI9#I$,C=&,3$W-#`W,C`V.#$Q.3$P M.3E#,T(V,#%#-#4T.#PO7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@ M("`@("`@(#QS=$5V=#IP87)A;7,^9G)O;2!A<'!L:6-A=&EO;B]P9&8@=&\@ M)FQT.W5N:VYO=VXF9W0[/"]S=$5V=#IP87)A;7,^"B`@("`@("`@("`@("`@ M(#PO7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS M=$5V=#IA8W1I;VX^&UP+FEI9#I&03=&,3$W-#`W,C`V M.#$Q.$0T140R-#9",T%$0C%#-CPO7!E/2)2 M97-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^&UP+FEI9#I&-S=&,3$W-#`W,C`V.#$Q0D1$1$9$,SA$,$-& M,C1$1#PO7!E M/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^ M&UP+FEI9#I&.3=&,3$W-#`W,C`V.#$Q0D1$1$9$,SA$ M,$-&,C1$1#PO7!E/2)297-O=7)C92(^"B`@("`@("`@("`@ M("`@("`@(#QS=$5V=#IA8W1I;VX^&UP+FEI9#I&03=& M,3$W-#`W,C`V.#$Q0D1$1$9$,SA$,$-&,C1$1#PO7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA M8W1I;VX^&UP+FEI9#I&1#=&,3$W-#`W,C`V.#$Q0D1$ M1$9$,SA$,$-&,C1$1#PO7!E/2)297-O=7)C M92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^&UP+FEI9#I",S,S-C8X0S$V,C`V.#$Q0D1$1$9$,SA$,$-&,C1$1#PO M7!E/2)297-O=7)C92(^"B`@("`@("`@("`@ M("`@("`@(#QS=$5V=#IA8W1I;VX^&UP+FEI9#I&.#=& M,3$W-#`W,C`V.#$Q.3=#,4)&,31$,37!E/2)297-O=7)C92(^"B`@("`@ M("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^&UP+FEI M9#I&.3=&,3$W-#`W,C`V.#$Q04-!1D(X1$$X,#@U-$4W-CPO7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS M=$5V=#IA8W1I;VX^&UP+FEI9#HP,3@P,3$W-#`W,C`V M.#$Q.3)",$-"0D%#1$1&.#E$0SPO7!E/2)297-O=7)C92(^ M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S M=$5V=#IA8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IP87)A;65T M97)S/F9R;VT@87!P;&EC871I;VXO<&]S='-C7!E/2)297-O=7)C92(^"B`@("`@("`@("`@ M("`@("`@(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^ M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P M;&EC871I;VXO<&]S='-C7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@ M("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&]S M='-C7!E/2)2 M97-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^&UP+FEI9#I#,4(P,35",#!!,C`V.#$Q.$,Q-$)#134Q04(W M,4,U.#PO7!E/2)297-O=7)C92(^"B`@("`@ M("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA M8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R M;VT@87!P;&EC871I;VXO<&]S='-C&UP34TZ M2&ES=&]R>3X*("`@("`@("`@/'AM<$U-.D1E&UP+FEI9#I#,4(P,35",#!!,C`V.#$Q.$,Q-$)#134Q04(W,4,U.#PO M&UP+F1I9#I#,4(P,35",#!!,C`V.#$Q.$,Q-$)#134Q04(W,4,U.#PO M&UP34TZ4F5N9&ET:6]N0VQA5)E9F5R96YC93PO7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$UF M7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@(#QS=%)E9CIF M:6QE4&%T:#XO57-E&UP34TZ36%N:69E&UP;65T M83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^ M_^X`#D%D;V)E`&2``````/_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`__``!0( M`.4$>P0!$0`"$0`#$0`$$0#_Q`!U``$``P$!``(#`0``````````"`D*!P8$ M!0$"`PL0``$$`P`!`P(#`PD$!`@'$0`"`P0%`08'"!$2"1,4(14*(A9W,2.V M%[+@Y03<8.C(TM79",R2TUH=8F%%A8R4U)DB(R!EY8E-5-E;70^-$EE>G M&O_:``X$`0`"``,`!```/P#?P;^#?P;^```````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````9-OD\L_)7S\^3.I^-GDG1)&@\ZT/5Z*TVQ MA;AO3_@U<:1`KM.T][LTB9H\+8VN3<^IY4F+QM6S+CU4A>\U=J[F0FM0 MI4AU M^/6O;U/T;D?'^;7$*)"J[&%`AWK3%>W?5UMK4>/JE9;UF)UCFI?GWLUYWU?C M?;83@`20\"^G]U\%/D9V3XO^U=3V'L/(]VUY_9_';<=TFRG;2H0WK=EN]=&K MGIST]V'6V];5VE7-@*?3$3>5J5PDHP^M$@`6^_(AY7M>%WB3U3N<9F/,VRLK MX^MVNW=?4U'D2%9?DJ6L`55_+'Y,?*Y7WO M8=RKKK=_''Q'YIW"9R7G>R<[L9_*MBZ1.:F74>IND7T.U:Z/L\69%U^0Z])C M.Q=>SZ>UM"G/PR`--_A/?WNU^&GB1M&T75MLFS;)XQ\%O]BV*_L9EQ>W][<< MKU2QM[JZM[%Z386MM:V$EQ^3)?<<>?><4M:E*5G.0!)P`&6/S!IO,SRG^7;I MWBIP7S%ZSXXT.K<1T_=X$36NE]2U[4/9#UO4)=K[M;TO::F)BXM+#;LJ5(2V MG*D,XPOUSC&0`2H\9?C0^17D'>N7]+ZI\E?3.O<\T_96K;;.:W/1^YVE7M]4 MF)*CN54RNV/<;&CEM9=?0Y[)+#C>5-X]<8SZ9P`)?_))J/R$]&IN2<\\"=RI M^:O[+<;4KL'1+BPI:9G6Z"`SKF-:;1=RJ?8]GKOOI\R4M?Y%`>L'$1\X]4M> M]+@`HU[SQ?YLOCBU>1Y1*\Q[SR!TG5[&')Z!1RNA="ZC44=5*GMQ<3;SG_5* MU,#&J29,Y,>3)IE-S(*',._S#37W#0`TA^"?E;4^:?B]S/R"KZIK7K+:8,^M MV_6F7G)#&N[KK=C)I-EKHC[W\Z]6.SH>94%2\Y<5!DLY<]'/=C``S\UE'UCY MQ_-+R(U/9.S[YS'P8\:KO.J0=3YQ9MQ%[RJ3R`/3\Z>Z[\.GR(<-\7Y?8MVZSX7^5/Y10Z;#Z+9?7= MT39+Z]8TV(]%<;;_`"VJN]6V-RM_,'H,>#63::T0IYI#S*7(X`U-@`XSY$]L MUGQPX;U3NFWH=>%W6JGA/$T:*W;=(Z'-NXFLS7=TD7U_%350;B MDH]BZ2XY%UZ(PXVQ7M1867I",R'\9]BF@!3;V6;\QGQ#3]-[5T/R,G^4?%+G M9(5)M,;9M[WKJNL(FR4+>:UK8\=)@M[?HR[J-`=^QLZAY+"9",(=7[W<1WP! M>SY(]2\I?)CPAY-TGXYIT?7^B=Y=T"X9NKQS5F7=&Y[LNLW5IMKDZ=M$:;65 M]M16++%>Z_%CR9:)'N^T3ES*'$@"F3KWAE\Y_C-IVP>2%1YT[#V"TT2M>VO: M>?:UUCIVWLXJJN,FQO)='SKH^LQ>?[1#JH\1;BX>(3,F0PE6&(SCB\LY`%T? MQ2^>$SSY\9T[]ME96TG5M!V1_0.G0*=MUBGL+>-70+6KVRFBO./N0:W9*N>E M2H^7%?0FL26T_P`TEO*@!5GL/A%\[/DG/OM^W/S5C^/K,^YG2-4YSKG5-UY] M(KJ;W/8JH]G!X1KJ:*&PB`IE&,/3K&:;OQ MQ?()8/[?L5QF7`Y]T.V7&GWD6Z;HY&SZ_P#_`%MAQHO[]:1O5/%<3"F2T.64 M:P6VP\M'H\Q'`&G````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````%4GRA_(O/\*=8T+GG(=19 MZ;Y2]WLLT?)-&=BS;.%7M*FQ*E6SW-35.LV5LN3<6#,&JKFW8ZK&8IS.'/IQ M7D*`%9&T^:OS(?'O-T'L'G7K&B=C\>-\OJZLW"#I]3HT:]Y8NTSAW%&S=Z!4 MZ]'K=D9CH<5$S99NJN>XTJ-B:AU:'4`#1O+Z%-W?ARN9#^FVXKW/,^F5I`&,+4.G_)\Q M\O?4M\HO'/C4WSOFZ)7QMTXM)O*A',ZC6DJ?*C8_';`QT+QKXI1-[KS+KC7FFJJO:=[/(JR MMZ)]ASF1SSZ7?;G\R>O]$;C39>&,;/E$EQ25)C9Q]!(`YM\+?3ODYB\<\5M# MUGQUXY8^!JK_`*!'D]JF7=2CIK>O2^E]"L-MG(JE]U@V.957T%Z;!8Q^Z2LJ MBLH5AMY.<2%@"PS4/D"[+?\`R]]2\`9FL\R:XYI&B5^T5.RQJ;:D=,D6$OD7 M.=^<9L+EW:>B>"'CWL';-R@K MV&V5,8U?GFCQYC<"7N^]VD:9(JJ;[UQM_P#+JJ-&@OS+"7AIY4:%'<4VVZ]E MIEP`4CZ1UK]0]US18?E'I=7R2KT#8*]6V:EP*RU?GM;;['JDA"K*MF5E;=P5 M;WB)8P$8Q$;F;-#L)C+B'&FE8=:7D`7O^:'EEH?A3X];KWW?8[UK&UY$2KUG M5HQ0`S_P#_`!/_ M`#XVO(WO.NMUWD\#A"*-WI$/@KFHZF]9S^7Y2[;HVE-6]&_K0D4;&OHQ)PK& MR1K*1!SB2U&6A6%``OH\%O,/2O.7QTU/O&G05T4F=)FZUO&H/2VY\G2]]HT1 M57NO.S6T-8EQLL3H\V$]EMI;]?,CN+;;6M3:0!,$`````$I=NZ-4;&Q[6FW46$^)K6QPGLI0O+CK+U-=1DI=7C'JIM: M,>N&P`1P\LD9W[]1#X74FH-9E6>@\AU5>Y9:2E*8&*7/=^@V#LQV/EU2,?NC M=0\)R]A&5K=;;_D4C*@!Z#]2/=6=EQOQ3Y!7O2&D]'[Q/LE8;;6XPY+UK6L: M]7XD(:?2Z\I#O0U*0UAI?ORG.??-U'9S+@4WC M-J]/B8\S^$"W9H/$RK=99^MCWLN.KK)Z$K1C&%MX7Z9]JOQ`&AT```$&/DVV MV@TOX^O,.XV5,95=,X%T+4HV)66<-8O]^I']%U12?KI6C[E&T['#RSZ8]^7L M)]F<+]N<`"&OZ?S2K?4_CET^VM$/-L]"Z;T[=:9MY/L4FH;N(VE-K0C*LJPS M(G:;(=1G.$^]+F%8QE.<*4`(C_IOE-ZO0>:_);U?T^AZ+U_5%;3'>PG[A;>8 M6V:U[\.N+^ZD_;WFK3DN^Y/HTIQ.DO.LYR/L6_*UJ;E.&I.4S%7VN]ZY@RS-3' MRA;TC'[O1%,JSZMMK:94OU2A6``:7@`4S?/EMM!KGQI]6I[E,95COVZ\CU+5 M,OY9PZB_A]"H]ZDJA_52I>9.=6TNRQGZ>4K^CE?KGV>[&0!)KXKM*M]`^/#Q M*UZ\0\W8N\CJ-H4U(3]-]B)ODVPWFLCNMY4I3:X]9L;*,I5Z*3[?16$YQE.` M!,KI6VT&@\YW_>MK3&7JVEZ5M6V[*B9EG$-5!KE%/N+E,K,A*X^(RJZ&YA?U M,91[?7W8SCU`!G1_3,:5;UOC_P"2/0)*'D4VV]JO5Q"L;S';4K"?;[VLIQG.4JPD`:8P`99O+^/&Z_P#J(/$+4=.:1BWY9J'+ MY&\.P\,J6W)TU?3>WS7;-3?TLLK=TBW@,8R\K*\MK:2GUPIM``-3(``````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````,RNI-H\COU&^^R[MO-O2>*G(5N:K&>=1)C5JZ'2M6I%N M*0C+K2,0.A=DL);2/7"FI>4+S[7$Y3@`74_(%RJN[5X3^4/.K&&B77$+G_`,\KP`<@^#?_`$MO%_\` M]=?^8CK8`*^N:?\`,O>0G\(*7_+7P\`'P?F9@J\@_D7^-GP_M%XE:9;7-5N6 MVTB5Y])U'O/2(M!L4B6PA>. MTTQ'8:;9889;2TRRRTG"&FFFD82AMIM"<82G&,8QC'I@`&:3YZ9,GJW>OC;\ M2E.J_=WJW:42=FA)=RA4R3LFY\]YIKCJ5*6PTPJ)!V.Z1A65^N?N/Y483G*@ M!I0;JZQFL;I&JZ`U3-0$U;50W#CHK&ZQ$?$1%MQ+GMBI_97ZJR@`:80```````8X.7;IY"(:[T'$S8$/*T/:+'?>?LJJ:J8J6U0N?F$1^>TT\REFQA1H\E MP`2Y^%N5I>Y^5GEAT/RR-]C5XA1X:%0W'9,H`?C]0"I6.]?%Q78>EJ4GUS[G0DKQC.<84G' MA=HR$5C'_23[TXSZ9_VXQD`$L/U%_\`I^U7^(/G']'-_`!9KX$?W%O"[_"; MXY_V/Z<`"60`,]_DY\*G7>Y^7/9_(CG/FK?<#H.U0Z-S8:S4M3V>1L.9%164 MM6K7;'\BZ3I$*]UM3NN19S;C\A*DR<^GV_JTAU8`B9R#J?FI\1OFWQ[QH\H. MQW/?/%OR$LX6O:?N5_9W=PQ4N6UI7:VQL5`YLDNUOM/L-+O[&%B[I4RY5?FL MF_6:][SC3J`!K#`!FC^<;JNQ^0W7/&;XN^-S<.[GUC>M7W'I\EA"Y4>AKIY#C$.OAO8QE+F,X`&A;D'+M5XERSGG(-(BJB: MES73M?TJ@:X67Q(U%ST_R(V*@NG_`"WY;-K:J5PAS8')]/(M$W%]/V?4F:Z6]:J9 MD7;KD^`FNO7L-1Y_W$F7"9`'J_`F[L^G?*YN.T_)HQ=Z3YVZYK$:%X]GVH`U6@`KM^5 MSQ_O_)7P)[]S?3Z^1;;K%H*S?=0JX;69$ZUN>=WU9N#E+71T(<+L_PXYOR7MW:>><:ZAP76L:#:U?3]IJ=(B;!J MFLN9B:?=:M9['*@5UVZK7,QXC\%AYRP;EQ'E?0PRIE:P!`3I'ECR/S'^>'PU MW7A5C9;-I//X&LW)C(D/LLY>7 M$=<0G+&6W%@#8``#+1\BEF]\E'R@\`^/73YLA_D_!9LK;N\V]=E:XS=BJ'!O MM\87(92IMI^CU*-"H(4C*LXCWUV^PXCU1GU`&HV#!AU<&'6UT5B#7UT6/!@0 MHK2&(L.'$91'BQ8S+>$MLL1V&TH0E.,82G&,8_``%"WSY^4%AHGCYJ?B1SC$ MFU[#Y:;#7ZRW25/\];M\^K[FM38LLLH2M>)F[[.]!IHK:O9B7'+?(N`UKD:98:;K:'MPN(J/:U?;[?/NWFZ6[:LIPZN&_L$]] M$3#F5+;A-LMYSGV8`!V+M'6M.X-R?H?9>@3OR_3N:ZE<[=?/I]N9#L2HAN2$ M5\!I2D_;;3ZJ5C``,_'P8\IVONO4/)SY/NO1/;MG:]UV MK3><1'6U.,5U1)MH=UNUA4OO-(P]50'6*[7:UUM*%M-54UI?KA?I@`:5```` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````9EO#7VZK^H8\\*BX5]";LG(-N_*F_:XGZZK>V\=M MXAI]'D,K_;U^,MWUPE2<^WU3E2,X5D`:!/(RVA4/CWW>\LG?HUU+QKI]M8/> MF,_2A5VD7DR4[Z9RG&?IL,JS^.4LZK\"MXG2TX2QLGDYT"ZK,X M2]C*X+'/.1ZZXI67&FT*SBRH9"?5O+B/3&,95[L*2D`<6YI_S+WD)_""E_RU M\/`!;)\K'^G5Y=?P@N?_`#RO`!R#X-_]+;Q?_P#77_F(ZV`"OKFG_,O>0G\( M*7_+7P\`'[_(,E-#\\?QO;3:.(C4]QHG/=4@OYPYG+ETKJ':(#4;/\W[/YZ9 MN$%M/HK.<9<_:QC'IG(`TS``RH_/QS>BWWS(^.;7M_DW-7S;I=T_S?9[?7WH M<*]AT4OJ?/H.XR:*PNH,RACW-?0[,[AV/9K+HE!5ZY=,=.V# M2;F#%@U%B[9QG:MO5>>Z6^Q*6^]G"U.NOHRCTQA.,_B`"RH`````$/?D$Z-= M\F\(O*;H&LONP]BH.)[WBBGL9]'ZRWMJ611UULQGW)QB14R[)$E'KZX][6/7 M"OY,@"#GP#\ZHM-^-[FVUUD.,S;=;W7JFZ[),;;QB3,G4N_7O-("9+V4X6I$ M:GT-C#:/7*$>Y6<>BE*]0!#[Y!_I\*^;SXZ^R:?[ZRX[0O1^7;LW!]J/SQN^ MWFPY)+L+-"O:F2M[4]\BQ5>Y2L(:K&5(1AQO"E`#^WZC1IS68?@CV+#'HUS; MM&X-+L/9(?\`M'+1KG^TML?:I](DC[E//EK]J\X8?9<2ZR\RZG"VG6G494AQIQ"L92K&N;]8IJM,YQJEWN&QS?3"G4UM'!>FO,1&LJ3F583,`#1SOFR*T[1]SVY#"92]5U38MD3% M5Z^V2JCJ)EFEA7HMO/M>S%]N?VD_R_RX_E`!GN_3@ZXWL/#O*#R'OUHM>C]2 M\C+#7-IV*2A*[.P;US4-:WAQ;KWLQ[$3K[J4U]S",XPXYZ95C]E'H`/*_J#_ M`*?(-V\#/+;6/?6]!Y?U:UKDV4'VHGV=91S=8W^B@OJ5[4/QJF?3V&&VE+2V MK%H^E>%)7^R`-,P```*U>N?$+\>G;ND3.K;YX]UBMON+!^VV5W5]LWK2*?:K M*2_F5(L+W7]0V6EIG;"5*6X[(DL,L2)CCJE2%NY]/0`52)YKSUS]07P+E7(- M2UK3N=^)_CW]G)U33:VOI*K7D9YYT?;XB5QX$:)]:;+V/LM=(EO.YDRI3DE2 MW7%*6KV`"]_S4\G-<\/O&;JO?=A^VD/:;KSK>ITLEQ2,;-O=PI-5IFNIPWZO MY9L;^4S]RMO"E,0D//9Q[6E9P`*I/@.\9[S6^-=#\TNK-2;#L?EMM-S?1KNU M;3BT5SUF]F3W;16,^UR.]T#=GIMF_P#LI3)B1X#J?5/MSD`7ZV%A!J:^=:VD MR-7UE9#DV%C/F/-QX<&#"97)ES)4AU26F(T:.VI:UJSA*4ISG.?3``,N'@;# MD?)U\JG://39JV3+X;XVKAZKPJ-8LK3#5.,-.2;KG+D:13-N*2A=CK:DN.HPMO``/;_*3\KWCOOGB7;\+\3^A MQ.V]?\I:R!SJFIM#@V]C-U_5=OF0Z[9&-AKU18=A"V79:F2[30J9:,62I,[W MK8^FTI*P!:S\='C%(\0?#CBO$+=J,WN--KSVP=#7%=1(;5O^XSY6S;/$3+:S MEJ0G$*7_+7P\`%LGRL?Z=7EU_" M"Y_\\KP`<@^#?_2V\7__`%U_YB.M@`KZYI_S+WD)_""E_P`M?#P`=5^?;@^_ MOZ+P'S:Y#`D2MY\0M]:OKS,*/(EO1=4FW6N[!3[7+C1L8E/5VC;GJ\93V6EM M?1BV`>X<*@]>VKLM/H.Q1M>;F[5R*WCV3_1JO9&H MR\SM>90;" MSZEXW;$_TVBJJ=M;MW=:D_"3#WRMHDL)Q-5[]AU'C/:]=UV'!Z9KV\/KU^ON+VLC-QIVSZ98.,?E MEO6;(XWF6U!8<7.B*=4PII6&TNN@">'BQYP^/_F;/ZPWX_;%8;?2;2U%U87\&?.9D:VQ:HBV\NI8_+G6?N7XT=+[S:\LX<9PAUP`2]`````! MP?RCXZGR#\<>X\1P\Q%D]1Y;NNF57-%-C4%F]C*'/YNLNU1Y&?3 M'KZ-_AZ9],@`H(^%GSRX_P"/W$]M$_++>Z3Q\ZIP'HF_1:Z!URZ@:A2/4EG M=3+R^H6+VZ?B4\'9-?W5^TP]`<>2J2F2RY%R^I;J6@!X)._UWRE?-=QS;>-_ M<;-XX^%=33W=CO>84G]WK*XTZZN]J@[#5XE(2WES:>DR:ZOKE9^DY*@5"YS2 M5(:R`"TCYI_&"^\H?!+>ZK3*QZZWODMW5=JU.GB,+?L+A6H0;BNV>IKVF<*D M29\G2;^R7&C-I6N5+99:2G*U)S@`1O\`#[YJ?$F+X-:7M':^GUVN]DY%SRLT M[52O[;:[AOMS!?6AO+NNSMKF0ZZ M%[4,I]U(]^Q[/I>@`ZO^HO\`]/VJ_P`0?./Z.;^`"=?C?O,SF'Q:\%Z57P8U MG/YYX!\NWF#6S%NM0["9J7CM17\:#*=8]'FXTMZO2VM2/VL)5G./Q`!&[XE_ MDWW;Y&OZ_OWQY=JO-OZG/ZJOR[]V;NVN/SK^L+^LC[S[W\T89^V_+OW':^G] M/U]_UU>[_HX`!_'JWSB^'W".S==X7U^HZSK6YPWF1?;%,:QT):4V6SW\F58RO3/IF3*7G'IC/H`"X7Q.\NN'_`"%\6W3? M.40=P_<%G:MCY#L,/>:2!16X]AWS7?6WT5ZOLIVMO[?/C637U:NZJM*TBE>9:EH5B)+L[G[)MU M2U8`!:C\L/R1;I\=>O<4N].YKJ_1U]3N=WJK"/LMQ;5":I.JP=:EQGH;E6T[ MEY4K-VXEQ*\?A[$YQG^7U`$ZN5]SE;SXE\W\EKB@8A3=P\==/[G:ZM63'%18 MDK8.:5V_3J"OL)32G5,,.RU1VGG$95E.,*4GU]<``J"OOU'/A)%YO-V;6]0[ M7;]`Q`5FLYG:ZO34CKUNI'M:8L]MC[#<:_!IT/Y]79+*I4C#./_+*=MY27&GX[J@!`O]0!Y6T6Y^2W$_#;9[39*'BG,+74>C=UG: M_!Q,N;.SV_#66AHH$>KIZN&VKH*E(BU]?%;:;QG.< MX0C&/4`'A?E1^3_4]J^,C2]W\?\`][:QCS9LMXYMKUCL-:U1WM+S_1]AN-6Z MX_,9@V5G%BS+MVJQ4,M8><^K7VCKV,H6WA.`!'OX\OEX^.WPG\4.:\-_*>X2 M-OAQ7]HZA=5/.J%R'?\`2]E^E*V28Q)?WJ.],A5:&H]7">6TRMROKX^5(2KU MP`"Z3Q<^4GQE\N=)[]T#EL?I4+7O&W5:S<>CKV_5*ZIF9IK6HW>Z8501:[8K MK-I);@\_GY6VK+/HK+6,95[\^T`9>?"7Y*?'S6_.[R#\]?,:)T*UZ%NB)L#C MM'I>MP=KBZ/67^7:>2W][:;'0KA+U/GU9"UZORE+V7XH<0TZI#?N5A"LX],@"ZH``````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````'E-XT72^F:I=Z+T/ M5:#=M,V2$Y77VK[150[JCMH3OIE3$VNGLOQGDI6G"D9RGW(6G"DYPK&,X`$1 M^'?&OX->.&[KZ3QSQSTO5MZP^[*@[+.F;/N-C0R'TJ;=>U16\7VR-:@XII:F M_6K3#SAM:D8_94K&0!.,`',HW%.-0NF6':8?).91.QV\-%?;=9C:%JK'3+.O M:K(-*W!L-\:JD;3-AMT]9&B):LVO4M4WS7+?3]XUG7 MMSU+8(:Z^^U;:Z6MV+7+NO<4E3D&WI+>-,K+*&XI&,J:>:6C.<8]I<\TFC^]_)=/T;7*?4M6I_S.QEW%C^5Z_00Z^IK_S"VL'Y M3_TF4?5DON.*]5K4K(`\]&XIQJ%TRP[3#Y)S*)V.WAHK[;K,;0M58Z99U[59 M!I6X-AOC54C:9L-NGK(T1+3DI2,1H[36,>QM"<`#HTJ+%G19,*;&8F0IC#T6 M7$E,MR(LJ+(;4S(C28[R5M/L/M+RE:%8RE2-<$XOX\:IC2>'\QTWE^L9>Q)DUFH4D2J_ M,IF$Y1BPNIK2,V-[98;S[/N9CS[_`+,83[_;C&,`#K@```````(8^0OQY>%_ ME5?M[9WC@.H[MMB&(L5S:XTS9--VB;%A*QF'&M-BT2\UBYMV(J<>QM$I]Y*& M_5&,81G*0`=KXAX]\3\;=/QH/"N9ZIS'5%2E3Y59K%C:?KV[Z^BUAMR&8=FBFV: MNLZY-A%9ENH;>PW]1"75X2K&%9]0!]M'TG38FFL-Y=P3A?#_`,\_ MJ6XMR;D'[S_EG[R_U7N6,:WZOPKCG3K:'F.J):=#YCI.Z6,541*T151INR4EE M)8S&0XK#>4JQ[,*SC'IZY`!TN@UZ@U2G@:[JU'3ZUK]4SF/5T=!60J>GK8^7 M%NY8@5EN<@`Y=TSQM\=>U6L"^['P/BW6KRJK_R MBKN>FRH<"NDW4NHU>MJJ^3;2:^JBL.25MY>6S&:1E64MHQ@`,]"J;R9FUHMJK8,A7U'H$';]5LJ+:8L!3N?J?01,PUAS]O"<* M_$`'VOCQXB>-7B?465-X]Z^WQ=SZEJ;8[%>(A^_[-F[VR_FV^T7$: M$IU:F6I,QUMI3BU(3A2U9R`/=]/X9Q+MT>GB=GX[RSKL77GIDB@C=/Y]J6_1 MZ.18HCMV#].SM=1;-UCTYN(TEY3.$*=2TC"LYPG'H`/=T6O4&KT%/JFLT=/K MNK:[3U^O:_K=%60JB@HJ"HA,UM51T]/7L1ZZLIZRNCMQX\9AM#++*$H0G"<8 MQ@`<8;\3O%AG;&]\:\:?']K>6I*9C6YM\;YTC;&YB'H^-/C_TC-_X"/!;_V+O$W_`-W/ MC_\`Z'``]E;>)WBQ?Z=J?.[WQI\?[KG^A/7,C1M&MN-\ZL=.TR1LZU5LJ?FQW+%-IEEQ\JDW-W14$[*9C4C7Y^P[DUJ]C;.V%C"M4U$/+,)J M/G#V7L@#T_.GNN_#I\B'#?%^7V+=NL^%_E3^44.FP^BV7UW=$V2^O6--B/17 M&V_RVJN]6V-RM_,'H,>#63::T0IYI#S*7(X`O!^1#RO:\+O$GJG9ME9 M7Q]:YS72F?N(DWH>U/?E.LKG1_>UB165$AU=C,;]Z,NQ(3J$JPM20`9]>*?# MMY#>87CU6>977_+3JM3Y8=3H'>E\H:GS)3M;25-PPNRU&+L%UBP[E776[^./B/S3N$SDO.]DYW8S^5;%TB_O=K\-/$C:-HNK;9-FV3QCX+?[%L5_8S+B]O[VX MY7JEC;W5U;V+TFPM;:UL)+C\F2^XX\^\XI:U*4K.<@"3@`,V/RSVWE%TGY#O M#[Q/\??)?IOCLSUGE=[->M-'Z!T'4:9VZ:M]XGN6.Q5FD[#39N%MUVGH884I M.7&LNJ_:]N?3``^;H_Q0_*!KFZ:AL-]\K/6-CHZ':-?N;G7I74O(1Z+?557; M1)UC2R69F\R(;K%I#86PM+K:VU)L,1]8T&35;#(V:[Q-VN-.@5[S3T6(RA]B-(G-J>_\F1A[*5H` M%!O7O#+YS_&;3M@\D*CSIV'L%IHE:]M>T\^UKK'3MO9Q55<9-C>2Z/G71]9B M\_VB'51XBW%P\0F9,AA*L,1G'%Y9R`+H_BE\\)GGSXSIW[;*RMI.K:#LC^@= M.@4[;K%/86\:N@6M7ME-%>-5WG5(.I\XLVXB]Y5)N;NBH)V4S&I&OS]AW)K5[&V= ML+&%:IJ(>6834?.'LO9`'I^=/==^'3Y$.&^+\OL6[=9\+_*G\HH=-A]%LOKN MZ)LE]>L:;$>BN-M_EM5=ZML;E;^8/08\&LFTUHA3S2'F4N1P!J;`!QGR)[9K M/CAPWJG=-O0X_0F6_FEY?>2W1M*@[GLNP9X%HNG1L2*'4JW7[.75M7E M+37$[\NH=:K[N+(AQ(L-MFPG9B.2WYV7'_J+`$N?B0[UWKCODUY"?%]Y1[M9 M=!V?CD:1M7(=VOIMC.L)^JP?R);E+#G6[LBTDT-WJNR5M[41WUK<@1\RV??E MM+2&P!*+Y$^4_)]W/K&@\Z\+NM5/">)HT5NVZ1T.;=Q-9FN[I(OK^*FJ@W%) M1[%TEQR+KT1AQMBO:BPLO2$9D/XS[%-`"FWLLWYC/B&GZ;VKH?D9/\H^*7.R M0J3:8VS;WO75=81-DH6\UK6QXZ3!;V_1EW4:`[]C9U#R6$R$80ZOWNXCO@#3 M_0=KL.X>)#/>^!P7)>Q=$X58=`Y72SVXC\EON6;4IV/7/38&T9; MA24K<3'4ZVO'O]G[0`,_-E\>_P`\O3:Y72MO\^D:3O3OW=Q'YIKO:^BZ?7L2 M<.8E,U%A7\KU.LY@P\^^WE"&&43*]#64)R[A"G$H`$AOB&^1+R*Z7V+J/@KY MK17E][Y/`NYM)M=C`@5NPVB=/M(=-M.H[8FF;:IKBUKVY[,VNM8R,(L8"'G' M''E?2>>`'3O/?P(^17R'\@I_1O&KSBO^!>!VN\[LM\^2OL'0-IZ MIMV=2TGG/.?(?R3L-TNG&(OU9]K$K;.;6ID5\&;(A0\X;4MYR78,-MH5[E92 M`-??B'I?4^>>,7#=,[?L]MN77J+G.O1^C;'?7MGL]S/VQ^)B;;MV6Q7$F797 MRS[L>B?.6U\ MKO'6%U/C7-M:TK2^V],;\++>EM*]^QZ[!_>WD:LO=#:9ZM?N5KOUJ_7L>C\7 M6,^DY_\`9_95F.`-''@;T;Y&=_\`ZU?^/[@G)N'_`)3^XW]4W]5US5VW[S_? M_OA^_GYY^6]IZ_\`;_DOV5-]M[_R[W_=N^GU_3/T0!68]\CWS+],93N_$/C& MJ]=YLXJ/81(/4XVX3=QLZ-Q/UFW:[,W;^0S)CL^-CWLO1Z20UZ+3E*7<93E0 M`E3\='RR->7O1ML\;^X\BL_'OR>TN%/L9&ES\6[=5LD.FRPF^9AP=A@P-@U; M9:/[E#KU3-P^M<3U?:?`M=PGJ_/-'YMO'#MEWU.E]F3 ML]!MLS<:)QU4:WK,$#R"\A]9YGJ$K=MKV!CG-/S37]LHHDG1M>?;HE7UQC; M=VW*6_-M-I@V+;*6LL-8B1FG:M.2[[D^C2G$YSG MU<`!^/G.1G=_,OXJN7ZLUF7OCG4KN;F*RE.'4P-NZ7P^JUZ2\ZSER4U$;FZI M9+6XI&&V4-+7C.?1?M`'H/U(]U9V7&_%/D%>](:3T?O$^R5AMM;C#DO6M:QK MU?B0AI]+KRD.]#4I#6&E^_* MCWTR"E&<,)MMEL.<=D;L\I5]NI"D.VTUMO.$K3[9BL8QG&<.)`$I_P!1?_I^ MU7^(/G']'-_`!9KX$?W%O"[_``F^.?\`8_IP`)9``SQ>0'TK[]1?X21H[.9S M6J^*^SN7#;K/N8KY.=7\LIL25A+V/8I2'KF!E+B/7*75)],X4C\`!H=```!X MKI6VT&@\YW_>MK3&7JVEZ5M6V[*B9EG$-5!KE%/N+E,K,A*X^(RJZ&YA?U,9 M1[?7W8SCU`!G1_3,:5;UOC_Y(]`DH>13;;US6M7JL.)]K;LO1]1_,;60QZJ] M7$*QO,=M2L)]OO:RG&K^GT/1>OZHK:8[V$_<+; MS"VS6O?AUQ?W4G[>\U:OI[O M16`!-KX[J2!0>!7AI!K6U-1W_&/B5VXE64YSF?LO/-?V.U<_92C'M=M+5Y>/ MP]<85^.D8_=Z(IE6?5MM;3*E^J4*P`#2\`"F;Y\MMH-<^-/JU/I M:IE_+.'47\/H5'O4E4/ZJ5+S)SJVEV6,_3RE?T)6O7B'F[%WD=1M"FI"?IOL1-\FV&\UD=UO*E*;7'K-C91E*O12?;Z*PG.,I MP`)_@`RS>.<>-UO]1WY,;SI;2$:[RW6=J;V1R%AG,3\TU7F'/N%[`S(<9^DU MB9(WR6^XM'HIW+S;F58SE+B\`#4?.G0:N#,L[.9%KJVNBR)UA83I#,2#!@Q& M5R) M)$^%J'C[3V;;GV5OM5:\_)T^Q1!=D\B]2UK=XCS<:SUFIJ-RWNTHY+J?>B-L;'/M:VK&M2?IYPK+<_ M,9:4*2K.,85C.0!0IUGLW"^N?//X/=D\9.@:IN]'O>BZ@UN>TZ9,:D*D[5E7 M:=!MJO8XZV6;&JO/ZNH%7&8S+>RUT=N2I*V\N0G7FLJPAQ7J` M,=K7EAU/RI\,?$SXG*:/;PNS+\B5\JWQ`&X?EG-]5X[S70N4:/!36ZASG4=?TO7(>,-_4 M;J=>6I:O52LY`![T`````````````````& M2?R.V/?>6_+GN%E\2-1<]/\`(C8J"Z?\M^6S:VJE<(?\`<29<)D`>K\";NSZ=\KFX[3\FC%WI/G;KFL1H M7CURNQI:>JX_4Z^S162G\:%:P]CV)G8;N)3VEA)J6D/28BLKG3DS)=AZ?:@# MHWZ@%2L=Z^*Y&%*]BNP]+4I/KGVY4G<_&;"593_)E2<+SZ9_V>N?_A`!IG`! MEHUE2D_J>.AX2I6,+TZ$E>,9SC"DX\+M&7A*L8_Z2?>G&?3/^W&,@`EA^HO_ M`-/VJ_Q!\X_HYOX`+-?`C^XMX7?X3?'/^Q_3@`2R`!1YY\_$IT[R[\JM8\D. M7^5=EX\RX_,F>:7TB@US8)6TPJ^"_=J^K1V.O;MJ#MA#V*%LDF-.BO28B$M- MXQZOI=4E``K"W]/GI\&_8^3[QM_D%M/E%XA=#VIK7-JBWLF_5%<6E+TRXJ,: MMM&P;8K0MXS1XD651*K;)UBP]*5_2D1GDK3ZXQGTS^.``4.?/GY06&B>/FI^)'.,2; M7L/EIL-?K+=)4_SUNWSZON:U-BRRRA*UXF;OL[T&FBMJ]F)<=R=A*O5K.``6 MB>#_`(R5/A]XM\BX#6N1IEAINMH>W"XBH]K5]OM\^[>;I;MJRG#JX;^P3WT1 M,.94MN$VRWG.?9@`&=;R.V/?>6_+GN%E\2-1<]/\B-BH+I_RWY;-K:J5PAS8 M')]/(M$W%]/V?4F:Z6]:J9D7;KD^`FNO7L-1Y_W$F7"9`'J_`F[L^G?*YN.T M_)HQ=Z3YVZYK$:%X]GVH`U6@`KM^5SQ_O\`R5\">_QRH%==NJUS,>(_!8>\ MUMB6AJQ>UN.WMR8R)#[+.7EQ'7$)RQEMQ8`V```RT?(I9O?)1\H/`/CUT^;( M?Y/P6;*V[O-O796N,W8JAP;[?&%R&4J;:?H]2C0J"%(RK.(]]=OL.(]49]0! MJ-@P8=7!AUM=%8@U]=%CP8$**TAB+#AQ&41XL6,RWA+;+$=AM*$)3C&$IQC& M/P`!%'SI\I*+PW\6^K=YMU1G;36J%RNT6GD*Q_\`6+HM_P"M5I=+AO&%N.QG M+F0A^9E"5J9KX\A[TREO(`*S?@+\8+?FWC?M/E'T3,F9U3RWV%W<7)UFS[;- MGGU596^-?DR%N)]_W.Z7<^PNW'&\X;DPY4%7M]S?J`"RGS[XUV#R%\/^X\4X M/LU#J/3ND:W6:U4W6S6,^IH\T4K::%S?:6?85E'L4V,C9^?LVE8C*(B_5R8G M"ELISEYL`9R?&WRX\L/A4G\]\6O,WQ]UZ/XV;#?7$^DZGH#2;"V6_<6BYNR[ M/`V:IF2ZG?9-0[/8^ZJ)\>!>1Z]MC#?M:Q&;=`&N&@OJ;::*EV?7;*)<:_L= M377U%;P'Q<\Y'N MVP:NXZSB0RUM;-)*8U9V0PIIY#L9K8'XRG$J3E&48S[O3'KD`%&_PB?'QX^= M*\7F_+'R'Y?IW>.E]SW3H$^!8=;I:WH596:WK^UV>HRUIU_9T6].]L5SM]%: M3)=C(CJFN)<:2E24IRIT`'''%K`&J3>]UUSFVD M;AT3<+!JIU/0]7O]QV:T>4A+5?0:U52KFWFKRXMM'MC0(;B_Q5C&?3^4`&"S MQX[1OG)/-7CWRH]!TBIU[BGD#Y7=QJ)SC,>$Y"H(&T?2@[].:]K#*(;FOU?4 M7WX4G*V7[&523<+S[,.Y6`-_;;C;S;;K3B'6G4)<:=;4E;;C:TX4AQM:OM MDJHZB99I85Z+;S[7LQ?;G]I/\O\`+C^4`&>[].#KC>P\.\H/(>_6BUZ/U+R, ML-'%NO>S'L1.ONI37W,(SC#CGIE6/V4>@`\K^H/^GR M#=O`SRVUCWUO0>7]6M:Y-E!]J)]G64U#\:IGT]AAMI2TMJQ:/ MI7A25_L@#^WZC1IS68?@CV+#'HUS;M&X-+L/9(?^T9DLM2([K3\=]IMYA]EQ+K+S+J<+:=:=1E2'&G$ M*QE*L9SC.,^N``9=?'+*ND_J/O*+:([;%@WH6B[-B1)0C/I7IU7G7*./+<1] MO]9M+[,NOHYG"0`2G_47_P"G[5?X@^OK^'T??\`[?0`%EGAS,DT?A-XKV&Z2F:V74>+/#YFV3K!^*Q' M@2:_DNL/WLJ=);5B$RS%=:=6ZM*L-)2G.<9]H`*"O`V'(^3KY5.T>>FS5LF7 MPWQM7#U7A4:Q96F&Y:Q/OZWFZD1Y*6UXDP:O-GMDQG&%*@7-E%SG.$J1Z@#3 MAOFR*T[1]SVY#"92]5U38MD3%5Z^V2JCJ)EFEA7HMO/M>S%]N?VD_P`O\N/Y M0`9[OTX.N-[#P[R@\A[]:+7H_4O(RPUS:=BDH2NSL&]Q$Z^ MZE-?F58_91Z`#ROZ@_Z?(-V\#/+;6/?6]!Y?U:UKDV4'VHGV=91S M=8W^B@OJ5[4/QJF?3V&&VE+2VK%H^E>%)7^R`-,P```*U>N?$+\>G;ND3.K; MYX]UBMON+!^VV5W5]LWK2*?:K*2_F5(L+W7]0V6EIG;"5*6X[(DL,L2)CCJE M2%NY]/0`52)YKSUS]07P+E7(-2UK3N=^)_CW]G)U33:VOI*K7D9YYT?;XB5Q MX$:)]:;+V/LM=(EO.YDRI3DE2W7%*6KV`"]_S4\G-<\/O&;JO?=A^VD/:;KS MK>ITLEQ2,;-O=PI-5IFNIPWZOY9L;^4S]RMO"E,0D//9Q[6E9P`*I/@.\9[S M6^-=#\TNK-2;#L?EMM-S?1KNU;3BT5SUF]F3W;16,^UR.]T#=GIMF_\`LI3) MB1X#J?5/MSD`:`0`9;ODXV*R^17Y&_'?XU]"F2W^;WV82CVIP`+%@```````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````9EOU`/^_P`^*W^+ M_3?Z9^,@`+S/-/C]OW[Q+\BN.:]A"MEZ!R/=:/5VG7/I,O[2JFDRM9BR'?QH[;B_QPA"LY]%>GID`4?\`PG_(=XX-/D'U+4N%]#X!M6_P`7 M%5U2SAZ0FXUW9=MO=T=S62+Q4%$[8:G9+NRA2ZSUS8LJ:;_FLI<3C``B)N?D M6WY3_.KX;=>URLLH_)+!&NZ]PS8+2&[7/;[SC4[_`*_0V&\Q($EEB9%I[GJ$ M+9$06D`"RWY]?(2ZU3QVT'Q/YPI^?U;R\WJKTZ-25CJ/S M1_2*6WIW;*(VA&%/LN[7MMA3U;25?33+CNS$84K#;B<@#W?F)\=5))^(9KQ7 MU&!%G[;XY\SI>AZ7*AQV/6YZ?H,"PV'>["$W(2G+,WH^;;86L>U;7H_;8SG/ MMQE.0!UCX9O*=7E)X+\VF7EM^9]$X_\`4XST#+[K:I[TG3XL3&I7,G'HA^1^ M=Z++K7')2T_S\]$K'O6MMS(`+6````````````````?67=/`V&FMZ"U93)J[ MRLGT]E'5A.4R(%G%=A3&586E2:K[* M=K;^WSXUDU]6KNJK2M(I7F6I:%8B2[.Y^R;=4M6``6P_-/XP7WE#X);W5:96 M/76]\ENZKM6IT\1A;]A<*U"#<5VSU->TSA4B3/DZ3?V2XT9M*URI;++24Y6I M.<`"-_A]\U/B3%\&M+VCM?3Z[7>RH5**:HL=,@8C MK1>M;VQ`8D*?;7]K729+B)2V&VLK`!S7X%.1;_NUWY4_(7U2M=KKGR@WJYB: M0B4WGZ\JE?VVUW#?;F"^M#>7==G;7,AUT+VH93[J1[]CV?2]`!U?]1?_`*?M M5_B#YQ_1S?P`6:^!']Q;PN_PF^.?]C^G``K9^-7Y<.A>='E%T[Q^VOD&FZ)5 MZ#S7=-YC;'KU]=V5A8S-5Z'HFE,P7X5DRB.Q&F1]NN,YR`" M0'DW\P'B_P"('D%=^/O=*GI5-;5VL:SM=?MVM:]!VG6K"!L<.3(3$DLQ[:)? MUUE%?BJ;]J8)&785KMEYFO?M:&CL\ZPB77ZE4JD+F2I,V2](4EI3B(0`LS^=CR@ M=\6O"6#QOGC+U)L'D&N1R*H?KDN,1M;Y?0U,-6^-Q7T+]&WK"CDQ*1ME6,Y5 M$LGW$YPIG'J`((?'E\O'QV^$_BAS7AOY3W"1M\.*_M'4+JIYU0N0[_I>R_2E M;),8DO[U'>F0JM#4>KA/+:96Y7U\?*D)5ZX`!=UX>_(!XW_(]3=DH./UW0,5 M>A5FM4^]Q]]UNLH$RX'3HNXPJ]FLQ"OK],Q*X^ISDR/J8;PCW-^F%^[/M`%) MGQ)^0NE_&WV?RF^/WRZVZ#R-V)U).W\[W7>)K.OZ'=27*R+0R;"9>6"F:O7X MF\:=645K63)3C41^,EQMUQIU#3;H`^)\AG8=/^5/SM\0O#7QINH?4>:K[*=K;^WSXUDU]6KNJK2M(I7F6I:%8B2[.Y^R;=4M6``7:?) MSYJ;/X%^.$'N.IZ30[_9R>E:QHSE#L5C85<'$._JMEGNSD2ZU#DC$F.[2(PE M.4Y2I*U>OX^F0`>D\-O,"W\E/!74_,#:-,K=:M+O6.M;+8Z906H`KEOOU'/A)%YO-V;6]0[7;]` MQ`5FLYG:ZO34CKUNI'M:8L]MC[#<:_!IT/Y]79+*I4C#./_+*=MY27&GX[J@!`O]0!Y6T6Y^2W$_#;9[39*'BG,+74>C=UG:_!Q, MN;.SV_#66AHH$>KIZN&VKH*E(BU]?%;:;QG.9U-5<0:ZR ML45\"TWZL0RX\W('J M,?S1^'WEGW#2/'[EE?V)C?-__>7\B=VK2J6HH4_NKJ%_NMG]_81-OM)$?W4V MMR,->UASWO90G/MPK*L`#[GR=^7_`,6?#_OMOX_=RK.GU%Y7ZUKNU1=JUS6* M_9M5FUVQ0WY#$5W$6\C[##LV'XRT*1B`ZQE.4J^MCU4E(`I"\U_-+H/S1[_S M?PK\).=[NQRF+N-;MG1=_P!OJ45[+BXF9%7#VK:VJIZV;U+FVH19TF4G$J3] M[;S5LM-Q4RFH[+P`UC\:Y;K?#^2\UX[J"%IUCF&CZQHM(I[&,29$#6*>)4M3 M9F<95]2?8?:Y?D+SG.7'G%*SG.F2Y%)"< M==B*96XN(RI6-2-EH& M-BL5?^,L-MH-9O:;6]PFO_\`\5VTAS''5>@`)&+\>>`N[3I.\.<.X^Y MNO-*.KUCG&X+YGI:]IY_K5'F=FEU[2=@529MM4HZ?-I)S%B0'F(\?[AWZ:$_ M47Z@#[':.)<8W?==7Z3NG(^8;?T71\PU:5OVT:#JE_NNH*KY[EK`5J^U6U3+ MO=?S!M'ER6$YQ[E>H`ZD````````` M````````"+GD9X4^*_EHU6H\AN*ZET>73QGH53>3,VM%M5;!D*^H]`@[?JME M1;3%@*=S]3Z")F&L.?MX3A7X@`^U\>/$3QJ\3ZBRIO'KC^I\RCW7V^+N?4M3 M;'8KQ$/W_9LW>V7\VWVBXC0E.K4RU)F.MM*<6I"<*6K.0!(X`%?.[_%1\>G1 M>AO]3VWQ;Y_.W*7.?LI\B#*VK7Z&TL)2_J2IUQI6N[#4Z3<2I3WJMUR57/*= M<4I:LY4I6<@">=+24VM4]7KVNU%904%'7PZBDHZ6!%JJ>GJJ^.W$KZRKK(+3 M$*OKX,5I+;++*$-M-IPE.,8QC``/*]&Y7R_L.OHU+K?-]"ZEJK=A&MV]9Z-I M^O;OKZ+6&W(9AV:*;9JZSKDV$5F6ZAM[#?U$)=7A*L85GU`'IZ"@HM4HJ75] M7I:G6]9UNIKJ#7==H*Z'3T5!14\-FNJ*6EJ*YF-7U5355\9MB-&8;;989;2A M"4I3C&`!RSGOC;XZ\CV6RW/E'`^+7]5C0T?3 MB1^D:!JF\L16_K(D>R,SL]3:-L(^X0EST3C&/?C"OY<>H`/2Z9H>C\XHV=8Y MYIFJ:'K49U;T?7M,UVHU>C8><0VVXZS4T<.#`:=<0RA*E);QG.$XQG^3``/+ M]/X9Q+MT>GB=GX[RSKL77GIDB@C=/Y]J6_1Z.18HCMV#].SM=1;-UCTYN(TE MY3.$*=2TC"LYPG'H`.0?\!'@M_[%WB;_`.[GQ_\`]#@`=9Y=P3A?#_SS^I;B MW)N0?O/^6?O+_5=SG3]`_>'\E_,/R;\\_=.FJ?S;\I_-I7VWW'U/H?73QGH53>3,VM%M5;!D*^H]`@[?JME1;3% M@*=S]3Z")F&L.?MX3A7X@`^U\>/$3QJ\3ZBRIO'KC^I\RCW7V^+N?4M3;'8K MQ$/W_9LW>V7\VWVBXC0E.K4RU)F.MM*<6I"<*6K.0!U'HW*^7]AU]&I=;YOH M74M5;L(UNWK/1M/U[=]?1:PVY#,.S13;-76=]V%?CZ^H`._@`C_OWB=XL=6V:9NO4?&GQ_Z1 MN5@S#CV&V[]QOG6X;-.CU\9N%`8F7VPZY8VLEF##90TRE;JDM-(PE.,)QC`` M/&_\!'@M_P"Q=XF_^[GQ_P#]#@`=?8X9Q*+S!7$8W'>61^,*9D1U\\T\8O'GGF[4?WOY+N&C<6YOJ6TT_P"9UTNG ML?RO8*#6J^VK_P`PJ;!^*_\`2>1]6,^XVKU0M2<@#U_1^$-:\II< M:UR[GNC\VUU*\.)H-!U.@TZEPXE/L2O%5KM?70<+2C\,9^GZXQ^``/<````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````KT^-7SR__``AW M"]K[3_55_5!^['6;WEW[M?OS^_\`]]^2Z?HFV?GGYS^Y^D_;?<_OM]O]M]JY M[/MO?]57U/8V`+"P`````````>0WGH6@\PUZ3MW2]XT_GFJ0EH;F;/O.RTNI M:]$<<2XMMN3=7\VOK6%K0TK.,+=QG.$YSC^3(`/XZ'TKG/5*-&SCZV MXM+;>P:'M5%M]&MQ32'DMHMM>GV,!2U,N)7C&'/7*58S_)G``/:@`````_"E M)0E2UJ2E"4Y4I2LX2E*4X]5*4K/IC"<8Q^.0`<2HO)CQOVC:'M(UKR!XCL6Z M1I+,.1J%%U;1+;:(\R0M;;$5Z@@7TBV:DO.-J2A"FL*5E.<8QG.,@`[<```` M`````````````````````````#CD7R*\?9V]JY=![KQR9TU#^(J^=1>G:3(W MM$K+WVV(RM19NU[`E_,C^;]F8_N]_P"SZ>OX``[&`#]''&V6W'77$---(4XZ MZXI*&VVT)RI;CBU9PE"$)QG.0W`>B[-.TKGW<>/[UN57EU-E MJ6G=,TO9]FKE,-+>>3.H:2[G6L3+++:EJPXTGVI3G.?PQD`'8``````````` M```````````````````````````````````````````````````````````` M```````````````````````````4VU70]1[5R3FUY=J:32TN_='T M[3K:W4^I2&4U==L-S73)ZGEHSA.&D+]V<9QC^0`'482]CY5U&32J<3?H&^GXJQ^``*K?@;\&_*3PP_P"*K_B5 MY?\`U;?UD_U&_N7_`/7;G>X?G/[G_P!<'[Q__J#MNT_EWY=^],#_`*W]#ZWU M_P":]_L<]@`I(X?_`,P+=?\`XP7R$_M%Z6`#>:```#!E^GL_U%:/^$'4?_,Z MH`&\T`````````````````````````````&>G]-7_<6ZO_BRWK^Q_A(`-"P` M``(-?(-P3R"\E>#1>2>.G87N&;/?[Y0N;AOD:[V&CE,\XCU6PXV.HCO:MA%S M.7;S7832HB'HS7MWT, MZ[:PVTY):Q_/8`%J_PK^<> M\>:OB]:N];G-7'7.-[6C1-JV-#,:,_N%),JHUKJ6UV4:*EEABYF,9E0I>6VT M(?>@9D?@IY24`"KGCO*,?.5YO>0'6^W;/MR_#GQSML:/R+1=:O%5=?L&9\V= M&IU19\=#J8>;^JHG+N]E1O\`R]:IL&*W(Q';;]@`_ETOB\?X3OD/\9^A<2V3 M:6/$_P`H+7'.^C:CLEPNVB4+2+JCJ=D8FS5Y:5/9UEC98%]3296/ODJCRXV7 MG&W5? M6T:9*I$LRHT-'W-:TNU3E>$Q<96H`&>_X1^>[IR;Y;/+CF71MP=Z!ONB<*ZS MJVX;J[.MK16R[#3]LX7#M+7%E>J5+OQM\9VAS37?(^5KUGT&SCSI,%5Q5[CO$G0=/I[E^(IF3C3H$ M^EM+"RC)4O[[[=E.4_S7M=`'MK[]-UX>2^<1*#6^F]LUWIL*O1A/3)%KKUU7 MS[WZ;'U)MIHBJ6OBJID2&W%LPX=A!DMI7A*YCN4^_(`O&X-H5[RKAO&.7[1L M2MOV;F_)^=:%L6VJ7,<5M%[I^H4^O6^Q*78NOV"U7=A7.2X1L?CWTNUYI=[7TJ_I-@GU5;K]DY9U<3 M5U3X\1UO8*BW8;0U+Q[\*;2A?K^&<^GX``OC`!F6YI_S+WD)_""E_P`M?#P` M::0`````9?\`8?@)[QY'3[[?_+#SNVBXWJ^N9UI`HX>O7O3:;6(LA3V8,)NZ MVW=MQEQ;:D_3`'-_`SL/E;\=?R*U/QP>1W1Y_4^2 M='^E`YY;VEI/MH54[>55A:<^VS1W+R3(MJ"JV"SK7*:SI%.YC,6"W'&OJ*9P M[)`%B_SH>6&\>/7BYK_,.23;6MZSY/;:YS2@LZ&2N+L%9JL1F)(W-_7W&,_> M8N+?\R@4[:VL)<91:K<;<;>0UG(`AKN_Z>KDE!X93).KWF\2O,S5]$>WG.W1 MMB>D:]LG1:VJS=S=`A:XTQ]I'UZ58,N5];-9]EDA_+4EUYU/O84`)\?"=YF; M/Y?>(3">DW#][UCBFQ9YGM]Y.4Z[9[14-5D.STS;;24Z_(>6G'U,*4`(Q_./VOJ6X[)XT_'+PVVF4FY>5>SUCV]64&8[$WVQ_:9+LO?&UY52?,KPZY+VR[S&3N\R!/U3I#$2/B)';WS3YSM+=S&(R77VX M\:_;89M&6TK5AIFQ?N:?QGW)_#"P!8+\^_2,:%\>J2O"<.,-3K6+TV.U[O3WNM)9Z+CV*5Z^U./9C/M1C& M`!"'YSF/ZZO._P"-;Q@3A$INXV2%-LJ]>/JL?EW7>L:;IC\R=':PEY41B!S^ M6I:E*SA+2'/;[?V\J`&I8`````````%#F]>5OD'5?.WQCQ4K^EVL;Q^V;FMI M=WG-4UNOJJ["T8X7U?:69;EDY4+V!M:+_7XGMRI.0!?&```` M`#%OY8^*&N>:WSZ]J\>]KVN[TJDVFDTFTD[!KT2#.M(KFK>)G.-@CM,1[+&8 MBD2GX"6UY5^.$*SG'X@`L'T?]-[PW1MTU#=H7D?UB;-T_:-?VF)#E:SJ"8LN M5K]M$MH\:2IE*74L/NQ,(7E.<*PG.?3/J`#2"`````````````````"I'PA^ M/?IGB]YE^;7DCMNZZ+L.J>3^[[IM.J4>NKO_`-X=>B[)U38]\AQMA19TT&M^ MX9K;M#+N8S[R!8UNOP&]6J[7:.\P+")$R[IU_>^?VFL\RIN91Z;5Z;7[&ODU]- MM6Y[4U9O/6R-UWU&KHMKIZJDE7>R-Z#U]'-H3MM$FIS`C+GP%?_93^R`#8 M=X&>%>K>!G$)?#]0W6_WRHE;U?;S^=[)`KJZR;E7]=15[\#Z-7G[5<=C%&E: M%^F%9^IG&?Y/7(`]?YM=^>\7/$_O'>H345^YYWS^TGZNS/:6_7O;G:N1]=TI MJQ8;4AQZOD[]V#KGD MG:[7L%78S-ZV.AEZO3P[Z=KT'9?J4YDT[\IK$]4RJ9K7(K+<-&4+R MH`=%^(3=N@>+GFMY7_%QO&X6>W:+S;-WOG$YUZXY)FUU9"L-;D,U\3*7/HU; M>X:)N5?;R(#3>(4:=$E*9RE3R_K@#2L`#)=^I/\`*9QZ5R#P]UFP7EF&S_75 MU1F/E649=?5-UWFU1*=;QC"?H-_FLY]A>]'V+C M&ZZO5[]6W6R3]DA3*N_>Q3P=EER'<1Y7V%W>/LT]W6*<_+I\>V2EMJ/A"TN@ M"]G9]KZ7YP_'K7[CXO[OGDW3>_\`+M&M]2W!-S;:^]SVTN;;7W-W93=T;,^Y M@S=D]"N]OIXRENY919?0?<]6T`"5/P9^;_;^WU_ M:_%GR:MK78NN^.)ZM+:9SEW^;]C2\I]%)4`#J>C_IO>&Z-NFH;M"\C^L39NG[1 MK^TQ(]XV2QN.9 M[IL^C7\W7M$U^IK'*R=;ZK95>CH7A.5,^J0!(SP7\L- MIV+X:)7D/O&Z;#L70^7<7\@U[)N&S;!,N-GLMCYI(WQW79DS8K9^79V5U.J( ME9E#CZG'UR'$IQ]3/MRH`5L?IY^M^3/?.]]XV?L'D'WOJ^F\[Y/45,;7NB]= MW_=M6A[5OFV19%5<9I=DV"R@?G,>GTFR9C.^SW(:??\`3\ZEZ-:Z`[S/JEAINTVFNP--7L*==T37ZFL19;ZP[F,ZYEMYZ.A>$Y4SZI`$C/!?RPVG M8OAHE>0^\;IL.Q=#Y=Q?R#7LFX;-L$RXV>RV/FDC?'==F3-BMGY=G974ZHB5 MF4./J0?>^KZ;SOD]14QM>Z+UW? M]VU:'M6^;9%D55QFEV38+*!^C[#4 MUSS4S+"L88RIQ'I[L*P`)`_J&/+[N/).^<&Y7Q/N'6.2*K^26V];4QRSHNYZ M#^_0*"1K M>OV6Q;1^0Q]IN;5NNF6C>YUGW:V\84XB.QC\,8SZ@#1H`#(!\Z?G'Y!;/Y0U MG@;PC9]BU:BIH^@5^UU6DW$FDV+I?2NE1:F\UK7K:WC.U\A%!7U-]68CP$OI MBORY2WI.7,HCXC@#SGC3\*?R*>,/D1XV=GQL_/[;6J[N7%-CZW2\NZQL<79( M.BPNAZU8[JQM<2_U_2ZC:(-=1.3,SHL.;9IDM(>2TE_"TX<`%_WRL]#\F.<> M(]O9>(ZMNQVZ]WW1=1U]K1-2B[IMDBOOK%YFZ8IZ:52WWTWUP&E95*;8P]$1 MA3J'&LI]Z0!D^ZK(^=GQOHW>Z=5WKS,U34X#T2197EEU>YVW4:7[I4=J*[L6 MH5^U[%K]#`=?<;:SF?7L1_K+PVK^<7[<@#1C\+_R5[7YU\VW71^RIK<]UXRB MA=N=AK(L2JB=&U'8,SXU;M7Y+"0S$K+ZLL*Q<:U;BM-0LJ?C.LH;^NIEH`59 M_J(?-SH2NK:[X8<[V:XUS2]>U*IVWKC-!:3*Z3NNS;?]650:C?I@24JG:W0Z MVU%GHB.^C4F7986ZVK,:,O``@3VOD/R#>`WA%L?*N]0OK^.?EY5:+6U.KKVQ MS8L<>Z5J>\:7V&HCS*YQO#6H;/=Z_J-C%DPH3CT.9A+BW5Y>A-^@`N-_3*?[ M@_)C^+^K_P!#$``J;^+O_7%T[^+_`);?V5=U`!H<^;?Y!-K\+.$:QIO(;9FF M[=W:9>5%!?H2U(L-&TJ@CPOWLVVN97AQN/?/2+B)!K774>U"WGWVO5V+CT`& M8[9?$OY$>!>.VB?)_(ZEM%.G2Y,2TVXGZ*WT=XD^#G=.V^8^R=?SSK*-B_.$ M,+4[D`&5"SW'S3^5CS%FV MNBR-KVSJ=Q87VU:'K<3<,TE!Q_2Z5_,N'"U^VL;"IJ-/IM5'GG\C6N[MJW(NE]N\@^,=1\?]$B\8Z)5:CU_==0_>Z^U[ M;=PO*W>-DCZ9LD.BO]CL-0V:L@KND9D*N8E='EY?>P[A>0!L7\R=\WC5_BMZ M=T/6MSVO7=_@>,>N7\#>:+8K>HW"%>OT6NO/W439J^9'NHUL\Z^M2Y*'TO*4 MM6C;AO_[O?G7]>'YS M^1_O99?DQ::IKN&GY"+?:I/1>BU6LQ'XT7_RN5%7>V$?+S+/\\ZUA2&_VU)`!ZOS M=\>2^Y;/"Z!U6[?E5G2=8Z+-G;-H^X*BYOV]+LYU&J#%TV>S M7Y?S"KZQQ=6F/#>:C*^FPI&`!LG^+KRNM?,CPOY9US:G67NA046>@=*>CM)9 M:F;GI`W9^S\6[TF7XYZ M^_L7>NE:=>\8Y*S':AOJJMQZ5,IZ6-L'T;'_`.;E.TD'[A]E4K_R-F0EMV5_ MY,AT`'8_(_E'G_\`&3Y$:5TKI?0=AINN[O&7O-)U/6M_NMLB[JY6V3"=AH]B MO9V(LC8WH,AYA%M73VW6'8\MKW8<:>3G(`WJ>*/=H'DWXW\7[W7Q68&.GZ#1 M[)95D;*U1JC8EQ_L]JI8RW'7G7(U-LL27%;6I65K0SC*OQSD`$@@`9J/GL^2 M;H?C\WJOBAP':Y^E[YO.L?OIU+?-=FOU^T:QILZ=*K-;UC6;B&I$BBN-FD5D MR1-DLN,S8T)F/AI6$S%*P`*XO!_XG_D2U7K_`(G>7MC4(K-9G=KXAO\`N]0Y MTA4#JZ>82^A:S9;);[;32G(J),"5IZG9,ZM]C``N]^;;Y# M=K\*>):IHW';1FI[EW.3=P*38<-M296A:-K[,-.S[9`8>;?CM[#+F6T2#6*? M1[$YJ_2;JU8 MQK72;.?AOUD4=I)LFYWHBU>E,PI:)3K249?^B`-5'PY>>MYYS>-$N3T>1%D= MNXY:6%E.Z9NFF\_P!7 MD:7,V/\`=96I44^7#4BN6TQ"3&BX:][#>/J-@#P_R$^)_P`AWA-NF@>2'>>\ M66Y;CTJUG8A=?YWTS=Y%SJNZM,L7,K5';*?7:K8T7I&C_4KVZYO%=F/"RAK# M26$MX`$L*G6OE'^;?C$K<:W?]4U#DW%-:A<\_=6=M&PZ?7=VZI2ZW53]LN9] M=K])-J[O9;MB8TO+EC]K3UKDMN-%PWAR<_@`>S_3_>;79*_R1G^'G3=RV+:M M$WC5]JFZ12[=;3K2?HF^Z+%?V"P@Z\[9.29$&HM];@67WE>E26L28S3S>$*P M_AX`;(@`````9Z?TU?\`<6ZO_BRWK^Q_A(`-"P`````.8=KZ?2<4X_U#KVQR M8L6DYIH6U;O/CPJ[%/;;9Q:R?*/:(DUU*_60NOA/7/I^``^+^I9I8[OAWQ+:/=E%A3>3-'2Q%)3C"DQ]@Y M=U&QEJ2]C.'&\I?U>/Z8Q^&?Y<_BG``+_N=WSNU<_P!&V=];KC^QZ=K-\\X\ MTPP\X[<4L*P<6ZQ%_P#)F75+D9RI+?["<_@G\/0`&9?XV?\`7K^1O_NAY"_Y M@^*@`U,@`R\?/;HN^<5\@O#/Y$M'J9-Q%Y%?:QIVTJ;^IB)6S]'WN3TS0(EH MXVA[+%5MSEQ=P7GE)^DE2&VE9RI]M.0!HPX9VC0_(CD>@=JYG;-7.E=$UV%L M--)0I.7XWW"R:3G/VES1633T*:PK]IB6PXVK\4Y`!U92DH2I:U)2A*< MJ4I6<)2E*<>JE*5GTQA.,8_'(`,NMIW'SJ^7WR,ZQI'AIW2V\6?#_AEFO77. MNZM.NZ>\W^Y3(DL0;=BZU695[/<2MES#=F0ZZ-85T&!2_2;2\`.Q^# MGESY=>,_FH]\;WR`[DSTB=MU.JW\?NV2U_7F[(C$>QFU423L#L6'.V"GVR+3 MSF&';/"K2%>0U0E.OH=:^D`)O_,/Y&]E\6/"K8NM\'W']Q.A0=^T"DB[!^[V MJ[/]*LN[5V-9QORK;MT/QYXMO.X77V5=6?G&T[;S?6K_`&"T_+J>)7U-?^86U@\[]"*PQ&:] M_M;;0C"4X`%6NC^8WD=B_<>.>J\XJ[ZAYW^Z.B,_86TCB'*]O> ME_O,YPVC_I9`%$/;^F]7YI^H!\B<<%U.%N/,XQN&WNYS]7&J:-1P)MQ.0VEQQYF#EK"?V\J2`.K^9_ M*/EJ^/W4FO-"O^0':/("JHKS7L]9T2SI+.KT?7$;!=X@,?8\XL+B_P!)LM(D M6]@Q72),*-16,;[UG+#2$M_68`&C+Q6[S5^3WCIQWOM17_E$?J&CU&R2Z;#^ M)2:2\6A<+9*1N5CT^Z9IMAARHJ'43X_C?INCIW6RKEJ?BUCO/8V^]NDXL)+>'F6UILMWKZIS"?3")CR6 M%^QSW^T`>S^5QA/2OEL^+/CT]K[^GJ;[4=ZFUF'6GL/PK3L,>3=(D0O8V\S# MEUO+O8Z[ES/U&D+PC"5-YRH`:8P`9`K+JT89C;"EIY2%^U/L:2OW_S>4@#U>Y,)ZA^I-T"!8M?F M$'B/&F'VF,.M26HBF^*[1LM8[);0AER#]IL72VI+:%9<7E[Z:_7V.>U(`T/] M>U)C?N3=0T23$^_C;KSO=M2D0?9]7[UC8]:LZ=V)]/WM_4^X;F91[?+W?=)>D8=C:QW5C8(C"I"''8J=OT/7(3Z4L>WZL>*Z[J M.5H_:^FMW+F4IPK"\J`&DH`&6_264\*_4F[I3I6B)3^0FCW#T-QYYKVN*V+B MM7O4Y#KCRD_27,WOG4EIA"?VUJ6VC&,^[T`!U_YTZ?J1N;42Y"YU5X[\W[^E\AIWX:;?\` M*/HXAL7.XJHLX7B[E5LNW@PZ^&XG+,FQG-9<2ZRR\RL`52=7X=\T/A+RG/FU M;^:5MV"ZTYNHVOLW`[>ZV+;]/H]66[$SN=7Y7Y37_AIXSZ3N MCVEZ54:/,V*ENW9S$*'=,5$B7HEGKUWL5Y$HK"!*NI4RZ3';?L$-Q&/H9RVV M`+J_CUX7YMD2D+UZ"S%@<^YE'3*@1,92[G M%4C.59_%QS^4`$I0```99M:_YGCH/_="%_DLT@`&ID`%<7R`[/\`(M!SR73O MC\TGGUK/VY&_2>I]#W_-+B-SF+0KTAK3\5F-AOX-2])V1V\L_>UFLN'U(@^Y M#3:4.+R`*A.N^1WSO^`5,SVSR+SQWR)XC4W$']]W*"DTEB#KU?;6,"KB09T[ M2-4YUMFOHERY*8\.R<@V41B6\C$GZON::6`-$?C-Y`Z5Y3\'YGW_`)[]PWJ_ M2M=;N8\"8[&>L*.RCRI-5L.MV;D1QV,JSUO8*^5!D9;5E&78ZLI_#.``9./& M?YJ/D%Z#RZ_Y)IU?,\H/,/HN_9B`&@75-_\RN?)[? M[:T_+N93OR+9M7;ZEL7*Y_Y3I46QYI,_*]5@TCGV^&'VG/9[)J%OYD)R`*GO M"KL/R9_*IX_MZY3^3\G@=/S[9-C@]:\E:O0==C[[OFV62DS]5YCH=%S[//*V MFI-/U*7%FVUBS(KYZY%C&3A3J$*PL`;M(EC.>EQ+*MRQ%D80ZM M]T`=C\EO%+YA^*&G`!<9\:?EW+\VO$3G7;+Z)"K][RY M;:7TJ%6-?0K&]YU20F)8SJZ/EUY46%?U[T2S;8RK/VR9OT?56$84H`0E^.7S M&\CN\?(!\BW$NK]%_>KF'".C]!H>4ZS^Z.B4?[JU-'VK;]2JXGYUK>L4^PWG MVNO5;$?ZEE+F.K^G]1:E.J4O(`X[\F7R*>4?B?\`(_XZNUL>+97T'3*IZ MRM='Z`WJ%\/V M^E=(A5:,-57[[:G(1%GV-8Q]1U<.%L%:_$LD1U9]8OWF6<96EM+BP!3SY:>3 M7FKYY^?FT>`7@WU2RX7S_BJ+-KKG5M=N;+6[3-MK3L*%NEO:[7K?_P!;(-;K MNR6#>OUM16.QUSK3+CLMSZ&<.00!X3RY\N?DA^,[CNQ\%ZKW*-ON\[$]KFX> M,/E;&U"AO++9MVK@G4M2TSRWZGX\^-V\P.I[S2TB-6;VG8JKG&V=*M+2BB M<_W.@B_O%0/W#+#$?7W8S$F6WAIN.E*76@!ER^+[F'R?;ET[S3A^&OD9QKDV MXZ]O>GQO(6VZ!1U%E7[WLLC8.PM4-AJK<[A'2T0X<*T@7SCJ6HU-C*)K.,M. M>W"(X`U.>;WF+_P$>'DKLW0,56Y=1C56M:/K-,AS[.JWKLES4KQGTQ'CU#B- M>C.5T^WF)9:BNYK83J&4MNJ;3@`4B4WCK\X_0N-X\XXGF%M=)U&UIOZR=5\6 MHDZR@U4W3GVOSB!6YT-36>5Q=EFU/M0!7=\F7R*>4?B?\C_CIR+E-O/V3ENY\=TV_LN&UFK<_E3>F M]'VSH'8=+U^E:W"]UN9MM"C8;:EI(;BH=C';8;;4XAO*U.?4`'.O*WQC^8OE MG*ME\SV_D!N;GHNAT$WHF_>/G/JVUUWFFIZ[6QXME?0=,JGK*UT?H#>H5S#K MKJ+:@C+D1(CJ\/R7W`%OWQH>7D[S;\1.>=LV&#"K-[P_;Z5TB%5HPU5?O MMJ99QE:6TN+`$^````9EOU`/^_SXK?X MO]-_IGXR``TT@`RS:U_S/'0?^Z$+_)9I``-3(`,LWQ*_ZRGRF_\`>_R._P`T M[8`-3(`*U?F$T&ZZ5\;'E9K5!'?E6,32]>W;+$9AR2\NMYET+3NDW>4LM84O M.$4NIR%*SC'[*<95G\,``^J^&GH%'T+XW?&B32O-9>U/6KKG]]#2^A]^MO-. MVF[JGF9>$)3]!VP@-QY[;><>N(TQK/KGU]<@"M3Q3SGM?ZA/S-ZQJ&6Y6F\P MT*7JE];1W4S(.=AUO3^5<71ZYRG"L@#29M. MS46E:QL>Y;191J;6=2H;?9MBN)B\-PZJBH:^1:V]E*!']Q;PN_PF^.?]C^G``I.^/]A/2OG4^1 MSI=BU]ZYH-#N>BUTGZK4MF!-KMUY[H,1>'VD,?2F(H=%E1DM>U7TVUNH7E2T M>[(`MM^4?4F-U^/+R_IY$3[UN'Q';=M2S[/J>Q_06&][C2_;[T>GV$G7$/\` MN]?V?I^OIGT],@"+OP(;;*V;XU^65LJ1B3G2-TZKJ3&[+YF_(_Y>5T5Z/IV\;WL M,77I.6WVH)>UN[#96TR-`@L1'M1\JG?O,27W4,ML-KVR,A67,H]/ M:O/\F,9R`-!6O[/K6V0?S/5MAH]EK?J+9_,-?MH%S!^LWGT<:^[KI$F/]1&< M>F4^[UQG^4`'W@`,1GZC?0Y>D>;O,^I57K$1T'BVM3$3F_P>QM>A;5L53)=3 MG.5)RJ+2N5&4Y],?C^'I^'KD`?.^[CRL\J_$#G.B,HL)%WXUZ'N5?$C26 M\L1;GLEG<;+/2EF0^AMEF)JM)725+4[[W&LXQ_X*LZ]JNLT3&7&65(INXR.+O<^I2(R6'^B=ICZS$=5AS#LVFYSJ%6_&DXS[\LYBHN-XL&4>F M,+^HTY[O7'L`!6A^HWT.7I'F[S/J55ZQ$=!XMK4Q$YO\'L;7H6U;%4R74YSE M2A[E7Q(TEO+$ M6Y[)9W&RSTI9D/H;99B:K25TE2U.^]QK.,?^"G*@!YWQ1\A%:O\`!-Y\Z"Y. M4JWK.O:KK-$QEQEE2*;N,CG--/KVE>Q:EM8A:S?R\IRC*U^Y:<*2GTRV`+0_ MTTO-ET7B[W/J4B,EA_HG:8^LQ'58+!E'IC"_ MJ-.>[UQ[``5.?(#"<\:?G0J^B-81$J'^[^.?;(RU>Y+BL9RWG.<93G/X`#P?S03-@[W\F7D14ZTTJP@<5YM30Y$C$EIQN%K M_.^7U^Z[8ZI#CC264QMENYL;Z:,K7EW.%>GJI24@#KG7?(15I^GT\<.=9G*D M73WDS=\JM$*<9;<7KVE6?0NGQ<*;2A67FJN/<4$9.,8;S[;RC MT3]!:/7'N]P`+D@`8GOG^X/T/A7FUI_F+JF)<6AZNQHUI4;;$;6[C6NO\?JJ M6E8KI65,N18LAS7=;J9\#ZBO_*\M2L)1G$9S(`-(/QJ_(CSWS_XQ&V"&Y`UW MM&EPZZL[#SG$AI+]9S7(JWW9DG1-FDI<7"=7[EQG<.1'5*<:^HZ`) MK=?[#S3@G.MGZSU[;ZK1N?Z?`S87VQ6ZW?HQV\K2S'BQ(D5J186EK82G$,1( M<5IZ5+D+2TRVMQ24Y`%$/3_GQ^/3KVC=?XU94_:XE-NW/MZT=O8]KYM3O:-> MHV36K2E0V[&H]ROMQ:K9JIF$+R_3M.)0KURC'H`"K;]-1,DH\W>O0$/+3#D^ M*VWS'X^/3Z;LF#USBK,1Y6/3U][#5@\E/_Q.9`!QGS"B-=7^>.5K=_A*X.S> M8OCGSRCYJXB_(`TM_.QJ$+: M?C+[O/?A/3;#2+CD^WT?T<84J)-1U;3];LIJT^Q:LLL:OLEA[\XRGVISE6<^ MF,XR`()?IE/]P?DQ_%_5_P"AB``5-_%W_KBZ=_%_RV_LJ[J`#W7ZCG??ZX6_*BSHC:E)]$^R.C'I[L*SD M`7P^??D=X/;+\LWR MKAWM#I%/N'3&Z*RBQYM;:7FITR\ZWB=&DMNM/,U=_/CSTISCT4[$1C/JG.<9 M`&SKY.[J10?'OY@SHN7<.O\`!]\I5?2?S'5]OLE4YKLS&7$H7E368EJO"T>G MHZCU1G.,*]<`#/U^F%U.NF;MYA;TZAG-MKFK<8U.$XJ.A4A-=NEMT>XM$-2\ MKPMAER3H4/*V\)SAU24*SG'T\>H`BQ^HYTN%K?GGJVR0(/V^>A>/.B;!;S4L M8;187U1MG0=-V[EM46+)8RM"'XTB92MH<0OW-J0K.%I6G.4*`&FWYYM6K]@^,OM= MM-;97)T;9^/[34J=8^LMJPE]6U'27'([GU6_M7LU6X24Y<]%^K:E(]O[?N2` M(=_IF[R3(\8/(/6U^_[.I[U'O&,9>ZO`E^UGZ>,MK^EK#/N5[U>_ M'ICT3[?50`I6^!#4*G:?DDYC.M8[,E6E:5U#;ZMI]GZ[6+9O4)VNQ9'L4M+> M'H;>QN/-+4E?TWFT+3C"TI6@`7=_J7]6KY?B3PK=G&V.N4<+W.8<3B-(W^YV1?TT_31]%'WFPN_L^J_57JKU_:]J0!V.B7>;!N6QV$UI.' M7/>]*;L8[2U^C>)*;C?NTQXR[OS>/Z04I8 MC5L#F%CKT"5&@)?3B.N"W';=92AU*FEMI]B\*3A6`!EB_3.;?)A>4/D%H*77 M,1-EX(SM[[.$YRRY)T?H>JTL5U:_JX2EQEKH3V$XRA6Y'1^E+0KTS_X25IQG&?]F<>H`+N/U*G]Q;E' M^++1?['^[``Z]^GT2E/QR:IE*4XROJO5%+SC&,94K%U'1A2LX_Z2O8G&/7/^ MS&,``SU?%W_KBZ=_%_RV_LJ[J`#>:`````#/3^FK_N+=7_Q9;U_8_P`)`!H6 M`````!G5^>SR&V:YUWCGQX<82Y<]=\HMKUB3LM/7O*Q*9TIK9F*_3Z27]):7 M(K>Z[[%2[EW.%-MPZ23AW&$.X4`"Z?QK\==+\:_'3FGCEK+2)VL:%I3&KSI+ MS6&5;)934/RMNOYS*,^CI^&#RE\ ME/#KRTA;1KG&MPVZ-M_-^E0]?M;V&Q"COS:O7]V-Z?R/QQH]SW3G.B=BUK=MM[G8ZS?:MJ M"=J5I'2*35M%IH&P5D"Z7/NZFUM9RESV*]SV5F<,-/IP\XR`->/%HLB#QSDT M*4VIF5$YGHD62RK.,J:D1]6JFGFU93E2[2L+C4=7?;8^W$T3?J]Q]U;59J?1X["*RZ8PMQFKO&,*6ZA,:8VIA"W,.Q+.Q:<3_)CW M)Q[E)3ZJP`('?I_^?P-/^.#0MFBQ6&9?5NA]4W>SD-X3]:8_5;?-YG'7(5C. M5>K,+G[:$ISZ8PG'KC'[6,H7[L)R`)8_J"?]./;?XI\K_P"W M'P`6"^!']Q;PN_PF^.?]C^G``I(YI_S+WD)_""E_RU\/``_4U_[@_&?^+^T? MT,6`#32`#,?SJ+&D?J8N\NOL-.NP>3T\J&XXC"E1I*_&'C$)3[.<_BVZJ),= M;SG'X^QQ6/Y,Y`!;/\KS++_QS^7*'VFGD)Y)9/)0ZVEQ.'HUE5R([N$KQG&' M6)#25H5_*E:<*QZ9QC(`.3?!RI2OBW\7LJ4I6<)[2G&59SG/M1Y#=:0A/KG_ M`,%*$XQC'^S&/0`%L0`.!>4?D%J/BOX_]3[[NZT*I.;ZK-N&:[+Z([VP7[RF MZ[5M6A.N?LHG[/LDR+`9SG]E*Y&%*]$XSG``I5^!3@NU;!1=Q^0[LK;\WK'E M-NFSQM`#32`#+-^F'_\`U"\OO^]_'_\`L;?P`:F0`9D/E383QGY=OC&\ MA4H7!@[A<:CS>[GX;RQ'7!H.IMT^QRUR?8^F3)B:OV-.'6\(POZ*&D^_'N3E M``Z#U_#G=/U#/C]J7U_N*#Q@X$]L]S!82KUB74K6]WV6%+?=QA66GGK/H6NY M7[OYM3#*$8QA2\JR`/K.2X5PK]1/W75\.8;IO)SA3EQ4QI:\X6]8XU#2-VL9 M$3+7HEY]JYYC=X1A>,81&=0!Y_XO8[79?F!^3OR!^FJ;!TBSV7EU M//PT^]%3'M.DIUZCG-R9#SBHS\[7>+N?11G&,Y8<<2G#:4Y0`#Q_G;T#1[+Y MZ/#:I[%O&HZ%RGB?/]>VR1L'0-BJ-1TRBV.JB=2ZA6VMAL&P2H]3!FVVP5=) M"84ZZTEZ4S&91Z.*PI0`NPZ%YC>`O1-!WCG]QYG>([M3O.H;+IUHU(\AN.28 M[E=LU+-I9K;\=>X^Q]E<::K"D9_!2?7&?Y0`5(?IS;/'0?"7R'Y!L*Y4BAA= MAV"'CZ;BFGH])T;F^LP+*O@RL:QMTJCA4B,@"V?QMZG\[=UW3FE5Y*>-O%=1X5-V)MGIFR:]>\MDW5 M1KOVDI3DJN8IN^;/:.OXEI:3Z,0)2_16?V/3US@`6D>3_EEPCP[YROI_>]VC M:CKSLS\KI834=^TV/:;I3+DA%+K%!!2Y/MI^66\K7E.$L1V\?4?<:;QE>`!1 M7Y&?.IX&^2/C)Y/<7C5?9M3V#>^%=?U+2'>A<\J,T5WNEEHE_'TEMF3I6X;M M,K M:/\`A-\C/[']Q`!7G^GPBQH_QSZXZPPTT[.ZWU*5,<;1A*I,E%E7PDOO9Q^+ MCJ8D-IO&<_C[&TX_DQ@`$2O/2#"D_J`OCS0_%CNH7RKF4Y:5M(SA&]GCR&FGX[_)^BLOL/-I=9>9 M=U"X0ZTZTO"D.-.(5G"DYQG&<9],@`I"_36*4KP6ZKA2E9PCRQWI*,9SG.$I MSR'A2\I3C/\`T4^]6<^F/]N/(::?CO\`)^BLOL/-I=9>9=U"X0ZTZTO"D.-.(5G"DYQG&<9],@`I M"_36*4KP6ZKA2E9PCRQWI*,9SG.$ISR'A2\I3C/_`$4^]6<^F/\`;G.0`]< M*9A3&[=IUS'XX6]%9]<>N,9P`+-O`C^XMX7?X3?'/^Q_3@`4D?I_O]_GRI?Q M?YE_3/R;`!^_SOJ5U/R;^,KQ@DY0]K_1.Q)5L5:ZMU,>Q5N70.8\]J,X7E>$R5>OLQZ96`-,;;;;+;;33:&FFD);::;2E#;;:$X2AMM"< M82A"$XQC&,8],8`!F:^*!I''/EF^3KQTJ'50M8LYNS](J*%E:\P8L'7^JQ/(::?CO\GZ M*R^P\VEUEYEW4+A#K3K2\*0XTXA6<*3G&<9QGTR`"D+]-8I2O!;JN%*5G"/+ M'>DHQG.%+RE.,_P#13[U9SZ8_VYSD`&A0```&9;]0#_O\^*W^+_3? MZ9^,@`--(`,LVM?\SQT'_NA"_P`EFD``U,@`RS?$K_K*?*;_`-[_`"._S3M@ M`U,@`\/TW<-'Y]SK>MYZ7.K:WGFI:EL&P;M-MV$2JQG5ZNKDR[O[R&MM[$]E MRO:<1F/A#BI&5?32E6583D`8]/#[B?R$]C3Y,=@^*N^5XB>(G2-TV%K3=!ZA MNL>9)V5^L88@S\\]5,T'=E:]>(=:PQBR9?@8@9QBNQ<2\P5NX`%G/P*[9QC6 M]`[1XYYYYL/+_,/G6X29GDW#WFTS>;=T"RA6K<(U'"5T?, M+_B>KM3,-)9B$3=COI$F>_P"GX?6DJ]``6X^!']Q;PN_P MF^.?]C^G``I(^(C_`%5?ES_B_P!6_P`QN_``NW\]_P"XMYH_X3?(S^Q_<0`5 ME?IT/]/VU_Q!]'_HYH``.A_.5Y>K\$?<+Z3N,2%+NZUY;?\VZC4X3,6E96GTPXS6HM MY6)"E,RT2$J;PE+66\Y<`%)_E/XE=.^"_J7(/++Q8ZQO.Y<+V+>:_2N@Z/NL MR$F?9/YB6-QC4-TSKT"FUO:*3:M;K;+$&?BMB2*B='PXWCZJF7``:HO^)[D' M_P"T/_V?/^)[_P#H_P#=!_\`M#_UW_\`D_\`R@`*`OU-W-T3^0>+_7D1TICCB6%F59]0!6-\34Z= MY7_)]XY7>TQ?OJ+B'C_0T":F=&9EQL47%_'NOY!3-N-_3>CIAR-JDLSL?4Q^ MU]7VY]%JP`"L_HU]L'`F/*WQ&82^B!-\@:"MV60XMUA:E>.UWV/5X4"1#4I2 ME.2;'U*E*:UJ5!9]V?7UPUC.,^GIC``K(_4W1'2ES4^ MD[IS>5*0VC"G4="UB)L\"/(=QZ..)85S&2IE.?5*/J.YQZ95GU`%8WQ-3IWE M?\GWCE=[3%^^HN(>/]#0)J9T9F7&Q1<7\>Z_D%,VXW]-Z.F'(VJ2S.Q]3'[7 MU?;GT6K``*S^C7VP<"8\K?$9A+Z($WR!H*W99#BW6%J5X[7?8]7A0)$-2E*4 MY)L=R^OG*U*^DJ+G'IG*O=@`;H/A@YPGFGQM>-D)QM*9^W4>R='L7<(PC,A6 M^;C?[!4.*Q[4J4IK6I4%GW9]?7#6,XSZ>F,`"A;]3+S=%/Y"^.?6&HZ64[]R M'8='?=0VA")4SF.W*N%O.J1Z*>E(A=/CMJ6KU5])#:?7T3C&`!X/XPM/M//O MR<^2WK6T17)L_IWC3W6A@,28:)K]7L/>K'%5JWTOII4TF;24-/)CL8;6AS*D MX4VK]C.0`4<3^N74S@^J\&PE;>NZYUS?^N+7]=66YEUNNF\UTUI/VWX(;76P M=`7GWY]V5XE^F/;[<^X`?Z3WAGSA/(?$KQKYIEM+(-:E M5.W\GV82GV*EW;LAW.,X]?5?XYSGUR`"2P`.(^17CWS#REX]N?$.O42+S3-S MK7(KRF_HMVU#:-)4NHVC6YSK+^*S9-?G>V1$?]BT86GV.(<96XVL`81)53V; MX6/D@J6GK>3:U^E7%7-7:0V7H-=V/Q[W&8A%BAZM^X6A#UC6PGV5LK4^U7;% M6>]M3WVK;B@!1^)G-Z>P6O5>D;ATGH%CF(^K[2SGR7D8RE2I=`Z5T/@5_UN MZW_8T37]HB7=QKEKL5)%H+:-*AR]<@:[%^VCM,PE,)=RQEQWZKCBUJ`%7'Z: MO^_3U?\`PF[U_;!PD`'(O*R6US[YZ57MUE*8=!YK^/.Y3%*5]LE-6N^Y=M6, MJ$(4K'IZ>[``@)^F4_P!P?DQ_%_5_Z&(` M!4W\7?\`KBZ=_%_RV_LJ[J`#T7ZBO6;&E\_Z^YE-.X@[AP?GES5OY;3AEQJO MN-RUF4RVZAUW"W69=&I2TJPVM.'$YRGVJ0M8`M*UC].!X@[?K6O;92^0/D(_ M3;11U.Q5+ZEA.?6:9V!-ON'0YT%U]*U MLN3*]GH33#Z49_F7FU,KQAUMS&`!IO\`.7_1]ZS_`(3=7_H]K``*C_TO7_VX M_P#[FC_[X$`%;?-=DK-4^?&VM[=Y+$)SY'NOT?UE+0VAN7M/:-UU>M4XMQ2$ M(:_,KAKW9SG\$^O^T`&FGYX=B@4GQC]UK)BTID;A?\=UVJ3E:49P:3MK MB$ISCU=5BKU>2KVX_'T3G/\`)C(`(4_IF:R4UXV^1=RO"?LI_;ZNLCJ]'/=F M54Z'2RI>,YRWAK*<-73'I[595^.?=C&/;E0`IL^`;9*RA^2/G<"P>2R]MW/^ MJ:W4Y4M"$N6:-2E;)AG.5J3ZJ<@:Z_A.$^JE+],8P`"[?]2[L4"-X?\`$-2< M6G%I=^2=5L4-OWIPI4#5^7]+K+)>&_3W+2B1N$3&58_!/NQC/_2P`"1WP!5D MJ!\;7.Y4C"<-770^LV<+.,.8RJ*UN,VF7E7O;0G*OO:E['[&5I],8_'W>Y.` M!=.`#!=Y?/-A>P[']1JNU_S(\<.A3G'6_M\_DDJRY5NOU4?M/^K2:V3^ MRO'K[L8]WMQG/MP`-Z(`,*/ZBK79U/\`(%"M9+;N(FV<'YU5>N$*3[L8]OI[5*`&RKNN]4"/%/LG2UO.)U='CWT+>E M/J^W2\F@3SBWO\O*]9&(F',5V/=GU>^GZ_\`A^G[0`,EWZ:'6I4KRX[IN",. M_947CE.UJ0K"$99Q*VOIG/+2'AQS+F%I=4SIC_LQA.<*QA6O['^$@` MT+````^@VO:*'1]6V7=-JLF*;6-0H+C:-CMY6F4LA&FZC?\#K+5O*VJBRDU;-5 M7,0D_P`_#S-T'EBV6IJF\I0Y9[`J2C'U,*RD`:A0`<@ZYX_<,[[60:CMO(.< M=7KZM[,BI9W[3J':%T\A>49=?IY-M!DRJEY]*,)<5&6TIQO.4*SE&'!C,0XD=OUPVQ&C-)989 M1C.'B_(.'!98Z/XW7=-91+AG*6)MAH&Z;#3:MLVOON8PG[IF%:V,"T8]ZO='S$ M?PSZ9D.)<`'I9G4]H\M?@2V[IMU,D6^X7?B1T'.T6BV4Z%IG,]& MJV:33=!UBDU#6*IC"?9!I-?KX]97,*5A*?K/8C1DY<I%?3W%WIVAS;=+332VX53V)N/=?=3/VWGH$"MZG]1;>4_ ML-NN91G*G,^@`TS``RZ?!+]?HGFG\F_<&%JEU-WOKWTK1UO"U3G^B]8Z;MS: MVIB\,K6I4:A^H\E+?IGZC:E^S]C"@!Z7;W4\N_4G:)86*D5L'N''8[34E#34 M=$]2^([+J]8F:M'U')JY6QF)5[%1&M=UNRMW)*5X0[E"F$0\JQGVJ]/3^3/\@`,_7Z9_5)D M#Q<[YN;S/TXFR]W:H83BF$MKD?NEH6M3)+B'LK^H_&0YM>$)_9PA+B7,85E7 MOPD`:2``9R_U'^KV$+Q^\:^XTF$(O.2>0;-?"FI7)1*KD[?J]E>M2T*8<9PB M,FZYS!2M6%I=2XIKV9QZJS@`?1?%'L4'R;^4;Y*/+BO3)G4M?&H>8:O:S7&W MLOV)<+H%-`?2TU(BK?7]-ES'T'OV`"97C)X<^./AS0;-J_CASK^KFBW&XBWVQP?WNWO;_S&VA0L5\:7 M]SO>S[1,B?3AX]GTV'&FL_RY3E7X@`C/\F?QP<_^0'D2Z_V56K=UTJ'*ETK:'8^,2INE;`_\`@O'HXY7258EL(5G#S,@`0W^#3R_ZAT#5 MNJ>%7D7BYQV_Q.FYIH\>_P"$%U_EK[@`#32`````#+-K7_,\=!_[H0O\EFD` M`U,@`RZ?(#KD+RY^^/N-)H5742L82VIQB/[??O,^;R?`/RII9'/M(D4VC^+7=;/2 MJE[5*%VLT^QH.5[+8T5AJT!R`J+K\VEL*^._$=B(9:/^$WR,_L?W$`% M?7Z?;_3CU+^*?5/^W&``1-\[?^8%^/'^$'/?[1?)``&A;N?^Y/L7\+.@_P!$ MK<`%'GZ:O^XMU?\`Q9;U_8_PD`'+/B(_U5?ES_B_U;_,;OP`'G;_`,P+\>/\ M(.>_VB^2``-"W<_]R?8OX6=!_HE;@`H\_35_W%NK_P"++>O['^$@`Y!^GAFM MI=HU6/4P,N)3)Q4:;676R7MPVUE25 M.1H$M%?%?13:<)QCUQE7[6$@#32`#,S\N?]N<8`!J7`!EF^)7_64^4W_O?Y'?YIVP`:F0`4X?/-MUQJOQL]9BT\ MEV)^^&U\QU&T>93C*?J,.K1GU2K*<@"7' MQNZK4Z;X!>'%12QVHT.9XYKH^PC=WX[88W6/%5F+'E+C<"O+U:W&&_5I_[J MVY+6R7<>B/?*]7E>KGJI0`YGYD=`\M=4^7?_`(C&_`3R0\G>8^-VJ0]'X76: M;J'3:[29=M;:FU.M-]C[=2\IZ!273\6]VZT3]-AC./*+K_;."Z'RW?_$WI/"=/X?X_<$UKGW6MP=V M=>M=ZJH>F,:ZQM&FINN;Z?5HKYM701K-&(5E_0[Y*E_4]7E_;O251$3.(;?JF'4J]F5.[Y&1H[$;UPASU3,>V) M+.<>G[6'/3U3Z^N`!%[X$=4F:W\:W*K"8S]#]]-RZMM<5*F$L.KAXWNWU=EY MWT6IQWZ_[LY6VM>$Y4SE'MQE'M4H`5X\9<<^5WYC=E[9)C_G?BUX/HBP=(^L MA3U%>W>OVUDSHLE&/1V+)D[ET!BPV9M2T(RY45#$=[\4IQD`:I````43_J(K MRCJ_CWS66CC.++9>W_/U&OIT51+PIQ&,YQA7LS M^"P`<&_JAZS_`/GIO_+6_P!4/_6[S_>S_P#GO^I?]=_^6_Z]_P#)@`FE\ZO- M7.B?&WV29%97(L.;7?/NE066VU.*RW4;?645V]GVI6IM$/5]DGOJ5Z>F$M9] MC@`*SOF*YE,T#Y+/):BAU[RD;AM^O[[2MQ6G7EVKG2-3UW M9YBH;24Y>>>7LEM+CY3A/KE]M6$^N/3.0!_H!\4Y^QR?C7).61DH1&YIS+0N M?QT-JPMM+&FZK5:ZTE"\8QA:$MUN,8SZ?C@`%9OSJ\U^I7IZ82UGUSA/KG``I?_3*<[59= MQ\F.L+BJ4WI_*M4Y^S,5G.$-O=%VU>PNL-IRCVN.J:YBG*E8SZMI],9QZ.`` MK.^8KF4S0/DL\EJ*'7O*1N&WZ_OM*W%:=>7:N=(U/7=GF*AM)3EYYY>R6TN/ ME.$^N7VU83ZX],Y`'^@'Q3G[')^-:N;#XD\@Z9%96](YMVZ/4SB3H,Z)K%I(B3(WVNU,ZPL-"W*N=OM)IIEHBKW6%7;!6S:=Z[S))3SC42.QEU32%@"^?]1)XPW_0/%7DO6M#HY=I& M\9=BN(^P5T%N1.E4_--ZJJ*JL[[.,ID3'X-#<:A48E+RK/THSJY#N?ILN+2` M*E?&7Y9_*>[\1*[X\N/<9J=HZ*[HNW:%K/8T['-;EZKRI55=S;Z;/U+%-]DB MQTS5'I&&+A=HTQ%CQFU*AOO)Q]0`??\`Z:O^_3U?_";O7]L'"0`???J*?&7: MN>^46L>5--72?W([1K>NTEMLY\QOEQY-K'J(4?#K]C=ZA;1$38T9I'O>BR9N$^]W#+:@!2IXC_/ M;Y">*O$*'@>S\GU/KT3G-;C5]!OMBO;G5-@UN@K&E1*?6+]B%7V+-]`UE#:( MT5.$P9#41I+"W%90E:0!I!^'[RY[SYI>/W3.Q=^J6ZJWF=UV.%H3-/J4G6-, MC\W:TS0U5E7J$F:J3-V.%5[1FW2_,D2ILCZZ\MK?S[,-M@#,I^GL_P!16C_A M!U'_`,SJ@`;PYT&':09E;8Q6)U?8Q9$&?"E-(?BS(5%DLN84V\Q(8<4 MA:58SA2U5%G05N;GU'KCURMN7;>VX>9AZ_!JX[;\Q#4J>VRF:X MTTJ3EM(`V*>2O.>5R?M.E7_F/Y*.Z(ZF2N$\O: MZ/IO0-BHXT2:CTS"GS;"I0S'>SG"6GW$+5G"<9S@`>Q\\_DV\L_,_5M'X/WK M7-=TI?)=BD+VC7=:UW8=9O=JZ55Q7M8VGM0+RFPY,:1!BQH;4>3-D M_P`WC&6FV0!L#^';QJ5,*"[:65XGG4RLG6]375#3;WYX^_3R7UKK\I5^8QVW(V$J6ZE*@!VOS0 M\[O)3Y.NF;_YV*VL-HV:; M&AQ<)0YA*6(K#:4>[#CC@`UT=*Y7M_@[\*NT\UU+9KC3.C\?\;GI,S:='O)M M%;4O1[JS1M&[V&M[#12(4^+Z;AL%A]"2RXAQQI6%9SZJR`"H3]/KY->2/9_, MOIFK]A\@^W]8UF!XQ[G?P==Z7U??-[HH5[%ZIQ>NC742HVB_M:^-;1J^UE,- MR4-X>0S)=1A6$N+QD`>B_44>$FYJWG6/-KGE!/N-6EZQ5Z/VA5/%?E2-6N-< M=D(U+>;7$=MQQBDMJ:2W5O2E92S$>KXR5YPJ2D`'U?B+\^ODAT?;_%/QFVCG M&B6>U[OV+B/(]S[5,L;A^WO-:V7H>M:K=W&-20VQ6Q=SL-?FN8UUZ"S4SYR[%],B/AUU+*7I&,L@#0 MM\$7@]MOBCXV[)T7JU!)UGK'D-:TVP2];M(V8UWJG/-;BS6='I[N,Y[GJZ[L MWKF?9R8^I?Q3ZI_VXP`#/3\7?\`KBZ=_%_RV_LJ[J`# M>:`````#/3^FK_N+=7_Q9;U_8_PD`&A8```&?S]1#Y*;/R#Q*U3C>J8D0G_) M+:[#7MGO&74MYC:)H[%5>WU$S[?20B1LUG85S+BDY]BJ]N4RO&MMLV=^-C1)#K/YO>S M7ELM.//KC1<-,?44EI.0`7S_`!I?)Y0?(]_75^1\@N.4_P!37]7'W7YKN$+; M/S[^L/\`?SZ'T/L]?HOL/RO]QE^[W?5^K]SCT]OLS[@!$[R6^\45\JFJ^B53\2-,JY;=?L>LMH93G,GZ*I,&78MOJ1E:& MT?\`BP`<2\%^/>3WR'>&J1,CQ9:=&OBM!\?/"3D_BKN2(5\BFYG9Z[T.,QG.:NQNN@R;K8>BUT9U M"_=(K%WNUSV&GOV5/,^B_:C*O;@`9^?#GR95\)O;^Z>%7E[6[DSPC9=RF](X MCURHH9E]#EQ942'6(N%08+*7K&MV?7*^N1/16I?<_JI5[OU5'UWH.H44'"W) MEW8:)L%?>V=-!BHSA<^SM=88GQX4=/JIZ:XTE.,JSC``*M_CZ^;OQ8Y;X<\:WV7ANH0N9P=/J=&V;9Y?0JW4<)H],CZM/K8+U36VN-?8BPWX]Q)K M4-R8Z_8M2,H`!'KP#O>L[7\\?4-R[=JJ]$Z+O/+]@WRPT9]UUZ?I&N[SR[G> MV:!IURM]MA[&PZMSZYJX%BA;;2FY\=Y.6V\X]B0!/;]0YX_=2[-XJ\XVSF6J MW&Z?U0]-D;#N5)KM;+MKN)JEWK%E62-F9KX3;TJ36T=@PPF9]-"U,LR?KJQA MEIU:0!*OXY?E"U[Y!)6U:]6\:WKFFQ\ZU2EL]XGWKL&7J;NRSYJJR;1:Q.85 M]_)Q&DL.N9Q,:C2&VO;A3><^JL`"NGFG_,O>0G\(*7_+7P\`%LGRL?Z=7EU_ M""Y_\\KP`<@^#?\`TMO%_P#]=?\`F(ZV`"RKJ&\Q>8PIIF1,:K\MH6K&4I4K&<_@`#!MX2_*91>.GD_Y M!^7O;>/W'<.S]M7-16V==MU=J\#286P7;MUM$2M8L==V%WV2&X59`@_14Q]C M6PUQ\>YM[.$@"[WAGZBG2>W=MX[QB)XL[3KTKKO4^?WI$1RMN$-M^KCK54XVVAQY;2< M@"'NZ_J%N1WOAI*CZS0[NQYE[/HKFCJT]C79$?7-=Z+8U?Y+-WV)LC$E,9_7 M8T]UR?70H^56:WL-1G6FL>Z0D`3\^%+PVV;Q!\/(*.CU!\<'BQ(\-_#KD'$;A M;+VYUU5,VCHLB.XAYC.^[E.?V#88$>0TE#PE/UX\%MS./GU$)U5VP] MJ<*2KZGMSCW>GM4`(=?IMN<*UOPYZ?T62VTB7TON5M'AK0C/U'=?T?5M;JX2 MW75)3E64W]E:IPC'N2C&/7W>JU)2`/C_`*DWFZ]C\0.4](C-(]4V&#,>3*QA2V$9OJ2K;4W^"'*YW\:WCPU M(;6W8[G&W7H=A[EMK0M.V[WL[.?;Z^U(`X#\ MWWAQU'L6A\MK;7ND#H/->O5=;%B[;I%+I M5CLU7:[!';PS92--MXDA49JJD24*<;9MG(,B/A7TE9=]GU5@"QCQ.\XJSRS\ M8MW\H-7YEM&J:]0VW28^JZIM$A#-[M%/HE6U85]BY+A0YE?'27*GM8S]2%0W MU!8/TDMM:\>C;L]=7G/K^VAO\?0`<'^&'4>@^07F1YD?);=Z'/YUS7M#.R:1 MS*MLO%YPU(RV`+)NC_(_?;U\7_8O.;@^GWG-KS68_:/-[Q@WOJ_ M=)>MS-MU_O6T<]KG=7H6M=KTZY4\]Y=LD1MZ$U(DI=F8L]LF94[[L94C*$^G M[/X@"VT`&6;6O^9XZ#_W0A?Y+-(`!J9`!F'^7.MW7PV^0;Q+^3BAU2XVKFM# M#K^>=0;I4(0]738B-KHY\21.6IMB%)WCFVZRHM9E_P!(^9E6M#KB<.-IR`/> M>:_RJRV.E;7J6L<;XOIFFV^U=,?VFQO: MZN;EWVRT-4YK]_]Q;S1_PF^1G]C^X@`KZ_3[?Z<>I?Q3ZI_P!N,``B M;YV_\P+\>/\`"#GO]HOD@`#0MW/_`')]B_A9T'^B5N`"CS]-7_<6ZO\`XLMZ M_L?X2`#EGQ$?ZJORY_Q?ZM_F-WX`#SM_Y@7X\?X0<]_M%\D``:%NY_[D^Q?P MLZ#_`$2MP`4>?IJ_[BW5_P#%EO7]C_"0`>4\T?`?S0X-YMO_`"#?&U6TVU[% MOC$M/6^2V=A20695E8QH3&S.R*[8K[6X>U:=O#U?'GRXK$YFTA737W4;^5I4 M4`0K^2[@?EQN/AYT#S/^016H5':_S[F?-.,\4T++3NF/?E M'N'PW^9?FQIO??'_`*3MVN=]Z''MM.V#4(:(SM\SKFU](M=*N-45=9B4^Q4> MV4^_OJ?PS*^ZA2(V&E-Y=0\VD`7,?+MXH;1YS>$.N[CS&ALF^R\N_)>X:#K+ M>5IV&R@SM>PO<="B*;;P_F^?J)2),5II"7I-I51V$93]7(`(*R M7MZTS=W?,G6==QJ-CS1_79,76]AZ-71LU2MJD['[FV*;6I5BUB5/@NH1:17< MNQ6F7L)1(4`)2_!YXB=`X-P;>^[=P@SX7=O\`S`OQX_P@Y[_:+Y(` M`T+=S_W)]B_A9T'^B5N`"CS]-7_<6ZO_`(LMZ_L?X2`#RGQ)_)SY2^8OF/V# MB':+/2)NCZ3R3H&X4C>NZ?&H+7%UK?4^;ZC6N2[!B6]]Q'Q4;/*PXW[$X6YE M*OP]OH`#2"`"D/YV?$CH/DAXOZOT#D-;;7_2_''<7M^@:S10G[*[OM3M8;$' M:VJ&OC)@0+)MI"7%NQX3[;:%NK;P`#D/)_P!1/XE2>)5UWVBGZ7K7 MC8*'D%3*^LVU;(V*PK&94VF6_'BR;?7 MM'U#6XM*W8J;;8L9,AY3>,N1W,-@#3>`#+-\2O\`K*?*;_WO\CO\T[8`-3(` M(6?(=XT3_+OPX[?PBB5&1MNT:W%M=%7,D(B15;QIUQ7;?JT*3-8L\1(2VXK;[^ M0SOWRF;EIUWI/*7JVST7AT.[8^D];NJJJC1(6:V1A/VMA&U70J%YFV?C85&< MNK-2&GEJ9D)P`--X`*2/U!/^G'MO\4^5_P#;CX`+!?`C^XMX7?X3?'/^Q_3@ M`4@_*1KF_>"?R#\'^4S1-3MMMYG:,5NA=_KZ6/AQV,Y&I'](D?F3ZL(C1,;7 MSJ4PS4/R,XCLW%*WAUQ&7&$J`'&OD9^2+6_DTU#F7@IX(:_O6\[%VC=-7L]] ML[O6['6H4"LH)"+J#KDF.XM^3F%2W<=FVN[-;:JVOC525MN/X6I;(`L<^0S; M)OQL_$I`Y?RB1*?NHFG:/XR:_MZ,MPY4*5LM'.B[COBVT>BH]M:557:O1\L9 M2J+936G4^B6O0`%$WQQ_,AR+P`\>FN/PO&'8]VVRYVJ\W+?=\C=&IJ+&RW%@ MXW!J6F*]W3+.7#K:/6Z^)%:97)=3]=+[R?9E]2<`"_+XZ?F+UGY">V[1QBEX M3>\PE:SRR[Z>Y?VF^5^T1YD>EVW2-453HKXFKTCC+TAS=4/8>RZI*4Q\I]F< MKQE(`^/YQ_+E=^!_>[/G?0?%G?MWY/(U;6=@UGK^L3Y=+7R;"T9>8MZ%W-WK MKNM6SU?:(;1EV/:,K9^KAM;*E^F5`"KUFN\I_G=\F>3[%T#CFQ<+\#>,7*K: M3'MDQ9EW#B;%/@4#NY[UN\"`Q7Y%(<:<0K.%)SC.,XSZ9`!S'0.'<4Y187=ORWC_+>;6NRN+>V.ST#G^IZ=87[ MSKB'G';N;KM372;5QQYM*U*?4YG*DXSG\<8`!U(`'F]NT[4-_P!=L]0WS5=; MW;4[IE,>XUC;J.LV37;:.AQ#R6+.EN8LVMGLI>;2O"76EIPI.,^GKC``/KM! MYKSGE.OM:GR[0-*YMJK#SLAC6=!U6BT[7V9#WIEY]JFUV!75S;SOMQ[E8;PI M7I^.0`>U`````!P79?%;Q@W/;,[YN'CAP7:]Y5)^\5N>R\?Y[>[8J9]13WW6 M=BM-=E7&9/UEY7[_`*WN]V-&CLI0TPPPTC"4(3C"4IQC&,8Q@`']P`?1;2Q9RM9V.-2J>3<2**W8J M51Y&(DA-F[7R&X"F):G64Q7L2E(]KF5HPA7IGW8]/4`&,M/?OU&O#XSFFS], M\B=LQCWQ(M@K@&G]SDP7O5UI4IO=M;TGRRS&9:CQVFF([#3;+##+:6F666DX0T MTTTC"4-M-H3C"4XQC&,8],``_H```#DMAP'A-MT&+UJUXKR2SZI"4RJ%TRPY MQITSH,14=&&V%1=SDTSFQQU,-X]J,HDX]N/PQZ``ZT```#DM)P'A.L[W8=2U MSBO)-?Z;;JD*MNBTG.-.JM[LU2_PE*L-N@4S&P352<9_G,N2%>__`&^H`.M` M```_C(CQY<=^)+89E193+L>3&D-(>CR([R%-O,/LN)4VZRZVK*5)5C*5)SG& M<>@`.+ZAXS^.'/MI?WG0O'[B.D;M)6XY)W#4.4Z)K6TR''<+2ZX_L%-0PK9U M;N'%85E3VB=)5(3*5T*+S/2X^\* ME(?^4=TB:W#VW8.];1T*N:U>^:V*O5KEMSWEVMQ''IK4>,EJ9FSU. M9A37MSE*,(5Z_M?@`+;0```````````````````?1['K&M;C42M?V[7J/::" M>E*9U'L=3`O*B8E"L*2F56V<>5"D)2K'KC"T9],@`\'SW@O#>23K*SY3QCD_ M,K*YR\JXL.>\ZU#2YULJ0]B0^JREZW3UK\[+[Z<+7EU2_G^T`'HM9U;6-*HZ_6--URAU+6JEG[>JU[6:BOH:.LC^Y2_H5]351XL"$ MS[U9S[6VTI]"XZ!GK..(\A_K45(3*5TS^K;3/ZP,RDN M*=3)SN?Y+^\>9"75Y5A?W/NPK.<^OKD`'70```````````````````<^YQ)5MS-(C8%/XD?SGOS(]WO_:] M?7\0`=C`!^CC;;S;C3K:'6G4*;=:<2E;;C:TY2MMQ"L92M"TYSC.,X],X`!R M+3O'G@/.MFG;KS[AW']%W*TRZJRVW3N9Z7K&S6*GVELO*G7U)20;67EYEQ2% M9<=5[DJSC/X9R`#L``````````````.%;%XN>,VW[7G?-L\=>%;1O&9#TK.Y M[%R/0+O:\RI'N^O)SL5EK\FWS(?]ZO>OZWN5ZY]L:?`O*K7*FGF6]?:NL;GN M5S;O,1X>G4$J"WB7A"DNNJ?;;PMK"\O-@#BWQK^(=QX6^+U'RW<+:JO.F;+M M6S]1ZM:T.5YH7]]W)Z+B9%IENQ83ST"FI*N!!PZIIOZZXJG4H0A:6T@"?(`` M```/JKRBI-FJ+"@V2GJM@H;:,Y#M:2\KXEM46<-WTP[$L*V>S(AS(SGI^TVX MA2<_[<``\ASGD')N/5DNEY'R_G?+*>PD_>3ZGG.DZUI%9-F8RZK$N7`UFLK( MLF3[GUY^HM"E>JU?C^.0`=$`````````````````````!0EW?SG^6/QY[7U: MBC_'T]Y!<1A[M?*Y-M?-JK:[+9[31'[%U.MNW+F@3>AH7,;C/M>]MVF@2D(0 MK+R/7"G,`"%'8]`^5+YBMBYUS'K?CZ[X8^+^L[+#W+9']KA6U9D```!R*5X^\%G; M^UU>;Q'D4SJ3+B'F>E2N;:9(W]IY&4Y0ZUN3M*O8FW$91C.%8DXSC.,``ZZ` M````#S6YWL[5M/VS9JO7+;<;/7-:O;VNU&@^WS>[5.J*N581- M2(Z8L;ZBTM_6=3[LXQZY`!6!X,>.W;[/R7\C/D!\F=%JN1]([[KVJ\]YWQB# M>Q=FN.:\GUB/3HRUNU]`CM5\S:MF?UBKD.M1U>D?+"_>EM3B8\<`6R````X7 ML'B]XT;9MN-_VKQWX7LV]XDN3,;KL')-`N=MQ,>RK+TO&QV.OR;C$EW*\^YS MZWN5ZY]<@`[@RRS&9:CQVFF([#3;+##+:6F666DX0TTTTC"4-M-H3C"4XQC& M,8],``_H```````#C^^^//`>JV\+8.H<.X_TB^K9Z7N%O`5&3E,= M4*RV&DL9L7+"59PC*%I]N,_AZ``ZI7U]?4P8=7508=965\9F'`KJ^,S"@P8< M=M+4>+#B1D-QXT9AI.$H0A*4I3C&,8Q@`'S``````?`M*JLO*Z;3W5=`N*FR MC.P[&KM(<>PKI\-]&4/Q9L*6V]&E1GD9SA:'$J2K&?3.``=0^ZJS>UJHK')ZG7VDK5EW*_ EX-31 4 exhibit311.htm Converted by EDGARwiz
Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Geoff Williams, certify that:

1.

I have reviewed this annual report on Form 10-K of Protect Pharmaceutical Corporation;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

July 11, 2013

/s/ Geoff Williams

Geoff Williams, Chief Operating Officer and Director

(Principal Executive Officer)

EX-31 5 exhibit312.htm Converted by EDGARwiz
Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Keith Elison, certify that:

1.

I have reviewed this annual report on Form 10-K of Protect Pharmaceutical Corporation;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

July 11, 2013

/s/ Keith Elison

Keith Elison, Chief Financial Officer

(Principal Accounting Officer)

EX-32 6 exhibit321.htm Converted by EDGARwiz
Exhibit 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Geoff Williams, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a)

the annual report on Form 10-K of Protect Pharmaceutical Corporation for the year ended December 31, 2012, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)

information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Northumberland Resources Inc.

Date: July 11, 2013

/s/ Geoff Williams

Geoff Williams, Chief Operations Officer and Director

(Principal Executive Officer)

EX-32 7 exhibit322.htm Converted by EDGARwiz
Exhibit 32.2

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Keith Elison, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a)

the annual report on Form 10-K of Protect Pharmaceutical Corporation for the year ended December 31, 2012, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)

information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Northumberland Resources Inc.

Date: July 11, 2013

/s/ Keith Elison

Keith Elison, Chief Financial Officer

(Principal Accounting Officer)

EX-101.INS 8 prtt-20121231.xml 860 22171 491667 860 513838 860 513838 70825 60985 16319 4507 4079 486826 477237 578049 542729 578049 542729 222865 222865 8348980 8342980 -9149034 -8594736 860 513838 100520 1353540 512619 728793 1480984 25726 482246 5888730 15953 124225 446939 -554298 -1435784 -9170193 640000 640000 -554298 -795784 -8530193 -4340551 -554298 -795784 -12870744 -0.01 -0.02 44573012 43862848 -30 -30 -30 2336880 1798 1346672 1348470 359592 359592 97 -97 19420 19420 -1046 -1046 -209112 -209112 1046 1046 209112 209112 33000 33000 -3721500 -3721500 1003012 1003012 5015 3716455 -3721530 -60 -30 -30 1003012 1003012 5015 3716455 -3721560 -90 -150 -150 1003012 1003012 5015 -5255 -240 800 599200 600000 160000 160000 2605 2605 -605105 -605105 1163012 1163012 5815 596550 -605105 -2740 10000 5000 15000 2000000 2000000 -12260 -12260 3163012 3163012 15815 601550 -617365 -1476 -1476 3163012 3163012 15815 601550 -618841 -1476 150000 150000 30000000 30000000 -150000 -150000 33163012 33163012 165815 601550 -768841 -1476 -1605 -1605 33163012 33163012 165815 601550 -770446 -3081 -2150 -2150 33163012 33163012 165815 601550 -772596 -5231 25000 1225000 1250000 5000000 5000000 26025 5283075 5309100 5205000 5205000 13284 13284 -7026356 -7026356 43368012 43368012 216840 7122909 -7798952 -459203 175 34125 34300 35000 35000 13046 13046 -795784 -795784 44573012 44573012 222865 8342980 -8594736 -28891 6000 6000 -554298 -554298 44573012 44573012 222865 8348980 -9149034 -577189 -554298 -795784 -12870744 6000 6000 721383 9904653 1250000 564300 3979 69599 9840 -23560 70825 11812 160081 491667 491667 9589 252579 486826 -21411 -485382 -506793 640000 640000 640000 640000 13046 13046 100 100 -145493 -145493 100 -132447 -132347 -21311 22171 860 22171 860 750000 750000 10-K 2012-12-31 false PROTECT PHARMACEUTICAL Corp 0001493526 --12-31 44573012 44573012 Smaller Reporting Company No No No 2012 FY NOTE 1 - ORGANIZATION AND HISTORY   Business and Organization   The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company).  The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987.  The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Companys operations ceased.  The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.      As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada.  Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies. NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Accounting Method   These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Companys fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.   Reclassification of Financial Statement Accounts <pre style='text-align:justify'>Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.</pre>   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.   Revenue Recognition   The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured.   Advertising Costs   The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively.     Research and Development   Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.   Stock-based Compensation   The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services.   Provision for Taxes   The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes.  The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.   The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a more-likely-than-not approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Companys financial statements.   Basic (Loss) per Common Share   Basic (loss) per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.   The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.0%'> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0'> Loss (numerator) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (554,298 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (795,784 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0in 0in 1.5pt 0in'> Shares (denominator) </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 44,573,012 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 43,862,848 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> Per share amount </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.01 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.02 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> </tr> </table> </div>   Recent Accounting Pronouncements   Management has considered all recent accounting pronouncements issued since the last audit of the Companys financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys financial statements.   NOTE 3 GOING CONCERN   The Companys financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern.  It is the intent of the Company to seek a merger with an existing, operating company.  In the interim, shareholders of the Company have committed to meeting its minimal operating expenses. NOTE 4 REORGANIZATION   A special meeting of the shareholders of the Company was held on June 15, 1995.  It was agreed upon at the meeting to effect a quasi reorganization whereby the accumulated deficit of the Company up to December 31, 1994 was eliminated against the paid-in capital of the Company. NOTE 5 RELATED PARTY TRANSACTIONS   Various startup expenses of the Company including purchase of property and equipment, officers compensation and general and administrative expenses have been paid for using funds provided by two directors of the Company. The liabilities are non-interest bearing, unsecured and due upon demand. The Company owed $16,319 and $4,507for such payables as of December 31, 2012 and 2011, respectively. These amounts due are for services rendered by related parties.   The Company has recorded advances from a related party of $100 and expenses paid by a related party on behalf of the Company of $3,979 as related party payables. As of December 31, 2012 and December 31, 2011, respectively, the related party payable outstanding balance totaled $4,079 and $-0-. These amounts are non-interest bearing, unsecured, and are due on demand.   Contributed Capital During the year ended December 31, 2012, a related-party has contributed various administrative services to the Company. These services have been valued at $6,000 for the year ended December 31, 2012.   NOTE 6 SALE OF PATENTS                 On January 31, 2011, the Company finalized and closed a Patent Purchase Agreement (the Agreement) with Grünenthal GmbH (Grünenthal), a company organized under the laws of Germany.  Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Companys rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively the Patents), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof.  The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.   In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (Nectid), a privately held New Jersey company.  Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company.  Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance was paid to Nectid.  The Company retains all other inventions, patents and technologies initially acquired from Nectid. NOTE 7 - STOCK PURCHASE AGREEMENT   On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Companys common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.   Under the terms of the Agreement, The Company has the right to deliver to Kodiak a put notice stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.   The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the pricing period, which is seven days from the date the put notice is delivered.   The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.   The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. These shares were issued on June 17, 2011.  Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.   In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.   The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.    As of December 31, 2012 the Company has initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares.  The Company has not registered with the SEC the shares to be issued to Kodak.  The Agreement expired on June 17, 2013.   NOTE 8 COMMON AND PREFERRED STOCK   On June 20, 2011, the Company received written consent from its majority stockholders to amend the Companys articles of incorporation to change the authorized capitalization. The board of directors previously approved the resolution to increase the number of authorized common stock from 50,000,000 to 100,000,000 shares and to authorize 10,000,000 shares of blank check preferred shares.   The newly authorized preferred shares may be issued from time to time in one or more series in the discretion of the board of directors. The board will have the authority to establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. No preferred shares have been issued.   On April 11, 2011, the Board of Directors appointed a new Chief Financial Officer, effective immediately and for a term of twelve months.  The Company issued 60,000 shares of its common stock at $1.05 per share to the officer as compensation for his services for an aggregate value of $63,000.  On the same date, the Company also issued 85,000 shares of its common stock at $1.05 per share to two consultants as compensation for professional services for an aggregate value of $89,250.   On June 17, 2011, the Company issued 150,000 shares of common stock at $1.01 per share to a consultant for services rendered. The cost of the shares was valued at the trading price on the issuance date of $1.01 per share for an aggregate value of $151,500.   On August 29, 2011 the Company issued 125,000 shares of its common stock to board members as compensation. The cost of the shares was valued at the trading price on the issuance date of $1.00 per share for an aggregate value of $125,000.   On August 29, 2011 the Company issued 750,000 shares of common stock pursuant to a consulting agreement. The cost of services was valued at the trading price of the shares on the issuance date of $1.00 per share for an aggregate value of $750,000. This amount was amortized as appropriate for 2011, with the balance recorded as a prepaid asset as of December 31, 2011.   On October 4, 2011, the Company issued 35,000 shares of common stock for services. The cost of the shares was valued at the trading price on the issuance date of $0.98 per share for an aggregate value of $34,300.   NOTE 9 RESEARCH AND DEVELOPMENT COSTS   On February 12, 2010, the Company issued 5,000,000 shares of its common stock pursuant to a Patent Acquisition Agreement to purchase various patents to be used in the commercialization of certain drugs. In accordance with ASC 730, the Company has recorded the cost of these expenses as research and development expenses.   As part of the Patent Acquisition Agreement, the Company has agreed to pay a royalty equal to 20% of gross sales from licensing fees or net sales.  Additionally, the Company is obligated to achieve the following developmental milestones:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%'> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> a) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> Commercially reasonable efforts must begin within 12 months of the agreement </td> </tr> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> b) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> File an Investigational New Drug (IND) application for at least one product within two years of closing </td> </tr> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> c) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> Initiate clinical studies for at least one product within three years of closing </td> </tr> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> d) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> Commercialize at least one product within five years of closing </td> </tr> </table>   NOTE 10 INCOME TAXES   The Company provides for income taxes under ASC 740 Tax Provisions. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.   ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.   The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 34% to net loss before provision for income taxes for the following reasons:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.72%'> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;padding:0in 0in 1.5pt 0in'>   </td> <td width="23%" colspan="2" valign="bottom" style='width:23.52%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.94%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;padding:0in 0in 1.5pt 0in'>   </td> <td width="15%" colspan="2" valign="bottom" style='width:15.86%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.94%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:#CCFFCC;padding:0'> Income tax expense at statutory rate </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="22%" valign="bottom" style='width:22.12%;background:#CCFFCC;padding:0'> (188,461 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.44%;background:#CCFFCC;padding:0'> (270,567 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:white;padding:0'> Stock issued for assets and services </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="22%" valign="bottom" style='width:22.12%;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.44%;background:white;padding:0'> 412,437 </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> Contributed services </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="22%" valign="bottom" style='width:22.12%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 2,040 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.44%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> - </td> <td width="0%" valign="bottom" style='width:.94%;padding:0'>   </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> Valuation allowance </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="22%" valign="bottom" style='width:22.12%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> (186,421 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> ) </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.44%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 141,870 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:white;padding:0in 0in 3.0pt 0in'> Income tax expense per books </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="22%" valign="bottom" style='width:22.12%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.44%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> </table> </div>   Net deferred tax assets consist of the following components as of: <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.0%'> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0'> NOL carryover </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (2,860,810 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (2,672,348 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0'> Stock issued for assets and services </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'> 2,642,531 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'> 2,642,531 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> Valuation allowance </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 216,239 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'></td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 29,817 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'></td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0in 0in 3.0pt 0in'> Net deferred tax asset </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 3.0pt 0in'>   </td> </tr> </table> </div>   Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $602,043 for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years. NOTE 11 SIGNIFICANT AGREEMENTS   On February 6, 2009, the Company entered into a Patent Acquisition Agreement, whereby it was assigned various patents for pharmaceutical products in exchange for 7,000,000 shares of the Companys common stock. 5,000,000 shares were delivered immediately to the assignor and 2,000,000 shares are held to be delivered upon the successful completion of $2,000,000 financing. The patents are also subject to a 40% royalty on revenues, a 10% milestone payment and an employment agreement. The Company is responsible for the completion of a development program to commercialize products using the patented technologies within 5 years.   NOTE 12 SUBSEQUENT EVENTS   In accordance with ASC 855-10, Company management reviewed all material events through the date of this report, and there are no other material subsequent events to report. Business and Organization   The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company).  The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987.  The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Companys operations ceased.  The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.      As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada.  Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies. Accounting Method   These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Companys fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.   Reclassification of Financial Statement Accounts <pre style='text-align:justify'>Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.</pre> Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates. Cash and Cash Equivalents   The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.   Revenue Recognition   The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured. Advertising Costs   The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively. Research and Development   Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable. Stock-based Compensation   The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services. Provision for Taxes   The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes.  The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.   The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a more-likely-than-not approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Companys financial statements. Basic (Loss) per Common Share   Basic (loss) per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.   The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.0%'> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0'> Loss (numerator) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (554,298 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (795,784 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0in 0in 1.5pt 0in'> Shares (denominator) </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 44,573,012 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 43,862,848 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> Per share amount </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.01 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.02 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> </tr> </table> </div>   Recent Accounting Pronouncements   Management has considered all recent accounting pronouncements issued since the last audit of the Companys financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys financial statements. 0001493526 2012-01-01 2012-12-31 0001493526 2012-12-31 0001493526 2011-12-31 0001493526 2011-01-01 2011-12-31 0001493526 1987-08-05 2012-12-31 0001493526 1988-01-01 1988-12-31 0001493526 1995-01-01 1995-12-31 0001493526 1996-01-01 1996-12-31 0001493526 2007-01-01 2007-12-31 0001493526 2010-01-01 2010-12-31 0001493526 us-gaap:RetainedEarningsMember 1987-12-31 0001493526 1987-12-31 0001493526 us-gaap:CommonStockMember 1988-01-01 1988-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1988-01-01 1988-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1988-12-31 0001493526 1988-12-31 0001493526 us-gaap:RetainedEarningsMember 1988-12-31 0001493526 us-gaap:CommonStockMember 1988-12-31 0001493526 us-gaap:RetainedEarningsMember 1989-12-31 0001493526 1989-12-31 0001493526 us-gaap:CommonStockMember 1989-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1989-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1994-12-31 0001493526 us-gaap:RetainedEarningsMember 1994-12-31 0001493526 1994-12-31 0001493526 us-gaap:CommonStockMember 1994-12-31 0001493526 us-gaap:CommonStockMember 1995-01-01 1995-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1995-01-01 1995-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1995-12-31 0001493526 1995-12-31 0001493526 us-gaap:RetainedEarningsMember 1995-12-31 0001493526 us-gaap:CommonStockMember 1995-12-31 0001493526 us-gaap:CommonStockMember 1996-01-01 1996-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1996-01-01 1996-12-31 0001493526 us-gaap:RetainedEarningsMember 1996-12-31 0001493526 1996-12-31 0001493526 us-gaap:CommonStockMember 1996-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 1996-12-31 0001493526 us-gaap:RetainedEarningsMember 2006-12-31 0001493526 2006-12-31 0001493526 us-gaap:CommonStockMember 2006-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0001493526 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001493526 us-gaap:RetainedEarningsMember 2007-12-31 0001493526 2007-12-31 0001493526 us-gaap:CommonStockMember 2007-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0001493526 us-gaap:RetainedEarningsMember 2008-12-31 0001493526 2008-12-31 0001493526 us-gaap:CommonStockMember 2008-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0001493526 us-gaap:RetainedEarningsMember 2009-12-31 0001493526 2009-12-31 0001493526 us-gaap:CommonStockMember 2009-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0001493526 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001493526 2010-12-31 0001493526 us-gaap:RetainedEarningsMember 2010-12-31 0001493526 us-gaap:CommonStockMember 2010-12-31 0001493526 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001493526 us-gaap:RetainedEarningsMember 2011-12-31 0001493526 us-gaap:CommonStockMember 2011-12-31 0001493526 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001493526 us-gaap:RetainedEarningsMember 2012-12-31 0001493526 us-gaap:CommonStockMember 2012-12-31 iso4217:USD shares iso4217:USD shares EX-101.SCH 9 prtt-20121231.xsd 000040 - Statement - Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 3 - Going Concern link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Note 11 - Significant Agreements link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Note 4 - Reorganization link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 8 - Common and Preferred Stock link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 6 - Sale of Patents link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 1 - Organization and History link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Note 1 - Organization and History: Business and Organization (Policies) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Note 9 - Research and Development Costs link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Note 12 - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Note 7 - Stock Purchase Agreement link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Note 10 - Income Taxes link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Accounting Method (Policies) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 5 - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Reorganizations link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 prtt-20121231_cal.xml EX-101.DEF 11 prtt-20121231_def.xml EX-101.LAB 12 prtt-20121231_lab.xml Accounting Method Note 6 - Sale of Patents Note 2 - Summary of Significant Accounting Policies Other accrued expenses Expenses paid by related party Cancelled stock, value Common stock issued for claims, value Professional Fees TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Entity Current Reporting Status Repayment of related party payable Issuance of shares for assets, shares Additional paid-in capital Accounts payable and accrued expenses Entity Central Index Key Amendment Flag Note 9 - Research and Development Costs FINANCING ACTIVITIES Services contributed by an officer Prepaid Expenses Recent Accounting Pronouncements Net Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Operating Activities Gain on sale of patent Statement {1} Statement LOSS BEFORE DISCONTINUED OPERATIONS EXPENSES TOTAL LIABILITIES Cash and Cash Equivalents Accounts payable Loss from disposition of subsidiary NET INCOME (LOSS) Income Taxes REVENUES Deficit accumulated during the development stage Related party payables Entity Filer Category Stock-based Compensation Research and Development Note 11 - Significant Agreements Common stock issued for prepaid services Statement, Equity Components Note 3 - Going Concern Common stock issued for research and development costs Common stock issued for expenses, value Accumulated Deficit Total Stockholders' Deficit Stockholders' Equity, ending balance Total Current Liabilities Advertising Costs Reorganization Change in accounts payable - related parties NET LOSS NET LOSS Common stock issued for expenses, shares Common stock Gain on sale of patents LOSS FROM OPERATIONS Document Fiscal Year Focus Provision For Taxes Net Cash Provided by Investing Activities Cancelled stock, shares Contribution of capital for services, value Contribution of capital for services, value Contribution of capital for services, value Entity Well-known Seasoned Issuer Reclassification of Financial Statement Accounts SUPPLEMENTAL CASH FLOW INFORMATION: Net loss Common stock issued for services, shares Equity Component WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Research and development Entity Public Float Document Period End Date Notes Issuance of shares for assets, value Common stock issued for claims, shares LOSS FROM DISCONTINUED OPERATIONS Accounts payable - related parties Current Fiscal Year End Date Basic (loss) Per Common Share Use of Estimates Note 1 - Organization and History INVESTING ACTIVITIES Balance common shares, ending balance Balance common shares, ending balance Additional Paid In Capital OTHER INCOME Common stock; 100,000,000 shares authorized, at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively TOTAL ASSETS Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Note 12 - Subsequent Events OPERATING ACTIVITIES Statement of Stockholders' Equity Preferred stock; 10,000,000 shares authorized, at $0.001 par value, no shares issued or outstanding LIABILITIES AND STOCKHOLDERS' DEFICIT Cash Entity Voluntary Filers Revenue Recognition Policies Note 7 - Stock Purchase Agreement Note 5 - Related Party Transactions NON-CASH FINANCING ACTIVITIES: Proceeds from related party payables Common stock issued for services Common stock issued for services, value Common stock issued for patents, shares Accrued officer salaries Entity Registrant Name Note 10 - Income Taxes Reorganizations: Change in prepaid expenses BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK STOCKHOLDERS' DEFICIT Document Type Business and Organization Changes in operating assets and liabilities Adjustments to reconcile net loss to net cash flows from operating activities Common stock issued for patents value General and administrative REVENUES {1} REVENUES CURRENT LIABILITIES Total Current Assets Note 8 - Common and Preferred Stock Note 4 - Reorganization CASH AT BEGINNING OF PERIOD CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD NET INCREASE IN CASH Capital contributed by officer Statement Executive compensation CURRENT ASSETS ASSETS Document and Entity Information: EX-101.PRE 13 prtt-20121231_pre.xml XML 14 R8.xml IDEA: Note 3 - Going Concern 2.4.0.8000090 - Disclosure - Note 3 - Going Concerntruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_LiquidityDisclosureGoingConcernNoteus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 3 GOING CONCERN   The Companys financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern.  It is the intent of the Company to seek a merger with an existing, operating company.  In the interim, shareholders of the Company have committed to meeting its minimal operating expenses.falsefalsefalsexbrli:stringItemTypestringIf there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date), disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 948 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47214-110998 false0Note 3 - Going ConcernfalseNote 3 - Going ConcernUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote3GoingConcern12 XML 15 R6.xml IDEA: Note 1 - Organization and History 2.4.0.8000070 - Disclosure - Note 1 - Organization and Historytruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 1 - ORGANIZATION AND HISTORY   Business and Organization   The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company).  The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987.  The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Companys operations ceased.  The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.      As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada.  Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies. falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 15 -URI http://asc.fasb.org/subtopic&trid=2122524 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2197480 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2209116 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2134480 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122150 false0Note 1 - Organization and HistoryfalseNote 1 - Organization and HistoryUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote1OrganizationAndHistory12 XML 16 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 12 - Subsequent Events
12 Months Ended

Dec. 31, 2012

Notes

Note 12 - Subsequent Events
NOTE 12 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report, and there are no other material subsequent events to report.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Stockholders' Equity (USD $)

Common stock

Additional Paid In Capital

Accumulated Deficit

Total

Contribution of capital for services, value at Dec. 31, 1994

Common stock issued for services, value $ 800 $ 599,200 $ 600,000

Common stock issued for services, shares 160,000 160,000

Stockholders' Equity, ending balance at Dec. 31, 1995 5,815 596,550 (605,105) (2,740)

NET LOSS at Dec. 31, 1995 (605,105) (605,105)

Contribution of capital for services, value at Dec. 31, 1995 2,605 2,605

Balance common shares, ending balance at Dec. 31, 1995 1,163,012 1,163,012

Common stock issued for expenses, value 10,000 5,000 15,000

Common stock issued for expenses, shares 2,000,000 2,000,000

Stockholders' Equity, ending balance at Dec. 31, 1996 15,815 601,550 (617,365)

NET LOSS at Dec. 31, 1996 (12,260) (12,260)

Balance common shares, ending balance at Dec. 31, 1996 3,163,012 3,163,012

Contribution of capital for services, value at Dec. 31, 2006

Common stock issued for services, value 150,000 150,000

Common stock issued for services, shares 30,000,000 30,000,000

Stockholders' Equity, ending balance at Dec. 31, 2007 165,815 601,550 (768,841) (1,476)

NET LOSS at Dec. 31, 2007 (150,000) (150,000)

Balance common shares, ending balance at Dec. 31, 2007 33,163,012 33,163,012

Contribution of capital for services, value at Dec. 31, 1987

Common stock issued for claims, value 97 (97)

Common stock issued for claims, shares 19,420 19,420

Common stock issued for services, value 1,046 2,336,880 1,046

Common stock issued for services, shares 209,112 209,112

Issuance of shares for assets, value 1,798 1,346,672 1,348,470

Issuance of shares for assets, shares 359,592 359,592

Cancelled stock, value (1,046) (1,046)

Cancelled stock, shares (209,112) (209,112)

Stockholders' Equity, ending balance at Dec. 31, 1988 5,015 3,716,455 (3,721,530) (60)

NET LOSS at Dec. 31, 1988 (3,721,500) (3,721,500)

Contribution of capital for services, value at Dec. 31, 1988 33,000 33,000

Balance common shares, ending balance at Dec. 31, 1988 1,003,012 1,003,012

Contribution of capital for services, value at Dec. 31, 2009

Common stock issued for patents value 25,000 1,225,000 1,250,000

Common stock issued for patents, shares 5,000,000 5,000,000

Common stock issued for services, value 26,025 5,283,075 5,309,100

Common stock issued for services, shares 5,205,000 5,205,000

Stockholders' Equity, ending balance at Dec. 31, 2010 216,840 7,122,909 (7,798,952) (459,203)

NET LOSS at Dec. 31, 2010 (7,026,356) (7,026,356)

Contribution of capital for services, value at Dec. 31, 2010 13,284 13,284

Balance common shares, ending balance at Dec. 31, 2010 43,368,012 43,368,012

Common stock issued for services, value 175 34,125 34,300

Common stock issued for services, shares 35,000 35,000

Stockholders' Equity, ending balance at Dec. 31, 2011 222,865 8,342,980 (8,594,736) (28,891)

NET LOSS at Dec. 31, 2011 (795,784) (795,784)

Contribution of capital for services, value at Dec. 31, 2011 $ 13,046 $ 13,046

Balance common shares, ending balance at Dec. 31, 2011 44,573,012 44,573,012

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The amount of capital contributed by the general partner.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 5

-Subparagraph (SAB TOPIC 4.F)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770

+ Details

Name: us-gaap_GeneralPartnersContributedCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 5 - Related Party Transactions
12 Months Ended

Dec. 31, 2012

Notes

Note 5 - Related Party Transactions
NOTE 5 – RELATED PARTY TRANSACTIONS

Various startup expenses of the Company including purchase of property and equipment, officer’s compensation and general and administrative expenses have been paid for using funds provided by two directors of the Company. The liabilities are non-interest bearing, unsecured and due upon demand. The Company owed $16,319 and $4,507for such payables as of December 31, 2012 and 2011, respectively. These amounts due are for services rendered by related parties.

The Company has recorded advances from a related party of $100 and expenses paid by a related party on behalf of the Company of $3,979 as related party payables. As of December 31, 2012 and December 31, 2011, respectively, the related party payable outstanding balance totaled $4,079 and $-0-. These amounts are non-interest bearing, unsecured, and are due on demand.

Contributed Capital

During the year ended December 31, 2012, a related-party has contributed various administrative services to the Company. These services have been valued at $6,000 for the year ended December 31, 2012.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 20 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Advertising Costs
Advertising Costs

The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively.

X

- Definition

Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=32704220&loc=d3e8275-108329

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6387522&loc=d3e8384-108330

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2127066

+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R29.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) 2.4.0.8000300 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Recent Accounting Pronouncements   Management has considered all recent accounting pronouncements issued since the last audit of the Companys financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys financial statements.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.No definition available.false0Recent Accounting PronouncementsfalseNote 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies12 XML 22 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 1 - Organization and History: Business and Organization (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Business and Organization
Business and Organization

The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company). The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987. The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Company’s operations ceased. The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.

As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada. Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies.

X

- Definition

The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.

+ References

No definition available.

+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R25.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies) 2.4.0.8000260 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_ResearchAndDevelopmentExpensePolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Research and Development   Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2127266 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 false0Research and DevelopmentfalseNote 2 - Summary of Significant Accounting Policies: Research and Development (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentPolicies12 XML 24 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Provision For Taxes
Provision for Taxes

The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.

The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a “more-likely-than-not” approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Company’s financial statements.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

An explanation as to the reasons for the omission of deferred income taxes related to the gain (loss) recognized on the stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockReasonForOmittingDeferredIncomeTaxProvisionOnGainLossRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Stock-based Compensation
Stock-based Compensation

The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of employee stock purchase plan activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R19.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Accounting Method (Policies) 2.4.0.8000200 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Accounting Method (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAccountingMethodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Accounting Method   These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Companys fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.  falsefalsefalsexbrli:stringItemTypestringA description of the accounting for each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 false0Accounting MethodfalseNote 2 - Summary of Significant Accounting Policies: Accounting Method (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAccountingMethodPolicies12 XML 27 R9.xml IDEA: Note 4 - Reorganization 2.4.0.8000100 - Disclosure - Note 4 - Reorganizationtruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_ReorganizationItemsDescriptionOfOtherReorganizationItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 4 REORGANIZATION   A special meeting of the shareholders of the Company was held on June 15, 1995.  It was agreed upon at the meeting to effect a quasi reorganization whereby the accumulated deficit of the Company up to December 31, 1994 was eliminated against the paid-in capital of the Company.falsefalsefalsexbrli:stringItemTypestringDescription of other reorganization items.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6916575&loc=d3e55730-112764 false0Note 4 - ReorganizationfalseNote 4 - ReorganizationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote4Reorganization12 XML 28 R12.xml IDEA: Note 7 - Stock Purchase Agreement 2.4.0.8000130 - Disclosure - Note 7 - Stock Purchase Agreementtruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 7 - STOCK PURCHASE AGREEMENT   On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Companys common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.   Under the terms of the Agreement, The Company has the right to deliver to Kodiak a put notice stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.   The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the pricing period, which is seven days from the date the put notice is delivered.   The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.   The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. These shares were issued on June 17, 2011.  Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.   In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.   The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.    As of December 31, 2012 the Company has initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares.  The Company has not registered with the SEC the shares to be issued to Kodak.  The Agreement expired on June 17, 2013.  falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Note 7 - Stock Purchase AgreementfalseNote 7 - Stock Purchase AgreementUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote7StockPurchaseAgreement12 XML 29 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Research and Development
Research and Development

Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 1 - Organization and History
12 Months Ended

Dec. 31, 2012

Notes

Note 1 - Organization and History
NOTE 1 - ORGANIZATION AND HISTORY

Business and Organization

The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company). The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987. The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Company’s operations ceased. The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.

As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada. Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Going Concern
12 Months Ended

Dec. 31, 2012

Notes

Note 3 - Going Concern
NOTE 3 – GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date), disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 948

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47214-110998

+ Details

Name: us-gaap_LiquidityDisclosureGoingConcernNote

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R11.xml IDEA: Note 6 - Sale of Patents 2.4.0.8000120 - Disclosure - Note 6 - Sale of Patentstruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_RevenueRecognitionSalesOfGoodsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 6 SALE OF PATENTS                 On January 31, 2011, the Company finalized and closed a Patent Purchase Agreement (the Agreement) with Grünenthal GmbH (Grünenthal), a company organized under the laws of Germany.  Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Companys rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively the Patents), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof.  The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.   In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (Nectid), a privately held New Jersey company.  Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company.  Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance was paid to Nectid.  The Company retains all other inventions, patents and technologies initially acquired from Nectid.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 15 -URI http://asc.fasb.org/subtopic&trid=2197222 false0Note 6 - Sale of PatentsfalseNote 6 - Sale of PatentsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote6SaleOfPatents12 XML 33 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Sale of Patents
12 Months Ended

Dec. 31, 2012

Notes

Note 6 - Sale of Patents
NOTE 6 – SALE OF PATENTS



On January 31, 2011, the Company finalized and closed a Patent Purchase Agreement (the “Agreement”) with Grünenthal GmbH (“Grünenthal”), a company organized under the laws of Germany. Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Company’s rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively “the Patents”), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof. The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.

In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent

Acquisition Agreement with Nectid, Inc. (“Nectid”), a privately held New Jersey company. Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company. Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance was paid to Nectid. The Company retains all other inventions, patents and technologies initially acquired from Nectid.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2197222

+ Details

Name: us-gaap_RevenueRecognitionSalesOfGoods

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.xml IDEA: Note 9 - Research and Development Costs 2.4.0.8000150 - Disclosure - Note 9 - Research and Development Coststruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCostsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 9 RESEARCH AND DEVELOPMENT COSTS   On February 12, 2010, the Company issued 5,000,000 shares of its common stock pursuant to a Patent Acquisition Agreement to purchase various patents to be used in the commercialization of certain drugs. In accordance with ASC 730, the Company has recorded the cost of these expenses as research and development expenses.   As part of the Patent Acquisition Agreement, the Company has agreed to pay a royalty equal to 20% of gross sales from licensing fees or net sales.  Additionally, the Company is obligated to achieve the following developmental milestones:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%'> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> a) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> Commercially reasonable efforts must begin within 12 months of the agreement </td> </tr> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> b) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> File an Investigational New Drug (IND) application for at least one product within two years of closing </td> </tr> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> c) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> Initiate clinical studies for at least one product within three years of closing </td> </tr> <tr align="left"> <td width="3%" valign="top" style='width:3.0%;padding:0'>   </td> <td width="3%" valign="top" style='width:3.0%;padding:0'> d) </td> <td width="77%" valign="top" style='width:77.0%;padding:0'> Commercialize at least one product within five years of closing </td> </tr> </table>  falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the preproduction design and development costs it incurs related to long-term supply arrangements, including whether such costs are capitalized or expensed as incurred. The entity also may disclose the aggregate amount of (1) assets recognized for agreements that contractually reimburse the entity for its pre-production design and development costs (2) assets recognized for molds, dies and other tools that the entity owns and (3) assets recognized for molds, dies and other tools that the entity does not own.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section S99 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105117-122735 false0Note 9 - Research and Development CostsfalseNote 9 - Research and Development CostsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote9ResearchAndDevelopmentCosts12 XML 35 R2.xml IDEA: Balance Sheets 2.4.0.8000020 - Statement - Balance Sheetstruefalsefalse1false USDfalsefalse$E12http://www.sec.gov/CIK0001493526instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$E11http://www.sec.gov/CIK0001493526instant2011-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_AssetsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0ASSETS2false 2us-gaap_Cashus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse860860USD$falsetruefalse2truefalsefalse2217122171USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Cash3false 2us-gaap_PrepaidExpenseCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse491667491667falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316 false2Prepaid Expenses4false 2us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse860860falsefalsefalse2truefalsefalse513838513838falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 false2Total Current Assets5false 2us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse860860falsefalsefalse2truefalsefalse513838513838falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 false2TOTAL ASSETS6false 2us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse7082570825falsefalsefalse2truefalsefalse6098560985falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false2Accounts payable and accrued expenses7false 2us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1631916319falsefalsefalse2truefalsefalse45074507falsefalsefalsexbrli:monetaryItemTypemonetaryAmount for accounts payable to related parties.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 7 false2Accounts payable - related parties8false 2us-gaap_DueToRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse40794079falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Related party payables9false 2us-gaap_AccruedSalariesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse486826486826falsefalsefalse2truefalsefalse477237477237falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765 false2Accrued officer salaries10false 2us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse578049578049falsefalsefalse2truefalsefalse542729542729falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 false2Total Current Liabilities11false 2us-gaap_Liabilitiesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse578049578049falsefalsefalse2truefalsefalse542729542729falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2TOTAL LIABILITIES12false 2us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse222865222865falsefalsefalse2truefalsefalse222865222865falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false2Common stock; 100,000,000 shares authorized, at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively13false 2us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse83489808348980falsefalsefalse2truefalsefalse83429808342980falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Additional paid-in capital14false 2us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-9149034-9149034falsefalsefalse2truefalsefalse-8594736-8594736falsefalsefalsexbrli:monetaryItemTypemonetaryCumulative net losses reported during the development stage.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 210 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921 false2Deficit accumulated during the development stage15false 2us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-577189-577189falsefalsefalse2truefalsefalse-28891-28891falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Total Stockholders' Deficit16false 2us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse860860USD$falsetruefalse2truefalsefalse513838513838USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 false2TOTAL LIABILITIES AND STOCKHOLDERS' DEFICITfalseBalance Sheets (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_BalanceSheets216 XML 36 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 4 - Reorganization
12 Months Ended

Dec. 31, 2012

Notes

Note 4 - Reorganization
NOTE 4 – REORGANIZATION

A special meeting of the shareholders of the Company was held on June 15, 1995. It was agreed upon at the meeting to effect a quasi – reorganization whereby the accumulated deficit of the Company up to December 31, 1994 was eliminated against the paid-in capital of the Company.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of other reorganization items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6916575&loc=d3e55730-112764

+ Details

Name: us-gaap_ReorganizationItemsDescriptionOfOtherReorganizationItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Basic (loss) Per Common Share
Basic (Loss) per Common Share

Basic (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.

The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.

For the

Year Ended

December 31,

2012

For the

Year Ended

December 31,

2011

Loss (numerator)

$

(554,298

)

$

(795,784

)

Shares (denominator)

44,573,012

43,862,848

Per share amount

$

(0.01

)

$

(0.02

)

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the effect of income (loss) on basic earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R24.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies) 2.4.0.8000250 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_AdvertisingCostsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Advertising Costs   The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=32704220&loc=d3e8275-108329 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 20 -Section 55 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6387522&loc=d3e8384-108330 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2127066 false0Advertising CostsfalseNote 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAdvertisingCostsPolicies12 XML 39 R10.xml IDEA: Note 5 - Related Party Transactions 2.4.0.8000110 - Disclosure - Note 5 - Related Party Transactionstruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_RelatedPartyTransactionsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 5 RELATED PARTY TRANSACTIONS   Various startup expenses of the Company including purchase of property and equipment, officers compensation and general and administrative expenses have been paid for using funds provided by two directors of the Company. The liabilities are non-interest bearing, unsecured and due upon demand. The Company owed $16,319 and $4,507for such payables as of December 31, 2012 and 2011, respectively. These amounts due are for services rendered by related parties.   The Company has recorded advances from a related party of $100 and expenses paid by a related party on behalf of the Company of $3,979 as related party payables. As of December 31, 2012 and December 31, 2011, respectively, the related party payable outstanding balance totaled $4,079 and $-0-. These amounts are non-interest bearing, unsecured, and are due on demand.   Contributed Capital During the year ended December 31, 2012, a related-party has contributed various administrative services to the Company. These services have been valued at $6,000 for the year ended December 31, 2012.  falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 false0Note 5 - Related Party TransactionsfalseNote 5 - Related Party TransactionsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote5RelatedPartyTransactions12 XML 40 R5.xml IDEA: Statements of Cash Flows 2.4.0.8000050 - Statement - Statements of Cash Flowstruefalsefalse1false USDfalsefalse$Y12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$Y11http://www.sec.gov/CIK0001493526duration2011-01-01T00:00:002011-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D870805_121231http://www.sec.gov/CIK0001493526duration1987-08-05T00:00:002012-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0OPERATING ACTIVITIES2false 2us-gaap_ProfitLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-554298-554298USD$falsetruefalse2truefalsefalse-795784-795784USD$falsetruefalse3truefalsefalse-12870744-12870744USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686 false2Net loss3false 2us-gaap_CostOfServicesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse60006000falsefalsefalse2truefalsefalse60006000falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryTotal costs related to services rendered by an entity during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Services contributed by an officer4false 2us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse721383721383falsefalsefalse3truefalsefalse99046539904653falsefalsefalsexbrli:sharesItemTypesharesThe increase (decrease) during the period in the number of shares issued.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Common stock issued for services5false 2us-gaap_IncreaseDecreaseInEstimatedFutureDevelopmentCostsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse12500001250000falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in standardized measure of discounted future net cash flow as a result of change in estimated future development costs.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 932 -SubTopic 235 -Section 50 -Paragraph 31 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62455-109447 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 932 -SubTopic 235 -Section 50 -Paragraph 35 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62500-109447 false2Common stock issued for research and development costs6false 2us-gaap_GainOrLossOnSaleOfStockInSubsidiaryus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse564300564300falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of gain (loss) on sale or disposal of equity in securities of subsidiaries.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 13 -Subparagraph g -Article 9 false2Loss from disposition of subsidiary7false 2us-gaap_IncreaseDecreaseInDueToRelatedPartiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse39793979falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse6959969599falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Expenses paid by related party8false 2us-gaap_IncreaseDecreaseInAssetsHeldForSaleus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse640000640000falsefalsefalse3truefalsefalse640000640000falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Gain on sale of patent9false 2us-gaap_IncreaseDecreaseInAccountsPayableus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse98409840falsefalsefalse2truefalsefalse-23560-23560falsefalsefalse3truefalsefalse7082570825falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Accounts payable10false 2us-gaap_IncreaseDecreaseInAccountsPayableRelatedPartiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1181211812falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse160081160081falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Change in accounts payable - related parties11false 2us-gaap_IncreaseDecreaseInPrepaidExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse491667491667falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse491667491667falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Change in prepaid expenses12false 2us-gaap_IncreaseDecreaseInAccruedLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse95899589falsefalsefalse2truefalsefalse252579252579falsefalsefalse3truefalsefalse486826486826falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Other accrued expenses13false 2us-gaap_NetCashProvidedByUsedInOperatingActivitiesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-21411-21411falsefalsefalse2truefalsefalse-485382-485382falsefalsefalse3truefalsefalse-506793-506793falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 false2Net Cash Provided by (Used in) Operating Activities14false 2us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse640000640000falsefalsefalse3truefalsefalse640000640000falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 false2Net Cash Provided by Investing Activities15false 2us-gaap_ProceedsFromContributedCapitalus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse1304613046falsefalsefalse3truefalsefalse1304613046falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received by a corporation from a shareholder during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Capital contributed by officer16false 2us-gaap_ProceedsFromRelatedPartyDebtus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse100100falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse100100falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from related party payables17false 2us-gaap_RepaymentsOfRelatedPartyDebtus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse-145493-145493falsefalsefalse3truefalsefalse-145493-145493falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 false2Repayment of related party payable18false 2us-gaap_NetCashProvidedByUsedInFinancingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse100100falsefalsefalse2truefalsefalse-132447-132447falsefalsefalse3truefalsefalse-132347-132347falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 false2Net Cash Provided by (Used in) Financing Activities19false 2us-gaap_IncreaseDecreaseInDepositsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-21311-21311falsefalsefalse2truefalsefalse2217122171falsefalsefalse3truefalsefalse860860falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 230 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585 false2NET INCREASE IN CASH20false 2us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse2217122171falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2CASH AT BEGINNING OF PERIOD21false 2us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse860860falsefalsefalse2truefalsefalse2217122171falsefalsefalse3truefalsefalse860860falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2CASH AT END OF PERIOD22false 2us-gaap_OtherNoncashExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse750000750000USD$falsetruefalse3truefalsefalse750000750000USD$falsetruefalsexbrli:monetaryItemTypemonetaryOther expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Common stock issued for prepaid servicesfalseStatements of Cash Flows (USD $)NoRoundingNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_StatementsOfCashFlows322 EXCEL 41 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V-C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)KF%T:6]N7V%N9%](:7-T;W(\+W@Z M3F%M93X-"B`@("`\>#I7;W)K5]O9E]3:6=N:69I8V%N=%\\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5?-%]296]R9V%N:7IA M=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?-5]296QA=&5D7U!A#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DYO=&5?-E]386QE7V]F7U!A=&5N=',\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,3)?4W5B#I7;W)KF%T:6]N7V%N9%](:7-T;W(Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O5]O9E]3:6=N:69I8V%N M=%\S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DYO=&5?,E]3=6UM87)Y7V]F7U-I9VYI M9FEC86YT7S4\+W@Z3F%M93X-"B`@("`\>#I7;W)K5]O9E]3:6=N:69I8V%N=%\V/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,E]3=6UM87)Y7V]F7U-I9VYI9FEC86YT7S@\+W@Z3F%M M93X-"B`@("`\>#I7;W)K5]O9E]3:6=N:69I8V%N=%\Y/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I7;W)K5]O9E]3:6=N:69I8V%N=%\Q,3PO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7S!B,3,S93`R7S8V-S%?-#)E8U\Y93EB7V8Q8F,P8S4W9C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!);F9O'0^4%)/5$5#5"!02$%234%#155424-! M3"!#;W)P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\ M=&0@8VQA2!#;VUM;VX@4W1O8VLL(%-H87)E2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^3F\\ M2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^3F\\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@+2!R96QA=&5D('!A6%B;&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`W.3QS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P8C$S,V4P,E\V-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'!E;G-E2P@96YD:6YG(&)A;&%N8V4@870@1&5C+B`S M,2P@,C`P-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!R96QA=&5D('!A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA6%B;&4@+2!R96QA=&5D('!A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'!E M;G-E6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V-C'0O:'1M M;#L@8VAA3QB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L.V)A8VMG2DN)FYB2!W87,@:6YC;W)P;W)A=&5D(&9O&ES M=&EN9RP@;W!E2!C M:&%N9V5D('1O(%!R;RU496-T+"!);F,N(&%N9"!I=',@9&]M:6-I;&4@=V%S M(&UO=F5D('1O('1H92!S=&%T92!O9B!.979A9&$N)FYB2!C:&%N9V5D(&ET2!H87,@96YG86=E M9"!I;B!L:6-E;G-I;F<@:71S('!A=&5N=&5D('!H87)M86-E=71I8V%L'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC M:65S/&)R/CPO'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG65A'0M86QI9VXZ:G5S=&EF>3Y#97)T86EN(&%M;W5N=',@:6X@=&AE($1E8V5M M8F5R(#,Q+"`R,#$Q(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!R M96-L87-S:69I960@=&\@8V]N9F]R;2!T;R!T:&4@<')E6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L.V)A8VMG2!A8V-E<'1E9"!I;B!T:&4@ M56YI=&5D(%-T871E6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG MF4@F5D(&]N;'D@=VAE;B!T:&4@<')I8V4@:7,@9FEX960@;W(@ M9&5T97)M:6YA8FQE+"!P97)S=6%S:79E(&5V:61E;F-E(&]F(&%N(&%R2!I6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG M:'0Z;F]R;6%L.V)A8VMG2!F;VQL;W=S('1H92!P;VQI8WD@;V8@97AP M96YS:6YG(&%D=F5R=&ES:6YG(&-O2!I;F-U6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[;&EN92UH96EG:'0Z,3`N-C5P=#X\=3Y297-E87)C:"!A;F0@ M1&5V96QO<&UE;G0\+W4^/"]P/B`\<"!S='EL93TS1&UAF5D(&%S(&5X<&5N6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG29N8G-P.S$L(#(P,#8@=7-I;F<@ M=&AE(&UO9&EF:65D('!R;W-P96-T:79E(&UE=&AO9"X@56YD97(@=&AI29N8G-P.S$L(#(P,#8L(&)A6UE;G1S(&9O6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG M:'0Z;F]R;6%L.V)A8VMG2!A<'!L:65S($%30R`W-#`L('=H M:6-H(')E<75I"!C;VYS97%U96YC97,@;V8@86QL(&5V96YT MF5D(&EN('1H92!F:6YA;F-I86P@2!R96-O"!A"!A6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG"!P;W-I=&EO;G,@=7-I;F<@82`F M(S$T-SMM;W)E+6QI:V5L>2UT:&%N+6YO="8C,30X.R!A<'!R;V%C:"P@"!P;W-I=&EO;G,N(%1H92!A9&]P=&EO;B!O9B!!4T,@-S0P M(&AA9"!N;R!M871E6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L.V)A8VMG2!T:&4@ M=V5I9VAT960@879E2!D:79I9&EN9R!T:&4@0V]M<&%N>28C,30V.W,@;F5T M(&EN8V]M92!A=F%I;&%B;&4@=&\@8V]M;6]N('-H87)E:&]L9&5R2!T M:&4@9&EL=71E9"!W96EG:'1E9"!A=F5R86=E(&YU;6)E6QE M/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T M=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM M87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH M96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$=VED=&@Z-S4N,"4^(#QT6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,"4@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.BXW,B4[<&%D9&EN9SHP:6X@,&EN M(#$N-7!T(#!I;B<^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,38E(&-O;'-P86X],T0R('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ-BXQ."4[8F]R9&5R.FYO;F4[8F]R9&5R M+6)O='1O;3IS;VQI9"!B;&%C:R`Q+C5P=#MP861D:6YG.C`G/B`\<"!A;&EG M;CTS1&-E;G1E'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIC96YT97([;&EN92UH96EG:'0Z;F]R;6%L/EEE87(F;F)S<#M%;F1E9#PO M<#X@/'`@86QI9VX],T1C96YT97(@6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH96EG:'0Z;F]R;6%L/C(P M,3(\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HN.38E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIC96YT97([;&EN92UH96EG:'0Z;F]R;6%L/D1E8V5M8F5R)FYB'0M86QI9VXZ8V5N=&5R.VQI;F4M M:&5I9VAT.FYO6QE/3-$=VED=&@Z-C0N,R4[8F%C M:V=R;W5N9#IW:&ET93MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L M/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,"4@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z+C'0M86QI9VXZ6QE/3-$=VED=&@Z,2XT,B4[8F%C:V=R;W5N M9#IW:&ET93MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P M.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,30E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C$T+C'0M86QI9VXZ6QE/3-$=VED=&@Z+CDV)3MB86-K9W)O=6YD.G=H M:71E.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M M86P^)FYB6QE/3-$=VED M=&@Z,30N-S8E.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^ M)FYB6QE/3-$;6%R9VEN+71O<#HP M:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G M:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B0\ M+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$T)2!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/BD\+W`^ M(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.BXW,B4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,2XT,B4[8F%C:V=R;W5N9#HC0T-&1D-# M.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^ M*#6QE/3-$)W=I9'1H.BXW,B4[8F%C M:V=R;W5N9#IW:&ET93MP861D:6YG.C!I;B`P:6X@,2XU<'0@,&EN)SX@/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.C$N-#(E.V)O6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M M86P^-#0L-36QE/3-$)W=I9'1H.BXY-B4[8F%C:V=R;W5N9#IW:&ET M93MP861D:6YG.C!I;B`P:6X@,2XU<'0@,&EN)SX@/'`@6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^)FYB6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H M/3-$,30E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XW-B4[ M8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!B;&%C:R`Q+C5P=#MB M86-K9W)O=6YD.G=H:71E.W!A9&1I;F6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L/B0\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#$T)2!V86QI9VX],T1B;W1T M;VT@'0M86QI9VXZ6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L/BD\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HN-S(E.V)A8VMG'0M86QI9VXZ6QE/3-$)W=I9'1H.C$N-#(E.V)O6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M M86P^*#`N,#(\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HN.38E.V)A8VMG6QE M/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T M=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM M87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH M96EG:'0Z;F]R;6%L.V)A8VMG6QE M/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T M=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM M87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH M96EG:'0Z;F]R;6%L.V)A8VMG'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$28C,30V.W,@9FEN86YC:6%L M('-T871E;65N=',@87)E('!R97!AF%T:6]N(&]F(&%S2!T;R!S965K(&$@;65R9V5R('=I=&@@86X@ M97AI7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!42!46QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG2!A;F0@97%U:7!M96YT+"!O9F9I8V5R)B,Q-#8[2!T=V\@9&ER M96-T;W)S(&]F('1H92!#;VUP86YY+B!4:&4@;&EA8FEL:71I97,@87)E(&YO M;BUI;G1E6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L.V)A8VMG2!O9B`D,3`P(&%N9"!E>'!E M;G-E2!O;B!B96AA;&8@;V8@=&AE M($-O;7!A;GD@;V8@)#,L.32!P87EA8FQE(&]U='-T86YD:6YG(&)A;&%N8V4@/&9O;G0@;&%N M9STS1%@M3D].13YT;W1A;#PO9F]N=#YE9#QF;VYT(&QA;F<],T18+4Y/3D4^ M("0\+V9O;G0^-"PP-SD\9F]N="!L86YG/3-$6"U.3TY%/B!A;F0@)#PO9F]N M=#XM,"TN/&9O;G0@;&%N9STS1%@M3D].13XF;F)S<#M4:&5S92`\+V9O;G0^ M86UO=6YT6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L.V)A8VMG2`S M,2P@,C`Q,2P@=&AE($-O;7!A;GD@9FEN86QI>F5D(&%N9"!C;&]S960@82!0 M871E;G0@4'5R8VAAF5D('5N9&5R M('1H92!L87=S(&]F($=E2!S;VQD('1O($=R M)B,R-3([;F5N=&AA;"!A;&P@;V8@=&AE($-O;7!A;GDF(S$T-CMS(')I9VAT M&-H86YG92!F;W(@=&AE(%!A=&5N=',L($=R)B,R M-3([;F5N=&AA;"!P86ED('1H92!#;VUP86YY("0Q+#8P,"PP,#`N(%1H92!# M;VUP86YY(&]R:6=I;F%L;'D@86-Q=6ER960@=&AE('-U8FIE8W0@4&%T96YT M2`R,#$P('!U M2!C;VUP86YY+B8C,38P.R!5;F1E2!A9W)E960@=&AA="!I;B!T:&4@979E;G0@ M=&AE($-O;7!A;GD@2P@=&AE($-O;7!A;GD@2!R971A:6YS(&%L M;"!O=&AE'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE M/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T M=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM M87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH M96EG:'0Z;F]R;6%L.V)A8VMG2!W:6QL(&9I;&4@=VET:"!T:&4@4T5#(&$@ M2!I2!C;&]S:6YG(&)I9"!P6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG7,@9G)O;2!T:&4@9&%T92!T:&4@<'5T(&YO=&EC M92!I2!H87,@=&AE(&]P=&EO;B!T M;R!S<&5C:69Y(&$@9FQO;W(@<')I8V4@9F]R(&%N>2!P=70@;F]T:6-E+B!) M;B!T:&4@979E;G0@;W5R('-H87)E6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L M.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG M:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L M.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P M,E\V-C'0O:'1M;#L@8VAA6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG28C,30V.W,@87)T:6-L97,@;V8@:6YC;W)P M;W)A=&EO;B!T;R!C:&%N9V4@=&AE(&%U=&AO2!A<'!R;W9E M9"!T:&4@6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG2!A;'-O(&ES6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG M:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG M:'0Z;F]R;6%L.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG2!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG M2`Q,BP@,C`Q,"P@=&AE M($-O;7!A;GD@:7-S=65D(#4L,#`P+#`P,"!S:&%R97,@;V8@:71S(&-O;6UO M;B!S=&]C:R!P=7)S=6%N="!T;R!A(%!A=&5N="!!8W%U:7-I=&EO;B!!9W)E M96UE;G0@=&\@<'5R8VAAF%T:6]N(&]F(&-E2!H87,@6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG M:'0Z;F]R;6%L.V)A8VMG6QE/3-$=VED=&@Z M,3`P+C`E/B`\='(@86QI9VX],T1L969T/B`\=&0@=VED=&@],T0S)2!V86QI M9VX],T1T;W`@6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/D-O;6UE2!R96%S;VYA M8FQE(&5F9F]R=',@;75S="!B96=I;B!W:71H:6X@,3(@;6]N=&AS(&]F('1H M92!A9W)E96UE;G0\+W`^(#PO=&0^(#PO='(^(#QT65A M6QE/3-$=VED=&@Z M,RXP)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO M<#X@/"]T9#X@/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$ M=VED=&@Z,RXP)3MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP M:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G M:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/F,I M/"]P/B`\+W1D/B`\=&0@=VED=&@],T0W-R4@=F%L:6=N/3-$=&]P('-T>6QE M/3-$=VED=&@Z-S6QE/3-$=VED=&@Z,RXP)3MP861D:6YG.C`^(#QP('-T M>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$ M,R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,RXP)3MP861D:6YG.C`^ M(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG M:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[;&EN92UH96EG:'0Z;F]R;6%L/F0I/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0W-R4@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-S6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L M.V)A8VMG7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA&5S/&)R/CPO6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG&5S+B!$969E"!B87-E'!E8W1E9"!T;R!R979E6QE M/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T M=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM M87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH M96EG:'0Z;F]R;6%L.V)A8VMG"!A6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG2!F961E M&5S(&9O6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H M/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.BXW)3MP861D M:6YG.C!I;B`P:6X@,2XU<'0@,&EN)SX@/'`@6QE/3-$)W=I9'1H.C(S+C4R)3MB;W)D97(Z M;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED(&)L86-K(#$N-7!T.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH M96EG:'0Z;F]R;6%L/D1E8V5M8F5R)FYB'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH96EG:'0Z;F]R M;6%L/C(P,3$\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HN.30E.W!A9&1I;F6QE/3-$8F]R9&5R.FYO;F4[<&%D9&EN9SHP M/CQP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG M:'0Z,3$U)3XF;F)S<#L\+W`^/"]T9#X@/"]T6QE/3-$;6%R9VEN+71O<#HP M:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G M:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE M+6AE:6=H=#IN;W)M86P^)FYB6QE/3-$=VED=&@Z,C(N,3(E.V)A8VMG6QE/3-$=VED=&@Z+CDT)3MB86-K9W)O=6YD M.B-#0T9&0T,[<&%D9&EN9SHP/B`\<"!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$=VED=&@Z,2XT,B4[8F%C:V=R;W5N9#HC0T-&1D-# M.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^ M*#(W,"PU-C<\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.BXY-"4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A M9&1I;F6QE/3-$=VED=&@Z M-38N,S@E.V)A8VMG'0M86QI9VXZ6QE/3-$=VED=&@Z,2XT,B4[8F%C:V=R;W5N9#IW:&ET M93MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,C(E('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C(R+C$R)3MB86-K9W)O=6YD.G=H:71E.W!A9&1I;F'0M86QI9VXZ6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D M('=I9'1H/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z+C6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^)FYB6QE/3-$=VED=&@Z,30N-#0E.V)A M8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^-#$R+#0S-SPO<#X@ M/"]T9#X@/'1D('=I9'1H/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z+CDT)3MB86-K9W)O=6YD.G=H:71E.W!A9&1I;F6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H M=#ML:6YE+6AE:6=H=#IN;W)M86P^)FYB6QE/3-$)W=I9'1H.C(R+C$R)3MB;W)D97(Z;F]N93MB M;W)D97(M8F]T=&]M.G-O;&ED(&)L86-K(#$N-7!T.V)A8VMG6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR M:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^,BPP-#`\+W`^(#PO=&0^(#QT9"!W M:61T:#TS1#`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HN.30E M.V)A8VMG'0M86QI9VXZ6QE/3-$)W=I9'1H.C$N-#(E.V)O6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P M.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,30E('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HQ-"XT-"4[8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O M;3IS;VQI9"!B;&%C:R`Q+C5P=#MB86-K9W)O=6YD.B-#0T9&0T,[<&%D9&EN M9SHP)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.BXY-"4[8F%C:V=R;W5N M9#HC0T-&1D-#.W!A9&1I;F6QE/3-$)W=I9'1H.C4V+C,X)3MB86-K9W)O=6YD.B-#0T9&0T,[<&%D M9&EN9SHP:6X@,&EN(#$N-7!T(#!I;B<^(#QP('-T>6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L M/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HN-R4[8F%C:V=R;W5N M9#HC0T-&1D-#.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^ M)FYB6QE/3-$)W=I M9'1H.C(R+C$R)3MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.G-O;&ED(&)L M86-K(#$N-7!T.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M M86P^*#$X-BPT,C$\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HN.30E.V)A8VMG6QE/3-$)W=I9'1H.BXW)3MB86-K9W)O=6YD.B-#0T9&0T,[<&%D M9&EN9SHP:6X@,&EN(#$N-7!T(#!I;B<^(#QP(&%L:6=N/3-$6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO M<#X@/"]T9#X@/'1D('=I9'1H/3-$,"4@6QE/3-$)W=I9'1H.C4V+C,X)3MB86-K9W)O=6YD.G=H:71E.W!A9&1I;F6QE/3-$)W=I9'1H M.C(R+C$R)3MB;W)D97(Z;F]N93MB;W)D97(M8F]T=&]M.F1O=6)L92!B;&%C M:R`R+C(U<'0[8F%C:V=R;W5N9#IW:&ET93MP861D:6YG.C`G/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^ M+3PO<#X@/"]T9#X@/'1D('=I9'1H/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.BXY-"4[8F%C:V=R;W5N9#IW:&ET93MP861D:6YG.C!I M;B`P:6X@,RXP<'0@,&EN)SX@/'`@6QE/3-$)W=I9'1H.C$T+C0T)3MB;W)D97(Z;F]N93MB;W)D M97(M8F]T=&]M.F1O=6)L92!B;&%C:R`R+C(U<'0[8F%C:V=R;W5N9#IW:&ET M93MP861D:6YG.C`G/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H M=#ML:6YE+6AE:6=H=#IN;W)M86P^+3PO<#X@/"]T9#X@/'1D('=I9'1H/3-$ M,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.BXY-"4[8F%C:V=R M;W5N9#IW:&ET93MP861D:6YG.C!I;B`P:6X@,RXP<'0@,&EN)SX@/'`@6QE/3-$)W=I9'1H.C$V+C$X)3MB;W)D97(Z;F]N93MB;W)D M97(M8F]T=&]M.G-O;&ED(&)L86-K(#$N-7!T.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH96EG:'0Z;F]R M;6%L/D1E8V5M8F5R)FYB'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO6QE/3-$)W=I9'1H.C$V+C$X)3MB;W)D97(Z;F]N M93MB;W)D97(M8F]T=&]M.G-O;&ED(&)L86-K(#$N-7!T.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH96EG M:'0Z;F]R;6%L/D1E8V5M8F5R)FYB'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO6QE/3-$=VED=&@Z-C0N,R4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A M9&1I;F6QE M/3-$=VED=&@Z+C6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN M;W)M86P^)FYB6QE/3-$=VED M=&@Z,30N-S8E.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/BD\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.BXW,B4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,2XT,B4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A9&1I M;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG M:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^*#(L-C6QE/3-$=VED=&@Z+CDV)3MB86-K9W)O=6YD.B-#0T9&0T,[<&%D9&EN M9SHP/B`\<"!S='EL93TS1&UA6QE/3-$=VED=&@Z-C0N,R4[8F%C:V=R;W5N9#IW:&ET93MP861D M:6YG.C`^(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/E-T;V-K(&ES6QE/3-$=VED=&@Z+C'0M86QI9VXZ M6QE/3-$=VED=&@Z,2XT M,B4[8F%C:V=R;W5N9#IW:&ET93MP861D:6YG.C`^(#QP('-T>6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,30E('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$T+C'0M86QI9VXZ6QE/3-$=VED=&@Z+CDV M)3MB86-K9W)O=6YD.G=H:71E.W!A9&1I;F6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML M:6YE+6AE:6=H=#IN;W)M86P^)FYB6QE/3-$=VED=&@Z,30N-S8E.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP M:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G M:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE M+6AE:6=H=#IN;W)M86P^,BPV-#(L-3,Q/"]P/B`\+W1D/B`\=&0@=VED=&@] M,T0P)2!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.BXW,B4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A9&1I M;F6QE M/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T M=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM M87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA M;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^)FYB6QE/3-$)W=I9'1H.C$T+C6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X M="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^,CDL.#$W/"]P/B`\ M+W1D/B`\=&0@=VED=&@],T0P)2!V86QI9VX],T1B;W1T;VT@6QE/3-$ M;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G M:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG M;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^)FYB'0M86QI9VXZ M6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H M/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.BXW,B4[8F%C M:V=R;W5N9#IW:&ET93MP861D:6YG.C!I;B`P:6X@,RXP<'0@,&EN)SX@/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1&UA'0M86QI9VXZ6QE/3-$)W=I9'1H.C$N-#(E.V)O6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B0\+W`^(#PO=&0^ M(#QT9"!W:61T:#TS1#$T)2!V86QI9VX],T1B;W1T;VT@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V-C'0O:'1M;#L@8VAA M6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L.V)A8VMG&-H86YG M92!F;W(@-RPP,#`L,#`P('-H87)E28C,30V.W,@ M8V]M;6]N('-T;V-K+B`U+#`P,"PP,#`@6%L='D@;VX@ M65A'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG2!M86YA9V5M96YT(')E=FEE=V5D(&%L;"!M871E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM M96=X+2T^/'`@F%T:6]N/"]U/CPO<#X@/'`@6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM M8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U M)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN M92UH96EG:'0Z;F]R;6%L.V)A8VMG2!H87,@8F5E;B!S965K:6YG(&YE=R!B=7-I;F5S6QE/3-$;6%R9VEN+71O<#HP M:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G M:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A M8VMG2P@=&AE($-O;7!A;GD@8VAA;F=E M9"!I=',@;F%M92!O;B!-87)C:"`R-2P@,C`Q,"!T;R!0'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG65A3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\P8C$S,V4P,E\V-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE M/3-$=&5X="UA;&EG;CIJ=7-T:69Y/D-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V)A8VMG3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P8C$S,V4P,E\V-C'0O:'1M;#L@8VAA2!C;VYS:61E2!L:7%U:60@:6YS=')U M;65N=',@=VET:"!M871U2!O9B!T:')E92!M;VYT:',@;W(@;&5S2X\+W`^(#QP('-T>6QE/3-$;6%R M9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P M+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM M8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z M;F]R;6%L.V)A8VMG7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMGF4@F5D(&]N;'D@=VAE;B!T:&4@<')I8V4@:7,@9FEX960@;W(@9&5T M97)M:6YA8FQE+"!P97)S=6%S:79E(&5V:61E;F-E(&]F(&%N(&%R2!I'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG2!O9B!E>'!E;G-I;F<@861V97)T M:7-I;F<@8V]S=',@9'5R:6YG('1H92!P97)I;V0@:6X@=VAI8V@@=&AE>2!A M65A2X\+W`^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V-C'0O:'1M M;#L@8VAA6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[;&EN92UH96EG:'0Z,3`N-C5P=#XF;F)S<#L\+W`^(#QP('-T>6QE M/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG M:'0Z,3`N-C5P=#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E M(')E8V]G;FEZ960@87,@97AP96YS92!D=7)I;F<@=&AE('!E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG M29N8G-P.S$L(#(P,#8@=7-I;F<@=&AE(&UO9&EF M:65D('!R;W-P96-T:79E(&UE=&AO9"X@56YD97(@=&AI29N M8G-P.S$L(#(P,#8L(&)A6UE;G1S(&9O3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V-C'0O:'1M;#L@8VAA2!A<'!L:65S($%30R`W-#`L('=H:6-H(')E<75I"!C;VYS97%U96YC97,@;V8@86QL(&5V96YTF5D(&EN M('1H92!F:6YA;F-I86P@2!R96-O"!A2!T:&%N(&YO="!T:&%T(&%L;"!O"!A6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG"!P;W-I=&EO;G,@=7-I;F<@82`F(S$T-SMM;W)E+6QI:V5L M>2UT:&%N+6YO="8C,30X.R!A<'!R;V%C:"P@"!P;W-I M=&EO;G,N(%1H92!A9&]P=&EO;B!O9B!!4T,@-S0P(&AA9"!N;R!M871E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S.B!" M87-I8R`H;&]S6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG M2!D:79I9&EN9R!T:&4@0V]M<&%N>28C,30V.W,@;F5T(&QO M2!P;W1E;G1I86QL>2!D:6QU=&EV92!D96)T(&]R(&5Q=6ET>2X@ M5&AE6QE/3-$)W=I9'1H.C$V+C$X)3MB;W)D97(Z;F]N93MB;W)D97(M M8F]T=&]M.G-O;&ED(&)L86-K(#$N-7!T.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH96EG:'0Z;F]R;6%L M/D9O'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I M9VAT.FYO6QE/3-$)W=I9'1H.BXY-B4[<&%D9&EN9SHP:6X@,&EN(#$N-7!T(#!I;B<^ M(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM M87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG M:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I M9'1H/3-$,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.BXW,B4[ M<&%D9&EN9SHP:6X@,&EN(#$N-7!T(#!I;B<^(#QP('-T>6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L/B9N8G-P.SPO<#X@/"]T9#X@/'1D('=I9'1H/3-$,38E(&-O;'-P86X] M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-BXQ."4[8F]R M9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!B;&%C:R`Q+C5P=#MP861D M:6YG.C`G/B`\<"!A;&EG;CTS1&-E;G1E'0M86QI9VXZ8V5N=&5R.VQI M;F4M:&5I9VAT.FYO6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH96EG:'0Z;F]R;6%L/EEE M87(F;F)S<#M%;F1E9#PO<#X@/'`@86QI9VX],T1C96YT97(@6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIC96YT97([;&EN92UH M96EG:'0Z;F]R;6%L/C(P,3$\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HN.38E.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE M:6=H=#IN;W)M86P^)FYB6QE/3-$=VED=&@Z,30N-S8E.V)A8VMG6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H M=#IN;W)M86P^)FYB6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I M;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH M96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP M,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T9#X@/"]T M6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN M+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP M:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/DQO'0M86QI9VXZ6QE/3-$=VED=&@Z,2XT,B4[8F%C:V=R;W5N M9#HC0T-&1D-#.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H M=#IN;W)M86P^*#4U-"PR.3@\+W`^(#PO=&0^(#QT9"!W:61T:#TS1#`E('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.BXY-B4[8F%C:V=R;W5N9#HC M0T-&1D-#.W!A9&1I;F6QE/3-$ M=VED=&@Z+C6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M M86P^)FYB6QE/3-$=VED=&@Z M,30N-S8E.V)A8VMG6QE/3-$=VED=&@Z+CDV)3MB86-K9W)O=6YD.B-#0T9&0T,[<&%D M9&EN9SHP/B`\<"!S='EL93TS1&UA6QE/3-$)W=I9'1H.C8T+C,E.V)A8VMG6QE/3-$;6%R9VEN M+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P M=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T M=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R M;6%L/E-H87)E6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M M86P^)FYB6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I M9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[ M;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO<#X@/"]T M9#X@/'1D('=I9'1H/3-$,30E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ-"XW-B4[8F]R9&5R.FYO;F4[8F]R9&5R+6)O='1O;3IS;VQI9"!B M;&%C:R`Q+C5P=#MB86-K9W)O=6YD.G=H:71E.W!A9&1I;F6QE/3-$)W=I9'1H.C$T+C'0M86QI9VXZ6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R M9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F M=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L/B9N8G-P.SPO M<#X@/"]T9#X@/"]T6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G M:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z M,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M;&EN92UH96EG:'0Z;F]R;6%L/E!E'0M86QI9VXZ6QE/3-$)W=I9'1H.C$N-#(E.V)O6QE/3-$;6%R9VEN+71O M<#HP:6X[;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM M87)G:6XM;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML M:6YE+6AE:6=H=#IN;W)M86P^*#`N,#$\+W`^(#PO=&0^(#QT9"!W:61T:#TS M1#`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HN.38E.V)A8VMG M6QE/3-$)W=I9'1H.BXW,B4[8F%C:V=R;W5N M9#HC0T-&1D-#.W!A9&1I;F6QE/3-$;6%R9VEN+71O<#HP:6X[;6%R9VEN+7)I9VAT M.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM;&5F=#HP:6X[;&EN M92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM87)G:6XM8F]T=&]M M.BXP,#`Q<'0[=&5X="UA;&EG;CIR:6=H=#ML:6YE+6AE:6=H=#IN;W)M86P^ M)FYB6QE/3-$)W=I9'1H M.C$T+C6QE/3-$)W=I9'1H.BXY-B4[8F%C:V=R;W5N9#HC0T-&1D-#.W!A M9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V M-C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN+71O<#HP:6X[ M;6%R9VEN+7)I9VAT.C!I;CMM87)G:6XM8F]T=&]M.C$P+C!P=#MM87)G:6XM M;&5F=#HP:6X[;&EN92UH96EG:'0Z,3$U)3MM87)G:6XM8F]T=&]M.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[;&EN92UH96EG:'0Z;F]R;6%L.V)A8VMG M28C,30V.W,@;6%N86=E;65N="!B96QI979E M3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P8C$S,V4P,E\V-C&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 42 R4.xml IDEA: Statements of Stockholders' Equity 2.4.0.8000040 - Statement - Statements of Stockholders' Equitytruefalsefalse1falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseCommon stockus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberCommon stockSharesStandardhttp://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseCommon stockus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$2falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseAdditional Paid In Capitalus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberAdditional Paid In CapitalUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAdditional Paid In Capitalus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$3falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseAccumulated Deficitus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMemberAccumulated DeficitUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAccumulated Deficitus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$4falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*truefalseEquity Componentus-gaap_StatementEquityComponentsAxisus-gaap_EquityComponentDomainus-gaap_StatementEquityComponentsAxisexplicitMemberEquity ComponentSharesStandardhttp://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDfalsefalse$na0001-01-01T00:00:000001-01-01T00:00:00USDUSD$1falseRowperiodPeriod*RowprimaryElement*2false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant1994-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 19942falseRowperiodPeriod*RowprimaryElement*7false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, valueduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse800800USD$falsetruefalse2truefalsefalse599200599200USD$falsetruefalse3falsefalsefalse00falsefalsefalse4truefalsefalse600000600000USD$falsetruefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, value3falseRowperiodPeriod*RowprimaryElement*8false 4us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, sharesduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse160000160000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse160000160000falsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, shares4falseRowperiodPeriod*RowprimaryElement*18false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stockholders' Equity, ending balanceduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse58155815falsefalsefalse2truefalsefalse596550596550falsefalsefalse3truefalsefalse-605105-605105falsefalsefalse4truefalsefalse-2740-2740falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant1995-12-31T00:00:000001-01-01T00:00:002Stockholders' Equity, ending balance at Dec. 31, 19955falseRowperiodPeriod*RowprimaryElement*16false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2NET LOSSduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-605105-605105falsefalsefalse4truefalsefalse-605105-605105falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 falseinstant1995-12-31T00:00:000001-01-01T00:00:002NET LOSS at Dec. 31, 19956falseRowperiodPeriod*RowprimaryElement*9false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2truefalsefalse26052605falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse26052605falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant1995-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 19957falseRowperiodPeriod*RowprimaryElement*17false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Balance common shares, ending balanceduration1995-01-01T00:00:001995-12-31T00:00:00 0us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse11630121163012falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse11630121163012falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 falseinstant1995-12-31T00:00:000001-01-01T00:00:001Balance common shares, ending balance at Dec. 31, 19958falseRowperiodPeriod*RowprimaryElement*10false 4us-gaap_StockIssuedDuringPeriodValueOtherus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.No definition available.false2Common stock issued for expenses, valueduration1996-01-01T00:00:001996-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueOtherus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1000010000falsefalsefalse2truefalsefalse50005000falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1500015000falsefalsefalsexbrli:monetaryItemTypemonetaryValue of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.No definition available.false2Common stock issued for expenses, value9falseRowperiodPeriod*RowprimaryElement*11false 4us-gaap_StockIssuedDuringPeriodSharesOtherus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.No definition available.false1Common stock issued for expenses, sharesduration1996-01-01T00:00:001996-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesOtherus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse20000002000000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse20000002000000falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.No definition available.false1Common stock issued for expenses, shares10falseRowperiodPeriod*RowprimaryElement*18false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stockholders' Equity, ending balanceduration1996-01-01T00:00:001996-12-31T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse1581515815falsefalsefalse2truefalsefalse601550601550falsefalsefalse3truefalsefalse-617365-617365falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant1996-12-31T00:00:000001-01-01T00:00:002Stockholders' Equity, ending balance at Dec. 31, 199611falseRowperiodPeriod*RowprimaryElement*16false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2NET LOSSduration1996-01-01T00:00:001996-12-31T00:00:00 0us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-12260-12260falsefalsefalse4truefalsefalse-12260-12260falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 falseinstant1996-12-31T00:00:000001-01-01T00:00:002NET LOSS at Dec. 31, 199612falseRowperiodPeriod*RowprimaryElement*17false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Balance common shares, ending balanceduration1996-01-01T00:00:001996-12-31T00:00:00 0us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse31630123163012falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse31630123163012falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 falseinstant1996-12-31T00:00:000001-01-01T00:00:001Balance common shares, ending balance at Dec. 31, 199613falseRowperiodPeriod*RowprimaryElement*2false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration2007-01-01T00:00:002007-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant2006-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 200614falseRowperiodPeriod*RowprimaryElement*7false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, valueduration2007-01-01T00:00:002007-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse150000150000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse150000150000falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, value15falseRowperiodPeriod*RowprimaryElement*8false 4us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, sharesduration2007-01-01T00:00:002007-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3000000030000000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3000000030000000falsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, shares16falseRowperiodPeriod*RowprimaryElement*18false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stockholders' Equity, ending balanceduration2007-01-01T00:00:002007-12-31T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse165815165815falsefalsefalse2truefalsefalse601550601550falsefalsefalse3truefalsefalse-768841-768841falsefalsefalse4truefalsefalse-1476-1476falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2007-12-31T00:00:000001-01-01T00:00:002Stockholders' Equity, ending balance at Dec. 31, 200717falseRowperiodPeriod*RowprimaryElement*16false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2NET LOSSduration2007-01-01T00:00:002007-12-31T00:00:00 0us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-150000-150000falsefalsefalse4truefalsefalse-150000-150000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 falseinstant2007-12-31T00:00:000001-01-01T00:00:002NET LOSS at Dec. 31, 200718falseRowperiodPeriod*RowprimaryElement*17false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Balance common shares, ending balanceduration2007-01-01T00:00:002007-12-31T00:00:00 0us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse3316301233163012falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3316301233163012falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 falseinstant2007-12-31T00:00:000001-01-01T00:00:001Balance common shares, ending balance at Dec. 31, 200719falseRowperiodPeriod*RowprimaryElement*2false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant1987-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 198720falseRowperiodPeriod*RowprimaryElement*5false 4us-gaap_StockIssuedDuringPeriodValueAcquisitionsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock issued pursuant to acquisitions during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for claims, valueduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueAcquisitionsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse9797falsefalsefalse2truefalsefalse-97-97falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock issued pursuant to acquisitions during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for claims, value21falseRowperiodPeriod*RowprimaryElement*6false 4us-gaap_StockIssuedDuringPeriodSharesAcquisitionsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period pursuant to acquisitions.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for claims, sharesduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesAcquisitionsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1942019420falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1942019420falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period pursuant to acquisitions.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for claims, shares22falseRowperiodPeriod*RowprimaryElement*7false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, valueduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10461046falsefalsefalse2truefalsefalse23368802336880falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse10461046falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, value23falseRowperiodPeriod*RowprimaryElement*8false 4us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, sharesduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse209112209112falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse209112209112falsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, shares24falseRowperiodPeriod*RowprimaryElement*12false 4us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.No definition available.false2Issuance of shares for assets, valueduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse17981798falsefalsefalse2truefalsefalse13466721346672falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse13484701348470falsefalsefalsexbrli:monetaryItemTypemonetaryValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.No definition available.false2Issuance of shares for assets, value25falseRowperiodPeriod*RowprimaryElement*13false 4us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssetsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.No definition available.false1Issuance of shares for assets, sharesduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssetsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse359592359592falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse359592359592falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.No definition available.false1Issuance of shares for assets, shares26falseRowperiodPeriod*RowprimaryElement*14false 4us-gaap_StockIssuedDuringPeriodValueConversionOfUnitsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Cancelled stock, valueduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueConversionOfUnitsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-1046-1046falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse-1046-1046falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Cancelled stock, value27falseRowperiodPeriod*RowprimaryElement*15false 4us-gaap_StockIssuedDuringPeriodSharesConversionOfUnitsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false1Cancelled stock, sharesduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesConversionOfUnitsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-209112-209112falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse-209112-209112falsefalsefalsexbrli:sharesItemTypesharesThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false1Cancelled stock, shares28falseRowperiodPeriod*RowprimaryElement*18false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stockholders' Equity, ending balanceduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse50155015falsefalsefalse2truefalsefalse37164553716455falsefalsefalse3truefalsefalse-3721530-3721530falsefalsefalse4truefalsefalse-60-60falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant1988-12-31T00:00:000001-01-01T00:00:002Stockholders' Equity, ending balance at Dec. 31, 198829falseRowperiodPeriod*RowprimaryElement*16false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2NET LOSSduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-3721500-3721500falsefalsefalse4truefalsefalse-3721500-3721500falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 falseinstant1988-12-31T00:00:000001-01-01T00:00:002NET LOSS at Dec. 31, 198830falseRowperiodPeriod*RowprimaryElement*9false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2truefalsefalse3300033000falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3300033000falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant1988-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 198831falseRowperiodPeriod*RowprimaryElement*17false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Balance common shares, ending balanceduration1988-01-01T00:00:001988-12-31T00:00:00 0us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse10030121003012falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse10030121003012falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 falseinstant1988-12-31T00:00:000001-01-01T00:00:001Balance common shares, ending balance at Dec. 31, 198832falseRowperiodPeriod*RowprimaryElement*2false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant2009-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 200933falseRowperiodPeriod*RowprimaryElement*3false 4us-gaap_StockIssuedDuringPeriodValueNewIssuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for patents valueduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueNewIssuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2500025000falsefalsefalse2truefalsefalse12250001225000falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse12500001250000falsefalsefalsexbrli:monetaryItemTypemonetaryEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for patents value34falseRowperiodPeriod*RowprimaryElement*4false 4us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for patents, sharesduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse50000005000000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse50000005000000falsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for patents, shares35falseRowperiodPeriod*RowprimaryElement*7false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, valueduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2602526025falsefalsefalse2truefalsefalse52830755283075falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse53091005309100falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, value36falseRowperiodPeriod*RowprimaryElement*8false 4us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, sharesduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse52050005205000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse52050005205000falsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, shares37falseRowperiodPeriod*RowprimaryElement*18false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stockholders' Equity, ending balanceduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse216840216840falsefalsefalse2truefalsefalse71229097122909falsefalsefalse3truefalsefalse-7798952-7798952falsefalsefalse4truefalsefalse-459203-459203falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2010-12-31T00:00:000001-01-01T00:00:002Stockholders' Equity, ending balance at Dec. 31, 201038falseRowperiodPeriod*RowprimaryElement*16false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2NET LOSSduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-7026356-7026356falsefalsefalse4truefalsefalse-7026356-7026356falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 falseinstant2010-12-31T00:00:000001-01-01T00:00:002NET LOSS at Dec. 31, 201039falseRowperiodPeriod*RowprimaryElement*9false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1328413284falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1328413284falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant2010-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 201040falseRowperiodPeriod*RowprimaryElement*17false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Balance common shares, ending balanceduration2010-01-01T00:00:002010-12-31T00:00:00 0us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse4336801243368012falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse4336801243368012falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 falseinstant2010-12-31T00:00:000001-01-01T00:00:001Balance common shares, ending balance at Dec. 31, 201041falseRowperiodPeriod*RowprimaryElement*7false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, valueduration2011-01-01T00:00:002011-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse175175falsefalsefalse2truefalsefalse3412534125falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3430034300falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued for services, value42falseRowperiodPeriod*RowprimaryElement*8false 4us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, sharesduration2011-01-01T00:00:002011-12-31T00:00:00 0us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3500035000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3500035000falsefalsefalsexbrli:sharesItemTypesharesNumber of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock issued for services, shares43falseRowperiodPeriod*RowprimaryElement*18false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stockholders' Equity, ending balanceduration2011-01-01T00:00:002011-12-31T00:00:00 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse222865222865falsefalsefalse2truefalsefalse83429808342980falsefalsefalse3truefalsefalse-8594736-8594736falsefalsefalse4truefalsefalse-28891-28891falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2011-12-31T00:00:000001-01-01T00:00:002Stockholders' Equity, ending balance at Dec. 31, 201144falseRowperiodPeriod*RowprimaryElement*16false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2NET LOSSduration2011-01-01T00:00:002011-12-31T00:00:00 0us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-795784-795784falsefalsefalse4truefalsefalse-795784-795784falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 falseinstant2011-12-31T00:00:000001-01-01T00:00:002NET LOSS at Dec. 31, 201145falseRowperiodPeriod*RowprimaryElement*9false 4us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 false2Contribution of capital for services, valueduration2011-01-01T00:00:002011-12-31T00:00:00 0us-gaap_GeneralPartnersContributedCapitalus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1304613046USD$falsetruefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1304613046USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe amount of capital contributed by the general partner.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770 falseinstant2011-12-31T00:00:000001-01-01T00:00:002Contribution of capital for services, value at Dec. 31, 201146falseRowperiodPeriod*RowprimaryElement*17false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Balance common shares, ending balanceduration2011-01-01T00:00:002011-12-31T00:00:00 0us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse4457301244573012falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse4457301244573012falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 falseinstant2011-12-31T00:00:000001-01-01T00:00:001Balance common shares, ending balance at Dec. 31, 2011trueStatements of Stockholders' Equity (USD $)NoRoundingNoRoundingUnKnownUnKnownfalsefalsefalseSheethttp://prtt/20121231/role/idr_StatementsOfStockholdersEquity446 XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 69 99 1 false 3 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://prtt/20121231/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information R1.xml true false R2.htm 000020 - Statement - Balance Sheets Sheet http://prtt/20121231/role/idr_BalanceSheets Balance Sheets R2.xml false false R3.htm 000030 - Statement - Statements of Operations Sheet http://prtt/20121231/role/idr_StatementsOfOperations Statements of Operations R3.xml false false R4.htm 000040 - Statement - Statements of Stockholders' Equity Sheet http://prtt/20121231/role/idr_StatementsOfStockholdersEquity Statements of Stockholders' Equity R4.xml false false R5.htm 000050 - Statement - Statements of Cash Flows Sheet http://prtt/20121231/role/idr_StatementsOfCashFlows Statements of Cash Flows R5.xml false false R6.htm 000070 - Disclosure - Note 1 - Organization and History Sheet http://prtt/20121231/role/idr_DisclosureNote1OrganizationAndHistory Note 1 - Organization and History R6.xml false false R7.htm 000080 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies Note 2 - Summary of Significant Accounting Policies R7.xml false false R8.htm 000090 - Disclosure - Note 3 - Going Concern Sheet http://prtt/20121231/role/idr_DisclosureNote3GoingConcern Note 3 - Going Concern R8.xml false false R9.htm 000100 - Disclosure - Note 4 - Reorganization Sheet http://prtt/20121231/role/idr_DisclosureNote4Reorganization Note 4 - Reorganization R9.xml false false R10.htm 000110 - Disclosure - Note 5 - Related Party Transactions Sheet http://prtt/20121231/role/idr_DisclosureNote5RelatedPartyTransactions Note 5 - Related Party Transactions R10.xml false false R11.htm 000120 - Disclosure - Note 6 - Sale of Patents Sheet http://prtt/20121231/role/idr_DisclosureNote6SaleOfPatents Note 6 - Sale of Patents R11.xml false false R12.htm 000130 - Disclosure - Note 7 - Stock Purchase Agreement Sheet http://prtt/20121231/role/idr_DisclosureNote7StockPurchaseAgreement Note 7 - Stock Purchase Agreement R12.xml false false R13.htm 000140 - Disclosure - Note 8 - Common and Preferred Stock Sheet http://prtt/20121231/role/idr_DisclosureNote8CommonAndPreferredStock Note 8 - Common and Preferred Stock R13.xml false false R14.htm 000150 - Disclosure - Note 9 - Research and Development Costs Sheet http://prtt/20121231/role/idr_DisclosureNote9ResearchAndDevelopmentCosts Note 9 - Research and Development Costs R14.xml false false R15.htm 000160 - Disclosure - Note 10 - Income Taxes Sheet http://prtt/20121231/role/idr_DisclosureNote10IncomeTaxes Note 10 - Income Taxes R15.xml false false R16.htm 000170 - Disclosure - Note 11 - Significant Agreements Sheet http://prtt/20121231/role/idr_DisclosureNote11SignificantAgreements Note 11 - Significant Agreements R16.xml false false R17.htm 000180 - Disclosure - Note 12 - Subsequent Events Sheet http://prtt/20121231/role/idr_DisclosureNote12SubsequentEvents Note 12 - Subsequent Events R17.xml false false R18.htm 000190 - Disclosure - Note 1 - Organization and History: Business and Organization (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote1OrganizationAndHistoryBusinessAndOrganizationPolicies Note 1 - Organization and History: Business and Organization (Policies) R18.xml false false R19.htm 000200 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Accounting Method (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAccountingMethodPolicies Note 2 - Summary of Significant Accounting Policies: Accounting Method (Policies) R19.xml false false R20.htm 000210 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesReclassificationOfFinancialStatementAccountsPolicies Note 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies) R20.xml false false R21.htm 000220 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies) R21.xml false false R22.htm 000230 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies) R22.xml false false R23.htm 000240 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies) R23.xml false false R24.htm 000250 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAdvertisingCostsPolicies Note 2 - Summary of Significant Accounting Policies: Advertising Costs (Policies) R24.xml false false R25.htm 000260 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentPolicies Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies) R25.xml false false R26.htm 000270 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies) R26.xml false false R27.htm 000280 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesProvisionForTaxesPolicies Note 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies) R27.xml false false R28.htm 000290 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasicLossPerCommonSharePolicies Note 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies) R28.xml false false R29.htm 000300 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) Sheet http://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) R29.xml false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 1995' Process Flow-Through: Removing column 'Dec. 31, 1994' Process Flow-Through: Removing column 'Dec. 31, 1989' Process Flow-Through: Removing column 'Dec. 31, 1988' Process Flow-Through: Removing column 'Dec. 31, 1987' Process Flow-Through: 000030 - Statement - Statements of Operations Process Flow-Through: 000050 - Statement - Statements of Cash Flows prtt-20121231.xml prtt-20121231.xsd prtt-20121231_cal.xml prtt-20121231_def.xml prtt-20121231_lab.xml prtt-20121231_pre.xml true true XML 44 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Operations (USD $)
12 Months Ended 305 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

REVENUES

Research and development $ 100,520 $ 1,353,540

Professional Fees 512,619 728,793 1,480,984

Executive compensation 25,726 482,246 5,888,730

General and administrative 15,953 124,225 446,939

LOSS FROM OPERATIONS (554,298) (1,435,784) (9,170,193)

Gain on sale of patents 640,000 640,000

LOSS BEFORE DISCONTINUED OPERATIONS (554,298) (795,784) (8,530,193)

LOSS FROM DISCONTINUED OPERATIONS (4,340,551)

NET INCOME (LOSS) $ (554,298) $ (795,784) $ (12,870,744)

BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK $ (0.01) $ (0.02)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING 44,573,012 43,862,848

X

- Definition

Pretax adjustment to an amount previously reported in discontinued operations that is directly related to the disposal of the component in a prior period. Examples of circumstances leading to such adjustments include the resolution of contingencies relating to the terms of the disposal transaction or relating to the operations of the component prior to its disposal, and the settlement of certain employee benefit plan obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

+ Details

Name: us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other income (loss) amounts, net of tax expense or benefit, relating to a disposal group that is classified as a component of the entity, exclusive of the following elsewhere enumerated categories: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2646-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 9 - Research and Development Costs
12 Months Ended

Dec. 31, 2012

Notes

Note 9 - Research and Development Costs
NOTE 9 – RESEARCH AND DEVELOPMENT COSTS

On February 12, 2010, the Company issued 5,000,000 shares of its common stock pursuant to a Patent Acquisition Agreement to purchase various patents to be used in the commercialization of certain drugs. In accordance with ASC 730, the Company has recorded the cost of these expenses as research and development expenses.

As part of the Patent Acquisition Agreement, the Company has agreed to pay a royalty equal to 20% of gross sales from licensing fees or net sales. Additionally, the Company is obligated to achieve the following developmental milestones:

a)

Commercially reasonable efforts must begin within 12 months of the agreement

b)

File an Investigational New Drug (IND) application for at least one product within two years of closing

c)

Initiate clinical studies for at least one product within three years of closing

d)

Commercialize at least one product within five years of closing

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the preproduction design and development costs it incurs related to long-term supply arrangements, including whether such costs are capitalized or expensed as incurred. The entity also may disclose the aggregate amount of (1) assets recognized for agreements that contractually reimburse the entity for its pre-production design and development costs (2) assets recognized for molds, dies and other tools that the entity owns and (3) assets recognized for molds, dies and other tools that the entity does not own.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section S99

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105117-122735

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R20.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies) 2.4.0.8000210 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_Reclassificationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Reclassification of Financial Statement Accounts <pre style='text-align:justify'>Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.</pre>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 false0Reclassification of Financial Statement AccountsfalseNote 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesReclassificationOfFinancialStatementAccountsPolicies12 XML 47 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Cash Flows (USD $)
12 Months Ended 305 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

OPERATING ACTIVITIES

Net loss $ (554,298) $ (795,784) $ (12,870,744)

Services contributed by an officer 6,000 6,000

Common stock issued for services 721,383 9,904,653

Common stock issued for research and development costs 1,250,000

Loss from disposition of subsidiary 564,300

Expenses paid by related party 3,979 69,599

Gain on sale of patent 640,000 640,000

Accounts payable 9,840 (23,560) 70,825

Change in accounts payable - related parties 11,812 160,081

Change in prepaid expenses 491,667 491,667

Other accrued expenses 9,589 252,579 486,826

Net Cash Provided by (Used in) Operating Activities (21,411) (485,382) (506,793)

Net Cash Provided by Investing Activities 640,000 640,000

Capital contributed by officer 13,046 13,046

Proceeds from related party payables 100 100

Repayment of related party payable (145,493) (145,493)

Net Cash Provided by (Used in) Financing Activities 100 (132,447) (132,347)

NET INCREASE IN CASH (21,311) 22,171 860

CASH AT BEGINNING OF PERIOD 22,171

CASH AT END OF PERIOD 860 22,171 860

Common stock issued for prepaid services $ 750,000 $ 750,000

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Subparagraph g

-Article 9

+ Details

Name: us-gaap_GainOrLossOnSaleOfStockInSubsidiary

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAssetsHeldForSale

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 230

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of change in estimated future development costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 932

-SubTopic 235

-Section 50

-Paragraph 31

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62455-109447

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 932

-SubTopic 235

-Section 50

-Paragraph 35

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62500-109447

+ Details

Name: us-gaap_IncreaseDecreaseInEstimatedFutureDevelopmentCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received by a corporation from a shareholder during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromContributedCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the number of shares issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (USD $)

Dec. 31, 2012

Dec. 31, 2011

ASSETS

Cash $ 860 $ 22,171

Prepaid Expenses 491,667

Total Current Assets 860 513,838

TOTAL ASSETS 860 513,838

Accounts payable and accrued expenses 70,825 60,985

Accounts payable - related parties 16,319 4,507

Related party payables 4,079

Accrued officer salaries 486,826 477,237

Total Current Liabilities 578,049 542,729

TOTAL LIABILITIES 578,049 542,729

Common stock; 100,000,000 shares authorized, at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively 222,865 222,865

Additional paid-in capital 8,348,980 8,342,980

Deficit accumulated during the development stage (9,149,034) (8,594,736)

Total Stockholders' Deficit (577,189) (28,891)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 860 $ 513,838

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount for accounts payable to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 49 R7.xml IDEA: Note 2 - Summary of Significant Accounting Policies 2.4.0.8000080 - Disclosure - Note 2 - Summary of Significant Accounting Policiestruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_SignificantAccountingPoliciesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Accounting Method   These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Companys fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.   Reclassification of Financial Statement Accounts <pre style='text-align:justify'>Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.</pre>   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.   Revenue Recognition   The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured.   Advertising Costs   The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively.     Research and Development   Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.   Stock-based Compensation   The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services.   Provision for Taxes   The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes.  The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.   The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a more-likely-than-not approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Companys financial statements.   Basic (Loss) per Common Share   Basic (loss) per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.   The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.0%'> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0'> Loss (numerator) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (554,298 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (795,784 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0in 0in 1.5pt 0in'> Shares (denominator) </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 44,573,012 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 43,862,848 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> Per share amount </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.01 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.02 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> </tr> </table> </div>   Recent Accounting Pronouncements   Management has considered all recent accounting pronouncements issued since the last audit of the Companys financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys financial statements.  falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790 false0Note 2 - Summary of Significant Accounting PoliciesfalseNote 2 - Summary of Significant Accounting PoliciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies12 XML 50 R17.xml IDEA: Note 12 - Subsequent Events 2.4.0.8000180 - Disclosure - Note 12 - Subsequent Eventstruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 12 SUBSEQUENT EVENTS   In accordance with ASC 855-10, Company management reviewed all material events through the date of this report, and there are no other material subsequent events to report.falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Note 12 - Subsequent EventsfalseNote 12 - Subsequent EventsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote12SubsequentEvents12 XML 51 R16.xml IDEA: Note 11 - Significant Agreements 2.4.0.8000170 - Disclosure - Note 11 - Significant Agreementstruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_ScheduleOfResaleAgreementsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 11 SIGNIFICANT AGREEMENTS   On February 6, 2009, the Company entered into a Patent Acquisition Agreement, whereby it was assigned various patents for pharmaceutical products in exchange for 7,000,000 shares of the Companys common stock. 5,000,000 shares were delivered immediately to the assignor and 2,000,000 shares are held to be delivered upon the successful completion of $2,000,000 financing. The patents are also subject to a 40% royalty on revenues, a 10% milestone payment and an employment agreement. The Company is responsible for the completion of a development program to commercialize products using the patented technologies within 5 years.  falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of resale agreements (also known as reverse repurchase agreements or reverse repos).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(m)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph m -Subparagraph 2 -Article 4 false0Note 11 - Significant AgreementsfalseNote 11 - Significant AgreementsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote11SignificantAgreements12 XML 52 R27.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies) 2.4.0.8000280 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_SaleOfStockReasonForOmittingDeferredIncomeTaxProvisionOnGainLossRecognizedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Provision for Taxes   The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes.  The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.   The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a more-likely-than-not approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Companys financial statements.falsefalsefalsexbrli:stringItemTypestringAn explanation as to the reasons for the omission of deferred income taxes related to the gain (loss) recognized on the stock transaction.No definition available.false0Provision For TaxesfalseNote 2 - Summary of Significant Accounting Policies: Provision For Taxes (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesProvisionForTaxesPolicies12 XML 53 R18.xml IDEA: Note 1 - Organization and History: Business and Organization (Policies) 2.4.0.8000190 - Disclosure - Note 1 - Organization and History: Business and Organization (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Business and Organization   The financial statements presented are those of Protect Pharmaceutical Corporation, a development stage company, (the Company).  The Company was originally incorporated under the laws of the state of Idaho on August 5, 1987.  The Company was incorporated for the purpose of purchasing, leasing or otherwise acquiring mining claims and rights and also to develop mines. The Company was unable to raise development money and the Companys operations ceased.  The Company has been seeking new business opportunities believed to hold a potential profit or to merge with an existing, operating company.      As of June 15, 2006, the name of the Company changed to Pro-Tect, Inc. and its domicile was moved to the state of Nevada.  Subsequently, the Company changed its name on March 25, 2010 to Protect Pharmaceutical Corporation. Since that date the Company has engaged in licensing its patented pharmaceuticals technologies.falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.No definition available.false0Business and OrganizationfalseNote 1 - Organization and History: Business and Organization (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote1OrganizationAndHistoryBusinessAndOrganizationPolicies12 XML 54 R3.xml IDEA: Statements of Operations 2.4.0.8000030 - Statement - Statements of Operationstruefalsefalse1false USDfalsefalse$Y12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instanceshares0UsdPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$Y11http://www.sec.gov/CIK0001493526duration2011-01-01T00:00:002011-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instanceshares0UsdPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D870805_121231http://www.sec.gov/CIK0001493526duration1987-08-05T00:00:002012-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_RevenuesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0REVENUES2false 2us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse100520100520USD$falsetruefalse3truefalsefalse13535401353540USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and development3false 2us-gaap_ProfessionalFeesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse512619512619falsefalsefalse2truefalsefalse728793728793falsefalsefalse3truefalsefalse14809841480984falsefalsefalsexbrli:monetaryItemTypemonetaryA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849 false2Professional Fees4false 2us-gaap_OfficersCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2572625726falsefalsefalse2truefalsefalse482246482246falsefalsefalse3truefalsefalse58887305888730falsefalsefalsexbrli:monetaryItemTypemonetaryExpenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Executive compensation5false 2us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1595315953falsefalsefalse2truefalsefalse124225124225falsefalsefalse3truefalsefalse446939446939falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2General and administrative6false 2us-gaap_IncomeLossFromContinuingOperationsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-554298-554298falsefalsefalse2truefalsefalse-1435784-1435784falsefalsefalse3truefalsefalse-9170193-9170193falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.13) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2LOSS FROM OPERATIONS7false 2us-gaap_ProceedsFromSaleOfIntangibleAssetsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse640000640000falsefalsefalse3truefalsefalse640000640000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 false2Gain on sale of patents8false 2us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-554298-554298falsefalsefalse2truefalsefalse-795784-795784falsefalsefalse3truefalsefalse-8530193-8530193falsefalsefalsexbrli:monetaryItemTypemonetaryPretax adjustment to an amount previously reported in discontinued operations that is directly related to the disposal of the component in a prior period. Examples of circumstances leading to such adjustments include the resolution of contingencies relating to the terms of the disposal transaction or relating to the operations of the component prior to its disposal, and the settlement of certain employee benefit plan obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759 false2LOSS BEFORE DISCONTINUED OPERATIONS9false 2us-gaap_DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-4340551-4340551falsefalsefalsexbrli:monetaryItemTypemonetaryOther income (loss) amounts, net of tax expense or benefit, relating to a disposal group that is classified as a component of the entity, exclusive of the following elsewhere enumerated categories: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 false2LOSS FROM DISCONTINUED OPERATIONS10false 2us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-554298-554298USD$falsetruefalse2truefalsefalse-795784-795784USD$falsetruefalse3truefalsefalse-12870744-12870744USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 false2NET INCOME (LOSS)11false 2us-gaap_EarningsPerShareBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-0.01-0.01USD$falsetruefalse2truefalsefalse-0.02-0.02USD$falsetruefalse3falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.No definition available.false3BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK12false 2us-gaap_WeightedAverageNumberOfSharesIssuedBasicus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse4457301244573012falsefalsefalse2truefalsefalse4386284843862848falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThis element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2646-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256 false1WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDINGfalseStatements of Operations (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_StatementsOfOperations312 XML 55 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Recent Accounting Pronouncements
Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of the Company’s financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Revenue Recognition
Revenue Recognition

The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 “Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

A description of the change in how a vendor allocates the arrangement consideration to various units of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 605

-Section 65

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=19773443&loc=SL6751214-165967

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 65

-Paragraph 1

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=19771798&loc=SL6749767-165964

+ Details

Name: us-gaap_RevenueRecognitionNewAccountingPronouncementAllocation

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 8 - Common and Preferred Stock
12 Months Ended

Dec. 31, 2012

Notes

Note 8 - Common and Preferred Stock
NOTE 8 – COMMON AND PREFERRED STOCK

On June 20, 2011, the Company received written consent from its majority stockholders to amend the Company’s articles of incorporation to change the authorized capitalization. The board of directors previously approved the resolution to increase the number of authorized common stock from 50,000,000 to 100,000,000 shares and to authorize 10,000,000 shares of “blank check” preferred shares.

The newly authorized preferred shares may be issued from time to time in one or more series in the discretion of the board of directors. The board will have the authority to establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. No preferred shares have been issued.

On April 11, 2011, the Board of Directors appointed a new Chief Financial Officer, effective immediately and for a term of twelve months. The Company issued 60,000 shares of its common stock at $1.05 per share to the officer as compensation for his services for an aggregate value of $63,000. On the same date, the Company also issued 85,000 shares of its common stock at $1.05 per share to two consultants as compensation for professional services for an aggregate value of $89,250.

On June 17, 2011, the Company issued 150,000 shares of common stock at $1.01 per share to a consultant for services rendered. The cost of the shares was valued at the trading price on the issuance date of $1.01 per share for an aggregate value of $151,500.

On August 29, 2011 the Company issued 125,000 shares of its common stock to board members as compensation. The cost of the shares was valued at the trading price on the issuance date of $1.00 per share for an aggregate value of $125,000.

On August 29, 2011 the Company issued 750,000 shares of common stock pursuant to a consulting agreement. The cost of services was valued at the trading price of the shares on the issuance date of $1.00 per share for an aggregate value of $750,000. This amount was amortized as appropriate for 2011, with the balance recorded as a prepaid asset as of December 31, 2011.

On October 4, 2011, the Company issued 35,000 shares of common stock for services. The cost of the shares was valued at the trading price on the issuance date of $0.98 per share for an aggregate value of $34,300.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the change in common stock outstanding.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R21.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies) 2.4.0.8000220 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_UseOfEstimatesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592 false0Use of EstimatesfalseNote 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies12 XML 59 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 11 - Significant Agreements
12 Months Ended

Dec. 31, 2012

Notes

Note 11 - Significant Agreements
NOTE 11 – SIGNIFICANT AGREEMENTS

On February 6, 2009, the Company entered into a Patent Acquisition Agreement, whereby it was assigned various patents for pharmaceutical products in exchange for 7,000,000 shares of the Company’s common stock. 5,000,000 shares were delivered immediately to the assignor and 2,000,000 shares are held to be delivered upon the successful completion of $2,000,000 financing. The patents are also subject to a 40% royalty on revenues, a 10% milestone payment and an employment agreement. The Company is responsible for the completion of a development program to commercialize products using the patented technologies within 5 years.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of resale agreements (also known as reverse repurchase agreements or reverse repos).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(m)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph m

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ScheduleOfResaleAgreements

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R22.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies) 2.4.0.8000230 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_CashAndCashEquivalentsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Cash and Cash Equivalents   The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.  falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122427 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03 false0Cash and Cash EquivalentsfalseNote 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies12 XML 61 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 7 - Stock Purchase Agreement
12 Months Ended

Dec. 31, 2012

Notes

Note 7 - Stock Purchase Agreement
NOTE 7 - STOCK PURCHASE AGREEMENT

On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Company’s common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.

Under the terms of the Agreement, The Company has the right to deliver to Kodiak a “put notice” stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.

The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the “pricing period,” which is seven days from the date the put notice is delivered.

The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.

The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. These shares were issued on June 17, 2011. Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.

In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.

The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.

As of December 31, 2012 the Company has initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares. The Company has not registered with the SEC the shares to be issued to Kodak. The Agreement expired on June 17, 2013.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2012

Notes

Note 2 - Summary of Significant Accounting Policies
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Method

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Company’s fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.

Reclassification of Financial Statement Accounts

Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.

Revenue Recognition

The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 “Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured.

Advertising Costs

The Company follows the policy of expensing advertising costs during the period in which they are incurred. The Company incurred no advertising costs during the years ended December 31, 2012 and 2011, respectively.

Research and Development

Research and development costs are recognized as expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.

Stock-based Compensation

The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services.

Provision for Taxes

The Company applies ASC 740, which requires the asset and liability method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion of the deferred tax assets will not be recovered.

The Company adopted ASC 740 at the beginning of fiscal year 2009. This interpretation requires recognition and measurement of uncertain tax positions using a “more-likely-than-not” approach, requiring the recognition and measurement of uncertain tax positions. The adoption of ASC 740 had no material impact on the Company’s financial statements.

Basic (Loss) per Common Share

Basic (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.

The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.

For the

Year Ended

December 31,

2012

For the

Year Ended

December 31,

2011

Loss (numerator)

$

(554,298

)

$

(795,784

)

Shares (denominator)

44,573,012

43,862,848

Per share amount

$

(0.01

)

$

(0.02

)

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of the Company’s financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 R13.xml IDEA: Note 8 - Common and Preferred Stock 2.4.0.8000140 - Disclosure - Note 8 - Common and Preferred Stocktruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 8 COMMON AND PREFERRED STOCK   On June 20, 2011, the Company received written consent from its majority stockholders to amend the Companys articles of incorporation to change the authorized capitalization. The board of directors previously approved the resolution to increase the number of authorized common stock from 50,000,000 to 100,000,000 shares and to authorize 10,000,000 shares of blank check preferred shares.   The newly authorized preferred shares may be issued from time to time in one or more series in the discretion of the board of directors. The board will have the authority to establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. No preferred shares have been issued.   On April 11, 2011, the Board of Directors appointed a new Chief Financial Officer, effective immediately and for a term of twelve months.  The Company issued 60,000 shares of its common stock at $1.05 per share to the officer as compensation for his services for an aggregate value of $63,000.  On the same date, the Company also issued 85,000 shares of its common stock at $1.05 per share to two consultants as compensation for professional services for an aggregate value of $89,250.   On June 17, 2011, the Company issued 150,000 shares of common stock at $1.01 per share to a consultant for services rendered. The cost of the shares was valued at the trading price on the issuance date of $1.01 per share for an aggregate value of $151,500.   On August 29, 2011 the Company issued 125,000 shares of its common stock to board members as compensation. The cost of the shares was valued at the trading price on the issuance date of $1.00 per share for an aggregate value of $125,000.   On August 29, 2011 the Company issued 750,000 shares of common stock pursuant to a consulting agreement. The cost of services was valued at the trading price of the shares on the issuance date of $1.00 per share for an aggregate value of $750,000. This amount was amortized as appropriate for 2011, with the balance recorded as a prepaid asset as of December 31, 2011.   On October 4, 2011, the Company issued 35,000 shares of common stock for services. The cost of the shares was valued at the trading price on the issuance date of $0.98 per share for an aggregate value of $34,300.  falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the change in common stock outstanding.No definition available.false0Note 8 - Common and Preferred StockfalseNote 8 - Common and Preferred StockUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote8CommonAndPreferredStock12 XML 65 R23.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies) 2.4.0.8000240 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_RevenueRecognitionNewAccountingPronouncementAllocationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Revenue Recognition   The Company will recognize revenue from the performance of its services and/or sale of its products in accordance with ASC 605 Revenue Recognition. Revenue will be recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is provided, and collectability is assured.falsefalsefalsexbrli:stringItemTypestringA description of the change in how a vendor allocates the arrangement consideration to various units of accounting.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 605 -Section 65 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=19773443&loc=SL6751214-165967 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 65 -Paragraph 1 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=19771798&loc=SL6749767-165964 false0Revenue RecognitionfalseNote 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies12 XML 66 R26.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies) 2.4.0.8000270 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Stock-based Compensation   The Company adopted ASC 718 effective January 1, 2006 using the modified prospective method. Under this transition method, stock compensation expense includes compensation expense for all share-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. During the years ending December 31, 2012 and 2011, the Company issued $-0- and $721,383, respectively, in share-based payments for services.falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of employee stock purchase plan activity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Stock-based CompensationfalseNote 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies12 XML 67 R28.xml IDEA: Note 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies) 2.4.0.8000290 - Disclosure - Note 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies)truefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_PolicyTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Policies2false 2us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Basic (Loss) per Common Share   Basic (loss) per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.   The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of December 31, 2012 and 2011.   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.0%'> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> For the Year Ended December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0'> Loss (numerator) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (554,298 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (795,784 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0in 0in 1.5pt 0in'> Shares (denominator) </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 44,573,012 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> 43,862,848 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> Per share amount </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.01 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:#CCFFCC;padding:0'> (0.02 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 3.0pt 0in'> ) </td> </tr> </table> </div>  falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the effect of income (loss) on basic earnings per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258 false0Basic (loss) Per Common SharefalseNote 2 - Summary of Significant Accounting Policies: Basic (loss) Per Common Share (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasicLossPerCommonSharePolicies12 ZIP 68 0001551163-13-000067-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551163-13-000067-xbrl.zip M4$L#!!0````(`&=O[T)V@%8%2D0``"08`P`1`!P`<')T="TR,#$R,3(S,2YX M;6Q55`D``W(XY%%R..11=7@+``$$)0X```0Y`0``[%U[#TU-2,)NL^O3Y]W-_3W?W^>.N21^8'MN3\D>19)7\S^WM M[X9T^_O@MY\??OK?$_+T]'3"K#'U.943TYN23@>A/`]]AP!V-WB''RW[AZ-) M&,[>G9[BUQ//'Y]"K[U3>VFX0(NSXSG=1T!E3.INW&-%@ MR.^.+YPBW(XD=U0Y:>+8[I.O]^:$36EG>0`CVYFWFOEAB(`565G`M=@2SP)FGHR]QU.X4#`ZO,6NP<#G M'#MBW+)A&*?\:G(KB%E7D?OK.A=W',',_]OWV/1=P$=]QT:$=_4N?)FQ'XX" M>SIS$`+_;>*ST0]'./A.,OB3Y\`Z(J>\GW@FWYW18$(L9MI3ZH"(7%U?'A'3 MR"7_R(6;_:=&@[=FBS#>>D+^F*EJ)= MG=!V`.:XTY,,O7V`=\RA(;-NJ9]J`)U=>ZZY$1_EGBH;*V&6D]LFV+S::U*_ M+:SG$7OP"MO4Y&!7ZJ<8N+K;94[AY-]3A_J;4]9[NM++,*2@T\9T\]/0[RMJ MOQ;=QOJN]76IF^)SB=HT5E^MJ_25C>BU-[#-*-092M;7>].IY]Z'GOGE']2) M6,V!*(JB]U(6;[F[!K0*8HP:M`:696/$3IU;B!&NW#,ZLT/JU'6A:EZV.>G<:(&T4IOT.7MDCC>;@J3>AW3,+H"$/_/M@)VSD6W:(6AM-(VXH3J/ M?$B2EEO49%#'D+N&I'93MK`QA)V.*,?W#N2+W;[:V]J(4IH(CHJ+[\1S+$AA M+_Z`)/&E2917UG>+0$HCPUI8[EC`J&].X,X4\^+0?AV0SWD@LB1I2HHI:_MN M!\6Y#J&II/TSR5"7`*F:JG4W0G3K>R,6!%SM+]EZ+_"YP,_(2B\=Z2UWUX!6 M;I1]1>\;ZA9HE3"WJT/0W:U(]V8$&@LBB+4=8#8OZM3DJ:+UT_%748\-2>9C M+UU1NMNDN9[%FJ[K?56J0?\#7M`\K*F=)5T`KHC).MGI]OM&:JQ&:@KU_2F[%T*T?NH@>NI+ET)_F2,:0F!%O&L9U9#:.=V8`IV,FO.S<$4 MBPDWHX'UKR@(T0D_>+>^[?FW#/ZU/E#;Q;FX<:'US`NH\R,;>3X3L_1`GYMJ MQU9`[7O8>3'O&UD5?(7#+E%T75.SBKYG%MR$$^9GC8WHDZ>8-Z/"QM<,6C;C M0U?M2IHF5^1#(Y099L"/BWZ::FVFLTW)E&M)"V1*9D.&D%WJ=RO1O*"^"XXH M`%&\GU"?_4@#V\0$QG8B2'QK\#2PDCX`@G0BI:2AA$A[@.1U@)3-`/W&<$&8 M68-'D,0QNXZF0^;?C'B[X"H(0$AY\^JL$DTQQ-,@_I93N*K2V@)`N0B@JO<4 MO:LW!'C'0C!QS$JXGBZLB%++VIJ$WO_G?7CQ!V8E06>YKYSPJYF$O(QPNSC; M!%.S<%-"O*1.PR^+Z1.E+N&9>/TU41!F54YU=3TU8P/+FE8$6H,?+@^A,R-(5:1SJ6,_[4'JD-\![G6J&9I1SN)B$%N#OP^@?((&)A@>$>.UHWQ&OYIDI`EO M&>TZE>ML"Z^8ES;9FPB&;'25@WH[@=F0I M7?>M!6!KT'<-4LQ*ZPQ.1*.C2(8L5S5J.QS!?K"V$LJM"X0J"TO#,&ZC,>P# MK9BL[;`\$9Q:P`=+PR@CNT7+YZY8:^/<0\OLH6CI2JJUB M;!5,TSQ7KY6/]Q59D_:7E.?]6E-$*944,GH3A;C)'!].J,ZXDL!+DK*5H75$ MVT+7*HZZ]8N*?D:39*U>66-##&M-05_N=;7=X*BF8'5K/77`Y"CVJA-KJKW& M5U+Z,]H$L[D*&P=M8(R]&IARWFS?P!@'8F#JJ14:F!HZ7QM,OE"R,P-C=.MP M`L*&?5D8H]LJFHV5.,.P@S,Q&2[MW,14X,W634P&P]IJI*9LS\`42*O2W=MR ME*%5FQ==VLU*5-,AK)M6S3"40QY&_M&Z[/:O`ZO%5!"=N9GI51K)WFHQ&=YO M"W2S.D=E*5=Z4GZ_[DY*,7D);H*E:5"@U8E>`*>V8ZUU' MK^HB4&5?SHEN"^):F=DCQ/P3,.V#B:U!&W.Z6+"I%J2E2+>+=`N8FGJS7JVZ M@:+T]E[;J(J?NP>\6B=GF..H:^*HF=JN.MZH1[4GR-AUO+>7J MR7VU5YTE#;5)JJ?XW7YO7WHO%>A]$S@;*Y9TT&HO[57M*_!F^VHO'8;:UU.M MGJSK77E[6$J49[<53*E?54QV44W;?!3[P;MQR:P"V^<60ZH5D.YE,#N!W=1K MU7K89UE^=NQA\\_<-`2TN1>K(:G[<+*%LK<[+UO5?/:VZF;[A^%F:VE8O[=5 M-UN@077<;%,%KK712N[MKWHN%6S/;P)G--NS,T57?+;]?0 M5-W'N&5#4TN[^GVIF]N4WR*6@@UZ>G6[UE1]:VVX4O:XSTC*[\9J!&=S3:Z^ MEW$OAJ9H,^,.#4W%W8Q;-C15]S-NV=#4TJY^7]&,[1F:O/YHBEHS@%J1`5^S M)WZEY!4D4C714*HO/LT);Q/JVJ?5E8-`FX=5HWY1"Y8P%JU->&*@M%K9_A81 M[Q;;I@6KRJK4DY1E(WLP5;?*2J8INBKU#W@<.<"J9,@'7#ZLHYB*5,G`[:UZ M6*RR;:-NMC>ONCM1E?0;N7:Y?[#`B30!TS#:SW"L/'*2E)ZJ[6U!,\^ZQH@V M#O]KJ'87WW&TX^RD4%L;`*D9!%?VFW)/K[N);4,4Z\Q!'\)+0S)V@J-">F+H MAK;\>'R+8'(4NYJA2&HK&&Q5].[%EC$WC%JJ2KBL9MZLLM/(JN"`A@9@F@8KZLHRWB*%6Q MW/D_;8/)KYOHNE&]\-O0^"F5*_'[>HE1_@W<3;`T-7E*'=E9?E/XCLUS^:O+ M=V:>E<,VS]7>LKTU\US.G5V8YZJF('<*WA9QE*J8L7S@7-M@\CK4[\MZ]:0? MSY^RPS;.&5CTM!&!\F"M$8':9PNLH';F!>'-Z)[YC[99^X"SK&?(=K4QE8)C M?2M269M\B<]7KNDSBF<'BO_K)WQ]!4_:JYCQ%1/=)NB5,JY&\R[*>#BAK$ML6T!(;!^XN MO>.Q7="W/IM!H+G929!=0^[U^NN@9;MO#4O)$8SMPHJ/5J]X^'>1U=#TM58L M3Z!E1/FSNS5%6V_YMXRI9`+UGIX^U+4VO&L6GM%@`B'NHVTQZ\>73P&#H"4^ ME,P=#\S0?MQD*CN*W)53REB=T%;P%9SHIFNJKAP(P)*<1)-ZF2.*-\1:(!W\ M@).?F&-=>C[&5G43C&Y95)FCT":B>@=OU@6W@LM7[B,+&LG>,K#JA+:`KQX/ M-X2:/O.T7E6UZ#3C[*K7^KY;@E%V4'H;B%+AR,LY&ZZMF1:%;*L.F5WNMQ4` M)0S9",L=Q!HOF'`&-Z-ZS"@Z/EGKIDWFNKY;`5%65MH4SPJ-N[1=ZII-/+1< M0:\+J&P%7`&_5*7;[1\(P+*Y516U!:P%63OC9\9N$'NI\MI$*.FX%?KYH%F1 M^[LBOWYJ]/5Y?R$.G+J!:^%_6"5_A+``M'0`4^K[+S![?#M0S:72)8Y4(M$V MJ)R89)A3'Q)_Y=BUYYK8I$I6G*]_+-4D"WIL0K&D^%*1N,7L=^>>&?%3K5]F M+*=\8$@[OWQ_NGQ?KK$H"%^XUCD8^WPOBB0K'?B+CU*M;#;O=`"7++Q\Z=!Q MOK,1<(2)?C)WSMM?N*$=OMRQL1V$/G7#:SHMP'1[=_-PK@Z&_Q*SCQ_)CHOZF:)QAF0]JESY5KL^1?VDB<"LR"#:]0PCUW9;-[I6>3[ M.!@[,*GSF5%_)4,[:6ZN:K8,=DL+L]4H+(&YC8:.;5XZ'JV[?%Y$.-7;$IU+ MVV'^&3!C[/D%\W,/=.$&`A&+YV.,3W#%D[HOZ=XS?2PS5?!^WOX^I&$4Y`E= M>QE&%;9:ZOH?GA.Y(?4%_=(^EVY?ZNPWYCB_N-Z3>P_>P7/!9>/2CE_6Z8IF M.?U?R-XE_%*`59G/V(HF*[H4%F)%IY>?B[I,-&`]D\51[QPLBGST`A!\=$/$\GF^<\/U?.ATV M?NYTOAF'[_'[C`3AB\-^^(:".WX_I?[8=CNA-WLGV6[RU<=CN=,_#+TP]*;O M9.E$FH7)CPX;B9L@HW=#U?)#]]T-J?AG[ M7N1:[YXF=L@$S`3\$#]<@YTD,NF0F[L/@^NK_QX\7-US]^XPF+V>$0'X"#_\&`70+@@(F&625@D^TNAM%@]Y M1`\31D:)<8)!)-:)S(3]8A8!MTO"B0?1HS$R^A<`Q<8G?G:08.O_TL+B!/-&`>,`X0.@X M+\1VS9@0X(+1@+O![ASZ%"`X_,R'@%^N+#KQB.>2032.@I!HQT0V]'XEDADZ M(T]0F47PD^#"3)QY#7[VF#B,?P"8Q,.@^,F&>R@>+HQ[',C4Q@U.Q'2H/14J MPN5`?(00Q2.AE_`+;V;!R6ISB_X#'$2Q(O8:XK#O*O_E+N] M]\`@4>_&@Y5-3.BL4E;`$,F0,9<$C'W!4;CLB0P3=?=F&&M@*(7U@"%S;$!C M(3C<-052,`-1`9\/XC'C>X*017!URGP0B"<[G`!:PIYM7@H]3O`ALP3]0GRO M3P7C.>I)KV9$`ZZ-/TD\@'4Y M)E>N><)EF=";D'@X%&$E,/1!0N*1%SQY13<@ED%9`LHY0CV1D- MA9&=97H/")"?V-=`+A?"TB8@.?_ M9[RJD%A1->D]N?_T\>/@[C.YN23W5Q^NKRXAT[]^((.SLYM/UP]7UQ_([Q7,*(DE%W(.OG((.:QWD+8PQ\11"S!BB"6AUMBN8BX8,8#'LPN M0ENPQQ2FW+##*`-V\EJ$X?6)]]PXW;%D M1DWQ##%,_MRUD[EO)\FVO=6VRV<99J`+[X"\C=UW_X),R1Z]+*B?,1^?U"!T MROM,I'Y9Z.1B_9O01R8R")^EQ!&B*H@<(*^:)H'<+!6PK**A%-*()==GKV"F M7Z_L?A)Y<[)I?HUL?K5#?763]R#TG$/09<*OB'U&Z#-QMZ^"-*Q_5@2`(;GR8E8`/)!#H`2^C8,*%H!X/0 MCX29X!84U!-T'^PI-R@^8UC?#2=8#2<.7VP11@<4F1L=&\P?3V+`.@X9P6T9 MA"UDY80,UB0+/(#+UJRLQ5S\5>])_+:_*LJQW)>Y44R$;,OASNB15K!/0^!],(;8S'_;>'N:QA19FG(=M#I\_G[DR6Q1.+Q&48,&)YQ M^X"V`HQ,D#PB#4I\"C8EP&<'XFLSW[,B4T1VR^61P?T9Z4E:4@OM]HODYX0D M/W)D0[8`9Q'/!;/W-&%NG/@!"JQ6C.QGO(A'?X8,0DF^TG6,T,&P!6!-",/M MH?$0*"#S?2S?\Y"0+R(%HKH?CPS[G,5;2H^%J?(\#K&C#ZN@[T2 MF7A]4KZHS%J/#,+?0&RH"MZBGZ]A1&D;-0+M\YX"H?2XD,1#&Y'IX*32U`2; MXNG]1?(C4AZT1T#!G.!O+[R4"[DE;GRSLA74Y%>LGJ[M%^NQN#H'-F)-:/06 MT[S&$54D"@/J:;.P,'`*&%\M1CE)O?^AEF7:&,4NAIH987KY0"@2*F#*L>,Z M=[+-O$!UA4H>QQILXV:6T';X/9`983T(2Q<8I^"+JOA&(HL%]M@5WCL43\QQ MYX^.W<0D"%L22;_8]"T4./P1I=TSM3Q>_,5Q&"!>7(B,#?%5W$'(-9L`GP$(1;`S(WTB?I60,;X4`=/<3"1H2,P.RN' M=$Q$/Y[(@WC3#B\ACZCMDT?^A%)2J"UK@C2BSK M;2)&?.8>Z//;"MW7,**,49W-'%R,XC:@*R5QUGP!#=6;KU]EEJ]>8N/(PZK% MHAU*`>Z!GC(2HC"7K!;R*/G19D_Q M7G(<'.2D"=^6=FSSR^A,*/7J\M&:'&!M//:#M MV%_`5N-TN+@'*EX6H(O44@ MJ&+7$(H0?V:K$6O@E] M42/B[(C%/6')A/)2$49:/IH8&SAGADEH5KB=;^5&I*]?>%Z?.BP>5:.!;9)O M\>68WV%E@HCGBPE_MO@MXCG\$<43Z,PGD*:K*%.+P?^U=ZV_;2)+_O`?<_\##)C<>@)9%O3W)#J"1E:QW M)[;/=@:7^W*@R);%#45J^+"C^^NOJKJ;+U-^R+9$40W,(++$1W=U]:^>744/ M%:6?\6GXD#L:(;J94';?,,V+R9*B#*'TKA*W-:@%CHL5C30FJEV_=.1"-3-O M3<=]PM!M\?H'IB#&[F?/[^=M2`5OE9W1]=IK['"[8$*[*KGUWBVFC7G!0GU% MG2(YV>X@%&Q=)*VP.#(Y"!;PQB,$?K\.'_%MEK)TQ2_];J/Y/IT#'TJ0&RZ2L3A8._>"7D>^ MX#9[(R?FRE?W.HWV^P]B^+@(&OYO-+J+"#\5!E5MMG@"%QQ%]BKZ-=+N""4KB*8E7WVFC^:TDWAMA]E$4;,>B+GHH'L#K M&I'[U12,9Y`O^V@B5)7Q@%[Y^JK(.G0V&IWG$;HZ!'UU^JVUT8U.H]]3K+H) M2#A^'IVK0\]JD$\AJD)4A:@U956%J+MG$OQU-/KT:33:>8)3G^L#+YYC^30_ M^'G#@NQQ,BI\>"515A>.?;=Y&;9W7'K0[7;TUO%@PS*L+BRJ4%2A:`5(JE!T MRRC:/^[J_4%'H>BKHV@53(""Q563H`SO)Z8=V,SSL=S0%HR"YQ*V9K"Q:>'V MC)2%_?0WO*H\?!MJUVP+=#IZM]_6-Y1)5GM,KTJ<0B&Y0O(J\;A"\K='\K8^ MZ+7T06?3OJ0]1O(J&$?WC%"Q`&VDU0XOP$5R1)47QMBVI^]1LM8,3RHC4FT_ MII.&A/*M1JL`\W5QPFS,3_AVA*[9#CB`EV\DW7@/T'SK@1H%WPJ^%7SO&WQO MVJNUC_"=-8*.J"I$^J?MW.[(7/>J8`L.7K9TS'1LQ.HG%X'O^5C`;*Y:/.W& MC+ZDG>FPXKCL\H0E>'A7%NH::(5P?VTY4Z)3^:`&Z M5K-:OB>.F,TI[L3VN;GNNT M_CLU`'.B9=J2_;,/=XVP)G[@G?D1VZLVZ^ULF_7/Y]A*?71^-AI?GA'!52?U M2L]H9?OK%=5[>7]1P#]1&_2U^H;FR_J9VHW/^[_0GA*ED6E7S1"63I4*^E)!8=%=/.F50\6)?5Y_&!_/.S?#!3'C3<5SA"V=ZVDDR\QA.5FO M*-7PD2%CWU'$L.`&QL$[R'J\J1<\7<^-BFXJ?Y&7O"5PYGJ^%&+AI40F+$?G M1!%O"S)GC-Z`5)@[GH.KF;Y7=F1ME*'^$R`\!_F7S`]N3$^PVBDP87C"0BMP MJ##M^?0(%/SU6IA(%V:$2@8U-" M(9H`-R:V=N758$W'/L1FV>;"B1!='O M?/]$'UM5O#-Z>MLXYOU_.GJWV:>N/EC'5[3&"!^MU5OHG(@O"5G2]A['@./- M=@N"&SSN/9E@*PR.P6`BX.1J[438[1DA]^`$IB`_--=,R@O_]^'9^=DX3<1) M]6^:.5Z.7X>BZPDRIWUK4D<8ZEYLYGB`6H:^,YJ\'7FRF6@+8?N7XL4>O'_6-DX/P]DK4;3YH.;ZJ>FTIF,SSE";1A<@]H/>4VT7,RO^]R MCWGBVW/]O'(/$"9Q"7%RY;HGIDN-:9[RNL@'O2?W$EXL[M'9OLO=U-&;_>,G M4RE_[V'SL/&46W/]CD*67V,)8$]YT!,`F3>XQ`L1$5-,SKVS+DA1/^S#P3NY ML`X8_E'@3*@@_XAK^X5(CE.G)2UT&US53UE/`?J0XXF(ER2TNA4Z6T%K2G0# ML+B*RD^8^3E5JJA[HHWFX+N>#E,B%>.Q\=5:O2U>[!$K MD:C0C!6#)R[OL`UJ`NY1_*A=F.1-OY!6ZQ#]8!3D/<"[TR9KR0]I9[6?N9/] MLS!D6]W6!P\N`%U9^SR?_%T[2.\NN2;S',1T2VK5W`N%OCC1AI?Q5HN@(G]F M0`7IM^?K!P,/8Y,'(/!2[,68V+?)F/.D"'V7G/5E`Z>6ABL#YK3T($&J;E)?9. M#YQ;DI]\<%*3SXT.W8?,GV:7Y3H=F+@'27.^<'PPLCZEW=GY4[]0TT^^;`'C ML1+3`F'.Z34+?,^QT$#S:BU==WM&IQAK`Q#Q;EBB*`D6T$NW&AG,MH#^QH`P+]A%/@DS.(QT,P637=> M2`VI/[%)0&@*2-I$IUZ",@EFUF7AADA3T>0\A7\BTQEB#EB6IY[5R,(Y_[Z` MX`N""@0HBKZXJTXUP[_ M)A?>22DXI$;N,`YLH9YO_2L$/=RO8\#_7:_3Y/8+CB$W*AE.,X4\XWW$LAXR'W*6 MQI4U8W;LLO,IU>CX#7O+7_#6\L,[,[#'\X7K+QF[PCYR4O^Y@*G_(1LF#\,P MGE.,++Q&C]5^!KCZVJ%V=7T^^J=V\?5R]/?AU5@;?KXZ]OOO(Q00)Z`(WIG43'Q.&5=IVWZA#I(;$R,7=Y7467!,R@"3`+SXN72`@J-^P=(?XKYXTM%RI].?Z M3?*(/3S9O(%1WJ!B2VXB$5/0YH[K(J%L4-A-C+1A3I2)X;=#\AK)9J[#D+SA M\K5FN:5"Z;-3!^4%3AI_NAJ/R`-V(SQ;-#*1#94.+7F,*B[+S8W$Y]Q9-V6";,_U!6A$G@_`P3*=UI$1I0^7;P`1I;W?W_A.)/+9/',OOTOY M)GO7ZF:,`?$@F7&>1MY##34-,,A+'B4V!&E_J"F!YI.,FV\N8'7`$1/OT='3 MR^_C1,0<'&9QFYDYJ-?\HATX/V-O^_?)QA4-$<.6![BZA^ M9@3B#?QA?#CHY:'H&BAQ\$3T;COS.8,9DIJ^P)S]I$MTAC(V_/X!-<<#!Z9; M7(VZ[(_Z[?CKO/3#+&"PD4'6PM;UP!S++#'F1[N:.4T$@6`5:<,$[):"*/QR MO@63U!;BI81]Q8XNBH@'=IIVW$HVD.O?H?\L854*;DI^+=TVF9;B4PSLY#9. M.J/,^YU0HAD3.2IBS/.80JEI^@S:*+Q>!;KF*',:\[J3NTD."PLS`X8P5LK] M(>&N9Q"1YXC#^T,T7/@0$RO,)K?8`T.M"U_6>Z=)R>F3J4A"")-6IYA*,G5] MX*ITOU#;\V2U&]IIUEGAQX%DS*E).P;SY8G/T\?H" MC8%)N6/%9?!,%$S.5,]NGSS?B@T-0A!NTTO40]AGZ`:>^+>L."K%JI6=49%5 MI:_,QT2,-F6$O`:7^!D+J:"^X'D.?JXA8Q_FS0,979=:7\#D646_ M8)?F?%MNZ.")DVHF,H8RAC"HJ69O?I2<92?`./JE0 M*'K=]_*$(O?^9:2DF=G''[BBE+D\9)8OPFR4I0._YR\`*1(DO_,4HP/G-O]* MP`,P^I)W!AJMN`8K$,V$&'F$\D7:.&$R5Q!BB:J0656UD2L[(Y`5P%0>MTA2 MAT#&G@.CBMIO4G"10A6763_!)8]>EKIL]%(72KKC$J]!SA&14?_@FDFRMU>[ M"W(V)ZE?XO`>;8'$U0'<>=PL4Y?N&[%K.T,4JU=V1EDFX6X"SH5QR$JB*DD$ MHRBA5K(AJ3HRP]X2?D_.@G=^0,$=>;X&G@&C$N%O,XU+A>GA3CTYIHE2,I`' M_BCX`7].DS.7R;,2+\;$-T$,P)/2W'R;X2$]L9VX))CP#`.1:E`\\5._9);Z M,?1PQ1&'HHK#-3#*L$#XQ8P/]'$3Z(HD:\G,I4YXSF?`7O(4*U?H$)8III?1 MZG+^N%61/1P3NA$D_`L+^%$!P-5*\WOQN>E(V8\%1?P*:F"[WOZE3)&'MPM/ MK@B#CFC!Z7GG:>K])2B\G_P`7[G'0VB>5.B2-`#4).K9O_LL/$'1)AY!G MC%&;GC,OE["4#1+BV3++Y5:RXUF94"JF!/*L*/+6Q]$,'H^15:%AB!.W7#,N MT0>D*Q;3)!88$!5!6N3%)&500[XVRY("!A`$\P MFNF?`M)EW0;Y$+BF>`D>7$K\H!.`)\"-&;.^9WR@,($I"Q#KI:RI":?5;^\@ M"WKL#EDM99SB^LD0L1#U24B=%!/\%[16'S8@J+US/Z"3%9D2)[83`J=F71;W M>3Z[%\A]26VO&,N7,3]A*LT>[%[>T4T M1Q&8$Q5X_,EH-+L8)1"Q,6&!B&/LFEDXOHZCF5',2QRIXI&/TI297IN"RIE! MG@L/*HA;"3F(1C*R#.4F6&G\CH$TAN?NF]D1`28+SUG2)$! M$Q,V;#Z1#?GP%1M6=D9/8\/^PPB9/RHC<)%.2Q0CDYP)$ZA\ ME`7S^O;+&;*?IA>"LB*BPU0+#,R6B!^5#+G-#2/`>_%A7'(D3E!Y6"*M/!+2 M41A&*444'UA1W\90.Z&R,X*=<`[*.:Y6YP%EH5T$Y'OIG9*[7Q]XFXWCP=/X MO-W1VW7/VRSSJS_3WYWSFE^(REWH<(^&GCV6Q;LN8&<'OAV3M7Y"[@+X^20] M!3:BBJ?[Y#L_SE?`NQH/+T=_)^_YR?B/\>_G%WA22!N=7]6VK$'=L"\Y_(KE M5O``;"GZ=4M\P?$67V\&JD]=O-^\EEB0"/\D`=9NKMT64A,V&0O/Q= MYO!G26W?W>:#^G%VX? M3:-^OPY$&B5Z@4NE$$)`4H0%-@43*4J._,!39:*IT9(IU<7#N`^0^T5-@_>4 M?]56?S*I)FJK/TZD3PY5+1&9D*@7\7`=5IXY`0M`.S@]._DY6ZN*NTDBS678 M'@N3%(0QGYSKN_.INB/WYO"3%PH%%`ILAU260H''B70J4J9ANSH>%3()H]AV M9+3^H3%(V+>,0A#N#QGP,N61Z,D!$PO=KQL=\OB8!K:B4P8AK_SK2?SS7V2:,<$ MSQW)*+/M3)-,YPF+[C#1F!]^O]=XDR-;K".J(BN5G5$I2P,;<@%"N?TEC$G-=F[E<3;> M'I0B=5BF),>8=[SR`7+9K>FXW*&'&]+#@B@.]0:ELP:N\QUSHND`))Y;I(.V M(6X0M`72VMYEPTEZ54]84D-5\5QE9W3-SX%S@+V/RQQ0,B?$9;L=7I(IJ;^; M;9*&GJ*E+(Z#4!='?K#4ILRF@^+I\PG)D)?:'2K1BQ$]%^-^$S;U@P?'):MF MI0$[[J3>@_B<[=SF;&:+BE44K>:W"^+UNZMC>/UNH]]Z<0ROVRNURC@U5[Z[ MVVNT!QG+#`0D_F\TNHL(/^VHI;:.Y=]DJ:5^$TL'S>*)%]K#9JV MVHUNZ_T'O@]A=!X3G^4D0M_%?GDNP``G]@.>A56;OD)K@3;I(8WS%S["!U=' MYO*FJ]0V]'OX7;MI8\F*M][+QQVUF142OI!X1O?UD-#H-@8]A80*"0M(:"@D MW#`29J>8W8XEVVU#-'EX8J\:/GR1:9$QUOXZ&GWZ-!KM?!SH-#7&1>HU!H-2 MHQTM]`U(VV=1-OMLHF&549!>^?J2>1U"&XU.JY9,_.X9QEUK'&(.!WNEM1%S7D$6?D9.@0%2!:+5!U.BL1;E.H_/#@=>* M9KV2P;-GK'JX81&]OPRJ<%3AZ`ZPZ6O9/'O&JAVCI7?:FS9X]I=-E=WSIE&> MFL0/1[X7!BMZUVP;M/1FI[EM M=VA-4'U;UI?"GJGM?4'^:KDX!BV49KX_O?M)E$^2M^:P65EM`;;CZGF M#(FQ5J-5D&/UR,G8V%&SMR)SS;A_RWF:-0'SBN1M*NA6T%T)Z'XC.T]!MX+N M2D%WG>R[0JWQ(]NYW9'%W*MZHV&N8,+^0N';YZ[L*Q2^*!;X$AV\AKD39^>_:Y89!$O_%C;=!L3/ M/N=#J-)FN^#Y[??VFTL/6OJ@U]0'QMLG[CR7TM6AZ':S+16.*AQ5.%IQ+@4< M[?5;>KLS4#CZZCA:!1N@'L'T2M12W.L*=:H(V`[E_Q>DVIZQ*HBT3DOOMC?B MW%*,J@!5`>J.\*D"5`6HU634*I@*=3V3MHV"$8]X9-19X[<5=NJL\69%HSIK M_#1!:O3T5OMXVZZVU>BCP%"!H0)#!88;`<-C?6"\?:GV5\/"*JCH]3Q45'Y( M8[ON)W4X=$M"21T.W8@L4H=#-WLX]$'/5DUPO"JA`X7="KL5=BOL5MC]AE$* M=0!^)V9T$C,M\NF0NS4SO1NF`;/Z=QX+PIFST!:!?^N$CN^%\BC\-=A?EVP* MS]6&%AV0-XX'/5WSP$CS%RPP(SPF[_IAR,]D8#K6G1G8](!WO2:V6&E3CM:4 M`6:9+KPPJ=T6L(4?T`,6<0!#9*%F!DP+X\F_&+P,!FIZ7@SWN,[,+HYN92FS#^8#`SS1#?%H?TM&DC M.#R\,3[E=>B`1N,?YMSQ^`BO`:Y^"A]#SO+ M>STT^GH^'9M3;\?#D>?QF?75\1R2>) MTZ4&VZY^0'+N:9_8)(AA&V@`!ZUF\U@GP!CY\X7I+34Z<`@[R_%P&VL79@3? M`(;\&0/`4/@UV0&Z=C>#:R=+S8FT.Q-+;80@C^'F6S-P_#C4%G1W2#BRF)DP M-HO%D6,!-`!DV;$%O\'&93\$).!U?1WFA?]K(=S!$D03`Q1%0AK:-=PB28(/-]W0SZ&F MUFF^UP)_:;K14H,G!>R6>3$+=?C)@)_FCLM@MAX^9HE+0`,W@8+P' MOT^NJQ/"T\(%%DQ!K1,I3=(D-VP3)GG+7']!3X(EN@G,.8X,*;III66#:8DH.;7EM M>#72!MWNH='4$P":FYYY0_L`8`M-S-"%1M^ MX_A/\(5:ITZ0%Z'@(0SU?,W'O]+GA,G&2A[IBYM7:(4K-F)NNYX'-Z;G_!^I MBB-`40P"TA^_F:$3GD\O`%WA;OX5XB+(A1,66H&SP*^&GCT$(L4>:K87<+,% M^+A/6S[&#Y(PM(99BM*ZQ&J?5WE&J$T(909W&;"ZL(,6G/5Q/\.&C&9@$.*F MO0C\"!6;B[SB-_+!9`QHU?6"P@'/O.$J"0"&KAUDU+Z?&QF")I^R"@XJH#X0 M#D;H@H:'YBI_$2IL'MBPA"BN>9=HE#0%_./4-F<^ZEO#^"8.(]`DT5KN/^F5 MN?=(K4J8Q?AL^`C*+>I)NN8R^@##Y)AUY\`U)JK6`7X-EBC5KG--9\ZW"/$! M_TBZ(@"9H!=>S,+&ZG'%'E6O0^@S\359.H/2S)821\L4:V&#HS_!@C$S^U%2 MP!1!1V:@C#/V'6?AL3MM(K>[OT#TC3TP(!A>YSHP&M*K9SZY!!8^JH\.MPNF M8$X@(7T-=,X;(5)0R?WAA!$1,O41"&8I'5_]MJ!8HUZS-C,:TF[\1PPFC=$E M>[3'[5'/G+."Z2<<1\0W`"Z'UX`NNG;J60WB90=VBNW/0;("W^,6F/N"R7*; M_8S=FK99RC"I)N`N]=(WXSOXR#SMBPD[6VO1J(VF&-0CB-?0KAS4DJ*9&7'M M)BIL(N;=F/0F3P,E@7D$&/C:Q,+*&])ASN(J57#>5'7)*4GR;IC01+C5KMC" M#,CHOF26?P/C8/9U8'JA:1'`I(_^PD!TV/NB"J7SUOC$E0I4_1F!Q`M7*$$D MKIE+:H`',,`]/*EJY-RWDLR4!1:@`%C.PH7;;IB'_G908>!WMA#W(DQ\]G:SLGCHA@@YZ7`X9PF*HR)OTJ:!/\]J M`51$-_L<`KT6Q]T0598P=*8.]\B7*77D5H19AFQ/O$"O`(4Y:(5;!)$MJ9GM M!U`6)XZ,^"G9@5=R!VJ">N%J',405888F?#TOT#K=Z;+].TC%D0F;MDY/5/N MP.(&,,JQ8&;>,JX-!RRS-^ MANQ\.H:IHJ]D;QCH*S?$DGDK05O]&5WSS4%X*?9\Z4Z#/2.VE!,M7T&JXHN& M8'7"]H&]BX8Y"[.>2[1)S>\@SI)-1+9Y&,;S!4=ETNS-Z91".O!X[GA$P2B@ M!,,L:=D3US$GCLOM8OS;!NGM^B'&L>%"W*$P$0KKK+@G*CA*'U!/5@TGD?IX MD>C+!J94',C@3B;>#Z3QR[T!0RO"D#\0+'8I.([!?ML!2@1".H81RI:9* M'J%RX#4RPQF8(OC/&!;FUG1Q8F2/+/?.D8I4H.6B#QEZ*'"K_HRR&CAUL+!9 M$%(L9`8/`(AR'5A0!*@P"F*^?PG:8%/`IL30,.[T@#'TY$4S]'MJ+KG5.1K` M]B$TP$I+9&[P`+:%O,)27FEHPP?4>E)O\MX).UV+=X->DRY[UVKI1M\@M)), M67R13J%G0$0'S(+EGA@`3\*K@HI/."R,`Q0G9^PNXWH)?`\^6H3H0Q=NY[)Q M3R!/4$?+D$>!7?5GE(M+."XJ",+VE7J'U`ZH%RRJ<@19"%^`>[(L'.+*$<`< M)E3(W[(I1&41Z%ZS*Y,+.OTR_FEH\DL:V82E@[,UWP,DOILQ3UAJ,`IT=4R= M'_ACH-DL8@$F#TY;.\'%*V5&E*ZT1_9I05-(F08G0+]XR1U MQ8ZY:<=O7']7/W'I@"UZW454*LGYZ&CVF?$]:[^M/8KG;(%U7Y*;8=89SMD# MV2HC:3#J)[JAES$D9S1=\*6#H?W(<47VIH?.#+2[47#&KDBKL!GFM8I4*49! M"9(&$U;)9\\S/_']PC<@?TQB^5+$,9D"FZ:!@FR\=5#TK1!*C_+?BB3[ M*TR]_0U3#G"GP>4THS&EMS)&!60O>$8%NW!-;X@[!J3D-0YE[R06D>-P@M32 MLN12@JOZ,\H*$]/VR2.)2FO?&&B,W(>H2_[#]#!5/YV^P7,D,IG7<]_FX078 MOE*$:',*(#6TKR+Q"?9[A)$FGL'/?]5YXCP!@>2DE]S:CH!GO6+4^]A M:3Q58%CF))0@:$,[*1'(^,5#$CGK^Q`UJ]\=-@^YUZ/?,O3VH)V7VSJ.*DL3 MD:7/#T!(4Z8\"?5U$3"/KB8]%^^\9&;H>Y_\X'SN1"@63D3!CN1$U(4DX+GW MV72\W_TP3*.5^P*L"1%HX8`J*FJT"S/*8>IBX6*`A""@TY3J4Q+4$<=_6)0+ MJ2P%-I*VE`:2D`O2\X^8?)'/@GS@09D7"N\LZ7->Q'T(F7(YZ`JF[#.+QZ$0 M8$4">T99%%&K\B!/@,AODK-`FW`:+!-],H>,S#.M2+R8YPX%"`B M5S-.&;&,,DIAV`&;`O7I+S$94`>)1/DSF-I)2<]FKOR*`P!3>IJ%'<$DW0II MJ?0SRA*31$"A`BA/[;=C]*.@W57R/G+A.!&JO',_P*.CW^D$V,ST,%%'!.R` MU@C1N,(4Z^(Q1PJME3T3W45XLW`9T;&P6ONU=WM&*Y6M3E/&3"8,7N()0RF3 M0T5')-'V=]#/2$E,3"1L)%L[2)UOQ+YB#Y+%!T]#]QM/)T$6@C$Y/%3,=3@S MXZ-$!CWD#'J(#'H(/"9_'7S`_1SXIC73Q:O3^.PZ[^<.#2*'8'=)DIE)?HWD M1(T#E,-#Y-ZJ?/$',E0*:LZKJ2(K[,>Q&>`BAA!D/`EIA0 MLDNQN@+55"#=R)+G0^0I:GPH'L?`8/1D20^YHQ&BBP@%]`W3O)BL)4I-2>\J M<:2"['?<&&]E8D>^=.1"_S)O3<=]PM!M\?H'IB#/E\<1H!:W!PN.6R72*SNC MZ[77V.'*_X1V57+KO5M,&[-"9:,J4!R2,TKNDK\9'2TVFY`FC_(X6I)(30^F MAC%8'-DB!=FDB-R8'LJO1F]$_1D1(&!E;^[D(BI6I/$R6K(8E*CX9#$7VZMC MH8627T2=I$OV:)2_>[[E;6C^MU&\WVA(M1&:\?6K9?#9DL,*NI%'XR>))_E MXSZ1]&NM4]FNUS`&SZN0_;0R=MD]7Z&UR!P4X"-\<'7`HDD7"`3-/>2NW8R_ M@::43GF,H>[Z3UK*ZG3B(+3K/VW42MX:L[%2H$L)?&4Q-L-3%`23TF\^DX; MS6\E\=X(LRO8C:7.Y%8-?Q_!@^I5Z5=\JAK^;I!55<=?A:@[P*8*416B[@BK M*D3=/9.@+EU3,>='._#B.1;R\H.?-RS(]JX9ZO9$65TX=F-MN?:82P^ZW8[> M.AYL6(;5A445BBH4K0!)%8IN&47[QUV]/^@H%'UU%*V""5#>'W+7@S)7/+?U MP&:>3XWO-F\4/)>P-8.-RG3YO9^RL)_^ALTT^WT1M6NV!3H=O=MOZQO*)*L] MIET:H6(`VTFJ'%^`B M.:+*JU]LV]/W*%EKAB>5$:FV']-)0T+Y5J-5@/FZ.&$VYB=\.T+7;`</\1 MZJ>6;1.776%9ZS<4C9JQ9WP(U\>V$Q4:4C]:`F]5C]9,1SG1##VM#QHR.<3" MN)*BD]1>TDS+\_%RT:]1GN^YJ$"0(I!!CH[N[NT;(K,:-?WLT.OWG3[_B@G>.V]U6[^-1>AM_ MYE'FH1]YG3'Q`IA7$)W`W'[%`@6'30/^^WB4?LNO8IZ=7@/_M0U\I)U<\?$H M?>C'(S&O>W,<;VF.V`[,]*+W1&^N/_MN61I_C+^,)_&6LSU\G M@WYST.S^K]$R6NUM3]MMM.WP6#[\8(Z][<^Q]X0Y]EXPQV9_Z_#3[#\./W#-^G,TFEN?H]%\`L0V7R#" M!_W_O8K&?Z*N%!Y>,BR.S&QI2[W=]&&6[`;5J5\__I@$KNW\PGY@*58G^L(+ M/]K.')M5^=[??DIL/:FRC:G$)`[9]U`C&_YP8*AIRYW\)/@#/QZ5ON=7(*P8 MR!/%-LF!]96.P7;VS>N,'B14AENX:4TEK'>243+C?R4>V:@DS:W%T+8O3,<^ M]4;F8B<7`R9`Q=A--YF'$YGN#B[,6"W,6J@Z>`FJ;D=S?K71*QF\66Y14FP# M5#Y67/U<>A^_B-[;QL"7C5[MR0U36:DFFR#Y<4>1_/DD/^Z\%LF5Y-D`O;5Z/6Y3D>1LJ?SON*BI7)C[152*IB@LS5@NS%BYU7X+^VXE'OMKHE::S66Y1 M4NS-J?SMN*>H7)4X?VXME$BJS,*,K6;S9?3>O8'##5%8PN`&2?VOV%6-7)&UXW%0IM<_F M_9>DU&XI%?W51J]V[H:IK$321DBNLAJ?3>^7Y-LUMYL#^^+1*QC<,)45#&Z$ MY"H-]MGT?DF^77.[:;`O'KV"P0U36<'@!DC^S6@JQJ[(F=_\6BCVK\S"C-7" MK(-+*BY+=X M@.W%U9_&=I(VC"T^KF3$\DG%NSX>I:-, M9L47$C[\/U!+`P04````"`!G;^]"7Y#"5+0%``"I0@``%0`<`'!R='0M,C`Q M,C$R,S%?8V%L+GAM;%54"0`#`L``00E#@``!#D!``#=7&UO MVS80_IP"_0]:^L$;4%E6O&Q)D*QP[:3UD#5&W&X%AJ&@I;--5"(UDK+C?S]2 MMCM9IF39=6O*7Y)*NCO>/0]Y/+ZDUZ^>PL":`..8DIN:6V_4+"`>]3$9W=0P MI_;%Q?FE[=9>_?;\V?4/MFWU&/5C#WQK,+-N.V]:CSS&`BQ.AV**&+RT6OX$ M$270IF$4"V!6EQ`Z04*VP%_*!Z_^4GZ+9@R/QL+ZL?V3==9H7-AG#;=I_=WK M?;QL]#ZV_OK]_=M_ZM9T.JV#/T(L::7NT="R;>5*@,GG*_5C@#A8,@C";T[' M0D17CJ.4G@8LJ%,VMG[NS#]FI'&!.U]`E42> MS)ED-(!'&%KJ]X?'KCY@1WUUL,\^O4:!,M`?`PA^:B7N7HE9!#>G'(=1`,MW M8P;#FU-EQ5Y:4?"^6#?B_.^,AP(O#A*"[^7SBGEX$D!\\)<-*)>V\U:ULV@H MH%[:>"U0W8JR6MKY6AKS(>*#!,>8VR.$(M58TX%`\.6;9!C9#7?1CUXL7G]J M<2X;7UH.T`""FUKFHW,8U]J(CW,<2SZEW4I1TV*K'B+F+:W(?R:\U'*[X$+" MX7$8)M9LF5["I?Z0T7`-G65C-..>%7/9$HV4%134+,I\8(M4.@65X^8/!T*W MQR!"V+]]BH!P:,>,`1$Y<.MES<4_)S8](6>&$#(/IYB(51ES"^603\ MX>+),+"7<6UD-)4<)?<8#7"`!0;>(GY?4._SF`;217[[KRP%9SD#9Z/:H0:] MY]&8"-Y#,S10I8[L).#W$%.>+BB1#K^CQ"M.#%O;.73W+$OD2EK9'BVS)^%, M0-)W^8;%X*?0V3`C;&'A""@O1LCLU+5PO"^K?E:&5YUP12G4QKU#5?`]V?)] M/'>M)R?)+FFC"`OEIYZN'.E*\I47N9ZPGPTAK$W#D)(DQ#]1$$/>TC$K5D6* MUF/5RU!R"'/;^1GITDE5D2!NQGJ1?#"&I$\-[JJVI+1U(4EJ_]+DQ;E>=3]?T7.I6)?^]5O]&1[ZM8-C?([3.M*45F M*K[-*=8D-G;)K7ED7!I"1NG=OPW[?56A1B>5D_8;IB6&;[+T-&YVV^_JS;@I M;.]+'U,V>SHP@8!&H9R!^@*-X)8(8!'#'#HPQ!X6^8J,W]@VOVN@;/$RR>0="N=!C=()E&*]G'SC(N>X.$T0\27S+$WA2 M5&)N8>!@^WW4`_#YG1PW;4H$PX-8=NSB/?0-2H<>]=O3MCHI%B-B]CEEVOO4 MNFW6@4'^G:$"E>/A>8B` M2=1VGT=T!@X48I=X#)"JD>:_NV3UTE).8!O5#.VU!=2E>^UF5,R>3=;]G]]5 M>PN!?T=9'P7EB5W7/#9N-=B8/<6\09@\L'O*^0-1_CX,DR52E_3C`<<^1BQO MGZZ,9K7I+86-V7LE,O(A%BJ$_,IO*5!MLM*1FGTLH1LC6#U&VY7GC)4C9SV+68E[.6;U@5LN<*A"N(M%S""U5=BF//?/ MN;:W[YF-43-$?II=G7Z1X;XUI\2MP5,HOE]=LOVR3ZK.JQ<:Q# MI\3-A4-2K-*-K/V!3;"72V9&J-JT92,NZL\[./@RON(P$M M3J?B!C#XTAJX2T!4@U/J+7P!F75!"%T"(3WPE_(/I_U2OK>X8V@V%]9OI[]; M^]WNH;W?[?6M?T:C;T?=T;?!WW]>?_JW;=WVD[U+-L6T'!B/PX M5C\F@$-+!D'XR=YZ<;'MQRM=;CI MA\U[G6^?+\?.''K`1H0+%4W0D:-CKI]?4D?'D\*E96RA_K+#9K9Z9/?V[7ZO M?G6Q[0\1T7&1UUFUZ0",]RP- M]EC<+>#)'D?>`L/PV9S!J1%'"%PQ?Z`X?Z&L=7)CFDL@S/$GT)9/(5$#JT", M<=;S8[ZW9;MP"GPL"D2\;;M0O-0#J$B"MTP7@%8;LCWH32`K$NJ:W0C.$.0F MPK7IHZ.Q(9=]/Z..+X,6X>\!<<^)0.+N@DPI\_1,MQNV,FZ'QC6^U+8CT&6. M((+4TTOYYYI3>"L@<:$;NE7X"PDM.W/O`583V7@.H>!9*5HW\G1<&/T\,NBQ M``(J,OEP.I2S4;"R9XW>8.WI:-CM,`D-G1,TX9@^5S"H0L%'."619E,J=5^(UC6 MCAU*A,S7T)(Q>)3HM>6SKET-VFVW>T+5HK5TO&*):1=5*B:^ MVHVA@>NB`,T((/>"G((%$@`GZI'YG;EENPPOYM:+QP7G/G3/?":'PP@R1-V_`/;A%WBC MWS&G79J^#1`N)0FUF[,-N,=SP"#/J-YFY^;*MT5##2=X<]X-'+F><4UVEO&W MUKVY&L90$:_BJ]JI&*1?=AEC^C=7QS@RXH4\J)V0.@=U`.\!EVNYK##EOEN? MYF88F`9#S94VD9YXC5_73N,@/XL0.=%2YC>UDUGGZE#,C1O;W?V: M*V$T^'C!#FLG6)!V&12+=FRN9&OAQVMV5#O-=)Z-?.;,Y40QG`XXAR)+";ME MHKDZ&B@QG`9T:R=ID(?Y-#78:*ZH)E(,JM;TD.>4DM6MS.'TJR0_RTC=MM%< M54VD&%2MZ^E/3EE-1IJKJY$6@[`5'@MM?D`Q$91-@\@"DV(H!QOCC6KX"M0'?;!P_W3##ET#UI">;#G9=/-D@(+C1V M-N*6B'X4>\D;<26/SV0GF1V`H/_R7=PU M&WS"Z]QI?&8FY@L5L#>,F!T0]Q/BXRSLLC-@"<7V?V/5)J5E;,#6?:O9R28 M+(LXH]=<]+Q:GR&*(6C3:%D4)?C-1=+!%=0%O+H;R`UF#.JZIABJ3,;+XBR% M_USD'0:[.;E8CR0GD#'H:H_%L&>T7A9]:0#DXN_H"G(H=T!SZ>(,+B&F"Z7/ M*>5%#=9$#V7QF!9$OMJX>T$J$;H#2LWD2X^VG.E7%E&^=./06\Q1TI5#3F$J'43,#T:,N049^G;7TYH!(9=T"I MF8SIT98AXXC1)5(WY#Y0IL^M*E'0C*)FXJ4"6H9N,H&0!5#-='X%Z=2%,_5#_P%8^^1]0 M2P,$%`````@`9V_O0B#;K?E.&P``@5,!`!4`'`!P4YFK+-UEVMSUZ0=6J)\;&Q)(\F7O'GS)D.3D,V&(E60LJUT^K\7`$F) M$@D0)$`*[H?D9`G872Q^)+"+W<7W?WU9^>`)HL@+@Q_.^F\OSP`,G-#U@H/O?[97__R^]]]_U^]'IBBT-TXT`7W6V`.KXU9M/%B"*)P&3_; M")X#PWVR`])@$*[6FQ@B8`5!^&3'F$-TCO]PWI[CW]9;Y#T\QN#KP3?@W>7E M=[UWE_WWX/^FTY\_7DY_-G[ZV^+S_[\%S\_/;Z'[8"/*Y:T3KD"O1T3QO>#7 M3^1_]W8$`1Y$$/WPYC&.UY\N+DBGEWODOPW1PP6F_?XB:_CF][_[ZBO:^--+ MY!UT>'Z?->]?_'Q[,W<>X4$4D]$D'2/O4T2_OPD=.AX!EH#9@OS5RYKU MR%>]_KO>^_[;E\C-";KT_!V;-8ICW+G_KO_N?3_7AE"I.?Q"EU0!_8\?/U[0 M7_.M,3DWWC7/4_]PD?QXU-KCB+-3*I[(K[Y'H0]G<`DHST_Q=@U_>!-YJ[4/ MWZ3?/2*X+"?G(W1!^E\$\,&.H4NT^)%HL?]'HL4_I%_?V/?0?P-(R[N9Q93L MXP&MI--%5S).(?)"UPR:"7O4NV.IY[&-8@FY<_T[DWR!WWFPD56& MZ"ROB;/\>V1I1_>4YB;J/=CVFKS?WE]`/XZR;^C2T+OLI^_&/Z1?_W*UB;P` M1A%>:.Z]@+Z0YW!M(SQL?SN#3O@0>+]A#2`[B&R'KC^&XX2;(,:KVRV,'T,W M$XOJXX(P&A&S%P7]%)&M)B M0LF@=1SBS>@?00\0PB!<@BF>JR".=`.MF":.\5AG?KJ#VMS#PBP]QP[B/?JG MH>\Y'HP6>%&YPLQ_94!.L+,T].H)*0W!=P2"F]7*1EN"PAQWD'NA9OQU0V<] M91VCM,F4=H=6;(`BB(VA(4S^M0(L)-K@#;]GWWL^?JH@Z_4HU%4:J74$E,'I M)'[$QKF=T`;P90V#2#\HUM'&,1#KS]'97U;`")' M1!DDFBGVP-KVJ&,))2SPWRC>ZH](CEJJ(5DY=1TNY#%^+UM1A)^0X0:1ES8U MS[_8_@8.PB!U$TZ6=WCOP<)F/1KRRWH3D66P.B">*]_'X(P(ZW/P1%CIAM%& M:BFLX\VG4@_,&LX_-EY$]\E-X'K0O56DE@DJ!=)PM0J#!*'`HSS!,D3`\6UO M%;U"S)8IJ`Y2S&,@C+TP2$J&YH8@WZ M\=7>'CMR6U`A;P<;A&`0S^`Z1,1@G\=VO#E^254V;PPW M44&D[`Q*'Z0,P(X#2%CH@BI1561HJC2T0C12>TZ!R=W`J8/]H8%E,,BT=L M:T^61A3!NI8K@T9;]@!?9!ET$E[$>"7@C"@7:A/8E,%Y^I5N`&VD)4'+0&1F MNX.PX;K4/K']J>VY5C"PUUYL^PRPLEI+P[)"#*F3Y!UIZNCK>0%P$NJZH:Y" M"N]J<@ M#714`&G3.6W9[,#\D.U;@0M??H3'9BZ[G0I#HYRU"@LCH0PH:8!IZX*GRL&7 MV!0\Q;>%#0/O+UVRQQSY]D,))@Y_E\)"*2NI%TQ&$!"*.LU\Z5#S,\Y1:Z=^ MTC7$]L34)P$$@4M<(6LBU!3!-8T^)VOM$$;>0X!_'L(GZ(>TP2",F+M[6:HJ MO+`JAB4=F?(1],`,1A!CYI&N?3E.@++2!;**-5?B^56'B.X>CS&,!W;TB*5_ M\ESH7FWO(HCWG",OP,8=MFT,+/93XE*\C_";VV%M\AH0DGX(F@LO@_N1-3;& M`VM\#8S!POI"/3Y1RB)\]AGH<=-9*&8#E3&7AE MM`">YAAY]YLX28^R`Q`NE_@7I!O8RG5P#"2>YKO<#D#B+4ACA/AV:WE;!4LW M1P2Y4U1*&)B:FIW<@1?7TTKE=[E*/N=B3U$8X(\.I%YK&HFZ3?Y?%9UEUL\)28-Q$8+9@]*T$7I<^!GZ[BA$)`^+`5V1GFTDC;#$DP'KM>UAHR8`49I=MZ;9 M=;KAL88R!%)&^)/598P#5C;9G-QX`;3P1W8@0Z&A@F@%%G,IRSFC"O[9_Q)%VR@F[[LP\!8D2WY9&FX?]]$ M,9%S$4Z1%Z(D;(.\@V["*)H$N/SIO)?`ZNS-%D9H*A-1],Q@MK?&<.P61JSHR%-1EKYT1M59?'3U$'>.KN M0=SMM#)75,7A`;N]]`-1*8K4`?W/4W,\U\_]7SGH8_0)3L!)$A@8F%&:):TX M&;J0@:`;0`32G37(:B9&G!&XY!]RG/J$M\L[9UJ5KU6LK_SY3QT1Y3)%H^2` MG7[(\=(-6K4T4C@DJC]K)Z[UD(^"$S?9C_JU4^6A3#25L8ZZ(4]8"4*5'=@3 MU!WBR`9O@I(M'G$63)9)\'DPW]Q'GNO9B)7))])3&G4UQ),R'3`#0*8:N'2; M2Z.C:=[!CHUN4*RAF6,PUIZY3OWNB6E!I&.[UG-M5'C/BRRE'.3F`ECCP>36 M!%\3F_0;W:!3.N(2#S=+RYVNAXF9"2.2J_0Y:J5CKRMA*)3-1DH#2U`T/ MC.&6K&%L-7=>*+#*X"\T4U4,4*EY/S._F.,[_:PWUE@9!?Y.;LSG@EWGL?T` MS2"&:(T\LN-:>HY'"KMM5AN:_)FDU!WW8#EAY0G+>UR5#4X&JBDODGJ4,0,N MY0;B1PC<7%1V1'CJ!FEU6BPX5A5CI,/'IEC+BQ^PR.D@#_-*8>1BQDK2V[5; MBJMU4`"?X(RTFQ4W\GR(!EB&A[!@,+):*]@`GUR,4:R64GF2BZX+MEU16B"MJ$3)?V4)(;=YCR ME9ZR)7YMIHE4W5.!U20LGMSR7IXAJ!NV:ZBC:&O5G*Y3O..QD+8/C0<$D[CT MRM=UH8/"-R]+&.FO0"QX&1`DH(`L(`V\B/14$(@F+)[U.OL?+)"4.4NJZH:Z&,HK12S4G MZY1A)&84>ROB(AIM8BRH8`V2^G1:"#,1%+V-E1CEC8J\@]O1L>Q(8]55!ZO4 MFO:35]&D%=3IUH.YKE?U:[5Z_H%H;>`VJPKW"@OG'^BF3L7\DGGKT@<3VUX` M7=-&`18KNH6K>R;Z&(T5>%IX0DB&Y>V._-(C+=TPQ1]\T952/04=O\9$BN>W M42Z_I0+YY!97D*>=%<2OAD^W(U@?W$3,\IH?#B+A<@Y@0.X=!_>V3^H4Z_9( MB)?U5UW(7TE2!O\@NHW"KNW4;TT>A:R&?XZ';G@1+\VJN@*K3!'J)XAB+Z)V M5R2:N5'52T%1:B&QI-;D/0L]JR`*ZJ!8F[K&W'2YP\/=[,#[C1X-TATGK&X(X@RYNZ"J4KE$.3\,K,_E4VL_O47^-YN`1_P6!%Y"8 MPL,:Y[V#ZT@T7"P;JJMV7I`>%VT>VTOY@,9D0R]HZY9T5&[WLH63S>H@V1PJ M+1>UDE=:,B)#T,%V9ZNARHZO@M?)79/)%2X-?)/YCNU>Y=.A=_(57N'3Q#_) MG+LN*Q>3N:#R<7V3Q78*ZA%=02;04<4]!(+"R0"JO%"<=N\F<664W!Y0:ZJZ3O(D::9$MD%2 MH@B_/'J$M=$>>*H^#RUE:HR#/'ND%P6 MXT6.[?\OM-$(?U-V92RKI53*2@5[J=R\E#1(:`-"'%#JNJ!(0`'Y_!6A">AP M-[^ODC##9GH8C$(T67EQ3'/YEA`A4OTU38^F16')!=V3("N?-H-.^!!XOT%6 M"KM"!O+6@?+!RD![QP#C&>F9/Z]>807#HB5XG+R@MA4\P4BFH'89@;8*:G.$ ME?(LE174WO%Z?66T.6H2+*-=.:F:^''P5N8)(OJH+>\"K]E-S44B[?IWF$++ MU8[#:/%]C%UJDK]*UPY3,;7Z=7-U`69I=8(!$B>=&R)2W\>8V(LI_Y_SC`Y)Q>*!GF2 M.FVBBBI4::OW'+9;W^$G_'+_,0B?@SG=?N)%FKS^CKW(U>T5U'RH$$5!]0?" MH?XUH0&QV?T1VS*\+HBJ54CQZY4Y(ASOTS7KM4Z7:/C$F1G[X;`5X95@E M!>[Y9>)$>\OOR>N)*97V>3>=WIBWYIB4"!\8\\]@=#/Y"5CCT61V2YW+GW2# M74WM%';D36:QT_.UI1=S2IKF&J@X+SMB)NN<\#$MW0!3'&7)@5>I3C7Q'937 MG&GB0&!0:M>+P!>_C;"1_3[_%?H6^.JJY6`0F>[N,'Z4>#\,5[;'0G%Y6VF< M.:B;HACCNP(\Q):#\[E#S$_0>'K$E:SQA$_N MM>GFWO<<;+'8QS9J>1L%+K02E@K<9@E50,GJ`A'NF(O.,::>VPY)FF8>\*%= MJ`[$;JWCR:5AG;YD!7N+5X/ M)3>!5H@C6T%*.RM/8,QE]VX*S<')/1,T;S*K=#M9-#;149T*._Q9/3EX$U/!<+"=F]S?U2@:YZ!_NRZT M,E';<)PYONVM7J?;K$Q%M9QE[.G4Y,YPFA5V&"`_W%]!-UF6=AY#W+/AQ>%R M#-N]/5R),M3D8?PG7""N1)VU;A%7"*X.:\CP,N[3^C9&X)(RQMR21/7IR->9 M:2JZ9#6X5U:LH;&:"L5IY*:X+2]"RGF?+,-V)#";2OD2J@20VM:DE;/RJ4TZ MNA2J=)#W*HC-PBGN;\@J*>!-5';0Z#E7VV1O.2`1/^(W\=2AI?#6AP9#D,$G M)0^^)D$2WQ"7%TCWX92W+@!5HB7V11&-9[H[B-\1PS6K8\PR#8\:28.RG*D, MVC!%XI/8T=0-8.4C/D8.3\\=7BN2*QDVP`9BZ'MNLIT-W"FI_1W$=K)OW45P M[@(XHQ*O'@-4RMG(7VC2TL!EO;V`7*N3%XZ>/'[VHEBC6_C:5F+A#I56X:-C M!FC%F48#0AUFA*H\`;'&7\SYPAI?`V.PL+Y8"TN_FZ*;:Z9Y,NBICT]RA7O2 MVDZ;.(IM6@V:`5IN%Y4UEI@"R>UQ:85KX*0N9LJC3OWK4PVH,K-,>F0GKC#% MU`ZGV%0%`+NLWNQ2QR#)CJ^/S!Q2U?L+36U`T[G"&7 MWA'(4_E)UG5>A>]",Y7KM[+:WOGCX#^#_N7E^67R7Q;08&_BQQ"1HC#GP([! M?U^^O;S\0%SX27C#.?CVV_,/?WI_?ME_1^VPW)\IA?20F?P8[E>3@IT4Q).W;7ZF M`>;9P4I282CA!'*L=$*6N&**4>@ZFFKSS7T$_[$A*1)/Q+%8>0K(;*\@D[Y" M%'DW]#MRO?N.#4CXZ`(O83T4L^2%YN3D+N$T,DC>)?PB[+CZ0E8BL]&V4M%10D8;*70=F.[-[%(>+AZ.<]'$%XY,H( M4=Z3H1M$.9HL5C^IF,F3W.EI!&[MMZ-P=Y7W?PH)*A5I;AE7U@U=OH$Q'H+Y M8C+X\?/D9FC.YME5N>;(&E@+W4!85TN'3F"\X6`Y?LE/\L[>'`,I M!R^FHQLX\F,K>%0+VFO75?(E]#=!;*/MR/,QNIC>D>-V"APB#-8*?"`[RB`A MK0L`*L=>='-P]=YE90]L#&]@6B(_24AY3@/]2389"@/\T:&[.\.G@K`+=34D MIJ`6B,P@Y(J$4,X@QUH73*I13K%PB/P4=[CW/[P^N6*OQ6HM;P/PQ9"R`PAI M#9..*H9G-3>TM!_6PCUURM_7`+(=V_99GA4SPQQ-1(PE.Q M1;5:T\S;!4F6$L\;4<]1879):^J0]EK_B3BM:?)W)@`P'A"$.I9LZD"?[&R5 MEO'5Y=9EEW^X72`[B/`+@T@GGIM0AX*"34IM<:4?B@_XH4CY`LH8Y#GK]E@T MT%!Q>])P1KNUL$F%9I(FBS_N`[P#-TUAR'OV]X)7;%ZDR2JQ[%4,3`KUDW$O MJ?EMC8WQX/"D2+NZWZHT5N9K4(>%T]S$FW^2A_">N6?G=5%Z^RY+(#DO?D(? M$%P(\3504MZJ/6&!!/+979?6K2ILI.+$M9ZS@P'9/&!#*N@"D:N3%XUJ>SKN,0U^M;+2= M+'?7G9LO]@J;](E;MC(J7:RW@ACU6F+*1ZQ?@AY(>`',3+\744V%%$/7&TR< M""K7*(X)UM[UWZ5(6WK^+S,8YJJN[(*+^T713-05]5+_E8V,;&DJM(8'ULT= MN3F+UF^>FK/DPBQR<]9@FDO;>:ZM)K@ M\FJ"M9MDLK03D%TW-7Z!R9;8?P<_*TF`SS-2DO-.".J"`]9`R_+:BRK5H!0G M>;E%DV6^T.'5)O("&$5#&#G(6Z>E$',1F&E`8..ZG$IXME>D4Z5*I);?E"FM M_Y*75A?P=ZI)X;*=ZM%U2A.'5F_:Y^/2&BI8]ER2SQC&%1L!6:HM&$B-AB5O M/T7$@`HSMNEU4_3Y\O><=7N\%&FOVMZ20(6.-0T&R4TH^+O=52CJZAQPB7=8 M^T!DD'+E%/^^B6):ZQC$(4"0`-;S(0A@#$A-?O(M^4S"P,#2#Y_34*/<4[83 M5K?[]^N(VFAY^\V:P.VA>PP`_ M)3[9PKDK+Z"G9J08(M\/7-5+&HZ"8LD`,65!=RSV`1/=T">HC&/^[W<^J\DR5O+5FYA=S?&?.P3_[_U)9.[R)C#%$$;RI$%0W#!\/E)&I>K+W M8&YCGMV-)ESJX[B#RN(>#&&D5N"[VLE`ZZO&"NDB`Q%7G*N:J9N7J9L]#W1R$B M"9XULY#KTE.88]QP*-)11-^!7E9DE>S@]A6VJ"BZ@51:7^P,8:FY[W+;EX^` ML6*XRKN0T^MX2QHQMXD-R2G85LH-1!KYW](TX5#C0PQ9%14WARHFN]ND86QV MD7_(L?23[1/7AA$/;(2V^.'D7M@@U%=)^J^PB%*[39+?:RS`E7EMC<-);F.:QS:*6;;6ZQX:YZ*I;&#F>"@VI%.E8PNKI2SGNN93 M=LJ3RR&D]]*S%D-.AQ;.&X^%D5K0S`6Y%6AF&G,3?P`$>;H!K5H#U<>!Y?-Q MFEQ]>,6`544GI?GZ;*&D%I^$%'#VU,']-LN$T@UH8OK@9>M7 MS=():HQ3ZX-YMG702%W5\`.F4M&3&47=L%(^5&:I[Q(%=Q@PESQND4`&>VE3 M^?`TC@!2:7,OT-F0(Q5R)>>.LFY0X8V^$`E6J?\3.5`KO/'E;=4Z5-OPP>M\ M^9B@YUU`]5UC1@@LJE&B-%)(8UB(X:$Y$,JS'+/`;VRT)2F^5K`,T2JI=5@^ MW<+=I+(?ZPBF)&2?>+O3?.T<*ZTR(^OH))\E*3Y;^='>X$_XN^PK_+][;'/A M;_X-4$L#!!0````(`&=O[T+K.CC=OA$``#4C`0`5`!P`<')T="TR,#$R,3(S M,5]P&UL550)``-R..11_W>ON'>QV(/>(C/'Z_ MAQCIOGGS^FVWM_?C/[_Z\H>_=;N=(25^Y$&__C?\M^F,HO%#V/G[Z3\Z1X>' M;[I'A[WCSG^&P]_?'@Y_[__VK[N?_KO?>7IZVH?^&%#9R[Y')IUN5X@2(/SY MG?CG'C#8X4I@]O[50QA.WQT>7>4>_HN)7-^^%(\W?KK@_C'7&FD$><%5$[D%S&3E`3P!HXZXN_'F\MBA0_$KP?(IY_. MB!=-(`Z3OWWLG^,0A;-+/")T(KEYU9%:O`MG4_C^%4.3:0"3[QXH'+U_)1KO M)HT+U+\V;OM@(?J40L:+R>^O^!>9;N%S"+$/_:1CH4$CRHG^YP($Q$OWN1<( MXR1T+ZWKWK*NW*X^Z;KHW[.0`B],V@G`/0S>[QE7.Z@J8MJX&/3VQ^3QP(=( M('0L/L@(T3WLS5WD:_[5I[C[&SA&HE<<7H,)S`FL+)86,$UBGV:%!=1+FN0? M)8-[2MN>ESB8\EB(PZ[W@`(_J3VB9%(!P$0(HM&A$S$N#9F*BB#8ZQ#J0QK' M\8W@GRARQYLMP#WSLV-X9U4KQOEHTS@/(46$Z^"?@5`'>+:E,4G$94*'J!F`>"?T-`U3%'6=0Q(M0J%W/QW8;=@4PF!-^&Q/M\ M^\"59X,H%.-H,553^X:NDF/\F,!0S-3WFV5J&-T'R+L(",@/GHO+.,E#1LEB MV-]L%O8+%$!ZRAUV3*CZ:9$MY23T.46+P7^[X>@4!\\;."4TY*YXRW&,F#HN M%1=WD@Z5ZHJIV>%FB?F5!!%'D<96HV8D7\Y)*I:457"PL?EQ+-9O,`A^QN0) MWT+`"(;^)6,1I$HN5.6=Y$2IO(*;C<^I%P.^"_Y-D8>H2CK&AU)A!1,;FUIG M!8NG_693C\!@5B/OWV`,&1UU\VSC:QS M@3S;TRH&.@+L7G(=L>X8@&ELI3`(6?)-WESG7W_J,\8[5ZR1*PJMY$NKBCH? MI1A)G"_;DF?IL19^5*+BFA;'ZU-Q"MB#`GGYD_5`QPJL:3&\/JY#"J<`^>?/ M4X@9G-N!`NCBLM8CKU!Q38OB#44;DRAC/_0YE=:T.+XJY%JL70%Y;>O>]=&] M0N`>!2A$D/'AG5QX?"`!EXJ=_Q'QH5[)$]6XNO4,F0.QIO7R1C@T&P=I*KC$ MD^&(:.7U\15BE^>1"(=L"&;@/H#A!>NYJP3'FE;=&R/S M!@8@A/X0T+0M8O^:8*\*I0;MN$:L"31K6M>O3^]9!.](H>0*'C45K"=,I^RZ M5O97\CP1)6Y!`*A)Q"PJ;#TE*B77M)QA/PWFCZ+5U_(;H:`<>Z=` M7]]Z?7VT*T^+7)X(59_Z]%I<'1CRMB!WTWC&]BL(HGP2EZZD]604JJ=@H<55 MA%3:DHZ"I6+6X[^LF`+\%J?_?=]'L3A#@/Q+?`JF*!2R%0^/%*6MIT*IIH*1 M%J?]9_`1!F0J]C]O0S"&YSB$=$H1@V=PA#P4\K%>-(GDZ/LLH@B/\S544X[5 M&[:>YR;`4YA$BXL'RT]5XZ&#_905*:>@H,4)?MD*;\TE;OOI*5=5YN*Z4 M#)%$"(6_LL%H,(4T/CY;-S=#T=HZDS047;9CV#<\_N$(EN5K+!5KR0\3.4K$ M;-NO5*BF/6NABCH9HS--QO!7L:)*V:1@_&''H"S9%C]S>\;C^6Y\F5VIRSO` MH$99Z_)`;CB"7/L''L130YZYX$IOTM5Q@*`2I:W+$!E2,H*,27DNH#+*+15S M@(IEU:Q+%AF,^!2!1U!Q.PH3Z<%56RP%^2A6W+G_D$GMD`J\(8Q=A#ZTG)N00`'HTL.)1XCD=ZB M2UPTJ.@`22;JVY?H@9@7.SGT7WR\/Q$)+(-1W_]?Q$)Y,PH94D1H?'3E`T!8 M1(@!YK6GA('@!(X(A;&!WH%GU8+M6OIRP#+6!+)]N2E:15-!+'F^Q*K)G8S! MJ+#R->0U:YK4:AVZ;EQ+M3D'%/.Q-^-/!'D!R@E@R!-K/RB(0JCR@+):#C!3JKA]N3>_ M07''*?3[CSR4CN%U-+F'=#"*+ZZ1Y^!]J86"-./J#K!G#D59\LXZM]J6M_Z: MV'(K:'536V\%7;>UO3\7JDBFTF1!D[JMY2W,A;L3B?UE&L2%6O;72EQDTQBR MNEIWP/I%P%@7L0),L/"$_C-2#5'T=6RA*F-=A9P4JVP=1:F$P5^@>`B4IT+. MR]E"AU5"D*N\:12F?K M]K9S"IV1"9=;-24K+.L:-0J-K=OW?E&,#['A)?]8.AQ8%+2%D_(Q0$HY=>!R M+M]JOF$LCF%BN:^/0XKNQ:1?G\E?7L\69I>,LF"_7*=^8\EU4[G/P.6B8:N4 MRU%3O"P0I[#'&R#RB,DU?)*_J#W8I*X3U!O"8-T@12%WO-I3D[]\99<)7`+" MNI&,SO+Z'G_HQUM&=7PP4]UE%@O`L'#9R2(XK$L8U%EALB/" MQP3EB9TU&G*97"U`UN4::BVT"9JU+;G,LQXBZQ(4US:K^=1S@T83130)C;5F M-N?8MW9>(Y-S:H3LN)X3E!NH;UTVI#;:U.`L7=%ETC(`V)=VJ#.U842]!_Z( M&(RT*.2FO.W.28H?O8:H0>LWN8OJ^&1+7F;$LWLAR$9"G M1NX&6C2VJ?SD18^MG6$1(@PI>41Y1D,M MWK^!0LV9G52!EAVZ/COY6SD2A:U+P#17L>CZF<>`7+TM)7P)'OL21$J%KOD(U[?RU^#;[+'>\L51.16R M;]@VICM7;4OYS8-C7PI)H4WF7IU:Q8?S5;>4V"*0[,LC,==^Y97P[2"Z"F#V MY98HI+_$CY`UL2NG:VB;Z=<":-]+\\RU6)G^OQKM-KZF3R']!<(`>PUXO:ZA M;:9?"Z!][P9,7YEM?"BJI-)6T%L&C'WO]$M+G)H2SL[@O5GZG807`4P!=U6K6Z=07G+>X6= MR*3"5M"I`T1!7YLI75SA/O;%'Y&A_`@">04;!X+2&==9^PIQH[I;0:HA3`I^ MC]V]'6OM]M'^%0(;M!#U-0-'WSI[BB.:3@.99`^"),?^$H\(G<0DEERX;5A[ M*VS$&"J%C;2X0):(>TVPQS\NUGFP7S!0$2]W"0B+:-D+T59N=BOL8G5P%0;3 MXA*;S,.8*Z3?Z"PJN16T%D*@8.IE%:SI$UP+:[F!'`F`T9_Q.8.ZI[C4#:[S M))>ZUZKFO:S5"`6?W8"LJ&1+GF:">785I$#)DB-6 MZW.E:Q+"WB`E$(_4/R'&":[]%A>SQC?C8CH)VK'QA6QW7+43WM/GDI&%KD9; MC\04HJ?88K-P6C^U`?!X@!K@3ZJYVG3W;3\,#;@/O/4;1SE5L/, MT6TTF0`Z&XQNT1BC$?(`#N;"T.F$NW"4OT)O`[8 MLF!C6-FM$&**2*N!X?@#X5+Q".=!BIMQ_VR3FW/R;+\[5ZZMQ!7Z(T(^"F<+ MV=+0"JP5RIC4=,N)C;!HU8._S4YJFO'A?*.;\^)\SSL_;FA*+^\7.H/,HV@: MCUSERE)!(:-Y?X7FW/+X^JBU&@9>I[,Z[BC`C.O7S`J=OOG-A0:U#+L@L4*0 M*,;4?*6@2@NNA8(*V+3J_=_%]P\,N;@X;,CE^<>P7GEB\ZOX$> MX7-109>`E@U&'PCQU<]Y;2777%B/0*M>^[V\+R2Y[[H_IE"N'S;COJK&-^?' M*@EV#EU_E6W,,$[L[3\!ZI]S6R$S"#/(#P,@][IB-V4LFDA[ M9_+UG*5+*&@A% MJ?NF4S=-WY`@N"!4>$;%0%.U/5?#2&7<6@T2;V]XLQP5D9^:O[^NF4"A[6%S MP4(KQBY@K'*X;@KY3%H\$D..K4APELB*NSHH\2,YN3Z##(UQ`?3J\WI6 M\%@9PW:3G0XOL4-OGCPWZ[W*[&W3=Y,9]5 MZVWCD8&3B"$,F;BF-EV@V=3>FGVW?N"@3,"69L2B^YEI:%"5MNT\'K[;#D\E5B#T>F$9K!WX:C"XIM?8/A`_%:.,"B%L.YH M@U+27>2K+'SB4:=DCQMR)/'71DN"%46OA#+TF%-62UWPDJI_B[$C^*$[Y:&,UI1K(LE)?+N(DJ-84T1 MHO.;7V-9E6.8\IKN1!8C'%R(+O*`CSPM>$HF0OHUY.4T(XIUT:5$WEUT62$% M=W&(-8VM\A#K_++J6>U#PZOTXD[4:AQ?%R*#S5;%*S?C3H2JCE#MX#3_1?QSS^>6_)O_`U!+`P04````"`!G M;^]"Y'!K-G\'``#)00``$0`<`'!R='0M,C`Q,C$R,S$N>'-D550)``-R..11 MV&O[R'"(AY3-AM[5'+_Z.APY(?>;R]^_M?)+[Z/)H+' M>41B-+U!9Z_?GE[*G"J")$_4-1;D"3J-EYAI@E=\D>6*"'3.&%]B!1+D$_@1 M]9Y`6W8CZ&RNT*-7C]&@WS_R!_UPB/Z:3#Z-^I-/I__YX\/O_^VAZ^OK'HEG M6!@IO8@OD.]K560T)PN,0'LFQ]YPX"#3U];#'Q2P`R##X].>[*T/G%83' M*65_-ZB_3D5:T0\#W3S%DE3DN?1G&&+UR3!>:K&WI<`IMU$'4SC!.18%*C MT;NUX`H"B^@6RJU!`!">$:$HD2O_.@C:Z5),DKMV"5@HHS]JAU(\O6N'@(6D M/V)?(IS>M2_`$N7I=W8WC?$!^H!TX>/E^0JOD14*A6@L/E^!_YO,)B^2*\6C MO^<\C6'"./L"*?GF`-%X?+`#7:%"J]I'_EHQ5\O2\035$?[%6=< M_AL5H"?!)EI=2"Y)?,%>F/)F))><)8F-JQDLN_%LV'`+4UE5V>$^MGE-991R MF0ORGBLRN,H7"RQN8/SIC,&<$6&F3J.(YTS!?#[A*8W`+RYA*,"7YJ51*.4:4!PBQ& M-1W0HXKF\8/WFY;$5NRHH+WP0_PGK$3I5A*TZ[5 MO$C>4`:C2G&Z&NJ22[86KGN(=`5QV%80-_723"O-:HY7Z=8%M\WWAF\Y#.TK M#L$IF,U;FD2NP!]MM^\0"@8#E2"=%1H#'(;U,)P)4JQN;/:PD3LL$S[?;IDP MU*%7C[<57&>C?5*F68V^A&5UK`\X")-&V9;R\3?`79G78O^[9EZC@:^W#<4) M3J5#EV'O/;LO", M_L^(MQE^D\R5]OO;S?@4"DV4SA2-,3Z"Y+;@#/:I$T$2(@2)3>JSV<1*[S*. M)<:.H%#`F4WJ"K!(OIVA&@/_[`JGY"*9P)+?L6+:H'(99;#=*,]TX@,0G?5* MF,X2^\Q'L'RAT3LNY82(PLNOYEB0EF:[;Z&[ICS+YN6N4YY1`3T"$/D8@1I5 M+!M%NLGOGNYS&B_U^;4T&U+9VDF'%=;E,(?M.$Q--C+".R?9_GWA%9;S-RF_ MEML_*ZR;74<4A^ZO"1H$&90'/_0;APX7M=4BK'-^IU)Q<6,]H["0NTQC.Z.` M0AW-K(I*O,Y(^V2[>R9+IQ&/VDB*G5EYE.N<5/V'"#J#(5(WYRSA8K&Y/]R% MVF6TXER^Y*X7=:@54*B&]>#-4Y]V+C(BBNM+VZ>E6KO+!$/WO+1&>?"#O]-$ M\S*']121$FKJ!-_*@'NBN3:4EFV%:U:#340IT-0VR+JUX?WFOHG@2ZKO,[[A MX@/^2MK:0=AQ75N(5F;+8[02CD`Z,N([1[$YRFC[+12S];(Y@9/'%?V6/>+( M',!:KJ(8U,YH^T2AWKZ!B?0_?0ELB5/2WG6(;X"[XGS83IR;W:EV%U.H*=%% MNW5]`,:=2O(EAYZ>+9V?U6]3NB+;DKK#PJ85$"J0.J,TAOJY^90QR2'[84E6 M=PYLEK&1N\QCB;CG9F4-:*B"6U]YZ(RT3U;\*,E%2W656:V;MG[.(+XA9;EJ3:H/(%;"6"[[F:*+`*!:VG17V^L"Q MJOF3J#F/V_IN8H-U1:KE4L*=OYNL*POA7:C:G.3PDH!@$D^P4#!+77I?"C\?3TA"XR+A0J M7AF_X\4C!,>;6_W+KQ[>^KK*#P?^,.Q]E;&'V*T7N(Y7N\%=%8B5"/2CQ(#E M"R)HI,6/M/CPV4[B-_GOHP%G[^^K!&?^WHK47A1K!0YMHK<^0=Y%FF'<^@P\ M(*F258V_?B]M4\'YEGQG53;?:.O"#L*=[[L+X>5S=H2G4@F8R,>>$CGQ=,[S M$II^=GV)/"UY0#1-4SQ-2<6M51E[N_&:=^['&7@"CW78CKTX+[Z0>4CF0$95 MKG^]%3S/QEY!3A59>,B\T2UK``Y2VCG4:Y!=N[F_8S=.@L(W MH/A_4$L!`AX#%`````@`9V_O0G:`5@5*1```)!@#`!$`&````````0```*2! M`````'!R='0M,C`Q,C$R,S$N>&UL550%``-R..11=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`9V_O0E^0PE2T!0``J4(``!4`&````````0```*2!E40` M`'!R='0M,C`Q,C$R,S%?8V%L+GAM;%54!0`#`Q0````(`&=O[T+P^_ODM@<``+)8```5`!@```````$```"D@9A* M``!P`L``00E#@``!#D! M``!02P$"'@,4````"`!G;^]"(-NM^4X;``"!4P$`%0`8```````!````I(&= M4@``<')T="TR,#$R,3(S,5]L86(N>&UL550%``-R..11=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`9V_O0NLZ.-V^$0``-2,!`!4`&````````0```*2! M.FX``'!R='0M,C`Q,C$R,S%?<')E+GAM;%54!0`#`Q0````(`&=O[T+D<&LV?P<``,E!```1`!@```````$```"D M@4>```!P XML 69 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Accounting Method (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Accounting Method
Accounting Method

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The Company’s fiscal year-end is December 31. The Company has realized no revenues from operations as of December 31, 2012 and is classified as a development stage enterprise.

X

- Definition

A description of the accounting for each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAccountingMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 70 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 10 - Income Taxes
12 Months Ended

Dec. 31, 2012

Notes

Note 10 - Income Taxes
NOTE 10 – INCOME TAXES

The Company provides for income taxes under ASC 740 “Tax Provisions”. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 34% to net loss before provision for income taxes for the following reasons:

December 31,

2012

December 31,

2011

Income tax expense at statutory rate

$

(188,461

)

$

(270,567

)

Stock issued for assets and services

-

412,437

Contributed services

2,040

-

Valuation allowance

(186,421

)

141,870

Income tax expense per books

$

-

$

-

Net deferred tax assets consist of the following components as of:

December 31,

2012

December 31,

2011

NOL carryover

$

(2,860,810

)

$

(2,672,348

)

Stock issued for assets and services

2,642,531

2,642,531

Valuation allowance

216,239

29,817

Net deferred tax asset

$

-

$

-

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $602,043 for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 55

-Paragraph 217

-URI http://asc.fasb.org/extlink&oid=32707879&loc=d3e36027-109320

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (c),(d)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

+ Details

Name: us-gaap_SummaryOfIncomeTaxExaminationsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 71 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Cash and Cash Equivalents
Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2012 and 2011 the Company had $860 and $22,171 of cash and cash equivalents, respectively.

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 72 R15.xml IDEA: Note 10 - Income Taxes 2.4.0.8000160 - Disclosure - Note 10 - Income Taxestruefalsefalse1false falsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_SummaryOfIncomeTaxExaminationsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 10 INCOME TAXES   The Company provides for income taxes under ASC 740 Tax Provisions. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.   ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.   The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 34% to net loss before provision for income taxes for the following reasons:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.72%'> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;padding:0in 0in 1.5pt 0in'>   </td> <td width="23%" colspan="2" valign="bottom" style='width:23.52%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.94%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;padding:0in 0in 1.5pt 0in'>   </td> <td width="15%" colspan="2" valign="bottom" style='width:15.86%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.94%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:#CCFFCC;padding:0'> Income tax expense at statutory rate </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="22%" valign="bottom" style='width:22.12%;background:#CCFFCC;padding:0'> (188,461 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.44%;background:#CCFFCC;padding:0'> (270,567 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:white;padding:0'> Stock issued for assets and services </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="22%" valign="bottom" style='width:22.12%;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.44%;background:white;padding:0'> 412,437 </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> Contributed services </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="22%" valign="bottom" style='width:22.12%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 2,040 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.44%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> - </td> <td width="0%" valign="bottom" style='width:.94%;padding:0'>   </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> Valuation allowance </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="22%" valign="bottom" style='width:22.12%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> (186,421 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> ) </td> <td width="0%" valign="bottom" style='width:.7%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.44%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 141,870 </td> <td width="0%" valign="bottom" style='width:.94%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> <tr align="left"> <td width="56%" valign="bottom" style='width:56.38%;background:white;padding:0in 0in 3.0pt 0in'> Income tax expense per books </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="22%" valign="bottom" style='width:22.12%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.7%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.44%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.94%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="0%" style='border:none;padding:0'> </td> </tr> </table> </div>   Net deferred tax assets consist of the following components as of: <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="75%" style='width:75.0%'> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2012 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td width="16%" colspan="2" valign="bottom" style='width:16.18%;border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2011 </td> <td width="0%" valign="bottom" style='width:.96%;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0'> NOL carryover </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (2,860,810 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:#CCFFCC;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;background:#CCFFCC;padding:0'> (2,672,348 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0'> ) </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0'> Stock issued for assets and services </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'> 2,642,531 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.42%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;background:white;padding:0'> 2,642,531 </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'> Valuation allowance </td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 216,239 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'></td> <td width="0%" valign="bottom" style='width:.72%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:solid black 1.5pt;background:#CCFFCC;padding:0'> 29,817 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCFFCC;padding:0in 0in 1.5pt 0in'></td> </tr> <tr align="left"> <td width="64%" valign="bottom" style='width:64.3%;background:white;padding:0in 0in 3.0pt 0in'> Net deferred tax asset </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="0%" valign="bottom" style='width:.72%;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="1%" valign="bottom" style='width:1.42%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="14%" valign="bottom" style='width:14.76%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> <td width="0%" valign="bottom" style='width:.96%;background:white;padding:0in 0in 3.0pt 0in'>   </td> </tr> </table> </div>   Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $602,043 for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years.falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 55 -Paragraph 217 -URI http://asc.fasb.org/extlink&oid=32707879&loc=d3e36027-109320 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (c),(d)(2)-(3) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319 false0Note 10 - Income TaxesfalseNote 10 - Income TaxesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DisclosureNote10IncomeTaxes12 XML 73 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Reclassification of Financial Statement Accounts (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Reclassification of Financial Statement Accounts
Reclassification of Financial Statement Accounts

Certain amounts in the December 31, 2011 financial statements have been reclassified to conform to the presentation in the December 31, 2012 financial statements.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_Reclassifications

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information (USD $)
12 Months Ended

Dec. 31, 2012

Document and Entity Information:

Entity Registrant Name PROTECT PHARMACEUTICAL Corp

Document Type 10-K

Document Period End Date Dec. 31, 2012

Amendment Flag false

Entity Central Index Key 0001493526

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 44,573,012

Entity Public Float $ 44,573,012

Entity Filer Category Smaller Reporting Company

Entity Current Reporting Status No

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2012

Document Fiscal Period Focus FY

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ References

No definition available.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 75 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)
12 Months Ended

Dec. 31, 2012

Policies

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 76 R1.xml IDEA: Document and Entity Information 2.4.0.8000010 - Document - Document and Entity Informationtruefalsefalse1false USDfalsefalseY12http://www.sec.gov/CIK0001493526duration2012-01-01T00:00:002012-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instanceshares0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$1true 1fil_DocumentAndEntityInformationAbstractfil_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Document and Entity Information:2false 2dei_EntityRegistrantNamedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00PROTECT PHARMACEUTICAL Corpfalsefalsefalsexbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Registrant Name3false 2dei_DocumentTypedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse0010-Kfalsefalsefalsedei:submissionTypeItemTypestringThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".No definition available.false0Document Type4false 2dei_DocumentPeriodEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse002012-12-31falsefalsetruexbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.No definition available.false0Document Period End Date5false 2dei_AmendmentFlagdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsexbrli:booleanItemTypenaIf the value is true, then the document is an amendment to previously-filed/accepted document.No definition available.false0Amendment Flag6false 2dei_EntityCentralIndexKeydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse000001493526falsefalsefalsedei:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Central Index Key7false 2dei_CurrentFiscalYearEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00--12-31falsefalsefalsexbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No definition available.false0Current Fiscal Year End Date8false 2dei_EntityCommonStockSharesOutstandingdei_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse4457301244573012falsefalsefalsexbrli:sharesItemTypesharesIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.No definition available.false1Entity Common Stock, Shares Outstanding9false 2dei_EntityPublicFloatdei_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse4457301244573012USD$falsetruefalsexbrli:monetaryItemTypemonetaryState aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.No definition available.false2Entity Public Float10false 2dei_EntityFilerCategorydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Smaller Reporting Companyfalsefalsefalsedei:filerCategoryItemTypestringIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Filer Category11false 2dei_EntityCurrentReportingStatusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Nofalsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Current Reporting Status12false 2dei_EntityVoluntaryFilersdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Nofalsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.No definition available.false0Entity Voluntary Filers13false 2dei_EntityWellKnownSeasonedIssuerdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Nofalsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.No definition available.false0Entity Well-known Seasoned Issuer14false 2dei_DocumentFiscalYearFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse002012falsefalsefalsexbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No definition available.false0Document Fiscal Year Focus15false 2dei_DocumentFiscalPeriodFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00FYfalsefalsefalsedei:fiscalPeriodItemTypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No definition available.false0Document Fiscal Period FocusfalseDocument and Entity Information (USD $)NoRoundingNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://prtt/20121231/role/idr_DocumentDocumentAndEntityInformation115

Statements of Stockholders' Equity (USD $)	Common stock	Additional Paid In Capital	Accumulated Deficit	Total
Contribution of capital for services, value at Dec. 31, 1994
Common stock issued for services, value	$ 800	$ 599,200		$ 600,000
Common stock issued for services, shares	160,000			160,000
Stockholders' Equity, ending balance at Dec. 31, 1995	5,815	596,550	(605,105)	(2,740)
NET LOSS at Dec. 31, 1995			(605,105)	(605,105)
Contribution of capital for services, value at Dec. 31, 1995		2,605		2,605
Balance common shares, ending balance at Dec. 31, 1995	1,163,012			1,163,012
Common stock issued for expenses, value	10,000	5,000		15,000
Common stock issued for expenses, shares	2,000,000			2,000,000
Stockholders' Equity, ending balance at Dec. 31, 1996	15,815	601,550	(617,365)
NET LOSS at Dec. 31, 1996			(12,260)	(12,260)
Balance common shares, ending balance at Dec. 31, 1996	3,163,012			3,163,012
Contribution of capital for services, value at Dec. 31, 2006
Common stock issued for services, value	150,000			150,000
Common stock issued for services, shares	30,000,000			30,000,000
Stockholders' Equity, ending balance at Dec. 31, 2007	165,815	601,550	(768,841)	(1,476)
NET LOSS at Dec. 31, 2007			(150,000)	(150,000)
Balance common shares, ending balance at Dec. 31, 2007	33,163,012			33,163,012
Contribution of capital for services, value at Dec. 31, 1987
Common stock issued for claims, value	97	(97)
Common stock issued for claims, shares	19,420			19,420
Common stock issued for services, value	1,046	2,336,880		1,046
Common stock issued for services, shares	209,112			209,112
Issuance of shares for assets, value	1,798	1,346,672		1,348,470
Issuance of shares for assets, shares	359,592			359,592
Cancelled stock, value	(1,046)			(1,046)
Cancelled stock, shares	(209,112)			(209,112)
Stockholders' Equity, ending balance at Dec. 31, 1988	5,015	3,716,455	(3,721,530)	(60)
NET LOSS at Dec. 31, 1988			(3,721,500)	(3,721,500)
Contribution of capital for services, value at Dec. 31, 1988		33,000		33,000
Balance common shares, ending balance at Dec. 31, 1988	1,003,012			1,003,012
Contribution of capital for services, value at Dec. 31, 2009
Common stock issued for patents value	25,000	1,225,000		1,250,000
Common stock issued for patents, shares	5,000,000			5,000,000
Common stock issued for services, value	26,025	5,283,075		5,309,100
Common stock issued for services, shares	5,205,000			5,205,000
Stockholders' Equity, ending balance at Dec. 31, 2010	216,840	7,122,909	(7,798,952)	(459,203)
NET LOSS at Dec. 31, 2010			(7,026,356)	(7,026,356)
Contribution of capital for services, value at Dec. 31, 2010		13,284		13,284
Balance common shares, ending balance at Dec. 31, 2010	43,368,012			43,368,012
Common stock issued for services, value	175	34,125		34,300
Common stock issued for services, shares	35,000			35,000
Stockholders' Equity, ending balance at Dec. 31, 2011	222,865	8,342,980	(8,594,736)	(28,891)
NET LOSS at Dec. 31, 2011			(795,784)	(795,784)
Contribution of capital for services, value at Dec. 31, 2011		$ 13,046		$ 13,046
Balance common shares, ending balance at Dec. 31, 2011	44,573,012			44,573,012

Statements of Operations (USD $)	12 Months Ended		305 Months Ended
Statements of Operations (USD $)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
REVENUES
Research and development		$ 100,520	$ 1,353,540
Professional Fees	512,619	728,793	1,480,984
Executive compensation	25,726	482,246	5,888,730
General and administrative	15,953	124,225	446,939
LOSS FROM OPERATIONS	(554,298)	(1,435,784)	(9,170,193)
Gain on sale of patents		640,000	640,000
LOSS BEFORE DISCONTINUED OPERATIONS	(554,298)	(795,784)	(8,530,193)
LOSS FROM DISCONTINUED OPERATIONS			(4,340,551)
NET INCOME (LOSS)	$ (554,298)	$ (795,784)	$ (12,870,744)
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ (0.01)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	44,573,012	43,862,848

Statements of Cash Flows (USD $)	12 Months Ended		305 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
OPERATING ACTIVITIES
Net loss	$ (554,298)	$ (795,784)	$ (12,870,744)
Services contributed by an officer	6,000	6,000
Common stock issued for services		721,383	9,904,653
Common stock issued for research and development costs			1,250,000
Loss from disposition of subsidiary			564,300
Expenses paid by related party	3,979		69,599
Gain on sale of patent		640,000	640,000
Accounts payable	9,840	(23,560)	70,825
Change in accounts payable - related parties	11,812		160,081
Change in prepaid expenses	491,667		491,667
Other accrued expenses	9,589	252,579	486,826
Net Cash Provided by (Used in) Operating Activities	(21,411)	(485,382)	(506,793)
Net Cash Provided by Investing Activities		640,000	640,000
Capital contributed by officer		13,046	13,046
Proceeds from related party payables	100		100
Repayment of related party payable		(145,493)	(145,493)
Net Cash Provided by (Used in) Financing Activities	100	(132,447)	(132,347)
NET INCREASE IN CASH	(21,311)	22,171	860
CASH AT BEGINNING OF PERIOD	22,171
CASH AT END OF PERIOD	860	22,171	860
Common stock issued for prepaid services		$ 750,000	$ 750,000

Balance Sheets (USD $)	Dec. 31, 2012	Dec. 31, 2011
ASSETS
Cash	$ 860	$ 22,171
Prepaid Expenses		491,667
Total Current Assets	860	513,838
TOTAL ASSETS	860	513,838
Accounts payable and accrued expenses	70,825	60,985
Accounts payable - related parties	16,319	4,507
Related party payables	4,079
Accrued officer salaries	486,826	477,237
Total Current Liabilities	578,049	542,729
TOTAL LIABILITIES	578,049	542,729
Common stock; 100,000,000 shares authorized, at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively	222,865	222,865
Additional paid-in capital	8,348,980	8,342,980
Deficit accumulated during the development stage	(9,149,034)	(8,594,736)
Total Stockholders' Deficit	(577,189)	(28,891)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 860	$ 513,838

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2012
Document and Entity Information:
Entity Registrant Name	PROTECT PHARMACEUTICAL Corp
Document Type	10-K
Document Period End Date	Dec. 31, 2012
Amendment Flag	false
Entity Central Index Key	0001493526
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	44,573,012
Entity Public Float	$ 44,573,012
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY